<SEC-DOCUMENT>0001390478-16-000134.txt : 20160809
<SEC-HEADER>0001390478-16-000134.hdr.sgml : 20160809
<ACCEPTANCE-DATETIME>20160809165711
ACCESSION NUMBER:		0001390478-16-000134
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160809
DATE AS OF CHANGE:		20160809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		161818744

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gale-20160630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDCFF540FB9B3C1EFDAE2BD1C0D1E0826"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Helvetica,sans-serif;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Helvetica,sans-serif;font-size:10.5pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;"><img src="logo-verticala10.jpg" style="font-family:Helvetica,sans-serif;font-weight:bold;height:106px;width:133px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Helvetica,sans-serif;font-size:24pt;font-weight:bold;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">(855)&#160;855-4253</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant's principal executive offices)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160; </font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act (Check one):</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:40%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253; </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;No</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">July&#160;31, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">, Galena Biopharma, Inc. had outstanding </font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">213,968,953</font><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s4CFDA22C841766A39371BD1C0D70A197"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">FORM 10-Q - Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">For the Quarter Ended June 30, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:82%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Part</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Item</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Page</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">No.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sC0D97535807114484F23BD1C0D91C421"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s59EDBE64746BB1D6DD0FBD1C0DC56122"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s59EDBE64746BB1D6DD0FBD1C0DC56122">2</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Balance Sheets as of June 30, 2016 (unaudited) and December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s01ADE7CB6C074F443CCFBD1C0123EA02">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2016 and 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s7096C7614149B4CDF24BBD1C013B06ED">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statement of Stockholders' Equity (unaudited) for the six months ended June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sB2F7F45B5FF8CC872461BD1C0154EB7D">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2016 and 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s2BC583B7E3C7CE06F76ABD1C01655742">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sC6932EED306A9778FAA5BD1C0F11D3C4"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sC6932EED306A9778FAA5BD1C0F11D3C4">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s3EEA3758A9917C0348F5BD1C12A4339E"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s06DA00B24373B248D27DBD1C11CF80CB">25</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s820B260EFA2ECE593D35BD1C12C6BF99"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s820B260EFA2ECE593D35BD1C12C6BF99">41</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sB0967174604C9EF65C96BD1C12FABAC5"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sB0967174604C9EF65C96BD1C12FABAC5">42</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sAAAB6A2B0CE0A2EA0372BD1C131C3001"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sDEF329FB0CDA935898E2BD1C134E82E7">43</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#s2C742C83F1F356885F63BD1C136F6667">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sEA106B89929C912F6FB5BD1C13C387C1"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sEA106B89929C912F6FB5BD1C13C387C1">48</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sEA106B89929C912F6FB5BD1C13C387C1"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Index to Exhibits</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sEA106B89929C912F6FB5BD1C13C387C1">48</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sB9EC333D621A10B73D01BD1C13F41D37"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Helvetica,sans-serif;font-size:10pt;" href="#sB9EC333D621A10B73D01BD1C13F41D37">49</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">EX-32.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;"><img src="logo-verticala11.jpg" style="height:106px;width:133px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sC0D97535807114484F23BD1C0D91C421"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I FINANCIAL INFORMATION</font></div><div><a name="s59EDBE64746BB1D6DD0FBD1C0DC56122"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160; 1. FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s01ADE7CB6C074F443CCFBD1C0123EA02"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">19,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">29,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">24,401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">21,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,398</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current assets of discontinued operations, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">45,284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">53,621</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">73,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">14,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">23,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Current liabilities of discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">47,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">57,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">53,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">68,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Common stock, $0.0001&#160;par value; 275,000,000&#160;shares authorized, 182,996,385 shares issued and 182,321,385 shares outstanding at June 30, 2016; 162,581,753&#160;shares issued and 161,906,753 shares&#160;outstanding at December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">314,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">296,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(290,487</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(279,383</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Less treasury shares at cost, 675,000 shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">20,321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">13,513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">73,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">82,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s7096C7614149B4CDF24BBD1C013B06ED"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,642</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,260</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,292</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,083</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,260</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,995</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation settlements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,800</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,800</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(611</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,436</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(13,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(21,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net income (loss) per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted-average common shares outstanding: basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,034,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted-average common shares outstanding: diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">185,477,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sB2F7F45B5FF8CC872461BD1C0154EB7D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.24561403508771%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:39%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Helvetica,sans-serif;font-size:7pt;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">162,581,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">296,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(279,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">19,772,727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with January 2016 common stock offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Common stock warrants issued in connection with debt financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock upon exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">408,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">67,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Stock-based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">166,830</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">182,996,385</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">314,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(290,487</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,321</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s2BC583B7E3C7CE06F76ABD1C01655742"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from continuing operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(21,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(5,327</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">141</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">256</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement insurance recovery</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Litigation settlement payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(19,900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(589</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,380</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in continuing operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(17,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(19,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from discontinued operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Changes in operating assets and liabilities attributable to discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(839</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(3,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(24,707</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(23,416</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for purchase of equipment and furnishings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Selling costs paid for sale of commercial assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid for commercial assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net cash used in discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(534</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">20,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Proceeds from common stock issued in connection with ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net proceeds from issuance of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Minimum cash covenant on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(24,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Principal payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(4,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(1,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">45,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Net (decrease) increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(10,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">21,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">29,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">23,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">19,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">45,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair value of warrants issued in connection with common stock recorded as cost of equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">5,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Reclassification of warrant liabilities upon exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">324</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sC6932EED306A9778FAA5BD1C0F11D3C4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s35284EEE1D34718DEA55BD1C018212A7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">1.  Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE-401 has completed a Phase 2 trial and we are advancing the asset into a pivotal trial. NeuVax is currently in multiple Phase 2 trials. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Developing hematology and oncology assets through clinical development, targeting areas of unmet medical need.  Our hematology asset is targeting the treatment of patients with essential thrombocythemia (ET) to reduce elevated platelet counts</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition of additional development programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer (i)&#160;to Galena, our wholly owned subsidiaries, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company&#8217;s capital resources consisted of cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$19.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;not including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of restricted cash. The Company will need to continue to incur significant expenses to advance our development portfolio and will need to raise additional capital to finance such activities.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 13, 2016, we closed the sale to certain institutional investors of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at a purchase price per share of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.45</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;in a registered direct offering, and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock with an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.65</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. The current unrestricted cash and cash equivalents as of the date of this filing will fund the Company's operations for at least six months.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional funding was received July 13, 2016 upon the closing of an underwritten registered direct offering of our common stock and a private placement of warrants for net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to the Company. Additional funding sources that are, or in certain circumstances may be, available to the Company, include 1) approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of restricted cash associated with our </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;sale of Debentures by amending the current agreement with the holder to reduce the minimum cash covenant as detailed in Note 4; 2) a Purchase Agreement with Lincoln Park Capital, LLC; and 3) At Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC. The Purchase Agreement and ATM are unavailable to the Company until </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75 days</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;after the closing of our July 2016 financing. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of the Company's product candidates and to support its other ongoing activities. However, the Company cannot be certain that it will be able to raise additional capital on favorable terms, or at all, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Restricted cash consists of certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Litigation Settlement Payable and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company follows the provisions of the FASB ASC Topic 718, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and six month periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation-Stock Compensation </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="sC69F4E7CB56CCC2AA3EEBD1C0189D3EE"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">2.  Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent purchase price consideration during the quarter ended June 30, 2016 reflects an adjusted probability and time line for the potential approval of NeuVax associated with the Phase 2 combination trial with trastuzumab. Previously, the valuation was measured using the probability and time line of the Phase 3 PRESENT trial, which was stopped in June 2016 due to futility as recommended by the Independent Data Monitoring Committee ("IDMC").</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See Note 7 for discussion of the Level 2 liabilities relating to warrants accounted for as liabilities. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s44D54525A1831F1F2DF6BD1C019F41B6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">3.  Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="sA63BAB5AC2503BD86018BD1C01A8F16C"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">4.  Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash final payment and granted to the lenders </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company entered into a&#160;Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;original issue discount, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25,530,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Senior Secured Debentures&#160;(the &#8220;Debentures&#8221;) and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock. Net proceeds to the Company from sale of the&#160;Debentures, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23,400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The&#160;Debentures&#160;mature November 10, 2018, accrue interest at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per year, and do not contain any conversion features into shares of our common stock. The Company intends to&#160;use the net proceeds from this offering to fund the costs associated with the close down of the Phase 3 PRESENT study of NeuVax and other clinical trials of our product candidates and to augment its working capital and for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Debentures carry an interest only period of six months following which the holder shall have the rights, at its option, to require the Company to redeem up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per month of the outstanding principal amount of these Debentures. Interest is payable at the end of each month based on the outstanding principal. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company is required to promptly, but in any event no more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;trading days after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company&#8217;s election and subject to certain conditions, in shares of the Company's common stock. If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or B) a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;discount to the prior trading day&#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debentures but not less than the monthly payment.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on the recommendation of the IDMC to stop the PRESENT Trial, the holder has the right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of this Debenture funded in cash by the holder on the closing date, plus all accrued and unpaid interest. If the holder elects such prepayment of the Debentures, then the number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by the Company. The Purchaser received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the closing on the sale of the Debentures at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years from issuance. Additionally, the Purchasers received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.43</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. As of June 30, 2016 and the date of this filing, the holder had not exercised its right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of the Debentures. The holder's right to require the Company to prepay the outstanding principal amount expires 30 trading days after June 29, 2016, the announcement date of the recommendation of the IDMC. Therefore as of June 30, 2016 the Debentures, net of unamortized discounts, are presented as current liabilities on the condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the&#160;Debenture&#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&#160;Debenture in cash. The Company&#8217;s obligations under the&#160;Debentures&#160;are secured under a Security Agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Until the holder exercises its right to require the Company to prepay some or all of the loan, the Company must also maintain a minimum of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash, which is included in restricted cash as of June 30, 2016. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Armentum Partners, LLC (the &#8220;Placement Agent&#8221;) acted as the&#160;placement agent&#160;in the offering of the&#160;Debentures and the Company agreed to pay the Placement Agent a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the funds received from the sale of the&#160;Debentures. The Company paid half of the placement fee upon funding with the remaining payable </font><font style="font-family:inherit;font-size:12pt;">at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">such time as the IDMC recommended in favor of the continuation of the PRESENT Trial or the holder waives the Company&#8217;s obligation to prepay the Debenture as a result of the IDMC&#8217;s recommendation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s2E3F71B26A8DB05B2BC7BD1C01ADC315"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">5. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we agreed in principle to resolve and settle the consolidated shareholder derivative action,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00382-SI, pending in the United States District Court for the District of Oregon against us and certain of our current and former officers and directors. On April 21, 2016, the District Court of Oregon held the final approval hearing of the settlement with the derivative plaintiffs after which the District Court continued the final approval hearing until June 23, 2016 and requested the parties submit additional briefing by June 9, 2016 on the fee request by the derivative plaintiffs&#8217; attorneys.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus costs, which will be paid by our insurance carriers. The settlement includes a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus costs, which is paid out of the settlement funds. The settlement agreement provides for a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;settlement payment to the class, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was paid by our insurance carriers and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash was paid by us on July 1, 2016, along with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">480,053</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares) paid by us on July 6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits. As of June 30, 2016 our insurance carriers paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in common stock on July 1, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In July 2016, we have resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">291,262</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) of our common stock, and in another case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,366,750</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follow as of June 30, 2016 (in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in cash  (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in common stock (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff to resolve the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we are not a target or subject of that investigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sE03C6EC2E3A2F4CA72A3BD1C01B404B7"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">6.  Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s Board of Directors upon its issuance. To date, the Company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. On July 14, 2016, shareholders approved a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;share increase to the Company's authorized shares of common stock up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in shares of the Company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of the Company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">631,221</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock, excluding the commitment fee shares. There were no sales of our common stock under the LPC purchase agreement during the six months ended June 30, 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in gross proceeds. The ATM is available to the Company until it is terminated by the Agents or the Company. During the first quarter of 2015, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the six months ended June 30, 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On March 18, 2015 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">January 2016 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;- On January 12, 2016 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,772,727</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock. The underwriters did not exercise their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expense paid by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:84%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">59,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sEBCD3B629F532797F4EABD1C01C4D56E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">7.  Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:17%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants issued to Consultants and Debtors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2016-2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in January 2016, March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">113.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">122.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">139.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">167.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">65.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">71.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*The March 2011 warrants expired in March 2016. The March 2010 warrants do not expire until September 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,515</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(6,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,075</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us and warrants issued in connection with debt financings. On May 10, 2016 upon closing on the sale of Debentures, we granted the holder warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77.13%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five and five tenths</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.26%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.87</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. These warrants are recorded in equity at fair value upon issuance. Additionally, on June </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upon closing on the public announcement of the interim analysis of the PRESENT trial, we granted the holder warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.43</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">106.63%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.35%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.27</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. These warrants are recorded in equity at fair value upon issuance.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s88B002605A3CD2CF2202BD1C0206096F"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">8.  Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#8212; The Company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.86</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share, respectively. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3,755,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.79</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock were reserved for issuance under the Company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the plan. On July 14, 2016, the shareholders approved the 2016 Incentive Plan into which the available shares in the 2007 Incentive Plan were transferred. There are </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,923,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares available for future grants based on adjustments in the 2016 Incentive Plan. The administrator of the plan determines the terms when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the Company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,952</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;were calculated based on the closing price of the Company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying options.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><a name="sC876C2C834D3D26D0388BD1C02299D6E"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">9.  Net Income (Loss) Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) (in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,034,593</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of dilutive securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">677,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,765,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,442,737</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">185,477,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="sE4245045069EE0939BEDBD1C0247040A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">10.  License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance. BioVascular has advised the Company of an alleged breach of the BioVascular agreement which the Company has denied. Both parties are discussing the dispute and it is anticipated that the dispute will be resolved. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 19, 2015, the Company and Sentynl Therapeutics Inc., a Delaware corporation (&#8220;Sentynl&#8221;), entered into and closed upon an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) sublingual tablets product (&#8220;Abstral&#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&#8220;Orexo&#8221;)  dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &#8220;Orexo Agreements&#8221;).  The Company&#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. In connection with such assignment, Orexo released the Company from any future obligations under the Orexo Agreements. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities and rebates related to Abstral for a period of time post-closing.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upfront payment and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of two one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$35 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 17, 2015, the Company and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&#8220;Midatech&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film (&#8220;Zuplenz&#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&#8220;MonoSol&#8221;) dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  The Company&#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain rebates and channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;upfront payment upon the closing and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$26 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Through a separate agreement with MonoSol entered into on December 16, 2015 (the &#8220;MonoSol License Amendment&#8221;), (i) the Company and MonoSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company paid MonoSol </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the upfront fee payable to the Company under the Purchase Agreement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of any future milestone payments received by the Company under the Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&#8217;s License and Supply Agreement, dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  As a result of such assignment, Midatech assumed all of the Company&#8217;s obligations under the MonoSol License.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s0A7FD18F38623AA325C9BD1C026D33AA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">11.  Discontinued Operations, Assets Held for Sale</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the fourth quarter of 2015, The Company sold its rights to its commercial products Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, the Company paid a success fee to the third party firm in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and agreed to pay </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of realized future revenue and payment streams. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, the Company paid a retention fee to the three employees in a combined total amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$352,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of cash consideration received as upfront payment in the transactions. These employees also received severance payments equal to one month&#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees who were part of the commercial business and did not accept employment opportunities at the companies that purchased Abstral and Zuplenz. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Abstral and related assets on November 19, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Zuplenz and related assets on December 24, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net proceeds from sales</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Less selling costs*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from sale, net of selling costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Selling costs related to the sale of Zuplenz and related assets were included in accrued liabilities as of December 31, 2015 and were paid in the first quarter of 2016. All other amounts were received or paid in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents amounts related to the discontinued operations in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:490px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:298px;"></td><td style="width:8px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:8px;"></td><td style="width:77px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(588</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,614</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;respectively, in selling, general, and administrative expense in discontinued operations. of which </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4CFDA22C841766A39371BD1C0D70A197"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:490px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:8px;"></td><td style="width:79px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="sF02DF9AFD5AE965AA903BD1C02F780F0"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">12.  Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company evaluated all events or transactions that occurred after </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements and below, the Company did not have any material recognizable or unrecognizable subsequent events.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 13, 2016, we closed the sale to certain institutional investors of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock at a purchase price per share of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.45</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;in a registered direct offering, and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares of common stock with an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.65</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On August 8, 2016, we amended the November 2014 Purchase Agreement with Lincoln Park Capital, LLC to increase the number of shares of our common stock that we can direct LPC to purchase from time to time, at its sole discretion and subject to certain conditions from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares, which number of shares may increase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">750,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;provided that the closing stock price of our common stock is not below </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.40</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on the purchase date, and further may be increased to up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;shares, provided that the closing stock price of our common stock is not below </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.75</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on the purchase date; provided, however, that the LPC&#8217;s committed obligation under any single regular purchase shall not exceed </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. In addition, we have removed the &#8220;floor price&#8221; at which the purchase price of shares of our common stock may be sold to LPC on any given day. The Company continues to control the timing and amount of any sales of our common stock to LPC. In addition, the Company may direct LPC to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the Common Stock is not below </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;on the purchase date.  Last, LPC will not purchase an aggregate number of shares that would result in the beneficial ownership by LPC and its affiliates of more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.99%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of the then issued and outstanding shares of our common stock. All other terms of the purchase agreement remain the same.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s06DA00B24373B248D27DBD1C11CF80CB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In this </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">section</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">, "Galena," &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours&#8221; and &#8220;us&#8221; refer to Galena Biopharma, Inc. and its consolidated subsidiaries, Apthera, Inc., or &#8220;Apthera,&#8221; and Mills Pharmaceuticals, LLC, or "Mills."</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">This management&#8217;s discussion and analysis of financial condition as of June 30, 2016 and results of operations for the three and six months ended June 30, 2016 and 2015, respectively, should be read in conjunction with management&#8217;s discussion and analysis of financial condition and results of operations included in our Amended Annual Report on Form 10-K for the year ended December&#160;31, 2015 which was filed with the SEC on March 11, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">The discussion and analysis below includes certain forward-looking statements related to the development of our products in the U.S., our future financial condition and results of operations and potential for profitability, the sufficiency of our cash resources, our ability to obtain additional equity or debt financing, possible partnering or other strategic opportunities for the development of our products, as well as other statements related to the progress and timing of our product commercialization and development activities, present or future licensing, collaborative or financing arrangements or that otherwise relate to future periods, which are all forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements represent, among other things, the expectations, beliefs, plans and objectives of management and/or assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; and &#8220;expect&#8221; and similar expressions are intended to connote forward-looking statements. All forward-looking statements involve certain risks, including the uncertainties and other factors described in our Amended Annual Report on Form 10-K for the year ended December&#160;31, 2015 that could cause our actual development activities, financial condition and results of operations, and business prospects and opportunities to differ materially from these expressed in, or implied by, those forward-looking statements. We caution investors not to place significant reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated) and we undertake no obligation to update or revise forward-looking statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="s98D0482FB3F61CC7719EBD1C11FF71D6"></a></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE-401 has completed a Phase 2 trial and we are advancing the asset into a pivotal trial. NeuVax is currently in multiple Phase 2 trials. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Developing hematology and oncology assets through clinical development, targeting areas of unmet medical need.  Our hematology asset is targeting the treatment of patients with essential thrombocythemia (ET) to reduce elevated platelet counts</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition of additional development programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The chart below summarizes the current status of our clinical development pipeline</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="pipeline8092016.jpg" style="height:375px;width:684px;"></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Hematology </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR)) </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401 contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent.  These adverse events may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration (C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">max</sub></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) is hypothesized to reduce the side effects, but preserve efficacy, potentially allowing a broader use of the drug.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">max</sub></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts, in patients with MPNs. Final safety and efficacy data from this pilot Phase 2 trial were presented in December 2015 and demonstrated a prolonged clinical benefit with a potentially improved safety profile.  We plan to submit a final Phase 2 manuscript at the end of 2016.  </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We  have analyzed our data and the treatment landscape for MPNs, with a current focus on Essential Thrombocythemia (ET) where we see an unmet medical need in patients who are intolerant to the current standard of care.  We are advancing GALE-401 into a pivotal trial and we plan to meet with the FDA by the end of the year to discuss our Phase 2/3 clinical trial design, development opportunities in ET patients, and confirmation of the 505(b)2 regulatory pathway for approval.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Thrombocythemia is a myeloproliferative blood disorder. It is characterized by the production of too many platelets in the bone marrow. Too many platelets make normal clotting of blood difficult. It can be either reactive or primary (also termed essential and caused by a myeloproliferative disease). Although often symptomless (particularly when it is a secondary reaction), it can predispose to thrombosis in some patients.</font><font style="font-family:inherit;font-size:9pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Primary Thrombocytosis (essential thrombocythemia or ET) is due to a failure to regulate the production of platelets (autonomous production) and is a feature of a number of myeloproliferative disorders. About a third of patients are asymptomatic at the time of diagnosis</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow; and, primary prevention intended to treat breast cancer earlier in the treatment spectrum. Once a patient&#8217;s tumor becomes metastatic, the outcome is often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have residual disease. Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, that are undetectable by current radiographic scanning technologies, can result in disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple clinical trials with NeuVax&#8482; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S) </font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S) is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS) suggesting a presence of isolated micrometastases, not detectable clinically, but, over time, can lead to recurrence, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocytes, or CTLs, causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Breast Cancer</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: According to the National Cancer Institute (NCI), over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients-those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence in situ hybridization (FISH) amplified-have a HER2 directed, approved treatment option available after their initial standard of care. This leaves the majority of breast cancer patients with low-to-intermediate HER2 expression (IHC 1+/2+) ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have two investigator-sponsored trials ongoing with NeuVax in combination with trastuzumab (Herceptin&#174;; Genentech/Roche).  </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;background-color:#ffffff;color:#262626;">The combination of trastuzumab and NeuVax has been shown pre-clinically and in a pilot study to be synergistic. Our Phase 2b clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient study enrolling HER2 1+ and 2+, HLA A2+, A3+, A24 and/or A26, node positive, and high-risk node negative patients. The endpoint is disease free survival and preliminary safety data will be presented in the fourth quarter of this year. Eligible patients will be randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival.  Genentech/Roche is providing the trastuzumab and partial funding for this trial.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;background-color:#ffffff;color:#262626;">&#32;Our second combination trial is a Phase 2 in HER2 3+ breast cancer patients who have completed neoadjuvant therapy with an approved regimen that includes trastuzumab and fail to achieve a pathological complete response, meaning they have microscopic evidence of residual disease and are therefore at an increased risk of disease recurrence. This multi-center, prospective, randomized, single-blinded Phase 2 trial is enrolling approximately 100 patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA A3+ and are determined to be at high-risk for recurrence. High-risk is defined as having received neoadjuvant therapy with an approved regimen that includes trastuzumab but not obtaining a pathological complete response at surgery, or those who undergo surgery as a first intervention and are found to be pathologically node-positive. These high-risk patients are known to have higher recurrence rates than other HER2 3+ breast cancer patients. Eligible patients will be randomized to receive NeuVax + GM-CSF (granulocyte macrophage-colony stimulating factor) + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is disease-free survival.  Funding for this trial was awarded through the Congressionally Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD), via annual Congressional legislation known as the Defense Appropriations Act. The grant was a Breast Cancer Research Program (BCRP) Breakthrough Award.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have also announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ, or DCIS, in collaboration with the NCI, potentially positioning NeuVax as a treatment for earlier stage disease. The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T-cell) response in vaccinated patients. The trial is currently suspended pending discussion around the outcome of the PRESENT clinical trial investigation. DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen. According to the American Cancer Society, in 2015 there were over 60,000 diagnoses of DCIS.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;24, 2016, the assembled Independent Data Monitoring Committee, or IDMC, met to conduct a pre-planned safety and futility analysis of the Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) clinical trial. On June&#160;27, 2016, the IDMC recommended that the Phase 3 trial &#8220;be stopped for futility unless it is determined that there has been a systematic reversal in the study drug treatments in the two arms, in which case the IDMC should reevaluate the clinical evidence.&#8221; We immediately stopped the PRESENT trial, and initiated an investigation into the causes of the recommendation. Our analysis of the data shows that there was a separation of the curves, albeit not statistically significant, with the control arm performing better than expected and the NeuVax arm performing consistent with our protocol assumptions for the control group. Because the study is deemed futile, we are officially closing the PRESENT trial, and we expect to present the data at a future medical conference.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Gastric Cancer</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: According to the NCI, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Infection with bacteria called Helicobacter pylori (H. pylori) is a common cause of gastric cancer and age, diet, and stomach disease can affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms. Gastric, or stomach cancer, is the second-most common cancer among males and third-most common among females in Asia and worldwide with over 63,000 new cases a year in India, where an initial clinical trial of NeuVax will be run. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We currently have an agreement with Dr. Reddy&#8217;s Laboratories to conduct a Phase 2 investigational study in gastric cancer in India. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:36px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">GALE-301 and GALE-302 </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha. FBP is a well-validated therapeutic target that is highly over-expressed in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells. Current treatments after surgery for these diseases are principally with platinum based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an extremely poor prognosis. GALE-301 and GALE-302 are immunogenic peptides that consist of a peptide derived from FBP combined with GM-CSF for the prevention of cancer recurrence in the adjuvant setting.  GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39&#8217;. Two trials are ongoing with our FBP peptides: the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial is ongoing in ovarian and endometrial adenocarcinomas, and the GALE-301 plus GALE-302 Phase 1b clinical trial is ongoing in breast and ovarian cancers.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;text-decoration:underline;">Ovarian Cancer</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">: According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at an annual rate of 11.9&#160;per 100,000 women in the United States, with an estimated 22,280 cases for 2016. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 80% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy is approximately 70%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease is most likely incurable.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of 25.1&#160;per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;text-decoration:underline;">Intellectual Property </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Patents and other intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including filing and prosecuting patent applications in the U.S. and other countries, protecting trade secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we do not believe patent protection is appropriate or obtainable. It is our policy to operate without infringing on, or misappropriating, the proprietary rights of others. The following chart summarizes our intellectual property rights: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:40%;"></td><td style="width:22%;"></td><td style="width:27%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Drug Candidate</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Scope</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exclusivity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Period</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-401 (Anagrelide Controlled Release)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Platelet Lowering</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer recurrence</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Gastric</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; (nelipepimut-S)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">DCIS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with trastuzumab</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">NeuVax&#8482; in combination with other compounds</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast cancer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2037</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALE-301 &amp; GALE-302</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Breast, ovarian and endometrial cancer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pending and/or issued</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2035</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><a name="sE0BD9893BDD519BFF7F8BD1C12204A31"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Recent Operational Developments</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Discontinued NeuVax&#8482; (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;24, 2016, the assembled IDMC met to conduct a pre-planned safety and futility analysis of the Phase 3 PRESENT (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">P</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">revention of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">R</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ecurrence in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">arly-</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">S</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">tage, Node- Positive Breast Cancer with Low to Intermediate HER2&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">E</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">xpression with&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">reatment) Trial. On June&#160;27, 2016, the IDMC recommended that the study be stopped for futility unless it is determined that there has been a systematic reversal in the study drug treatments in the two arms, in which case the IDMC should reevaluate the clinical evidence. We immediately stopped the PRESENT trial, and initiated an investigation into the causes of the recommendation. Our analysis of the data shows that there was a separation of the curves, albeit not statistically significant, with the control arm performing better than expected and the NeuVax arm performing consistent with our protocol assumptions for the control group. Because the study is deemed futile, we are officially closing the PRESENT trial, and we expect to present the data at a future medical conference.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Derivative and Securities Litigation - The U.S. District Court for the District of Oregon granted final approval of the settlements previously reported.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we reached an agreement in principle to settle the consolidated shareholder derivative action,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Galena Biopharma, Inc. Derivative Litigation,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;Civil Action No.&#160;3:14-cv-00382-SI pending against us and certain of our current and former officers and directors. Following the hearing on June&#160;23, 2016, on June&#160;24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of $4.5 million plus costs, which will be paid by our insurance carriers. The settlement includes a payment of $15 million in cash by our insurance carriers, which we will use to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">&#160;In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. Following the hearing on June&#160;23, 2016, on June&#160;24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of $4.5 million plus costs, which is paid out of the settlement funds. The agreement provides for a settlement payment of $20 million to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid by our insurance carriers and $2.3 million in cash was paid by us on July&#160;1, 2016, along with $1 million in shares of our common stock (480,053 shares) paid by us on July&#160;6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Securities Litigation Opt Out Claims</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have resolved claims brought by shareholders and others that relate to the securities litigation mentioned above in one case for $150,000 plus $150,000 in shares (291,262)&#160;of our common stock, and in another case for $1.5 million in shares of our common stock (3,138,951 shares). The 3,430,213 shares issued in connection with such settlements are included in the offering covered by this prospectus.  The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented GALE-401 Combined Safety Data</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;13, 2016 we presented combined safety data from our GALE-401 clinical trials at the European Hematology Association 21</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Congress. A total of six trials have been run with GALE-401, five Phase 1 trials in healthy volunteers (N=98), and one Phase 2 single arm, open label pilot study in MPN patients (N=18). The poster, entitled, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Anagrelide Controlled Release (GALE-401) Safety Profile Consistently Well Tolerated in Myeloproliferative Neoplasms Patients and Healthy Volunteers&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;was designed to characterize the safety profile of GALE-401 in all subjects treated to date. The results demonstrated that GALE-401 is well tolerated in MPN patients as well as in healthy volunteers and we observed predominantly mild to moderate toxicities that did not reveal any unexpected AEs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Received Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;10, 2016, we announced that the U.S. Food and Drug Administration, or FDA, granted two orphan-drug designations for Galena&#8217;s two cancer immunotherapy peptides derived from Folate Binding Protein (FBP) for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39&#8217;).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented GALE-301 Phase 1/2a Primary Analysis</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;6, 2016, we presented the primary analysis from the Company&#8217;s GALE-301 Phase 1/2a clinical trial at the American Society of Clinical Oncology Annual Meeting 2016. The poster, entitled, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence,&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;demonstrated that the vaccine is well tolerated and immunogenic. In the optimal dose group, the results demonstrate potential clinical benefit for GALE-301 to prevent recurrence in these patients, and that boosters may sustain this effect.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Received Fast Track Designation for NeuVax&#8482; (nelipepimut-S) PRESENT Clinical Trial</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June&#160;1, 2016, we announced that the FDA has designated NeuVax&#8482; (nelipepimut-S), combined GM-CSF, as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Appointment of Mary Ann Gray, Ph.D. to Board of Directors</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effective April 25, 2016, the Board increased the number of directors from eight to nine directors and appointed Mary Ann Gray, Ph.D. as a Class III director.  Dr. Gray will be listed in Galena&#8217;s 2016 Proxy Statement as a nominee for election at our 2016 Annual Meeting of Stockholders. Dr. Gray is President of Gray Strategic Advisors, LLC, which provides strategic advice to both public and private biotechnology companies. Previously, she spent three and a half years with the Federated Kaufmann Fund focusing on both public and private healthcare investments. Prior, Dr. Gray was a sell-side biotechnology analyst for nine years. Earlier in her career, Dr. Gray held scientific positions at Schering Plough and NeoRx, managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute, and worked in a hospital laboratory.  Dr. Gray currently serves on the board of directors of several publicly traded biotechnology companies: TetraLogic, Inc.</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Juniper Pharmaceuticals, Senomyx, Inc. Previously, Dr. Gray also served on the boards of Acadia Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;Dyax Corp., GTC Biotherapeutics, Inc., Telik, and Apthera, Inc. (private). Dr. Gray has a Ph.D. in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer, and she received her B.S. in biology from the University of South Carolina. She completed her postdoctoral work at Northwestern University Medical School and Yale University School of Medicine.&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented GALE-301/GALE-302 Clinical Booster Data</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On April 19, 2016 data from the booster phase of the Company&#8217;s GALE-301/GALE-302 Phase 1/2a clinical trial was presented at the American Association for Cancer Research (AACR) Annual Meeting.  The poster, entitled, &#8220;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comparing an attenuated booster (E39&#8217;) vs. E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients,&#8221;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;randomized patients to two different boosters: E39 (GALE-301), versus E39&#8217; (GALE-302). The purpose of the study was to evaluate the immune responses and determine which booster, if either, would provide a sustained immune response and potentially longer disease free survival (DFS) rates.&#160;The use of the wildtype peptide (GALE-301/E39) demonstrated the same tolerable safety profile as the attenuated peptide (GALE-302/E39&#8217;) with only Grade 1 local reactions and minimal Grade 2 toxicities.&#160; Importantly, the percentage of patients who received two booster inoculations and remained disease free was significantly better in the drug treatment arm, versus the control arm (p=0.02), regardless of which booster was used. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Announced a Notice of Allowance of a U.S. Patent for NeuVax</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On February 8, 2016, we announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax&#8482; (nelipepimut-S):&#160; inducing and maintaining an immune response to HER2 expressing tumor cells in patients in clinical remission with a tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 (FISH &lt;2.0); inducing and sustaining a cytotoxic T-lymphocyte (CTL) response to HER2 in patients in clinical remission from a tumor with a FISH rating of less than about 2.0 (FISH &lt; 2.0); reducing risk of cancer recurrence in patients in clinical remission from a tumor with a FISH rating of less than about 2.0 (FISH &lt; 2.0); and preventing bone only recurrence of a HER2 expressing cancer.  This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Presented Observational Study Data in Gastric Cancer Patients at the ASCO 2016 Gastrointestinal Cancers Symposium</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 21, 2016, we presented data from an observational study in gastric cancer patients at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium.&#160; The study was conducted by our partner, Dr. Reddy&#8217;s Laboratories Ltd, who will conduct a Phase 2 clinical trial of&#160;NeuVax in gastric cancer patients in India. The poster, entitled, &#8220;An observational study evaluating the expression of HER2 (1+, 2+, and 3+) with HLA A2+/A3+ in gastric adenocarcinoma patients&#8221; showed that approximately 25% of the patients met the projected clinical protocol population of all levels of expression of HER2 and HLA A2+ and/or A3+ as defined for the planned NeuVax Phase 2 clinical trial.&#160; Results indicate an acceptable potential for enrollment rate, given the high incidence of gastric cancer in this population, and will inform the screen failure rate in the planned Phase 2 clinical study.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Closed Public Offering and Debt Financing</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2016, we closed the previously announced underwritten public offering of common stock and warrants.  The net proceeds to us were approximately $20.2 million. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, we closed on a Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a 6.375% original issue discount, a total of $25.5 million Senior Secured Debentures. The net proceeds to us were approximately $23.4 million.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 13, 2016, we closed the previously announced underwritten registered direct offering of common stock and warrants. The net proceeds to us were approximately $11.7 million.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s11F5E7D06CF595D7AF27BD1C05779AD2"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Results of Operations for the Three and Six Months Ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#32;and 2015</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;&#32;For the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, our net income was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Income from continuing operations for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a loss from continuing operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily driven by a non-cash net change in our warrant liability of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$18.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;loss in the first quarter of 2015 to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$14.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gain in the first quarter of 2016. In addition, to the non-cash gain on our warrant liability, the revaluation of our contingent purchase price consideration as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;resulted in an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash gain for the three months then ended compared to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash gain for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, our net loss was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$26.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Loss from continuing operations for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a loss from continuing operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which was primarily driven by a non-cash net change in our warrant liability of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;from a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;loss in the first half of 2015 to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;gain in the first half of 2016. In addition, to the non-cash gain on our warrant liability, the revaluation of our contingent purchase price consideration as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;resulted in an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash gain for the three months then ended compared to a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;non-cash loss for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the third quarter of 2015, the Company completed its strategic review and concluded to solely focus its resources on its clinical development pipeline and our management and Board of Directors committed to pursue a plan to sell or otherwise divest the Company&#8217;s commercial business. These actions caused the Company to meet the relevant criteria for reporting the Company&#8217;s commercial business as discontinued operations. Discontinued operations for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 is comprised of the revenue, expenses, gains and losses of our commercial business. Our loss from discontinued operations for the three months ended June 30, 2016 was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a loss from discontinued operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the three months ended June 30, 2015.  Loss from discontinued operations for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$6.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared with a loss from discontinued operations of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended June 30, 2015. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Further analysis of the changes and trends in our operating results are discussed below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(9,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,391</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net income (loss) per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net income (loss) per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Operating loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(18,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,785</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(455</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share, discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development expense consists primarily of clinical trial expenses, compensation-related costs for our employees dedicated to research and development activities, and licensing fees and patent prosecution costs. Research and development expense for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The majority of our research and development expenses to date relate to our Phase 3 PRESENT clinical trial using NeuVax as a HER2 directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment. The trial costs are more significant during the recruitment and enrollment phase. We established more than 140 sites in 13 counties and screened over 3,300 patients in order to enroll qualifying patients who currently have no available treatment options to maintain their disease-free status after their standard of care. Once the patient is enrolled, they enter the monitoring phase, which lasts the later of three years of treatment or an event (recurrence or death). On April 14, 2015 we announced the completion of over-enrollment in the PRESENT trial of 758 patients, which was 7.7% higher than called for under our FDA-approved Special Protocol Assessment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease of 14% for the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in research and development expense was primarily due to the decrease in enrollment efforts surrounding our Phase 3 PRESENT clinical trial, partially offset by additional consulting expenses incurred preparing for the interim analysis of PRESENT on June 24, 2016. The decrease of 11% for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in research and development expense was primarily due to the decrease in enrollment efforts surrounding our Phase 3 PRESENT clinical trial, partially offset by additional consulting expenses incurred preparing for the interim analysis of PRESENT on June 24, 2016.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The completion of over-enrollment in April 2015 reduced expenses related to the trial as we entered the monitoring phase and continued toward our interim analysis on June 24, 2016, which resulted in the stop and eventual termination of the Phase 3 PRESENT trial in the third quarter of 2016. The decrease in recruitment and enrollment expenses related to the Phase 3 PRESENT clinical trial were partially offset by recruitment, enrollment, and monitoring expenses in our other ongoing or planned clinical trials. We expect the second half 2016 research and development expenses to decrease as we close down the Phase 3 PRESENT trial upon the recommendation of the IDMC, will reduce headcount, and will focus on our other ongoing and planned clinical trials. The close out of the Phase 3 PRESENT trial is expected to cost $2.5 - $3.5 million over the second half of 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative expense includes compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. General and administrative expense for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The 65% increase in selling, general, and administrative expense for the three months ended June 30, 2016 compared to the three months ended June 30, 2015 was driven by an increase of $0.8 million in legal expenses incurred with final approval of the settlement of our class action and derivative litigation on June 24, 2016 and the ongoing SEC investigation and other governmental investigations, as well as $0.2 million in stock based compensation. The 34% increase in selling, general, and administrative expense for the six months ended June 30, 2016 compared to the six months ended June 30, 2015 was driven by an increase of $0.4 million in legal expenses incurred with final approval of the settlement of our class action derivative litigation on June 24, 2016 and the ongoing SEC investigation and other governmental investigations as well as $0.4 million in stock based compensation. We also incurred additional personnel expenses including recruitment fees for two new directors for our Board and replacing our chief financial officer. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Non-Operating Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense) for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(611</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(432</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of the contingent purchase price liability<br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The increase in our net non-operating income (expense) during the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was primarily due to a significant decrease in the change in fair value of warrants accounted for as liabilities. This decrease in the estimated fair value of our warrant liabilities was primarily due to the decrease in our common stock price, which is one of the most impactful inputs into the pricing model we use to estimate the fair value of our warrant liabilities. The stock price as of June 30, 2016 was $0.47, a decrease of 65% and 68% for the three and six months ended June 30, 2016, respectively. In addition to the decrease in the fair value of warrants, our contingent purchase price consideration related to the approval of NeuVax also decreased. The interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial triggered an intangible asset and goodwill impairment analysis of the carrying amount and the fair value was determined to exceed the carrying amount as of June 30, 2016 based on the other ongoing and planned trials with NeuVax. The contingent purchase price consideration is fair valued at each reporting period and the lower probability and extended time line for approval were updated to align with the valuation performed of NeuVax and significantly decreased the fair value which are the two largest variables impacting the liability.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The change in fair value of warrants and the change in contingent purchase price consideration are both non-cash. Management believes these adjustments may not always accurately reflect the operating, economic activities, or obligations undertaken by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015, there was no income tax benefit or expense recognized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the quarter ended September 30, 2015, we completed a strategic review of our commercial business and operations, and as a result of that review we sold the assets of our commercial business during the fourth quarter of 2015.  We believe this disposition allows us to focus our resources on our valuable and expanding clinical development programs and maximize the value of these assets to our shareholders. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(588</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,614</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification of assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Discontinued operations are comprised of net revenue, cost of revenue, and expenses attributable to our commercial operations, which were sold in the fourth quarter of 2015.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Net Revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations comprises revenue from the sale of Abstral, which was provided by our commercial operations. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Additional Channel Obligations</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations in the first quarter of 2016 is comprised of larger than anticipated rebates of Abstral sales that we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement. The additional channel obligations for the three months ended June 30, 2016 relate to adjusted Medicaid billings from previous quarters since the first quarter of 2014.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cost of revenue </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of direct products costs and related overhead, Abstral royalties based on net revenue, inventory obsolescence, and other direct costs. </font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and development expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;included in discontinued operations consists of expenses related to our Abstral RELIEF trial and other product stability costs.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-indent:36px;"><font style="padding-bottom:8px;font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;padding-right:12px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Selling, general and administrative expense </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, consulting, and other outsider services necessary to support the commercial operations. During the three and six months ended June 30,2016 we incurred $2.2 million and $4.6 million respectively, in selling, general, and administrative expense in discontinued operations, of which $2.2 million and $4.4 million for the three and six months ended June 30, 2016, respectively, related to legal expenses from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. We expect the third quarter of 2016 to incur similar legal expenses and wind down during the fourth quarter of the year. These legal proceedings are further disclosed in Part II, Item 1. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="s441489694038ACE8A1A7BD1C12927239"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$19.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;as of December&#160;31, 2015. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The decrease of approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;in our cash and cash equivalents from December&#160;31, 2015 to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;was attributable primarily to $24.7 million used in operating activities, $1.1 million in selling expenses related to the sale of our commercial products in the fourth quarter of 2015, and $4.7 million in payments on long-term debt. The decrease was partially offset by $20.2 million in net proceeds from issuance of common stock and warrants to purchase common stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, we entered into a&#160;Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a 6.375% original issue discount, a total of $25.5 million Senior Secured Debentures&#160;(the &#8220;Debenture&#8221;) and warrants to purchase up to 2.0 million shares of the our common stock. Net proceeds to the Company from sale of the&#160;Debentures, after payment of commissions and legal fees, were approximately $23.4 million. The&#160;Debentures&#160;mature November 10, 2018, and accrue interest at 9% per year and contain no conversion features to shares of our common stock. The Debentures carry an interest only period of six months following which the holder shall have the rights, at its option, to require the Company to redeem up to $1,100,000 of the outstanding principal amount of the Debentures. Interest is payable at the end of each month based on the outstanding principal. We can pay the applicable redemption amount in cash or, at the Company&#8217;s election and subject to certain conditions, in shares of the Company's common stock. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debentures but not less than the monthly payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the&#160;Debenture&#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&#160;Debentures in cash. The Company&#8217;s obligations under the&#160;Debentures&#160;are secured under a Security Agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. The Company must also maintain a minimum of $24.0 million in cash based on the public announcement of the interim analysis of the PRESENT Trial, which is included in restricted cash as of June 30, 2016. The Company is in discussions with the holder in the event that the holder does not require the Company to prepay the outstanding principal to potentially amend terms of the Debenture. Their right to require the Company to prepay the outstanding principal amount expires 30 trading days after June 29, 2016, the announcement date of the interim analysis. Therefore as of June 30, 2016 the Debentures, net of unamortized discounts, are presented as current liabilities on the condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 13, 2016, we closed the sale to certain institutional investors of 28,000,000 shares of common stock at a purchase price per share of&#160;$0.45&#160;in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price of$0.65&#160;per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses are expected to be approximately&#160;$11.7 million. The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. The current unrestricted cash and cash equivalents as of the date of this filing will fund the Company's operations for at least six months.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company will need to continue to incur significant expenses to advance our development portfolio and will need to raise additional capital to finance such activities. The Company cannot be certain that it will be able to raise additional capital on favorable terms, or at all, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the sale of Debentures and July 2016 registered direct equity offering, the Company has a Purchase Agreement with Lincoln Park Capital, LLC and At Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC. The Purchase Agreement and ATM are unavailable to the Company until 75 days post closing of our July 2016 financing. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of the Company's product candidates and to support its other ongoing activities. However, the Company cannot provide assurances that such additional capital will be available on acceptable terms or at all.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015 ($ in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">For the Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from continuing operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(17,588</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(19,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in continuing investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by continuing financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows provided by (used in) continuing operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows from discontinued operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(7,119</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(3,980</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in discontinued investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows used in discontinued operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,169</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,514</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(24,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(23,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,056</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(568</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Cash flows provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">45,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Total increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(10,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in operating activities increased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared to the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The increase in cash used in operating activities was driven by an increase of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;cash used in our discontinued operating activities, partially offset by a reduction of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the continuing operating activities. The increase in total net cash used in continuing operating activities was due to payments made for severance and exit costs related to our sales and marketing team and payments on channel liabilities for Abstral and Zuplenz.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Investing Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The increase was due to $1.1 million of payments for selling costs paid in the first quarter of 2016 that were incurred from the sale of commercial assets in the fourth quarter of 2015 compared to the $0.5 million milestone payment for U.S. rights to Zuplenz during the first quarter of 2015. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, compared with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$45.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The decrease was primarily attributable to $47.4 million in net proceeds from the issuance of common stock and warrants to purchase common stock during the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;compared to $20.2 million in net proceeds from the issuance of common stock and warrants to purchase common stock during the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The cash flows provided by financing activities were partially offset by principal payments on long-term debt of $4.8 million and $1.9 million for the six month periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;and 2015, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="s3EEA3758A9917C0348F5BD1C12A4339E"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In our Annual Report on Form 10-K for the year ended December&#160;31, 2015, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December&#160;31, 2015 that are not included in Note 1 of the accompanying condensed consolidated financial statements for the three and six months ended June 30, 2016. Readers are encouraged to read our Annual Report on Form 10-K in conjunction with this report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><a name="s820B260EFA2ECE593D35BD1C12C6BF99"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are exposed to certain market risks relating primarily to interest rate risk on our cash and cash equivalents and risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage the latter risks by investing primarily in money market mutual funds.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sB0967174604C9EF65C96BD1C12FABAC5"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of the end of the period covered by this quarterly report on Form 10-Q, our principal executive officer and our principal financial officer (the &#8220;Certifying Officers&#8221;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), such as this quarterly report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q:</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There has been no change in our internal control over financial reporting that occurred during the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="sAAAB6A2B0CE0A2EA0372BD1C131C3001"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART II - OTHER INFORMATION</font></div><div><a name="sDEF329FB0CDA935898E2BD1C134E82E7"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we agreed in principle to resolve and settle the consolidated shareholder derivative action,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00382-SI, pending in the United States District Court for the District of Oregon against us and certain of our current and former officers and directors. On April 21, 2016, the District Court of Oregon held the final approval hearing of the settlement with the derivative plaintiffs after which the District Court continued the final approval hearing until June 23, 2016 and requested the parties submit additional briefing by June 9, 2016 on the fee request by the derivative plaintiffs&#8217; attorneys.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of $4.5 million plus costs, which will be paid by our insurance carriers. The settlement includes a payment of $15 million in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. The District Court has set the final approval hearing of such settlement for June 23, 2016.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of $4.5 million plus costs, which is paid out of the settlement funds. The agreement provides for a settlement payment of $20 million to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid by our insurance carriers and $2.3 million in cash was paid by us on July 1, 2016, along with $1 million in shares of our common stock (480,053 shares) paid by us on July 6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We have resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for $150,000 plus $150,000 in shares (291,262) of our common stock, and in another case for $1.5 million in shares of our common stock (3,366,750 shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff to resolve the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we are not a target or subject of that </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">investigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="s2C742C83F1F356885F63BD1C136F6667"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In addition the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2015 filed and our most recent Quarterly Report on Form 10-Q for the three months ended March 31, 2016 with the SEC, you should consider the following new or updated risk factors:</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our common stock is currently trading at prices less than $1.00, which is the minimum bid price requirement under NASDAQ&#8217;s continued listing standards. If our common stock continues to trade at such prices, our common stock may be subject to delisting from the NASDAQ Capital Market.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The continued listing requirements of the NASDAQ Capital Market require that the closing bid price of our common stock not be less than $1.00. Following our announcement on June 29, 2016, that we had stopped our PRESENT trial, the closing bid price of our common stock has been less than $1.00. If the closing bid price of our common stock remains under $1.00 for a period of at least 30 consecutive trading days, we expect to receive a letter from NASDAQ advising us that we are not in compliance with its continued listing requirements under NASDAQ Listing Rule 5502(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we would then have 180 calendar days to regain compliance with the $1.00 minimum bid price requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of our is at least $1.00 per share for a minimum of ten consecutive trading days during this initial 180-day compliance period. If compliance is not achieved within the 180-day period, NASDAQ would provide written notification to us that our common stock is subject to delisting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event that we fail to regain compliance with NASDAQ continued listing standards by the expiration of the applicable cure period or any extension period, NASDAQ will commence suspension and delisting procedures with respect to our common stock, which could impair the value of your investment. If our common stock is delisted from NASDAQ Capital Market in the future, such securities may be traded over-the-counter on the &#8220;pink sheets.&#8221; Such alternative market, however, is generally considered to be less efficient than, and not as broad as, NASDAQ. Accordingly, delisting of our common stock from NASDAQ could have a significant negative effect on the trading volume, liquidity and market price of our common stock. In addition, the delisting of our common stock could adversely affect our ability to raise capital on terms acceptable to us or at all and could reduce the number of investors willing to hold or acquire our common stock.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We are, and in the future may be, subject to legal or administrative actions that could adversely affect our financial condition and our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we are not a target or subject of that investigation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Litigation is inherently uncertain. We have incurred and may continue to incur substantial unreimbursed legal fees and other expenses in connection with these or other legal and regulatory proceedings that may not qualify for coverage under, or may exceed the limits of, our applicable directors and officers liability insurance policies and could have a material adverse effect on our financial condition, liquidity, and results of operations. These matters also may distract the time and attention of our officers and directors or divert our other resources away from our ongoing development programs. An unfavorable outcome in any of these matters could damage our business and reputation or result in additional claims or proceedings against us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">The terms of our outstanding indebtedness may inhibit potential acquirers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are prohibited by the terms of our outstanding indebtedness from disposing of any of our business or property, except with the consent of our lenders or if we were to prepay the outstanding indebtedness and related fees in accordance with the loan security agreement. Our outstanding indebtedness may inhibit potential acquirers or other interested parties from seeking to acquire all or a part of our business or assets, and there is no assurance that our lenders would consent to any proposed future transaction that might be beneficial to our stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">You may have difficulty evaluating our business, and our historical financial information may not be representative of our future results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We recently announced the recommendation by the IDMC to stop the PRESENT Trial for futility and based upon our investigation we closed down the trial. As a result, we will focus our resources on our pipeline of other product candidates. Thus, we will have no recurring revenues unless and until we are able to obtain marketing approval of one or more of our other product candidates and our historical financial information may not be representative of our future results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Risks Relating to Our Financial Position and Capital Requirements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain sufficient financing, and may not be able to develop our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had cash and cash equivalents of approximately $19.6 million as of June 30, 2016. In addition, we have approximately $24 million of restricted cash that is reserved for a lender who has the option to redeem all, or part, of such amount within 30 trading days of our public announcement on June 29, 2016, of the discontinuation of the Phase 3 PRESENT Trial upon the IDMC&#8217;s recommendation on June 27, 2016. As of the date of this prospectus, the lender has not redeemed the approximately $24 million in full or in part.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We had no revenue for the quarter ending June 30, 2016, and our cash burn from operations for the quarter ending June 30, 2016 was approximately $11.5 million. In addition, we paid off our loan with Oxford Finance LLC for a total of $3.1 million. The Company has stopped the PRESENT Trial and has completed the investigation. based upon the results of the investigation, the estimated cost to close out the PRESENT Trial will be between $2.5 million to $3.5 million. On July 1, 2016, we paid $2.3 million for the securities class action settlement. We believe that our existing cash and cash equivalents together with the net proceeds we received on July 13, 2016 from selling 28,000,000 shares of common stock and 14,000,000 warrants (the &#8220;July Financing&#8221;) should be sufficient to fund our operations for at least six months. This projection is based on our current planned operations, stopping the PRESENT Trial and investigation of the causes of the failure of such clinical trial, anticipated payments for defense costs for the cooperation and discussions with the staff in the SEC investigation and other governmental investigations, resolution of the SEC investigation and is subject to changes in our plans and uncertainties inherent in our business. We will need to seek to replenish our existing cash and cash equivalents prior to the end of 2016. We also have funding available under our amended purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with MLV &amp; Co. and Maxim Group LLC described in the previously filed prospectuses, but there is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of our future funding needs. Additionally, in connection with the July Financing, we have agreed not to issue any shares of our common stock (including under our purchase agreement with Lincoln Park Capital Fund, LLC and under our sales agreements with MLV &amp; Co. and Maxim Group LLC) for a period of 75 days from the date of the closing of the July Financing.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At our annual meeting of stockholders adjourned on July 15, 2016, our stockholders approved an increase in our authorized common stock from 275,000,000 to 350,000,000. We are not able to predict whether these additional shares will be sufficient based upon our current stock price to meet the Company&#8217;s ongoing financing requirements to maintain the Company&#8217;s operations. If we fail to obtain additional future funding when needed, we could be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability, and may lead to uncertainty about our ability to continue as a going concern.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Substantial funds were expended to develop our technologies and product candidates, and additional substantial funds will be required for further preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In the event that we are unable to achieve or sustain profitability or to secure additional financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. Our financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or other events will all affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our security holders or may otherwise adversely affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">If we raise funds through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute your ownership in us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The terms of debt securities may also impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Risks Relating to Our Development Programs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Our Phase 3 PRESENT clinical trial has been stopped due to futility and though we are conducting an investigation of the causes for the failure of the clinical trial, we are not certain that the investigation will result in the reason(s) for the failure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On June 27, 2016, the Independent Data Monitoring Committee conducting the pre-planned interim analysis of the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">PRESENT Trial recommended that we stop the clinical trial because of futility. We have conducted an investigation of the causes of the failure of the trial, which has resulted in the trial being closed down. The investigation has not yet provided the reasons for the failure of the clinical trial. The investigation has caused us to unblind the data of the clinical trial. The PRESENT Trial may no longer likely be considered a registrational clinical trial. Even if we determine the causes of the failure, NeuVax may never be approved for the treatment of patients with Node positive HER2 negative breast cancer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="sEA106B89929C912F6FB5BD1C13C387C1"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9% Original Issues Discount Senior Secured Debenture of Galena Biopharma, Inc. **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Securities Purchase Agreement dated May 10, 2016 between Galena Biopharma, Inc. and Purchasers.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Subsidiary Guarantee dated May 10, 2016 between Galena Biopharma, Inc. and JGB Collateral LLC. **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Registration Rights Agreement dated May 10, 2016 between Galena Biopharma, Inc. and Purchasers.** **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Security Agreement dated May 10, 2016 between Galena Biopharma, Inc. and JGB Collateral LLC.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Mark W. Schwartz, Ph.D.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of John T. Burns*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Sarbanes-Oxley Act Section 906 Certification of Mark W. Schwartz, Ph.D., and John T. Burns*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Instance Document.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation.*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Filed herewith. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Previously filed as an Exhibit to the Company&#8217;s Form 10-Q filed on May 10, 2016 (File No. 001-33958) and incorporated herein by reference.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="sB9EC333D621A10B73D01BD1C13F41D37"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: August&#160;9, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">/s/ </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">John T. Burns</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">John T. Burns</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Vice President, Finance and Corporate Controller (Principal Accounting Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Date: August&#160;9, 2016</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>gale20160630ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s305277AFBC28A360DCFFBD1C32091FF0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, Mark W. Schwartz, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August&#160;9, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>gale20160630ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB573FDA7F749EA83EAB0BD1C32B09932"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">I, John T. Burns, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dated: </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August&#160;9, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ John T. Burns</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">John T. Burns</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Vice President, Finance and Corporate Controller (Principal Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>gale20160630ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s31351D6FE0B53CF2632FBD1C3354222A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the accompanying Quarterly Report of Galena Biopharma, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officers of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:8%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">/s/ John T. Burns</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">John T. Burns</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Vice President, Finance and Corporate Controller (Principal Accounting Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August&#160;9, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">August 9, 2016</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>gale-20160630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:ff1d672848364e97bd1f8ebb3baa3f17,x:af85137de63b4acea1271ad6b9b962a8-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:gale="http://www.galenabiopharma.com/20160630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20160630.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-13</xbrli:startDate>
			<xbrli:endDate>2016-07-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul14_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-13</xbrli:startDate>
			<xbrli:endDate>2016-07-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2MAY8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-07</xbrli:startDate>
			<xbrli:endDate>2013-05-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-09</xbrli:startDate>
			<xbrli:endDate>2016-05-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-10</xbrli:startDate>
			<xbrli:endDate>2016-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Jun29_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gale:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-09</xbrli:startDate>
			<xbrli:endDate>2016-05-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SecuritiesLitigationOptOutSettlementCase1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-24</xbrli:startDate>
			<xbrli:endDate>2016-06-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-24</xbrli:startDate>
			<xbrli:endDate>2016-06-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:SecuritiesLitigationOptOutSettlementCase2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-06</xbrli:startDate>
			<xbrli:endDate>2016-07-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul01_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jun_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_ShareholdersSecuritiesLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">gale:ShareholdersSecuritiesLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Apr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-10</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-12</xbrli:startDate>
			<xbrli:endDate>2016-01-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Mar18ToApr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul142016">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:JanuaryTwoThousandSixteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-29</xbrli:startDate>
			<xbrli:endDate>2016-07-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-24</xbrli:startDate>
			<xbrli:endDate>2015-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MonosolRxLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-16</xbrli:startDate>
			<xbrli:endDate>2015-12-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:MidatechPharmaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-24</xbrli:startDate>
			<xbrli:endDate>2015-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gale:SentynlTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember_us-gaap_NatureOfExpenseAxis_gale_LegalExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">gale:LegalExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralandZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:AbstralandZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember_us-gaap_NatureOfExpenseAxis_gale_LegalExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">gale:LegalExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Dec24_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec24_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-24</xbrli:startDate>
			<xbrli:endDate>2015-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Nov19_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:AbstralMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov19_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:AbstralMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-19</xbrli:startDate>
			<xbrli:endDate>2015-11-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">gale:CommercialBusinessSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheOneMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gale:SaleOfStockTermAxis">gale:SaleOfStockTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug8_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-08</xbrli:startDate>
			<xbrli:endDate>2016-08-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheTwoMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gale:SaleOfStockTermAxis">gale:SaleOfStockTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheTwoMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gale:SaleOfStockTermAxis">gale:SaleOfStockTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheOneMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="gale:SaleOfStockTermAxis">gale:SaleOfStockTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug8_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="day">
		<xbrli:measure>gale:day</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2016Q2YTD" id="Fact-E6295A81CE000019C010BD1C00E9725E">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q2YTD" id="Fact-05B7596E46DFE6284F52BD1C00EDA6E6">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q2YTD" id="Fact-FB57002B7EF4FD14AB07BD1C00E88136">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q2YTD" id="Fact-B4A4949A755DC67E0034BD1C00EAC81A">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q2YTD" id="Fact-77C646C6851E58A66BE3BD1C00EACBAC">2016-06-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q2YTD" id="Fact-E7F4CA6C6CD248480B2BBD1C00E95502">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q2YTD" id="Fact-83D05582B4FAC1E44508BD1C00EB9251">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q3SD" decimals="INF" id="Fact-743821A426EF868A31F1BD1C00E8F980" unitRef="shares">213968953</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2016Q2YTD" id="Fact-C587CCAC2FBA89AF21E8BD1C00EA560C">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2016Q2YTD" id="Fact-1F05AA66EFE849F7CC68BD1C00E8FDEF">Galena Biopharma, Inc.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2016Q2YTD" id="Fact-C14FF5F407B01CF67CBBBD1C00EA4DE5">GALE</dei:TradingSymbol>
	<gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds contextRef="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-6" id="Fact-133D3699CD3EA183EDC1BD1C007D4FCC" unitRef="usd">20000000</gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds>
	<gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds contextRef="FI2015Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="2" id="Fact-DBFF7E3B5C004D4C42DDBD1C00A44218" unitRef="number">0.03</gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2015Q2YTD" decimals="-3" id="Fact-F07A4E9A9971229299FCBD1C00CEE4F1" unitRef="usd">-3115000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4AD42429D49CB8CA2393BD1C00D4EE25" unitRef="usd">10520000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2015Q2YTD" decimals="-3" id="Fact-DE09E0C5D184DF004F81BD1C00E77ECD" unitRef="usd">-238000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2016Q2YTD" decimals="-3" id="Fact-62226E7E60D41758A80BBD1C00A94298" unitRef="usd">5327000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q2QTD" decimals="-3" id="Fact-CAECB0A14B0ED34D3F3770BA9024C356" unitRef="usd">83000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D5D065F955378E55BFDD70BA9033CF6D" unitRef="usd">-238000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2016Q2QTD" decimals="-3" id="Fact-43DB04A0A2335D143C7A70BA90162F1D" unitRef="usd">5497000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F32A1F81F4F79BBA7BC570BA902C4686" unitRef="usd">5327000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2016Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-C6A47920CD49DF26DB5DBD1C00957FCB" unitRef="usd">-5327000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-FAA63B2B74E687B45ECCBD1C008BC3A4" unitRef="usd">-10520000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A6EF7C0804E4AD6CA0CDBD1C009080F6" unitRef="usd">-184000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-E193BA39D5CC9301887FBD1C0085A080" unitRef="usd">-909000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-BAF509978A4D96108335BD1C00867F20" unitRef="usd">-1515000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-736921BCB236E44DD41DBD1C00BC2993" unitRef="usd">-96000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-E6075029CDDFC68803DDBD1C00BE0942" unitRef="usd">-6668000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-4B705F6D1F4BED7EEF78BD1C00BE7D07" unitRef="usd">-1148000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2CF42B81D7C340CC67E3BD1C00AB8494" unitRef="shares">502000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-EB01B4D2E886A68BB206BD1C0090D06F" unitRef="shares">502000</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-41C117A21904739D1862BD1C00ED6593" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-BBA189DA6833D2B5EB5FBD1C00CA25E5" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-AB54350BA2C341D48384BD1C00EB30CC" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-6EF5B13AE7D4E9AF0522BD1C00ED4F7F" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantOrRightExercised contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-89C2C921291B40046D0ABD1C00739DA9" unitRef="shares">0</gale:ClassOfWarrantOrRightExercised>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-86D48C4591490E0227E9BD1C00932BFA">2020-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-9F98F0F22BE205394450BD1C008D32D4">2014-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-B02341CBD9BE3C229E81BD1C008210B7">2017-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" id="Fact-D5073B44A51617967E90BD1C00EC65FB">2021-01-12</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-17F26602C580BB5DD794BD1C00A5510F">2020-03-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-9A9AF740C7BB649326E8BD1C00E8064C">2018-09-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice contextRef="D2013Q2MAY8" id="Fact-EE7020C1E4BC7D62C3DABD1C00EC10A5">P20D</gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice>
	<gale:ClassofWarrantorRightExercisePeriod contextRef="D2016Q3Jul13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-BCA808C7D275B034CD585B2CDB634D94">P5Y</gale:ClassofWarrantorRightExercisePeriod>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-AC8FA941631E9CEB8D175B6B6BE9621C" unitRef="shares">31000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-4BE86F33546706F2835A5B6B6B0F6C2C" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-9A85AB71D04ED8F2B7365B6C2B79F590" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q2YTD" decimals="-3" id="Fact-7550BB0B23B2496F71E3BD1C00A213B8" unitRef="shares">31000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-434FDCF86B418505E0D9BD1C00E54D85" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-E3E72FD6AE4997CAFC265B6B67990C6D" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-5507497919AE862E79355B6B688904BB" unitRef="shares">0</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F6FA06AF9E0D2F73F54BBD1C00869EFB" unitRef="shares">15643000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-654D7C218A0658D060D2BD1C00A73DE9" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-3918974B276EE76ED2CFBD1C00A3394D" unitRef="shares">2000000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-6E029E151B356DCBD5D6BD1C009F6D17" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-BA82ADFF2B34B01FF9B5BD1C00AC60BD" unitRef="shares">13643000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-19011D264C34C1D58255BD1C0084B535" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-14DFE79D8696C6FE83CBBD1C0074D863" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightIssuedDuringPeriod contextRef="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-1CA0AE540B710D9971E95B28B77F18AF" unitRef="shares">14000000</gale:ClassofWarrantorRightIssuedDuringPeriod>
	<gale:ClassofWarrantorRightTerm contextRef="D2013Q2MAY8" id="Fact-334478949521FE11EC82BD1C00F9782D">P7Y</gale:ClassofWarrantorRightTerm>
	<gale:ClassofWarrantorRightTerm contextRef="D2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-7844624FBEE85E52D773BD1C00C361F6">P5Y</gale:ClassofWarrantorRightTerm>
	<gale:ClosingPriceOfCommonStock contextRef="FI2016Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="2" id="Fact-7426C18DF6826BD1F2B0BD1C00F39040" unitRef="usdPerShare">0.47</gale:ClosingPriceOfCommonStock>
	<gale:CommonStockAdditionalSharesAuthorized contextRef="I2016Q3Jul142016" decimals="INF" id="Fact-41ED6FDD02EE685CBD1658EF7E751D06" unitRef="shares">75000000</gale:CommonStockAdditionalSharesAuthorized>
	<gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan contextRef="FI2016Q2" decimals="-3" id="Fact-9DF5B89E5156D036E333BD1C0060B801" unitRef="shares">461000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2015Q4" decimals="-3" id="Fact-686928A548F47D9C9A9CBD1C0078BCA7" unitRef="usd">6142000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2016Q2" decimals="-3" id="Fact-DC1391B4E39D5F12B9DBBD1C0092105B" unitRef="usd">815000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2015Q4" decimals="-3" id="Fact-4586ED9EDA1A39A1D837BD1C00B4A18D" unitRef="usd">3294000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2016Q2" decimals="-3" id="Fact-907D2855A46886904E6ABD1C006883ED" unitRef="usd">3208000</gale:ContractResearchPayable>
	<gale:DebtInstrumentCashFacilityFee contextRef="I2013Q2May8" decimals="INF" id="Fact-0693DDD08407FD943E6BBD1C00E7D9DA" unitRef="number">0.01</gale:DebtInstrumentCashFacilityFee>
	<gale:DebtInstrumentCashFinalPayment contextRef="I2013Q2May8" decimals="INF" id="Fact-EC04EAE5A3E36B308E5EBD1C00E3A555" unitRef="number">0.055</gale:DebtInstrumentCashFinalPayment>
	<gale:DebtInstrumentCovenantLiquidityCovenant contextRef="I2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-94B4F7F75C49FD97738FBD1C00E503AF" unitRef="usd">24000000</gale:DebtInstrumentCovenantLiquidityCovenant>
	<gale:DebtInstrumentPlacementAgentFeePercentofFundsReceived contextRef="D2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-9CDFDF853EBF6513281EBD1C007FD0C3" unitRef="number">0.02</gale:DebtInstrumentPlacementAgentFeePercentofFundsReceived>
	<gale:DebtInstrumentPrincipalThatCouldBeRedeemed contextRef="I2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-BC94AE519F76B4046987BD1C00E15FF3" unitRef="usd">1100000</gale:DebtInstrumentPrincipalThatCouldBeRedeemed>
	<gale:DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="3" id="Fact-533FD53FCEE74420C2235B84866B4A09" unitRef="number">0.075</gale:DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate>
	<gale:DebtInstrumentRedemptionNumberofDaysMaximum contextRef="D2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-30DCB02E9E96088E2D7556B4E73A8523" unitRef="day">3</gale:DebtInstrumentRedemptionNumberofDaysMaximum>
	<gale:DebtInstrumentRestrictionofFundsPeriod contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" id="Fact-13CE3E3C5167A0024D3B56A40BFA40F5">P75D</gale:DebtInstrumentRestrictionofFundsPeriod>
	<gale:DebtInstrumentTermInterestOnly contextRef="D2013Q2MAY8" id="Fact-2AE80BDD32FB21D9244FBD1C00C2409B">P12M</gale:DebtInstrumentTermInterestOnly>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2015Q4" decimals="-3" id="Fact-F9191A120FAB3273519FBD1C00723550" unitRef="usd">-279383000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2016Q2" decimals="-3" id="Fact-23E65D269805AEE91E1CBD1C007D5025" unitRef="usd">-290487000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DentInstrumentOriginalIssueDiscountPercent contextRef="I2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="5" id="Fact-7DBEA7C9B1C11D1E0F0DBD1C00706ED1" unitRef="number">0.06375</gale:DentInstrumentOriginalIssueDiscountPercent>
	<gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B6E7822A34E3C0785088589743818160" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations>
	<gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FFE045CD31CBE967214FBD1C006076FA" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations>
	<gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-A5598FE477535F24A1935897401D2CB6" unitRef="usd">656000</gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations>
	<gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-621558160CC6CBBB04D5BD1C00D5E5DA" unitRef="usd">1666000</gale:DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations>
	<gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet contextRef="D2015Q4Dec24_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_ZuplenzMember" decimals="-3" id="Fact-266153426006BCBD5208BD1C00FB9FE4" unitRef="usd">2700000</gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet>
	<gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet contextRef="D2015Q4Nov19_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralMember" decimals="-3" id="Fact-BFDD009ACEBE5ACF5E93BD1C00FAE490" unitRef="usd">7533000</gale:DisposalGroupIncludingDiscontinuedOperationConsiderationNet>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-6B30AE79DC4626EC541EBD1C00DFA27F" unitRef="usd">900000</gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-D1C0FCCF0EAD84CB5C30BD1C00DEE8F3" unitRef="number">0.05</gale:DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-A5610B41EA857599DD57BD1C00DE12CB" unitRef="usd">352000</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees>
	<gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="INF" id="Fact-407AB116DA3E614C22CEBD1C00DF0109" unitRef="number">0.03</gale:DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-B5964C06F709E0CA693FBD1C00A33CA0" unitRef="usd">94000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0DE8E2C98B51A1568AFEBD1C00E4D63A" unitRef="usd">179000</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-43314C7DF70C4597D40ABD1C00F6C59A" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FE3087B216001A8F4860BD1C007529F3" unitRef="usd">0</gale:DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment>
	<gale:DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralandZuplenzMember" decimals="INF" id="Fact-AC0C393E8EB13E382A34BD1C00E08F43" unitRef="usd">30000000</gale:DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments>
	<gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="D2015Q4Dec24_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_ZuplenzMember" decimals="-3" id="Fact-940002E7864E60BE64D5BD1C005F4F8E" unitRef="usd">1050000</gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
	<gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="D2015Q4Nov19_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralMember" decimals="-3" id="Fact-7B49D01DDF5837F25405BD1C00688BA4" unitRef="usd">815000</gale:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EFE86980A7E2D2EECFF1BD1C00F7BA5F" unitRef="usd">3755000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2016Q2YTD" id="Fact-634AB63E611C1CB534B3BD1C00F3086E">P2Y9M15D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees contextRef="FD2016Q2YTD" decimals="2" id="Fact-1F6679F422D9EEA33600BD1C00F9462F" unitRef="number">0.15</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement contextRef="FD2016Q2YTD" decimals="2" id="Fact-710BCD5768068BF88F08BD1C00F60ACB" unitRef="number">0.08</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-6FCB9EBCC940A5C3B269BD1C00B6C554">P1Y3M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-8D687CDFF24EA000C724BD1C00A92CC2">P1Y11M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-BD0CCEF1DFB35345B37FBD1C00A990B4">P2M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-2C6C157E5461FCAEFDADBD1C00B2BCE3">P4Y2M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-D9D4B36ECBE47D9B7F64BD1C00AC6C6F">P1Y</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-80F2495E8C9B6C52C2C1BD1C00AB8F91">P2Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-0756B2E8FDE042305140BD1C00F3708E">P9M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-61DAFA840D640A262185BD1C00F2D849">P1Y5M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" id="Fact-1CCDCAF580EC68BBFA76BD1C00DC5383">P4Y6M7D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-532BF82509CD76B8779DBD1C00F1C6DF">P3Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-1E879D07F03D8D0E1ED7BD1C00EE4BDA">P3M</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-027DF02711CF52876CC3BD1C00B7D7D7">P2Y2M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-BB7C8A23EEC752F7F19DBD1C00853942" unitRef="usd">324000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-FAF868D36D4203B9EF08BD1C00BDCE1E" unitRef="usd">278000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-061324CE5137CBB6F49DBD1C00BD63A4" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-19DDD4C3B9B1F1B00CE5BD1C008C82C3" unitRef="usd">46000</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-2292F1343ADB67AEF2AEBD1C008E5C9B" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-92A9D6D146EAD77030DCBD1C0087277B" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsExercised contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-680B880A1893B113437FBD1C00824EF4" unitRef="usd">0</gale:FairValueOfWarrantsExercised>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D4402D2626325DABA7DBBD1C00D0CA75" unitRef="usd">10296000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2016Q2YTD" decimals="-3" id="Fact-858E69569D26A5003867BD1C009DBD6B" unitRef="usd">5590000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-C9F0F82C261AED35783DBD1C0092A677" unitRef="usd">14518000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A9CF88AA14860C13B58EBD1C0085F42D" unitRef="usd">537000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-6BD3A1E1AEA2449706B1BD1C00897F83" unitRef="usd">1565000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-CEB4FB5A0BAB2646ED5EBD1C008C5623" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6B8CD90678F70D2F490CBD1C00BF4B6C" unitRef="usd">146000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-C5C8ADC31CB0C4D0F6ADBD1C0083582C" unitRef="usd">10337000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-EC8353DBFA10E966AFCDBD1C00916D79" unitRef="usd">1933000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2" decimals="-3" id="Fact-394136BAA3DBF6E0E5BCBD1C008D4EA9" unitRef="usd">9264000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-B0E7C29ECE4770AEEFB8BD1C008D7A25" unitRef="usd">75000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-3A81D3308484E2AE9C4BBD1C00891589" unitRef="usd">656000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-16EC14C1960B0B92BB63BD1C00818910" unitRef="usd">4075000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-F79AC24CE5D9C0EEBBC1BD1C0088B82D" unitRef="usd">4000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-F4F8DF2DF78C26AE080FBD1C00BA0EB8" unitRef="usd">3669000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-43A0A113C367F6C603FDBD1C00BB3B93" unitRef="usd">785000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4" decimals="-3" id="Fact-CA3F064EBEDE4FF28893BD1C00991733" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-989D8D8583E69D452587BD1C00A43232" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-946733D03E11F2901CF8BD1C00745035" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A394C1B4FA989421515DBD1C00CE4729" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1C478BE1E4B7914667C6BD1C00B3BA21" unitRef="usd">14518000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q2" decimals="-3" id="Fact-B63D66566657179188CBBD1C008E53E1" unitRef="usd">9264000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D0FEC3FB4B9F0A752663BD1C00FBB0DD" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-844D497AD0B47DC581B0BD1C00C10A1B" unitRef="usd">9264000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8DFDF38CD5565BB004E1BD1C009D132F" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-330576DC0AE9DB1BBB37BD1C00916784" unitRef="usd">9264000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD" decimals="-3" id="Fact-84FD587EA2AB68315477BD1C008724A1" unitRef="usd">5590000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-5B407382783588B1B53C58E5178F6D9A" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-1D7E79C1328C04E8A25158E5171083B4" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-1F8B8BCC8527C3DA56BBBD1C008C942A" unitRef="usd">5590000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-8D5466C75110C759D6B058E518111060" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-41A7B270D7BC7E3613DCBD1C0082839B" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2016Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-669AF6E11A407B3C0757BD1C008376DC" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2013Q2May8" decimals="2" id="Fact-A2661C6672F1E4C90CCCBD1C00F0E231" unitRef="usdPerShare">0.87</gale:FairValueofWarrantsGrantedperShare>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-863C643C3D50C1209C7B5B4C700A87E9" unitRef="usdPerShare">0.27</gale:FairValueofWarrantsGrantedperShare>
	<gale:GALE401rights contextRef="FI2015Q4" decimals="-3" id="Fact-74CDAA98AFF0D58AEDE3BD1C007849BA" unitRef="usd">9255000</gale:GALE401rights>
	<gale:GALE401rights contextRef="FI2016Q2" decimals="-3" id="Fact-2E0B6369490F5A425C00BD1C00AE5187" unitRef="usd">9255000</gale:GALE401rights>
	<gale:InProcessResearchDevelopment contextRef="FI2015Q4" decimals="-3" id="Fact-06C61F56A54DE15790E1BD1C0079A10B" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2016Q2" decimals="-3" id="Fact-05DE6E24D48286FB995ABD1C007921A3" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:IncreaseDecreaseinRestrictedCashforFinancingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-895CEA19E88E96E38AAB51C8A5474D0A" unitRef="usd">0</gale:IncreaseDecreaseinRestrictedCashforFinancingActivities>
	<gale:IncreaseDecreaseinRestrictedCashforFinancingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-8D8AE0B7A8DF573550B151C8A53B48E6" unitRef="usd">24000000</gale:IncreaseDecreaseinRestrictedCashforFinancingActivities>
	<gale:IssuanceofCommonStockforLitigationSettlement contextRef="D2016Q2Jun_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-3" id="Fact-794463BBFEE090122605BD1C008B5D68" unitRef="usd">2650000</gale:IssuanceofCommonStockforLitigationSettlement>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-375DB779292EE7F4DDA258802EAA4606" unitRef="shares">480053</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-82BAFB8A7ADE08E85B2B5B918FDBF4D7" unitRef="shares">291262</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockShares contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-AC8FB62A4B6DDDA2107C5B9208BFF1EC" unitRef="shares">3366750</gale:LitigationSettlementIssuanceofCommonStockShares>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q2Jun_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-B318F65EEF1091F6B4C7BD1C008111F9" unitRef="usd">1000000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q3Jul06_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-3189AB53C147194778B7587C5A8E7B9F" unitRef="usd">1000000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-3" id="Fact-3B9355F88FA973932F855B917BB00AC0" unitRef="usd">150000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LitigationSettlementIssuanceofCommonStockValue contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase2Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-84275132EFF46E308A4E5B921FE094D4" unitRef="usd">1500000</gale:LitigationSettlementIssuanceofCommonStockValue>
	<gale:LossOnWarrantExchange contextRef="FD2015Q2QTD" decimals="-3" id="Fact-732392050A4133D393E1BD1C0068CD43" unitRef="usd">4267000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D7937E3C96EF3C7F9193BD1C006938B5" unitRef="usd">3115000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2016Q2QTD" decimals="-3" id="Fact-5B766F89DE5AF8031028BD1C00D5126E" unitRef="usd">-14392000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2016Q2YTD" decimals="-3" id="Fact-2EB45E3CF3CD9759FBD1BD1C006A3F07" unitRef="usd">-10520000</gale:LossOnWarrantExchange>
	<gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents contextRef="FD2015Q2QTD" id="Fact-D2B3068CC53EA957F356BD1C00A70869">P90D</gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2015Q2YTD" decimals="-3" id="Fact-676300925DE07DE8B284BD1C0088F33E" unitRef="usd">0</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2016Q2YTD" decimals="-3" id="Fact-994FBAFD163B7C603F0CBD1C0071E071" unitRef="usd">233000</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NumberofSharesPerUnit contextRef="I2015Q1Mar18" decimals="INF" id="Fact-1FF6EB98EF630E05802BBD1C009405DE" unitRef="shares">0.50</gale:NumberofSharesPerUnit>
	<gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan contextRef="FI2016Q2" decimals="-3" id="Fact-E8558A64647A41D7D025BD1C008CEEF1" unitRef="shares">10923000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
	<gale:PaymentsforLegalSettlementsPaidbyInsurance contextRef="D2016Q3Jul01_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-5DAB28EDCB5156966F83579523AA841E" unitRef="usd">16700000</gale:PaymentsforLegalSettlementsPaidbyInsurance>
	<gale:PaymentsforLegalSettlementsPaidbyInsurance contextRef="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" decimals="-5" id="Fact-13425FCF42C00B4DD9CFBD1C00838678" unitRef="usd">21700000</gale:PaymentsforLegalSettlementsPaidbyInsurance>
	<gale:PaymentsonDisposalofProductiveAssets contextRef="FD2016Q2YTD" decimals="-3" id="Fact-444B35FFFD97BB36A142BD1C009E41D2" unitRef="usd">1050000</gale:PaymentsonDisposalofProductiveAssets>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Apr10" decimals="-5" id="Fact-936A2E217AD57A128FFEBD1C00A67AA0" unitRef="usd">5400000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Mar18ToApr10" decimals="-5" id="Fact-7AB435970ED2BFE93F96BD1C00A60124" unitRef="usd">40800000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2016Q1Jan12" decimals="-5" id="Fact-30DE56C654E843F2ED11BD1C007D1318" unitRef="usd">20200000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:PurchaseAgreementConsiderationReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-4" id="Fact-F5770D95F44F595FDB35BD1C00D270D4" unitRef="usd">29750000</gale:PurchaseAgreementConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementConsiderationReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-7F1C2713A6778450CEA4BD1C00D52D88" unitRef="usd">12000000</gale:PurchaseAgreementConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-6" id="Fact-D037D248FBBD8ECD0BCBBD1C00E15FFC" unitRef="usd">26000000</gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-A323CEA3E1A0A3BF4D3FBD1C00D456DA" unitRef="usd">4000000</gale:PurchaseAgreementContingentConsiderationReceivableUnderAgreement>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-6" id="Fact-F4C3AD110A54E45407E9BD1C00D20ECE" unitRef="usd">70000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-6" id="Fact-45FAB350E54AB3C2754EBD1C00D85873" unitRef="usd">12000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-755CE8257D8C5CD0B070BD1C0067B874" unitRef="usd">35000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementContingentConsiderationThresholdNetSales contextRef="D2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-DCC6CA6E5EA4F0C7040FBD1C00EC5D74" unitRef="usd">25000000</gale:PurchaseAgreementContingentConsiderationThresholdNetSales>
	<gale:PurchaseAgreementPaymentofUpfrontFee contextRef="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember" decimals="0" id="Fact-378E7442C2E3D5A10F20BD1C00CB84C0" unitRef="usd">900000</gale:PurchaseAgreementPaymentofUpfrontFee>
	<gale:PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived contextRef="D2016Q4Dec16_us-gaap_CounterpartyNameAxis_gale_MonosolRxLLCMember" decimals="2" id="Fact-A01C62F9B967009E4FC8BD1C00DBF556" unitRef="number">0.20</gale:PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived>
	<gale:PurchaseAgreementTerm contextRef="D2014Q4Nov18" id="Fact-0A8B3613E8C2D18C883EBD1C00A59C6F">P36M</gale:PurchaseAgreementTerm>
	<gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement contextRef="I2015Q4Dec24_us-gaap_CounterpartyNameAxis_gale_MidatechPharmaPLCMember" decimals="-4" id="Fact-7092DA3E888E0969C6A7BD1C006A8F74" unitRef="usd">3750000</gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement>
	<gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement contextRef="I2015Q4Nov19_us-gaap_CounterpartyNameAxis_gale_SentynlTherapeuticsInc.Member" decimals="INF" id="Fact-8E013DC5B096AB148F7DBD1C00646A6D" unitRef="usd">8000000</gale:PurchaseAgreementUpfrontPaymentReceivableUnderAgreement>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D380AEA9127D379176A8BD1C00D6DA6E" unitRef="usd">0</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2016Q2YTD" decimals="-3" id="Fact-69DEEC145BC214B7BC2CBD1C00A0A5F4" unitRef="usd">324000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:SaleOfStockMaximumConsiderationReceivedPerTransaction contextRef="D2016Q3Aug8_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-0CB2BA048C007381ED626BB7B6D7E4F9" unitRef="usd">2000000</gale:SaleOfStockMaximumConsiderationReceivedPerTransaction>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue contextRef="FD2016Q2YTD" decimals="-3" id="Fact-AA96E78A1CE1A61255E5BD1C00E76D43" unitRef="usd">0</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue contextRef="FD2016Q2YTD" id="Fact-8606EE88B605D388B646BD1C00E5D8B1" unitRef="usd" xsi:nil="true" />
	<gale:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="INF" id="Fact-6756DAEBAA3360C1ADD65790F5B12BCF" unitRef="shares">1200000</gale:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod>
	<gale:StockAvailableforIssuanceSharesNewIssues contextRef="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-1BAB7DB8B20058181C1BBD1C007BE6F3" unitRef="shares">2965909</gale:StockAvailableforIssuanceSharesNewIssues>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q1Mar18" decimals="INF" id="Fact-E4750E5BC274477A5B50BD1C006D430A" unitRef="shares">1826923</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q2Apr10" decimals="INF" id="Fact-EF0943470B82BE4B5A33BD1C007C25CF" unitRef="shares">3653846</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-6BF42067EE2F320F2850BD1C00AF17DE" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-24E4AE4C4AE71D1A4286BD1C00AEFF2E" unitRef="usdPerShare">1.83</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-142FCDD24685142ADB9ABD1C00B16CF5" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-2B43A5D69C43686B306CBD1C00A4A8E3" unitRef="usdPerShare">2.08</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-9B2CE7C1EDA13D940705BD1C00AEB42D" unitRef="usdPerShare">2.02</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-3917B941D8FCDD7DBFEDBD1C00AAD714" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-1FCF848A4EC14FD32F47BD1C00F55AF7" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-4C7787D58223351E6A53BD1C00F195DD" unitRef="usdPerShare">1.75</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="2" id="Fact-721CC129C419EB5B2AAEBD1C00EF3F31" unitRef="usdPerShare">1.42</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-BDF0639178113594C86DBD1C00F21EA8" unitRef="usdPerShare">2.08</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-6D1904719AE16BA0E680BD1C00ED5475" unitRef="usdPerShare">1.92</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-53589673D00BD0F155A9BD1C00EE0DC4" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-3AB9114591159ADBCC7CBD1C00ABDE19" unitRef="number">0.6560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-EA2478DB403EF174A051BD1C00AC7D60" unitRef="number">0.7637</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-29950A66CAAB2A55FB7EBD1C00AD1801" unitRef="number">0.4798</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-C420640D563D4049AD1EBD1C00B148E0" unitRef="number">0.7585</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-6A94D7FC0239012AACF6BD1C00AB6F30" unitRef="number">0.7141</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-2AECD036C9C30ABF787BBD1C00A8138B" unitRef="number">0.7470</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-B975BBDC4889BFA9D35DBD1C00F0774E" unitRef="number">2.1893</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-24DC07E8C77AA1381789BD1C00EFDD13" unitRef="number">1.6741</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="4" id="Fact-7D8C14A5F360350CDD71BD1C00B5ABC4" unitRef="number">1.1370</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-EA3D61773DEB336C8BC5BD1C00EE2E47" unitRef="number">1.2236</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-D67B9D25305FCBFEE900BD1C00EFE54C" unitRef="number">2.1893</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-505870BEBF57E8D258D7BD1C00ED35C9" unitRef="number">1.3926</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-AADFBC75CE3AEED5C888BD1C00AECA9B" unitRef="number">0.0077</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-61A9D68CC2CD3A9BF4C0BD1C00B2B1C1" unitRef="number">0.0105</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-008F3480F59547EBF68FBD1C00A6FFAC" unitRef="number">0.0000</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-9C0FDD4ED8B3DB77B7F7BD1C00B7C99E" unitRef="number">0.0158</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-AD390242E0403A000C7FBD1C00A5F84E" unitRef="number">0.0000</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-A952CDD52423AFDC11A6BD1C00B00531" unitRef="number">0.0124</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-A9C2C3A517CA04F5D677BD1C00EFAA48" unitRef="number">0.0042</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-F882F0967DF60D657836BD1C00F100CD" unitRef="number">0.0051</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="4" id="Fact-EDFCEEA38532E8C14AECBD1C00B59C53" unitRef="number">0.0094</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-79BA3DEB0CB62CC59DC3BD1C00F2E4D9" unitRef="number">0.0082</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-145FB58E1FA609926A6DBD1C00EFA48C" unitRef="number">0.0019</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-99F57350136365A81B86BD1C00B82165" unitRef="number">0.0061</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsGrantedNumberofShares contextRef="I2013Q2May8" decimals="INF" id="Fact-5D9E3F02ACD84F327022BD1C00F241B8" unitRef="shares">1000000</gale:WarrantsGrantedNumberofShares>
	<gale:WarrantsGrantedNumberofShares contextRef="I2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E13EB6302CBE27B8FC325B4B52BA908D" unitRef="shares">1000000</gale:WarrantsGrantedNumberofShares>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-D57D89B32E256E3A9B29BD1C008939AB" unitRef="usd">1597000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-D15AB6ED811EDEEF2163BD1C006CEBA6" unitRef="usd">1273000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9D96F5623575DBE0D53FBD1C009E3D30" unitRef="usd">5292000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-701662395AC57256F7C2BD1C007522EB" unitRef="usd">4703000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-BF34368DA8C3517D5527BD1C006761F5" unitRef="usd">435000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-E4CC51530862F9EF13BCBD1C0061FA20" unitRef="usd">560000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-FECD208FB2535B42E830BD1C00A2BC58" unitRef="usd">296730000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q2" decimals="-3" id="Fact-BD2A2E3AB032315AEA56BD1C008DD381" unitRef="usd">314639000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D7CF0CB37AD5D146E66FBD1C0091C92D" unitRef="usd">1278000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CB8F00F87EAB2C2B520ABD1C009C9D92" unitRef="usd">1278000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q2YTD" decimals="-3" id="Fact-5C6BAAA9C5B9882F2ECCBD1C009D2EEB" unitRef="usd">5590000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-229E613DCC929DDF5F2C5695B67D1E46" unitRef="usd">1139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8EAEAEF6A14AB278A8E456955CF85C3E" unitRef="usd">1139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3B75D759E67B76B294A3BD1C0095DBEA" unitRef="usd">5590000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-1BC823D121E79E7305A8BD1C008E3D07" unitRef="usd">93000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-9907DB583BF2D2D167BBBD1C0096CE56" unitRef="usd">296000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-94941BA5EC751C50E187BD1C0090539D" unitRef="usd">389000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DC71341A73BA5AAF3795BD1C00A27EA8" unitRef="usd">170000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-7A115F4A39AE23A1E275BD1C00A109B5" unitRef="usd">590000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-0CB86ED91317C7DA19AEBD1C00A104EC" unitRef="usd">760000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DE14D3F23FB485311330BD1C00936E7B" unitRef="usd">108000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-CD82D420C8F8D986AE16BD1C008F174B" unitRef="usd">514000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-955A3241CD37F0A88E11BD1C0096F366" unitRef="usd">622000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3E9F4E94042F8B834B76BD1C00B55EBF" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-41B47DE0137C0A934E9BBD1C00A039CB" unitRef="usd">235000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5103DEF25BDA80F519B7BD1C00A0F796" unitRef="usd">1043000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember" decimals="-3" id="Fact-753CE105EA04B79DA383BD1C00A04F5B" unitRef="usd">1278000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2QTD" decimals="-3" id="Fact-881300278628E2E9AD973867868567B9" unitRef="shares">33719000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0F4D0D40D6935E7C48FC386786A0DCC9" unitRef="shares">11411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-D8A0E59F1FB47352E48F38678677F143" unitRef="shares">22308000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD" decimals="-3" id="Fact-CE7EBEB0C9FA41341ADEBD1C00790DAD" unitRef="shares">33719000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F2EF284E6C35EF52FD80BD1C007989AF" unitRef="shares">11411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-1AADA0A0633A4347F22CBD1C007A24FC" unitRef="shares">22308000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD" decimals="-3" id="Fact-243FDD8E3BCD7C61CB6738678664FEA2" unitRef="shares">27959000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5EA7787EE5DACA5C20173867864A7283" unitRef="shares">6442000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-7A85809877F20FEABCBC38678695ABD2" unitRef="shares">21517000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EC8399CF35B390168895BD1C0077C47A" unitRef="shares">47727000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-311825A46B83DE00A842BD1C007E22F7" unitRef="shares">10309000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-ECD850673A9181A385ABBD1C007AA50C" unitRef="shares">37418000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-326715616D510DE09FF5BD1C00F799B1" unitRef="usd">82144000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q2" decimals="-3" id="Fact-FD9488C2AB5C429E2FD4BD1C0077839F" unitRef="usd">73778000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-E8CA88585D04FB378DFEBD1C0074E99E" unitRef="usd">53621000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-9755A79992D644158879BD1C009584AB" unitRef="usd">45284000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2B405C88CE78D4187BA2BD1C00CDB6B3" unitRef="usd">29171000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E4ADD928ED7F65CA3A0BBD1C00C94F81" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AD6D55DC534EC256B3B0BD1C00C22528" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DECA3DBA937C81529287BD1C00B5E3D9" unitRef="usd">29171000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-39138B3AD515AC45A45FBD1C00B95FB1" unitRef="usd">18169000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-064A42A091711102CBD3BD1C00DE389D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-EB7690B0ED5CA71E1AF7BD1C009F75B9" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1D58C0C016E0D4635138BD1C00F60B62" unitRef="usd">18169000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-397CB2B92F7D99B9B79CBD1C00D99323" unitRef="usd">392000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3ECD0DE3BC3D31C63C8DBD1C00D6BD51" unitRef="usd">83000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-58EA28C613B785155C69BD1C0098BEE0" unitRef="usd">392000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-63CC40941A99BB751E57BD1C007E7BB6" unitRef="usd">83000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-957D39B84EE87A5ABE81BD1C0085FC3C" unitRef="usd">23650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q2" decimals="-3" id="Fact-598C0D6C8DBD89014262BD1C0065D0D0" unitRef="usd">45279000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-2403CD574B84C4BDA0CEBD1C008A4174" unitRef="usd">29730000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-3" id="Fact-835B34019146FDFE0BCCBD1C00959BC4" unitRef="usd">19590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-5" id="Fact-DAFA0A2ACCA8464F93F651D2CD603BE2" unitRef="usd">19600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-75553609E95C0FE5BE99BD1C00AE1140" unitRef="usd">29171000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B4382DC43D01E61CE5A1BD1C00CF7472" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0E55D11CCD077548F72EBD1C00B29E99" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-603477681FCB5AB31CB2BD1C00ADA0DC" unitRef="usd">29171000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AED567C80C7729145578BD1C00C701D0" unitRef="usd">18169000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C40132DB74DAB29DC1C2BD1C00CDCF6E" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-10E838DD23A24F7EFAC3BD1C00B0AADF" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2AA68AF2C1A3165F1213BD1C009610DA" unitRef="usd">18169000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q2YTD" decimals="-3" id="Fact-8D4DA9225617153E27F6BD1C008A7A15" unitRef="usd">21629000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C181EDC2080EE6E1451ABD1C00ECF3FE" unitRef="usd">-10140000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2015Q2YTD" decimals="-3" id="Fact-DBE308B366DDA010068FBD1C00EE3A4A" unitRef="usd">-534000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9312F9BD0A3AA8BF6C35BD1C0064AFC2" unitRef="usd">-1050000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2015Q2YTD" decimals="-3" id="Fact-E696357C436429E584D3BD1C00D60DC1" unitRef="usd">-3980000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BB71792CDB0C15C6C9FABD1C006C4032" unitRef="usd">-7119000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q2May8" decimals="INF" id="Fact-E867725D7AD06EB0D582BD1C00FAD252" unitRef="usdPerShare">2.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q1Mar18" decimals="INF" id="Fact-245EC43DD01ED84C7A0CBD1C006D9BDC" unitRef="usdPerShare">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Jan12" decimals="INF" id="Fact-2AAF3E1229E46622C4BCBD1C00808F7A" unitRef="usdPerShare">1.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2Jun29_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-3AF0E7A641A9992D1AF656C8E17ACAA5" unitRef="usdPerShare">0.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2May10" decimals="INF" id="Fact-79F05BC4FC3E0AF036D6BD1C00F0894A" unitRef="usdPerShare">1.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E1466D56D59078CDC043BD1C007C2B6F" unitRef="usdPerShare">1.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Jul14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-D1CD17DC3EFCA51B64D558B4B04A7303" unitRef="usdPerShare">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-1A02384E3EAD9341C8AE5B4BA528E68E" unitRef="usdPerShare">0.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="I2016Q1Jan12" decimals="INF" id="Fact-35238539E9A18665D08ABD1C0076A257" unitRef="shares">0.60</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-57DD42174456BFC95B63BD1C00FA76C0" unitRef="shares">182186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q1Mar18" decimals="INF" id="Fact-931FEE61C07ADF69050EBD1C0072B6C6" unitRef="shares">1826923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q1Jan12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-891A0BBB8C1C61C2A60ABD1C007E39F6" unitRef="shares">1779545</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-1749F8D91E94FCD4C7B0BD1C00684449" unitRef="shares">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-B3B29CDBC4AD67FBCA0DBD1C00B4F502" unitRef="shares">22308000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-2FAE44620E616A8D1F01BD1C00840553" unitRef="shares">816000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-71F6C68C687E92029CE8BD1C009CB174" unitRef="shares">482000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-3E0357E81DB14A5A7173BD1C00A125F7" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-B91120BFC27A81FA87D5BD1C009D2A23" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-F1BE43750998C00E33B3BD1C00B079B1" unitRef="shares">14006000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-442AC28CEE6BF107BA63BD1C00DF13C0" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2" decimals="-3" id="Fact-7E4CB384E3951853D880BD1C006024CB" unitRef="shares">37418000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-EBE60EB11FD76F26B70EBD1C0086D525" unitRef="shares">283000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-690D9128028B543C23E7BD1C00B0BD2D" unitRef="shares">2482000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-81247ED173D88CA182A9BD1C00766A43" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_JanuaryTwoThousandSixteenWarrantsMember" decimals="-3" id="Fact-743BA56310251AE66DB0BD1C00B45E06" unitRef="shares">13643000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-59EE19818A6CD664AF21BD1C00CB7619" unitRef="shares">14006000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-BA2D57D0E7DC719A5ECDBD1C00612E74" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q2May10_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-2D034808BEF92BBEA30D56CB89E2E165" unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q2May9_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-5E595E2E9D30FC43D211BD1C00FAE60D" unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-7796D2E0B3DFCE522F46BD1C00730DAD" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q2" id="Fact-C8FC27C37519D38F739EBD1C0084FB8A" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q2" decimals="-3" id="Fact-8533FC9A3C88D9CED456BD1C009043A4" unitRef="shares">59111000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2016Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-6653DE4E01CB1782D81C6BB1BC59C2D9" unitRef="shares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheOneMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-6DA3E7AD57E7C3191FAC6BB1BC7099AE" unitRef="shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheTwoMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-5A2DE06F054EF60C97EA6BB22E472771" unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2016Q3Aug8_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-E2C8C51426EE54D7984B6BB1BC50BFD0" unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-446C31702EEF6359C5F3BD1C00BE14BD" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q2" decimals="INF" id="Fact-E7D4D4D1B2E9F7578CE4BD1C00C3CBFC" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-87EAD0FAF11F7DA29180BD1C0088E991" unitRef="shares">275000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q2" decimals="INF" id="Fact-E724BD84859955D72890BD1C00C522B2" unitRef="shares">275000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2015Q1Mar18" decimals="INF" id="Fact-B90781DA36CBC7470B55BD1C00B9E54B" unitRef="shares">3653846</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2016Q3Jul142016" decimals="INF" id="Fact-6C2BD920AE294FCF2D8A58EA8E5880B3" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-EA884D7FA129A793EC74BD1C008B0ECB" unitRef="shares">162581753</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q2" decimals="INF" id="Fact-2D591E1B5AC3D5FFA10EBD1C00C9C347" unitRef="shares">182512117</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-87BADDE9418E4ADD3C2CBD1C00C02625" unitRef="shares">161906753</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q2" decimals="INF" id="Fact-C9EB7CEE272CFE39A908BD1C00C9BA42" unitRef="shares">181837117</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-72AFFDD107D2011CA980BD1C008CE861" unitRef="usd">15000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q2" decimals="-3" id="Fact-89977ABE043259B942DDBD1C009018CD" unitRef="usd">18000</us-gaap:CommonStockValue>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E26712A03C38D0ED3764BD1C00B25512" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0B048636A76B052C757DBD1C008F3BC7" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-00BFB8DFA51CD8B0A6F7BD1C009BBACF" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-41551B7A71F106FB9938BD1C00FB3317" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5518A83E83434F4785DFBD1C00B06FD1" unitRef="usd">6142000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-42D06E7E26C14F92B369BD1C006049D6" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F7F86EA4CA58743C0E3BD1C00C44BE3" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-921BBFE0B73C20631A87BD1C00953DBA" unitRef="usd">815000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-109EAF632D8AADB69153BD1C00F95453" unitRef="usd">815000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2C1B45FF9305871E0509BD1C006013B4" unitRef="usd">815000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q2QTD" decimals="-3" id="Fact-143500D96AD41E7BCC4EBD1C007ED417" unitRef="usd">9083000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A2ED0D5DF351C7A6243CBD1C00C4DCD5" unitRef="usd">17995000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q2QTD" decimals="-3" id="Fact-01F72E3E9DDBF6955777BD1C00A3D6C2" unitRef="usd">9292000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q2YTD" decimals="-3" id="Fact-5247378604F5044388E4BD1C006BABD8" unitRef="usd">18260000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember" decimals="-6" id="Fact-4B406920D7AD9051A96EBD1C00C32D32" unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q2_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember" decimals="INF" id="Fact-218A2C80712B1CD7F637569A1E974CD4" unitRef="usd">25500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-C7E216EBC153ED756910BD1C00E7A73C" unitRef="usd">25530000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q2May8" decimals="INF" id="Fact-1A5D105CEDA9E1953DB1BD1C00F8F839" unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-2C388F3439C71C105C52BD1C00BCD577" unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="3" id="Fact-93D80BBB8BECB8D7E39BBD1C009F97A2" unitRef="number">0.075</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentTerm contextRef="D2013Q2MAY8" id="Fact-87F892D2305F203B93E0BD1C00C7EAFD">P30M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-18B8AF67F0B090AEBA01BD1C00823460" unitRef="usd">5418000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q2" decimals="-3" id="Fact-9574F41A75670E5A8272BD1C008576EA" unitRef="usd">5418000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-DE8797F60E5DD74BAEEDBD1C007B4887" unitRef="usd">171000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2016Q2" decimals="-3" id="Fact-18912F8B384222EBE0B4BD1C00B98D01" unitRef="usd">218000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q2YTD" decimals="-3" id="Fact-E245271DD0023583C067BD1C00F7050D" unitRef="usd">181000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-BA4839FDBD1332B48C19BD1C00B3CCE7" unitRef="usd">20000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q2YTD" decimals="-3" id="Fact-44FE3416ED48812D7BC2BD1C006988AA" unitRef="usd">777000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-34F1DD7300DEAC9C806CBD1C00B66BBA" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-C11AE1B0F677351DA146BD1C00D5720D" unitRef="usd">392000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-EACFCFC8E78573F709C2BD1C00D9C131" unitRef="usd">83000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2659E8BECA6F070767F4BD1C00D3D034" unitRef="usd">1491000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-84DC2F79312527E47EA4BD1C00D3B654" unitRef="usd">1299000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-FBAF6D1FFE43E967B93DBD1C00DAFC43" unitRef="usd">4434000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-72AF1F7B0914F2C378F9BD1C00D94F8B" unitRef="usd">2428000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="I2015Q4Dec24_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_ZuplenzMember" decimals="-3" id="Fact-85BD1DA84C926E07A1F9BD1C00FCFA25" unitRef="usd">3750000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="I2015Q4Nov19_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_AbstralMember" decimals="-3" id="Fact-1BB224CF29D39E9B201ABD1C005E0F67" unitRef="usd">8348000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-9DE9EF3D26F1CA9752A6BD1C009BF860" unitRef="usd">468000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6F7B0514F851E387108CBD1C00D222C2" unitRef="usd">861000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-ADBF4049721A6AE8B7C7BD1C00A11C30" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3C290BCE962948735CD7BD1C00BE2CB0" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-93DE7A82C8AAD21289F9BD1C0083DA59" unitRef="usd">442000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-4909684C126EF8E01439BD1C00CDF8F3" unitRef="usd">588000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E6C603C578BF59B84777BD1C00D28623" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-57627B78BEA353FAB90EBD1C00DB4EB3" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5D524C1A791A96691AE5BD1C0077543F" unitRef="usd">4581000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-4CD19677F76799815630BD1C00DC307D" unitRef="usd">8921000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0E8AAD386C3DAEBA33DDBD1C00CCD7A8" unitRef="usd">2233000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-5" id="Fact-BF8061205F58C519581EBD1C00E03847" unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember_us-gaap_NatureOfExpenseAxis_gale_LegalExpensesMember" decimals="-5" id="Fact-173BBC36ABF3105CC937BD1C00E2D683" unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-5" id="Fact-C06BAD773D6BAE5599CD5897ECE47809" unitRef="usd">4600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-08442D68D4DC0CE1AD95BD1C006317C5" unitRef="usd">4614000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember_us-gaap_NatureOfExpenseAxis_gale_LegalExpensesMember" decimals="-5" id="Fact-9D4A38500179805A3E15589821ECEA02" unitRef="usd">4400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-74639A0D5CAC576928FCBD1C00BFD5D4" unitRef="usd">17000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-81A6DC78FC96FA1F992CBD1C00C38083" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-2A43FD7631876A99E036BD1C00F4D8D3" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-37B49F4F36CF40788B64BD1C00811EA5" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-4E5D006BCC5A87D81D25BD1C00CDE76E" unitRef="usd">3382000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E966D07A9CBDA815C9CBBD1C00CE105F" unitRef="usd">6132000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-CEB109100332289BAB2ABD1C006E8B9D" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0EA24BE2FA951FD8D1D4BD1C00839DE1" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q2QTD" decimals="2" id="Fact-8F0FE2243C76CAA389E7BD1C00CCA812" unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q2YTD" decimals="2" id="Fact-A30B83EA19A6A17120B8BD1C007575FE" unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-5F2480129C1236F9F6B8BD1C0087FDF7" unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2YTD" decimals="2" id="Fact-73D7623B0E743ACA6F59BD1C00C6489D" unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-48288900B2779170AB63BD1C006B148D" unitRef="usd">1535000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-2AE52C807B928F45AE85BD1C00B5C465" unitRef="usd">935000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D6E53C2754A274DC47C9BD1C00A5C1A1" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1B25A6F4A7882CAB6D72BD1C00AF14A1" unitRef="usd">14518000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A75C6400E40E61C2EA5CBD1C00DDDA82" unitRef="usd">6142000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6142379F8C4916ECAC8FBD1C00A6BE7D" unitRef="usd">20660000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A706F6BEA915DDBE9307BD1C00E518D1" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DC68B3B2E57A64CA1CEEBD1C00A8E3DB" unitRef="usd">9264000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6E28DA56A10A90C4D8E1BD1C006CE5E1" unitRef="usd">815000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D91E08414C535F36016DBD1C00E26E90" unitRef="usd">10079000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-063848DD4B1155F8C3A2BD1C00F40006" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="4" id="Fact-FFB650DA7A6DCEEFBDED5B4C541F57C2" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2013Q2MAY8" id="Fact-1AD10F746ED209D45217BD1C00F04761">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" id="Fact-95ACE572CB9278E2FED25B4C1DB63BE3">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-2F567541D574514BC83BBD1C00F1A6E8" unitRef="number">0.7713</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="4" id="Fact-5176AFED51CC84C5F7975B4BEEDB2230" unitRef="number">1.0663</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-3EA4F7B62F0A39BCA18BBD1C00F3EEA2" unitRef="number">0.0126</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q3Jul29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="4" id="Fact-C9C48B75EC49B9BCED575B4C3C21E21F" unitRef="number">0.0135</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-1033FE8D6F50FDB890B7BD1C0072AD0A" unitRef="usd">5898000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q2" decimals="-3" id="Fact-350A3CF3CFDC9FC51E87BD1C00EC5BBC" unitRef="usd">5898000</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E7A87806D7032DA2D515BD1C00AA66F6" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-92F70DD60266370C33D9BD1C00E43447" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-3BE818C4BB411C2347E1BD1C0091B85F" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-5BB48977D4B5A8EA3C7CBD1C007D8A24" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q2QTD" decimals="-3" id="Fact-5C03E72F3C02B56DDF49BD1C00F68AA2" unitRef="usd">-13474000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2F84B2F2DA67B55BB535BD1C0065721A" unitRef="usd">-21780000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q2QTD" decimals="-3" id="Fact-BF2BDD6070C6C6C667A9BD1C00CAADDD" unitRef="usd">8278000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q2YTD" decimals="-3" id="Fact-FF461B02444251B39F92BD1C00C2FBA6" unitRef="usd">-4824000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q2QTD" decimals="2" id="Fact-D128F8BCFD675826E8C7BD1C00D7D942" unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q2YTD" decimals="2" id="Fact-4B4F53850D8F1C51E503BD1C00C19ADE" unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2016Q2QTD" decimals="2" id="Fact-A6A078EAE98CEE9F7F88BD1C0078351C" unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2016Q2YTD" decimals="2" id="Fact-E9DC8F619DBCAD7C8C34BD1C006D482C" unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q2QTD" decimals="-3" id="Fact-40F6BE07F0B966934430BD1C00D87F9A" unitRef="usd">-2186000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-952F0BE20DD05497AECFBD1C00AC9DFA" unitRef="usd">-2186000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q2YTD" decimals="-3" id="Fact-8CC73B57DD7C46BA7D2ABD1C00C6F531" unitRef="usd">-4417000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-0EFE2FB98DF2886F6678BD1C00DA17E9" unitRef="usd">-4417000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2016Q2QTD" decimals="-3" id="Fact-FFB413A5BD32B58DDD94BD1C00CBA2DB" unitRef="usd">-2889000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2016Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-DA003AB9C134C1886893BD1C00C57249" unitRef="usd">-2889000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2016Q2YTD" decimals="-3" id="Fact-2F62AF40B1B7ED12F9E8BD1C006B1DD2" unitRef="usd">-6280000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-6E05E6E8266598C33087BD1C00DD0FAE" unitRef="usd">-6280000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2015Q2QTD" decimals="2" id="Fact-6F190831C69887FE4A90BD1C00C9F986" unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2015Q2YTD" decimals="2" id="Fact-E9CABC99267CB4614645BD1C00C55132" unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2016Q2QTD" decimals="2" id="Fact-89513765455C75189492BD1C00844F2A" unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="FD2016Q2YTD" decimals="2" id="Fact-F858D115F0A5710E593EBD1C00C6C092" unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q2YTD" decimals="-3" id="Fact-9EB85F2B8EF0541425AFBD1C00B29829" unitRef="usd">-825000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0E32784B0B25DC9936A8BD1C00BBF7CD" unitRef="usd">-324000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1E4A9B594ED18AD87FD5BD1C00A434F4" unitRef="usd">-1380000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D09F58AAC068F17241DCBD1C00A1504D" unitRef="usd">-589000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2015Q2YTD" decimals="-3" id="Fact-4C67296B7B1606372AFEBD1C00D11A3C" unitRef="usd">-437000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="FD2016Q2YTD" decimals="-3" id="Fact-794F628F76E1D7199B3BBD1C00A0AB10" unitRef="usd">839000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
	<us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-CB1F9D76CDAF57889D82BD1C00AC0200" unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
	<us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DCE4AF430733A7C3A003BD1C00D75A44" unitRef="usd">-19900000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2015Q2YTD" decimals="-3" id="Fact-FE2068CC33F2ACF1FD91BD1C00F781BC" unitRef="usd">0</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-08DEDD878C7F75CF7E5CBD1C00D43CB2" unitRef="usd">-21700000</us-gaap:IncreaseDecreaseInInsuranceSettlementsReceivable>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q2YTD" decimals="-3" id="Fact-76DC1253AF3AF40195D4BD1C008A5124" unitRef="usd">-256000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A38C2E04925CD9560585BD1C00CE7B8F" unitRef="usd">-141000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2015Q2QTD" decimals="0" id="Fact-1298A5D48919ED75472E58D32DDC47CE" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2015Q2YTD" decimals="0" id="Fact-68DF672457042D1DE4A158D32DB3D599" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2016Q2QTD" decimals="0" id="Fact-399D3FD97F214DC9621758D32DA1D762" unitRef="shares">2765458</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2016Q2YTD" decimals="0" id="Fact-D1D3AFA0F501C868955F58D32E192165" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q2QTD" decimals="0" id="Fact-FB64D91BF7846BC8660B58D949EA6CB0" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q2YTD" decimals="0" id="Fact-A49B52643E4F2B11A1FB58D949E3D5C9" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q2QTD" decimals="0" id="Fact-4EFB09381B5A5ACE5EA958D949E667E8" unitRef="shares">677279</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q2YTD" decimals="0" id="Fact-64B29F0D463DAD45716358D949DE4C2F" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-13215FF058340F98D7EABD1C00714BDD" unitRef="usd">21700000</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InsuranceSettlementsReceivableCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-B97E55C048B16D9D6C49BD1C009280C2" unitRef="usd">0</us-gaap:InsuranceSettlementsReceivableCurrent>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-8A2A8F7197D00957FE44BD1C0066CCD8" unitRef="usd">-207000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q2YTD" decimals="-3" id="Fact-C3D0701E286D358B42EDBD1C00C3E296" unitRef="usd">-432000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-D827BD1A57CDE358CE49BD1C00C4D177" unitRef="usd">-519000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B227EEA172EAB8DED399BD1C00C32C20" unitRef="usd">-611000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestPaid contextRef="FD2015Q2YTD" decimals="-3" id="Fact-0AF08D38F65189065E5BBD1C00941122" unitRef="usd">312000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q2YTD" decimals="-3" id="Fact-139EF2FB23A12AF6764ABD1C00608A68" unitRef="usd">606000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-26C027F572434C571DCBBD1C00B1F261" unitRef="usd">28000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-C03732F6619269A8E149BD1C00AFDACC" unitRef="usd">0</us-gaap:InterestPayableCurrent>
	<us-gaap:LegalFees contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-A2993EA706DEC6690FB956D9A73DBF4D" unitRef="usd">4500000</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-5" id="Fact-AD14C1BEF0BC567FD01C57920A5D0231" unitRef="usd">4500000</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-A75E02A845C598AB6331BD1C007B664C" unitRef="usd">68631000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q2" decimals="-3" id="Fact-987FB1A534AF1CFB84E4BD1C009FE34A" unitRef="usd">53457000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-67CC4647E3DBBB41B23EBD1C009A68A3" unitRef="usd">82144000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q2" decimals="-3" id="Fact-6941BC9333E076429A44BD1C0096CD20" unitRef="usd">73778000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-17A4E173F93C6657299FBD1C00D13984" unitRef="usd">57071000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-70C46B6AB461890F3A9CBD1C0087D971" unitRef="usd">47224000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-432DDE916A02EDEB7D87BD1C00945932" unitRef="usd">5925000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2015Q4_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-F9FA25AA8807A85A0BC8BD1C00DB334D" unitRef="usd">5925000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-1E16006665D140125683BD1C00995D7B" unitRef="usd">3727000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="FI2016Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-951525FB56258F1315BFBD1C00DAE68F" unitRef="usd">3727000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F9BEEE08891D1041191DBD1C009BF67F" unitRef="usd">25000000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationReserveCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-652105DE99BC670123C8BD1C00AA5CE7" unitRef="usd">5100000</us-gaap:LitigationReserveCurrent>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-6" id="Fact-59FEFDB2142555B231815794E2BC388D" unitRef="usd">-20000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q2SD" decimals="-3" id="Fact-96D8C11E8968C18E6284BD1C008BC89A" unitRef="usd">26800000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="D2016Q3Jul31_us-gaap_LitigationCaseAxis_gale_SecuritiesLitigationOptOutSettlementCase1Member_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-3" id="Fact-BCF14C86180EC8E958065B8E4F6DC353" unitRef="usd">-150000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2015Q2QTD" decimals="-3" id="Fact-9D1D4DC7DA81D383ECCA578E85A88F45" unitRef="usd">0</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2015Q2YTD" decimals="-3" id="Fact-EF3DF6C843FC716DDA5E578E88EE823D" unitRef="usd">0</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q2QTD" decimals="-3" id="Fact-8D04BAEF4CDF691A6A42578E84091DD1" unitRef="usd">-1800000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q2YTD" decimals="-3" id="Fact-05E37A25C9952D1682F2578E87494A55" unitRef="usd">-1800000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" decimals="-3" id="Fact-507089EE1CAFD86552A3BD1C008AB7E8" unitRef="usd">-5000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" decimals="-3" id="Fact-6DDA620D1540565112C0BD1C008E4775" unitRef="usd">-20000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q2YTD_us-gaap_LitigationCaseAxis_gale_ShareholdersSecuritiesLitigationMember" decimals="-3" id="Fact-928B702103D3300073CB5B425E22EEF3" unitRef="usd">-1800000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-DBFFD528F3A1AFD3988CBD1C009B26F8" unitRef="usd">4739000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-6C732B5282652A4C6A7FBD1C007A30B2" unitRef="usd">23157000</us-gaap:LongTermDebtCurrent>
	<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="I2016Q3Aug8_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="4" id="Fact-DB9D5B9AD3D38209ADE86BD5DB7598FF" unitRef="number">0.0499</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-84B363EE9DBAB3E34C05BD1C00D57E81" unitRef="usd">45613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EF61203CD6CBEA6DE4F3BD1C00CFDF5E" unitRef="usd">15623000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-C67D7E0B4E4D33025EA5BD1C00CFA83F" unitRef="usd">-568000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EB7D8ED23B9ADBAD1BF1BD1C00D06BCA" unitRef="usd">-1056000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q2YTD" decimals="-3" id="Fact-5CFB34A3D8E354B85688BD1C00D6B49C" unitRef="usd">-34000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B87AC8CC18D82D7F76B9BD1C009AFD47" unitRef="usd">-6000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D3D8DE3F8840EDD09195BD1C00D03F0A" unitRef="usd">-23416000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-3D41AF31EB1262FA5954BD1C009982B3" unitRef="usd">-24707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q2YTD" decimals="-3" id="Fact-FDC6F4646772AC113F00BD1C00CD3D4F" unitRef="usd">-19436000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E7D668498BC358079890BD1C007BA4B2" unitRef="usd">-17588000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-D9FE9C5A2775C4078630BD1C00D728B6" unitRef="usd">-15660000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1CC5E8DDBBE9FA7AA37BBD1C006A6056" unitRef="usd">-26197000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-55D964635014AD36B2FDBD1C00C1E749" unitRef="usd">5389000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9F3858227293354EFBC8BD1C00C27D45" unitRef="usd">-11104000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-26BF3103940C1524A32BBD1C00909E68" unitRef="usd">-11104000</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-400506FE9729351D6B94BD1C00C0E72A" unitRef="usd">-9083000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2YTD" decimals="-3" id="Fact-9B90470BB0895E441A21BD1C006D5DD5" unitRef="usd">-17995000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-8D4A92C309CF406C318BBD1C00A9A19B" unitRef="usd">-9292000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D370F01612189F78E71ABD1C0073E7A9" unitRef="usd">-18260000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-7F99D086EACCBB20411DBD1C00D1EF45" unitRef="usd">-4391000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q2YTD" decimals="-3" id="Fact-B0FA2D983542F7A018FBBD1C00C4C4E1" unitRef="usd">-3785000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-FFC7C3768C221461AC97BD1C00976563" unitRef="usd">17570000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-6E0A180B05619B44AF83BD1C006F45DE" unitRef="usd">13436000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2016Q2Jun_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-3" id="Fact-5AB014B3DA05C68B54A2BD1C008721BD" unitRef="usd">2450000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2016Q3Jul01_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-EA54B732062DB2D939A6BD1C006947C9" unitRef="usd">2300000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-35C801CC09154F7D40F7BD1C00B3BEE1" unitRef="usd">500000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-743943B7A703DECCD747BD1C00B5A388" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2015Q2YTD" decimals="-3" id="Fact-B834A199395D82CE4DF1BD1C00C9CAC4" unitRef="usd">534000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q2YTD" decimals="-3" id="Fact-EABF9E3472F4B88F051EBD1C00D6480B" unitRef="usd">34000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E8099F6CEA169FA905AFBD1C00B4BF96" unitRef="usd">34000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q2YTD" decimals="-3" id="Fact-21195BDDE1C118CE7475BD1C00D881FC" unitRef="usd">6000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-1E02BFA304FF4C6BA06FBD1C00B47162" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-EA95FFD3F37F3991B6CEBD1C00CD675B" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q2" decimals="INF" id="Fact-0AC48EE162980A756146BD1C00C85080" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-EE3CB4007C2A2596CD8EBD1C00CCBC61" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q2" decimals="INF" id="Fact-D26A000B5DA4CE703FDEBD1C00BA53F0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2BC03656D2E7A06F48E5BD1C0074189D" unitRef="usd">1398000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q2" decimals="-3" id="Fact-721A051DC7C1AB98505EBD1C00930B32" unitRef="usd">1210000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="D2016Q2Jun24_us-gaap_LitigationCaseAxis_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" decimals="-6" id="Fact-74D63FE33BE1DA1F5B3256DF3330EC3C" unitRef="usd">15000000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
	<us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-100F9CA2CD3A933F76B8BD1C008CE23D" unitRef="usd">21700000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A5DB923E243F63DB9C6FBD1C005F2C55" unitRef="usd">2000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A22BC3282DE3506A0392BD1C00B621FE" unitRef="usd">49000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q2YTD" decimals="-3" id="Fact-B7423FABAE8BC59B7C24BD1C0089B1A7" unitRef="usd">47416000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0C6ECAACD348AEF5606ABD1C00D4010C" unitRef="usd">20189000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2015Q2YTD" decimals="-3" id="Fact-8CA2A22B57F5FF6B4198BD1C009C8C30" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-605B1FD8AA2D499D56D5BD1C009FB523" unitRef="usd">23641000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="D2016Q2May9_us-gaap_DebtInstrumentAxis_gale_SeniorSecuredDebenturesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-259405F81424588C3965BD1C00694949" unitRef="usd">23400000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="D2016Q3Jul13_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-2B12CD1FABD371F2695E589FC66291AD" unitRef="usd">11700000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-391B8CE6EC8FD9CCBEA5BD1C0062AFF5" unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7A78E3608D21362E4FAABD1C0067B9E0" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q1Mar18" decimals="-6" id="Fact-AD31AAAF1A4AAEA258A8BD1C00615165" unitRef="usd">38000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2EC38EDA9B94619580ECBD1C00BB755E" unitRef="usd">110000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2016Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-5D912AB5C12FA9F41CECBD1C006CFA51" unitRef="usd">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2016Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-B2E756D8A90B949C54F5BD1C00846050" unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2016Q2YTD" decimals="-3" id="Fact-77F941D8CF0233DE7C32BD1C00C88DC7" unitRef="usd">78000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-62B18605ADA01579637FBD1C006C53E0" unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EFFDE300E1ED422BEC01BD1C00DCCC2F" unitRef="usd">261000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-31EB92EFFF77658D19E1BD1C00F225E9" unitRef="usd">335000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q2" decimals="-3" id="Fact-3201EE689CEC90AEAA52BD1C0088E248" unitRef="usd">259000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-A4DB807CF9CB53934762BD1C009A3DE5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-4F3BC302F15505331F0DBD1C00A8786D">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q2YTD" decimals="-3" id="Fact-B88F81B1D4B2B6136289BD1C008919A9" unitRef="usd">1914000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F31AC875BFD95B2A54A3BD1C00E8215B" unitRef="usd">4779000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-EFDA88E13D5701704B87BD1C00C2A7AE" unitRef="usd">7197000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-5FD124645D1F0AE1436CBD1C00704261" unitRef="usd">13022000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-9CF29AB7DEBE86AF20FCBD1C00C64966" unitRef="usd">6175000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4C4BA24F05CFA0283566BD1C006F39F3" unitRef="usd">11618000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-766B890E5729845A723ABD1C009A1728" unitRef="usd">401000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-5" id="Fact-B4C3FA5A89CA14E79A1951D11EBE2DD9" unitRef="usd">24400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-3" id="Fact-D478FB40A0974CD6767BBD1C00D03973" unitRef="usd">24401000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-6" id="Fact-FB008A0B754A238D24E056905E91C883" unitRef="usd">24000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-491F473515DC3922EBFBBD1C00CFA672" unitRef="usd">1886000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-9D54F61BD92302D91FE9BD1C00C5B99C" unitRef="usd">4973000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-2546E52C7963CCBE6990BD1C00611E21" unitRef="usd">3117000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F6989D30FE3ED2656637BD1C0066AB7B" unitRef="usd">6642000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q2YTD" decimals="-3" id="Fact-392D41EE55DD3FED4C01BD1C0086CAFC" unitRef="usd">759000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_gale_CommercialBusinessSegmentMember" decimals="-3" id="Fact-E8AAC3467610B4BB25B3BD1C00B6CB4C" unitRef="usd">512000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-304496A30ABE1B48873FBD1C00636623" unitRef="usd">1278000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2016Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-3EBDC9CFCC64B34250A9BD1C00F8848D">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-C8C443D2684D320F15E0BD1C006B95F7" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-497A302842441728F1EBBD1C00D660F1" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2QTD" decimals="INF" id="Fact-11B3FC9225211782AC25BD1C0061221A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2YTD" decimals="INF" id="Fact-01D996B150E5C7E2168EBD1C00F447E3" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-196C77E4E73B6BD4EBEABD1C0070E899" unitRef="number">0.7332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-471E53E63791A77A88D1BD1C00658BE4" unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q2QTD" decimals="INF" id="Fact-9580BD5F3E3C818B8083BD1C005FA5A4" unitRef="number">0.763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q2YTD" decimals="INF" id="Fact-353F19E7CB85F1EF601FBD1C00862E4C" unitRef="number">0.7563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-03AC3B10F67F42A6DADABD1C006F051D" unitRef="number">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-FE2CB039A5F2B9CD761BBD1C00FCA544" unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2QTD" decimals="INF" id="Fact-CE07C202A21F911FD707BD1C007360A8" unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2YTD" decimals="INF" id="Fact-C3FE3B8D47299E3F7B85BD1C00F386B8" unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2016Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-2552E3E59E0289FF0D56BD1C00F7BCED" unitRef="shares">26500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-2DD55DFB9C0543AE00FFBD1C00F2924C" unitRef="shares">10923000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q2" decimals="-3" id="Fact-435C84F79122FF535007BD1C00E68D8E" unitRef="shares">5970000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q2" decimals="2" id="Fact-23B1B195EC751ADF4A04BD1C00F19A08" unitRef="usdPerShare">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q2YTD" decimals="-3" id="Fact-00E54CB7ABDF7D316C69BD1C00E6B860" unitRef="usd">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D84D1C9BA01C0731A5DEBD1C00E58C66" unitRef="shares">2952000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q2YTD" decimals="-3" id="Fact-875F8ACED844669C0BC8BD1C00E1C1C1" unitRef="shares">166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-488FF6C9001063B8FC22BD1C00F6BEB2" unitRef="shares">10309000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2QTD" decimals="2" id="Fact-33B2DB91C121C2A4DF48589526CFFCD7" unitRef="usdPerShare">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2YTD" decimals="2" id="Fact-2664517EE86F0DE7246EBD1C00F43610" unitRef="usdPerShare">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4" id="Fact-8F7766B9DAEC21BCE0E0BD1C00DE73A3" unitRef="usd" xsi:nil="true" />
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q2" decimals="-3" id="Fact-F6745AFEF3B1E46AE356BD1C00DDFBB2" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="-3" id="Fact-5C26D5DD102E806B48B1BD1C00E744DC" unitRef="shares">13262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q2" decimals="-3" id="Fact-459A4E95315617B2BBEDBD1C008F5A12" unitRef="shares">10309000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-5BE9BAE608ED90622138BD1C00E3D092" unitRef="usdPerShare">2.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q2" decimals="2" id="Fact-9D1625AEC6F859683364BD1C00E5424A" unitRef="usdPerShare">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2016Q2" decimals="-3" id="Fact-43A3F09DB038E3D95C94BD1C00E66CD7" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q2YTD" decimals="2" id="Fact-04306A8BA30EE4EE9458BD1C00E66735" unitRef="usdPerShare">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q2YTD" decimals="2" id="Fact-E8020037D38CE881D34DBD1C00E6AB1A" unitRef="usdPerShare">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q2YTD" decimals="2" id="Fact-3F5DFBB55B209A14271ABD1C00DEE876" unitRef="usdPerShare">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="INF" id="Fact-204864D7CE35865C5D70BD1C007BDA31" unitRef="usdPerShare">2.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q1Mar18" decimals="2" id="Fact-372F33060D81F7F4168FBD1C00B82BFD" unitRef="usdPerShare">1.56</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheOneMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-BDADC3553CECEF35341F6BB775C36598" unitRef="usdPerShare">0.40</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q3Aug8_gale_SaleOfStockTermAxis_gale_SaleOfStockTrancheTwoMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-AB0111FA4AB55CBA1DD36BB78E4E143A" unitRef="usdPerShare">0.75</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2016Q3Aug8_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-11E068FDD247FE8D53BB6BB7A0913BB5" unitRef="usdPerShare">0.50</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2016Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-3EDB67E32D62082E82DFBD1C00F52C8C">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q2QTD" id="Fact-3EEB6A374C0E935DB6A9BD1C00F9BC9B">P5Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q2YTD" id="Fact-F529A201E1E3DB19A7FDBD1C00613DB4">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2QTD" id="Fact-D1916E9B02A51E6BED5ABD1C0062AC6E">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2YTD" id="Fact-C9AE886F29F45E9971E9BD1C00F1A4E1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-A8EF7E423159060B5CD7BD1C00F5E8F7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q2YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-3956058FBEE6F8F7A429BD1C00F592C4">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q2YTD" id="Fact-718AD149106EBA9653C1BD1C00F78D3F">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q1Jan12" decimals="INF" id="Fact-C5D2224D3CC09A77B771BD1C00A51F37" unitRef="usdPerShare">1.10</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2016Q3Jul14_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-0E0D84FA3773890DC9BE58B35185AFCD" unitRef="usdPerShare">0.45</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A6C1AC49976644A4BE84BD1C00B33586" unitRef="shares">162581753</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-19E815B629459661B5D9BD1C009EB0E2" unitRef="shares">182996385</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-65AAAA930C4BECD4F586BD1C009D8CEF" unitRef="shares">408058</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C808A9D4AC2056F3F433BD1C00C6E937" unitRef="shares">67017</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-008C4101727DD70C1C4CBD1C006D5EFC" unitRef="shares">631221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q1Mar18" decimals="INF" id="Fact-8D9A12674339FA1158D1BD1C00B01836" unitRef="shares">24358974</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q1Jan12" decimals="INF" id="Fact-D63EE8CBF1AF20934016BD1C0073ACE1" unitRef="shares">19772727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2016Q3Jul13_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-86C023A488C9A12194BF58A520693B5A" unitRef="shares">28000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-C528FEDE83999BE1349FBD1C0076D96B" unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-D0043CFEEAC1CD1D429BBD1C00621D7D" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-571CACDC27BA1C9F8C42BD1C009D64E6" unitRef="shares">19772727</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-0DCE6714F8A52B931DD5BD1C00D7687B" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q2YTD" decimals="-3" id="Fact-98BEA92F2B456667D208BD1C00E1E0B3" unitRef="shares">167000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B3D4765EE8D7B774CC64BD1C0097D91E" unitRef="shares">166830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-3CFE4A04F621233ED50EBD1C009868A3" unitRef="usd">557000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5D2500995F89C0CCA547BD1C00CE6140" unitRef="usd">557000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FD36CA112E9F62CEDD6CBD1C00C70584" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q2YTD" decimals="-3" id="Fact-ACBBE41D19C9EBBB9B6ABD1C0081B541" unitRef="usd">78000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3430ACBCD72AC75616CDBD1C009C911E" unitRef="usd">78000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2016Q1Jan12" decimals="-5" id="Fact-11D428BF46DAE3A35E4FBD1C007CA1D8" unitRef="usd">21800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q2YTD" decimals="-3" id="Fact-69DA3E01A9540EE307FBBD1C00C96F07" unitRef="usd">20189000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D90B386AA76B245A5E34BD1C00CCFA90" unitRef="usd">20186000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7A461D435B3F7A4B1C53BD1C0093470E" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4FD0A6708DD2D26F8465BD1C00994D12" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8AF756E31DA3C130672DBD1C007AAF5B" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-CB69006B440A6D5419D3BD1C00A2ACF7" unitRef="usd">13513000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q2" decimals="-3" id="Fact-72CA278F07F1060981CABD1C00A39C04" unitRef="usd">20321000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-3" id="Fact-B9D9BB792CFFC77F4F5EBD1C00767395" unitRef="usd">13513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1A1A917C7413BF97F3C1BD1C007F0F4F" unitRef="usd">296730000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F6AF2490049878471ED0BD1C009AF384" unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D07A819A344B9D4D0823BD1C009C92F1" unitRef="usd">-279383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4C072C55129703356263BD1C00946B55" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q2" decimals="-3" id="Fact-7B3FC3DF86E04769178CBD1C00801A04" unitRef="usd">20321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-846482467C140228C739BD1C00CC3EC1" unitRef="usd">314639000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FFF1AAB55CDFC2953E7ABD1C0093B188" unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8CEB78092EFEC188C438BD1C008DC560" unitRef="usd">-290487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-5C886424E1B3E722BB8BBD1C009C16E1" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q4" decimals="INF" id="Fact-7BED58CBD95B44C1B474BD1C00C50721" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q2" decimals="INF" id="Fact-B5732E78DDBB5D71BD51BD1C00CA2F9D" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-883AF6B9D06AD6E5E67CBD1C00E4F551" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q2" decimals="-3" id="Fact-B788CEC807B78E6A86ACBD1C0074F236" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q2QTD" decimals="0" id="Fact-A1C6C46D0351A976337B58DA80819311" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q2YTD" decimals="0" id="Fact-5172A96B134FD00D0B5B58DA808C1452" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q2QTD" decimals="0" id="Fact-C4B9A0C51BF71FA2749658DA8084E33F" unitRef="shares">3442737</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q2YTD" decimals="0" id="Fact-9AEC5CAF2E787A0E342458DA8087D512" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q2QTD" decimals="0" id="Fact-72FCFE6D813EC0CF4DE051A744177D4B" unitRef="shares">161383398</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q2YTD" decimals="0" id="Fact-64FE244C3EDD48F5B5B151A7441E9B15" unitRef="shares">148647581</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2QTD" decimals="0" id="Fact-9141122C5B9A90EA791451A7441AA4F8" unitRef="shares">185477330</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2YTD" decimals="0" id="Fact-2B28C50015592DE31BAE51A74411719D" unitRef="shares">180703456</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q2QTD" decimals="0" id="Fact-5F231633EB5932555A4BBD1C00911681" unitRef="shares">161383398</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q2YTD" decimals="0" id="Fact-5FB2F3B8F9585C29803CBD1C0077BF3A" unitRef="shares">148647581</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2QTD" decimals="0" id="Fact-DA80D3DE8DA99CE47F14BD1C0079952A" unitRef="shares">182034593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2YTD" decimals="0" id="Fact-0FF032752D51DDA63F68BD1C00C5F371" unitRef="shares">180703456</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock contextRef="FD2016Q2YTD" id="Fact-F33BC205CC6892C19A60BD1C00F4A72F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Other Equity Financing Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(1,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(6,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(1,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(10,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
	<gale:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="FD2016Q2YTD" id="Fact-CC1A0AE98F3EF8A78AE1BD1C0070A2E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On March 18, 2015 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;January 2016 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On January 12, 2016 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,772,727&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.42&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,965,909&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,779,545&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,779,545&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The underwriters did not exercise their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,965,909&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expense paid by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;59,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
	<gale:ContingentConsiderationPolicyPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-4F6E29797E5DD45278CABD1C00972549">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ContingentConsiderationPolicyPolicyTextBlock>
	<gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-D1EEEDF90F4EB98ABF19BD1C0098DB2B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
	<gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock contextRef="FD2016Q2YTD" id="Fact-5C4E8E72466571933BB5BD1C00D72B42">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;47,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock>
	<gale:ScheduleOfWarrantActivityTableTableTextBlock contextRef="FD2016Q2YTD" id="Fact-878B1584041FD5CCDF69BD1C00F356E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Other Equity Financing Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants issued to Consultants and Debtors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;13,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;15,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;13,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2016-2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2014-2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock contextRef="FD2016Q2YTD" id="Fact-88097DDC72A42356793BBD1C00F5832F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;113.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;122.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;139.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;167.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;218.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;218.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;74.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;65.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;47.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;71.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2016Q2YTD" id="Fact-3F198705656C24FA9643BD1C00FB7D98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2016Q2YTD" id="Fact-C06D07004EF8E86E43FFBD1C00BDFBA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-19E2629905DB0B2E22FCBD1C00AD6D0C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2016Q2YTD" id="Fact-72C66ABA7730F8C3FB1BBD1C00AB26A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-C5AAD3BB15365AAA08B0BD1C008373EA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;3, 2015, we agreed in principle to resolve and settle the consolidated shareholder derivative action,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, Civil Action No.&amp;#160;3:14-cv-00382-SI, pending in the United States District Court for the District of Oregon against us and certain of our current and former officers and directors. On April 21, 2016, the District Court of Oregon held the final approval hearing of the settlement with the derivative plaintiffs after which the District Court continued the final approval hearing until June 23, 2016 and requested the parties submit additional briefing by June 9, 2016 on the fee request by the derivative plaintiffs&amp;#8217; attorneys.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, granting final approval to the settlement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On the same day, the Court also issued an opinion and order awarding attorney&amp;#8217;s fees of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus costs, which will be paid by our insurance carriers. The settlement includes a payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,200,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December&amp;#160;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Securities Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, Civil Action No.&amp;#160;3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Securities Litigation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&amp;#8217;s fees of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus costs, which is paid out of the settlement funds. The settlement agreement provides for a payment of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; settlement payment to the class, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$16.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; was paid by our insurance carriers and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash was paid by us on July 1, 2016, along with &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of our common stock (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;480,053&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares) paid by us on July 6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits. As of June 30, 2016 our insurance carriers paid &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company paid &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in common stock on July 1, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In July 2016, we have resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; plus &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;291,262&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;) of our common stock, and in another case for &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of our common stock (&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,366,750&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The litigation settlements are summarized as follow as of June 30, 2016 (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Class action settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Derivative settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shareholders securities litigation settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the insurance carriers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the company in cash  (paid in July 2016)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the company in common stock (paid in July 2016)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff to resolve the investigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&amp;#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&amp;#8217; pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&amp;#8217; attorney&amp;#8217;s fees. To our knowledge, we are not a target or subject of that investigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&amp;#8217;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&amp;#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-6FA20DEA9D654AC6790CBD1C00AC12ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q2YTD" id="Fact-A8E0EC17428931A842ECBD1C009B5C8B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company&amp;#8217;s cash equivalents were invested in money market mutual funds. The Company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-62D9D8B3D509F1BBB0EFBD1C00B19B38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-518889C3C5227CC777D4BD1C00C48089">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "Loan"). The Loan payment terms include &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of interest-only payments at the fixed coupon rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8.45%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, followed by &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash facility fee and a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; cash final payment and granted to the lenders &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-year warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,186&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.47&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, which equaled a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On May 10, 2016, the Company entered into a&amp;#160;Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.375%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; original issue discount, a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25,530,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Senior Secured Debentures&amp;#160;(the &amp;#8220;Debentures&amp;#8221;) and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock. Net proceeds to the Company from sale of the&amp;#160;Debentures, after payment of commissions and legal fees, were approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$23,400,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The&amp;#160;Debentures&amp;#160;mature November 10, 2018, accrue interest at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per year, and do not contain any conversion features into shares of our common stock. The Company intends to&amp;#160;use the net proceeds from this offering to fund the costs associated with the close down of the Phase 3 PRESENT study of NeuVax and other clinical trials of our product candidates and to augment its working capital and for general corporate purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Debentures carry an interest only period of six months following which the holder shall have the rights, at its option, to require the Company to redeem up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1,100,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per month of the outstanding principal amount of these Debentures. Interest is payable at the end of each month based on the outstanding principal. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company is required to promptly, but in any event no more than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; trading days after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company&amp;#8217;s election and subject to certain conditions, in shares of the Company's common stock. If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or B) a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; discount to the prior trading day&amp;#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debentures but not less than the monthly payment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Based on the recommendation of the IDMC to stop the PRESENT Trial, the holder has the right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of this Debenture funded in cash by the holder on the closing date, plus all accrued and unpaid interest. If the holder elects such prepayment of the Debentures, then the number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by the Company. The Purchaser received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the closing on the sale of the Debentures at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.51&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, maturing &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years from issuance. Additionally, the Purchasers received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.43&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. As of June 30, 2016 and the date of this filing, the holder had not exercised its right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of the Debentures. The holder's right to require the Company to prepay the outstanding principal amount expires 30 trading days after June 29, 2016, the announcement date of the recommendation of the IDMC. Therefore as of June 30, 2016 the Debentures, net of unamortized discounts, are presented as current liabilities on the condensed consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s obligations under the&amp;#160;Debenture&amp;#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&amp;#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&amp;#160;Debenture in cash. The Company&amp;#8217;s obligations under the&amp;#160;Debentures&amp;#160;are secured under a Security Agreement by a senior lien on all of the Company&amp;#8217;s assets, including all of the Company&amp;#8217;s interests in its consolidated subsidiaries. Until the holder exercises its right to require the Company to prepay some or all of the loan, the Company must also maintain a minimum of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$24.0 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in cash, which is included in restricted cash as of June 30, 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:12pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Armentum Partners, LLC (the &amp;#8220;Placement Agent&amp;#8221;) acted as the&amp;#160;placement agent&amp;#160;in the offering of the&amp;#160;Debentures and the Company agreed to pay the Placement Agent a fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the funds received from the sale of the&amp;#160;Debentures. The Company paid half of the placement fee upon funding with the remaining payable &lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;such time as the IDMC recommended in favor of the continuation of the PRESENT Trial or the holder waives the Company&amp;#8217;s obligation to prepay the Debenture as a result of the IDMC&amp;#8217;s recommendation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q2YTD" id="Fact-F50568E00D019BDDD7ADBD1C00F6EF01">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions ASC&amp;#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted in consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation from continuing operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;73.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The weighted-average fair value of options granted during the three and six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.36&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.86&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company&amp;#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&amp;#160;718-10, which averages the contractual term of the Company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to its employees, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3,755,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.79&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,500,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock were reserved for issuance under the Company&amp;#8217;s 2007 Incentive Plan, including &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the plan. On July 14, 2016, the shareholders approved the 2016 Incentive Plan into which the available shares in the 2007 Incentive Plan were transferred. There are &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,923,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares available for future grants based on adjustments in the 2016 Incentive Plan. The administrator of the plan determines the terms when an option may become exercisable. Vesting periods of options granted to date have not exceeded &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The options will expire, unless previously exercised, no later than &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from the grant date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the Company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The aggregate intrinsic values of outstanding and exercisable options at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were calculated based on the closing price of the Company&amp;#8217;s common stock as reported on The NASDAQ Capital Market on &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.47&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&amp;#8217;s common stock and the exercise price of the underlying options.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-496FBD4CEC0EA8EF94FBBD1C00AB2845">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-24770FE10DB83F4C3B75BD1C00DF34FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Discontinued Operations, Assets Held for Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2015, The Company sold its rights to its commercial products Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets and Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, the Company paid a success fee to the third party firm in an amount of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$900,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and agreed to pay &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of realized future revenue and payment streams. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, the Company paid a retention fee to the three employees in a combined total amount equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$352,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of cash consideration received as upfront payment in the transactions. These employees also received severance payments equal to one month&amp;#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees who were part of the commercial business and did not accept employment opportunities at the companies that purchased Abstral and Zuplenz. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Abstral and related assets on November 19, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Sale of Zuplenz and related assets on December 24, 2015&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net proceeds from sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;8,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Less selling costs*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Proceeds from sale, net of selling costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;7,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*Selling costs related to the sale of Zuplenz and related assets were included in accrued liabilities as of December 31, 2015 and were paid in the first quarter of 2016. All other amounts were received or paid in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$30 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents amounts related to the discontinued operations in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:490px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets of discontinued operations, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:298px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:77px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-operating income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; respectively, in selling, general, and administrative expense in discontinued operations. of which &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:490px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Purchases of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash paid for acquisition of Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-EEE7F624E70966100485BD1C007120A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Income (Loss) Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q2YTD" id="Fact-582715E2EAFFB96FDC36BD1C00F37A18">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Net Income (Loss) Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss) (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(26,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,034,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;161,383,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;180,703,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,647,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;677,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,765,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,442,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;185,477,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;161,383,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;180,703,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,647,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;27,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;47,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q2YTD" id="Fact-FE1E83E6821CB163C228BD1C00BEFDEA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending Level 3 liabilities for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-C7E31029D462E3B57BC1BD1C00C049F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows ASC&amp;#160;820, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, (&amp;#8220;ASC 820&amp;#8221;) for the Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q2YTD" id="Fact-78B89B1A3E2AF69E496FBD1C009E5BE3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-11713DA5FD07D666D1BCBD1C00BF3C1E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company follows ASC&amp;#160;820, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, (&amp;#8220;ASC 820&amp;#8221;) for the Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(5,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Balance at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent purchase price consideration during the quarter ended June 30, 2016 reflects an adjusted probability and time line for the potential approval of NeuVax associated with the Phase 2 combination trial with trastuzumab. Previously, the valuation was measured using the probability and time line of the Phase 3 PRESENT trial, which was stopped in June 2016 due to futility as recommended by the Independent Data Monitoring Committee ("IDMC").&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;See Note 7 for discussion of the Level 2 liabilities relating to warrants accounted for as liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-C9F3F3116367EEB0A0B7BD1C00AA23B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-F1E193D92C756E2FAE70BD1C009807F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and six month periods ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-D590A2AA6504C09BD033BD1C00DB9FF8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance. BioVascular has advised the Company of an alleged breach of the BioVascular agreement which the Company has denied. Both parties are discussing the dispute and it is anticipated that the dispute will be resolved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On November 19, 2015, the Company and Sentynl Therapeutics Inc., a Delaware corporation (&amp;#8220;Sentynl&amp;#8221;), entered into and closed upon an Asset Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (fentanyl) sublingual tablets product (&amp;#8220;Abstral&amp;#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&amp;#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&amp;#8220;Orexo&amp;#8221;)  dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &amp;#8220;Orexo Agreements&amp;#8221;).  The Company&amp;#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. In connection with such assignment, Orexo released the Company from any future obligations under the Orexo Agreements. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities and rebates related to Abstral for a period of time post-closing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The total potential consideration payable to the Company under the Purchase Agreement is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$12 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, comprised of an &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upfront payment and up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, consisting of two one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$35 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 17, 2015, the Company and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&amp;#8220;Midatech&amp;#8221;), entered into an Asset Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film (&amp;#8220;Zuplenz&amp;#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&amp;#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&amp;#8220;MonoSol&amp;#8221;) dated July 17, 2014 (the &amp;#8220;MonoSol License&amp;#8221;).  The Company&amp;#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain rebates and channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The total potential consideration payable to the Company under the Purchase Agreement is &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$29.75 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, comprised of an &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$3.75 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upfront payment upon the closing and up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$26 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$12 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$70 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Through a separate agreement with MonoSol entered into on December 16, 2015 (the &amp;#8220;MonoSol License Amendment&amp;#8221;), (i) the Company and MonoSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company paid MonoSol &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$900,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the upfront fee payable to the Company under the Purchase Agreement and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of any future milestone payments received by the Company under the Purchase Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&amp;#8217;s License and Supply Agreement, dated July 17, 2014 (the &amp;#8220;MonoSol License&amp;#8221;).  As a result of such assignment, Midatech assumed all of the Company&amp;#8217;s obligations under the MonoSol License.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:LegalCostsPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-BE34C85DD8BACEC7986FBD1C00AE6690">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation Settlement Payable and Insurance Recoveries &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-CD9BCABF16D5B9039780BD1C00A9BDA3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Effect of Recent Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation-Stock Compensation &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2016Q2YTD" id="Fact-F62111AECDB32FCBCA47BD1C00F0A706">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following is a summary of warrant activity for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Other Equity Financing Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants issued to Consultants and Debtors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;13,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;15,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Outstanding, June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;13,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2016-2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Varies 2014-2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in January 2016, March 2015, September 2013, December 2012,&amp;#160;April 2011,&amp;#160;March 2011,&amp;#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;113.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;122.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;139.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;167.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;218.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;218.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;74.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;76.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;65.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;47.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;71.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;*The March 2011 warrants expired in March 2016. The March 2010 warrants do not expire until September 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;January 2016 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Other Equity Financing Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;10,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;1,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;537&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;5,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Fair value of warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(1,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(6,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(1,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;(10,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;Warrant liability, June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;3,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Warrants classified as equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Equity-classified warrants consist of warrants issued in connection with consulting services provided to us and warrants issued in connection with debt financings. On May 10, 2016 upon closing on the sale of Debentures, we granted the holder warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.51&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;77.13%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five and five tenths&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk-free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.26%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The fair value of the warrants granted was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.87&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. These warrants are recorded in equity at fair value upon issuance. Additionally, on June &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; upon closing on the public announcement of the interim analysis of the PRESENT trial, we granted the holder warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.43&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;.The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;106.63%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.5&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years, risk-free rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.35%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The fair value of the warrants granted was &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.27&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. These warrants are recorded in equity at fair value upon issuance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2016Q2YTD" id="Fact-C7DDFDF316CE672C6A54BD1C00952554">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt; Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Galena Biopharma, Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. The Company&amp;#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, our novel cancer immunotherapy programs including NeuVax&amp;#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE-401 has completed a Phase 2 trial and we are advancing the asset into a pivotal trial. NeuVax is currently in multiple Phase 2 trials. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We are seeking to build value for shareholders through pursuit of the following objectives:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Developing hematology and oncology assets through clinical development, targeting areas of unmet medical need.  Our hematology asset is targeting the treatment of patients with essential thrombocythemia (ET) to reduce elevated platelet counts&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition of additional development programs.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; or &amp;#8220;our&amp;#8221; refer (i)&amp;#160;to Galena, our wholly owned subsidiaries, Apthera, Inc., or &amp;#8220;Apthera,&amp;#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company&amp;#8217;s capital resources consisted of cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$19.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; not including &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$24.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of restricted cash. The Company will need to continue to incur significant expenses to advance our development portfolio and will need to raise additional capital to finance such activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On July 13, 2016, we closed the sale to certain institutional investors of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock at a purchase price per share of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.45&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;in a registered direct offering, and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock with an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.65&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$11.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. The current unrestricted cash and cash equivalents as of the date of this filing will fund the Company's operations for at least six months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional funding was received July 13, 2016 upon the closing of an underwritten registered direct offering of our common stock and a private placement of warrants for net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$11.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to the Company. Additional funding sources that are, or in certain circumstances may be, available to the Company, include 1) approximately &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$24 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of restricted cash associated with our &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$25.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; sale of Debentures by amending the current agreement with the holder to reduce the minimum cash covenant as detailed in Note 4; 2) a Purchase Agreement with Lincoln Park Capital, LLC; and 3) At Market Issuance Sales Agreements (ATM) with FBR &amp;amp; Co. (formerly MLV &amp;amp; Co. LLC) and Maxim Group LLC. The Purchase Agreement and ATM are unavailable to the Company until &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75 days&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; after the closing of our July 2016 financing. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of the Company's product candidates and to support its other ongoing activities. However, the Company cannot be certain that it will be able to raise additional capital on favorable terms, or at all, which raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Discontinued Operations &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the Company&amp;#8217;s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation Settlement Payable and Insurance Recoveries &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions of the FASB ASC Topic 718, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and six month periods ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, the Company&amp;#8217;s cash equivalents were invested in money market mutual funds. The Company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Effect of Recent Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation-Stock Compensation &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2016Q2YTD" id="Fact-EEF568EB02D674BCEAC1BD1C009EF9D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q2YTD" id="Fact-2AF136FB5FDA581BF404BD1C00A29588">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q2YTD" id="Fact-086A2E85143524A1A21CBD1C009BF035">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q2YTD" id="Fact-BAB75245241F97F19CEABD1C00FBEF79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2016Q2YTD" id="Fact-66B7EB07C82ED86AFC81BD1C00DF404E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents amounts related to the discontinued operations in the balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:490px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of assets included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts receivable, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current assets of discontinued operations, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;392&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Carrying amounts of liabilities included as part of discontinued operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;4,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total current liabilities of discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:298px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:77px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(1,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(861&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amortization of certain acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(8,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Non-operating income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Impairment charge from classification as assets held for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(6,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(4,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; respectively, in selling, general, and administrative expense in discontinued operations. of which &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:490px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Purchases of property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash paid for acquisition of Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q2YTD" id="Fact-E3FF78FEB7D25782656F58CDB1C4714B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Net income (loss) (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(15,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(11,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(26,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;182,034,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;161,383,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;180,703,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,647,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;677,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,765,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,442,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;185,477,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;161,383,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;180,703,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;148,647,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(0.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q2YTD" id="Fact-EF8E50329F6D2B0C8BDCBD1C00F8681A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; and 2015, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total stock-based compensation from continuing operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;389&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2016Q2YTD" id="Fact-174ECE64BD2D090F1715BD1C00BD2D49">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;18,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;9,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;815&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Observable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;29,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;14,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="FD2016Q2YTD" id="Fact-717DD1B601ABA3DA4319BD1C008EEC9A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The litigation settlements are summarized as follow as of June 30, 2016 (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Class action settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Derivative settlement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shareholders securities litigation settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Paid by the insurance carriers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;21,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the company in cash  (paid in July 2016)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Payable by the company in common stock (paid in July 2016)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;26,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2016Q2YTD" id="Fact-797B7077E9020E317CC9BD1C00F81CA5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The following table summarizes option activity of the Company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;13,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;(2,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Outstanding at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options exercisable at June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q2YTD" id="Fact-5BE24B77CF2E147E4693BD1C00F82A20">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;76.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;73.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q2YTD" id="Fact-D6B5F42603DB54248F65BD1C00A3C1D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company follows the provisions of the FASB ASC Topic 718, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q2YTD" id="Fact-C3B61E8ADF3583901BA3BD1C00A33A6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&amp;#8217;s Board of Directors upon its issuance. To date, the Company has not issued any preferred shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The Company has authorized up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;275,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. On July 14, 2016, shareholders approved a &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;75,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; share increase to the Company's authorized shares of common stock up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;350,000,000&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;November 2014 Purchase Agreement with Lincoln Park Capital, LLC - &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in shares of the Company's common stock, subject to certain limitations and conditions over the &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.5 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of the Company's common stock at &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share and the Company issued &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;631,221&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting commissions and other offering expenses. In addition to LPC&amp;#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; from LPC&amp;#8217;s subsequent purchases of a total of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2.7 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock, excluding the commitment fee shares. There were no sales of our common stock under the LPC purchase agreement during the six months ended June 30, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;At Market Issuance Sales Agreements &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with FBR &amp;amp; Co. (formerly MLV &amp;amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of the gross proceeds from the sale of shares, up to a total limit of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in gross proceeds. The ATM is available to the Company until it is terminated by the Agents or the Company. During the first quarter of 2015, we received &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; in net proceeds from the sale of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the six months ended June 30, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On March 18, 2015 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;January 2016 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; - On January 12, 2016 the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;19,772,727&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$21.8 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;0.60&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$1.42&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,965,909&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,779,545&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;1,779,545&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of common stock. The underwriters did not exercise their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;2,965,909&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expense paid by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:8pt;"&gt;As of June&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;37,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;10,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;59,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2016Q2YTD" id="Fact-CC1964D188B908DDEEA8BD1C00968821">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:Helvetica,sans-serif;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gale-20160630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20160630" xmlns:gale="http://www.galenabiopharma.com/20160630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20160630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20160630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20160630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20160630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentation" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationPolicies" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - Business and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.galenabiopharma.com/role/BusinessCombinations">
        <link:definition>2102100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails">
        <link:definition>2402402 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables">
        <link:definition>2302301 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails">
        <link:definition>2416404 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails">
        <link:definition>2416405 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails">
        <link:definition>2416402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails">
        <link:definition>2416403 - Disclosure - Discontinued Operations, Assets Held for Sale - Net Proceeds from Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleNotes" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes">
        <link:definition>2116100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails">
        <link:definition>2416406 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAssetsHeldForSaleTables" roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables">
        <link:definition>2316301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail">
        <link:definition>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesDetailsDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails">
        <link:definition>2408402 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesNotes" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes">
        <link:definition>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails">
        <link:definition>2408403 - Disclosure - Legal Proceedings, Commitments and Contingencies (Schedule of Litigation Settlements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesTables" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables">
        <link:definition>2308301 - Disclosure - Legal Proceedings, Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.galenabiopharma.com/role/LicenseAgreements">
        <link:definition>2114100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail">
        <link:definition>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.galenabiopharma.com/role/LongTermDebt">
        <link:definition>2107100 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails">
        <link:definition>2407401 - Disclosure - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.galenabiopharma.com/role/NetLossPerShare">
        <link:definition>2113100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCommonSharesExcludedFromNetLossDetail" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail">
        <link:definition>2413403 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
        <link:definition>2413402 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables">
        <link:definition>2313301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNotes" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes">
        <link:definition>2112100 - Disclosure - Other Income (Expense) (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTableDetails" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails">
        <link:definition>2412402 - Disclosure - Other Income (Expense) Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTables" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables">
        <link:definition>2312301 - Disclosure - Other Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails">
        <link:definition>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskNotes" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes">
        <link:definition>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables">
        <link:definition>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2111100 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockBasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails">
        <link:definition>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail">
        <link:definition>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2311301 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail">
        <link:definition>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2309301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2117100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.galenabiopharma.com/role/SubsequentEventsDetails">
        <link:definition>2417401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.galenabiopharma.com/role/Warrants">
        <link:definition>2110100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsChangesInFairValueOfWarrantLiabilityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail">
        <link:definition>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail">
        <link:definition>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleOfWarrantActivityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail">
        <link:definition>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.galenabiopharma.com/role/WarrantsTables">
        <link:definition>2310301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails">
        <link:definition>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="gale_AbstralMember" name="AbstralMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AbstralRightsNetMember" name="AbstralRightsNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_AbstralandZuplenzMember" name="AbstralandZuplenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_AprilTwoThousandElevenWarrantMember" name="AprilTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" name="AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" name="AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessAcquisitionCashHeldByAcquiredEntity" name="BusinessAcquisitionCashHeldByAcquiredEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantsOrRightsExpirationDate" name="ClassOfWarrantsOrRightsExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" name="ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExercisePeriod" name="ClassofWarrantorRightExercisePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExpired" name="ClassofWarrantorRightExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightIssuedDuringPeriod" name="ClassofWarrantorRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CommercialBusinessSegmentMember" name="CommercialBusinessSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockAdditionalSharesAuthorized" name="CommonStockAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ConsultantWarrantsMember" name="ConsultantWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentConsiderationPolicyPolicyTextBlock" name="ContingentConsiderationPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationNetSalesThreshold" name="ContractualObligationNetSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationPotentialPaymentsfromNetSales" name="ContractualObligationPotentialPaymentsfromNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CustomerFiveMember" name="CustomerFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerFourMember" name="CustomerFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerThreeMember" name="CustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCashFacilityFee" name="DebtInstrumentCashFacilityFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCashFinalPayment" name="DebtInstrumentCashFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest" name="DebtInstrumentContingentPaymentofPrincipalandAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCovenantLiquidityCovenant" name="DebtInstrumentCovenantLiquidityCovenant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" name="DebtInstrumentPlacementAgentFeePercentofFundsReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentPrincipalThatCouldBeRedeemed" name="DebtInstrumentPrincipalThatCouldBeRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" name="DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRedemptionNumberofDaysMaximum" name="DebtInstrumentRedemptionNumberofDaysMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentRestrictionofFundsPeriod" name="DebtInstrumentRestrictionofFundsPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentTermInterestOnly" name="DebtInstrumentTermInterestOnly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DecemberTwoThousandTwelveWarrantMember" name="DecemberTwoThousandTwelveWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DeficitAccumulatedDuringDevelopmentalStage" name="DeficitAccumulatedDuringDevelopmentalStage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DentInstrumentOriginalIssueDiscountPercent" name="DentInstrumentOriginalIssueDiscountPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations" name="DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" name="DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" name="DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" name="DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" name="DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedYearOfPatentExpiration" name="EstimatedYearOfPatentExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsExercised" name="FairValueOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" name="FinitelivedIntangibleAssetsAcquiredContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold" name="FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" name="FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency" name="FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FutureMilestonePayment" name="FutureMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_GALE401rights" name="GALE401rights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" name="GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" name="GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_IncreaseDecreaseinRestrictedCashforFinancingActivities" name="IncreaseDecreaseinRestrictedCashforFinancingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_IssuanceofCommonStockforLitigationSettlement" name="IssuanceofCommonStockforLitigationSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_JanuaryTwoThousandSixteenWarrantsMember" name="JanuaryTwoThousandSixteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LegalExpensesMember" name="LegalExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment" name="LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_LincolnParkCapitalLLCMember" name="LincolnParkCapitalLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockShares" name="LitigationSettlementIssuanceofCommonStockShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LitigationSettlementIssuanceofCommonStockValue" name="LitigationSettlementIssuanceofCommonStockValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_LossOnWarrantExchange" name="LossOnWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MLVCo.LLCandMaximGroupLLCMember" name="MLVCo.LLCandMaximGroupLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandElevenWarrantMember" name="MarchTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandFifteenWarrantsMember" name="MarchTwoThousandFifteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandTenWarrantMember" name="MarchTwoThousandTenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" name="MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MidatechPharmaPLCMember" name="MidatechPharmaPLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MiscellaneousOtherIncomeExpense" name="MiscellaneousOtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MonosolRxLLCMember" name="MonosolRxLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NetProceedsFromExerciseOfCommonStockWarrants" name="NetProceedsFromExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofCommericalProducts" name="NumberofCommericalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofDosingStrengths" name="NumberofDosingStrengths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" name="NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" name="NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofSharesPerUnit" name="NumberofSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofTopPerformingPharmacies" name="NumberofTopPerformingPharmacies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OrexoMember" name="OrexoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_OxfordFinanceLLCLoanMember" name="OxfordFinanceLLCLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PaymentofMilestonePayment" name="PaymentofMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PaymentsforLegalSettlementsPaidbyInsurance" name="PaymentsforLegalSettlementsPaidbyInsurance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PaymentsonDisposalofProductiveAssets" name="PaymentsonDisposalofProductiveAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" name="PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" name="ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementConsiderationReceivableUnderAgreement" name="PurchaseAgreementConsiderationReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" name="PurchaseAgreementContingentConsiderationReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_PurchaseAgreementContingentConsiderationThresholdNetSales" name="PurchaseAgreementContingentConsiderationThresholdNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementPaymentofUpfrontFee" name="PurchaseAgreementPaymentofUpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" name="PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementTerm" name="PurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" name="PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_SaleOfStockMaximumConsiderationReceivedPerTransaction" name="SaleOfStockMaximumConsiderationReceivedPerTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SaleOfStockTermAxis" name="SaleOfStockTermAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SaleOfStockTermDomain" name="SaleOfStockTermDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SaleOfStockTrancheOneMember" name="SaleOfStockTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SaleOfStockTrancheTwoMember" name="SaleOfStockTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" name="ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTableTextBlock" name="ScheduleOfWarrantActivityTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesLitigationOptOutSettlementCase1Member" name="SecuritiesLitigationOptOutSettlementCase1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SecuritiesLitigationOptOutSettlementCase2Member" name="SecuritiesLitigationOptOutSettlementCase2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeniorSecuredDebenturesMember" name="SeniorSecuredDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SentynlTherapeuticsInc.Member" name="SentynlTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeptemberTwoThousandThirteenWarrantMember" name="SeptemberTwoThousandThirteenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ShareholdersSecuritiesLitigationMember" name="ShareholdersSecuritiesLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_StockAvailableforIssuanceSharesNewIssues" name="StockAvailableforIssuanceSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesOverallotmentOption" name="StockIssuedDuringPeriodSharesOverallotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoZeroZeroSevenIncentivePlanMember" name="TwoZeroZeroSevenIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsGrantedNumberofShares" name="WarrantsGrantedNumberofShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ZuplenzMember" name="ZuplenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ZuplenzRightsMember" name="ZuplenzRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>gale-20160630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20160630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20160630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20160630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20160630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20160630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20160630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20160630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20160630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20160630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="gale-20160630.xsd#NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20160630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20160630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20160630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20160630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20160630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20160630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20160630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20160630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:href="gale-20160630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20160630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20160630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20160630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20160630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20160630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20160630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_4bc2eb0b-84ca-cbf9-99d8-76b29500d829" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_gale_ContractResearchPayable_4bc2eb0b-84ca-cbf9-99d8-76b29500d829" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_df866d05-0665-6819-5031-77017d332796" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_df866d05-0665-6819-5031-77017d332796" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed9fae98-3ae1-7659-630e-7314e2eeb5de" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_5eb5cd7b-d4b6-2ad3-92c0-76b294becbba" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_InProcessResearchDevelopment_5eb5cd7b-d4b6-2ad3-92c0-76b294becbba" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_532dc099-52b6-80d5-da7b-76b295d2d4af" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_gale_GALE401rights_532dc099-52b6-80d5-da7b-76b295d2d4af" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_764ac536-ae18-42ab-58db-4d138c5c1d6c" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_764ac536-ae18-42ab-58db-4d138c5c1d6c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6a60d556-a11e-4bed-09d1-f2c511f699d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_f5035bac-57b6-ced4-a27c-507fbcd9d0a0" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LitigationReserveCurrent_f5035bac-57b6-ced4-a27c-507fbcd9d0a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d8bb4f8c-0b6c-70b0-8758-76b294c35cec" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_d8bb4f8c-0b6c-70b0-8758-76b294c35cec" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_98fd51f5-5a5b-1d70-7b57-76b2954c26ea" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_98fd51f5-5a5b-1d70-7b57-76b2954c26ea" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_83c4ac54-425f-5554-ad41-76b294c7c447" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_83c4ac54-425f-5554-ad41-76b294c7c447" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_91fa3a94-6938-759c-56b1-ed6c1c3fabd3" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_91fa3a94-6938-759c-56b1-ed6c1c3fabd3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_IncreaseDecreaseinRestrictedCashforFinancingActivities" xlink:label="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_867C78A3517E5F5907AB51C8962AD5B2" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_867C78A3517E5F5907AB51C8962AD5B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentsonDisposalofProductiveAssets" xlink:label="loc_gale_PaymentsonDisposalofProductiveAssets_441258D48BA56758597C97ADC8AF6079" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:to="loc_gale_PaymentsonDisposalofProductiveAssets_441258D48BA56758597C97ADC8AF6079" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8bb79809-c54b-b06e-b2e8-230e4404bbe5" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2341918a-c49e-5d4b-79f6-51d4e80ea39b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_02062355-baa7-b9b2-b5da-76b294da86de" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_02062355-baa7-b9b2-b5da-76b294da86de" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_5c7cc403-9251-319a-1e5f-76b295603ec3" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_5c7cc403-9251-319a-1e5f-76b295603ec3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_35950518-de38-091b-1ea1-23860fdcd45e" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_35950518-de38-091b-1ea1-23860fdcd45e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_4e971f83-b0ee-5556-07c2-8a2cb9967d77" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_4e971f83-b0ee-5556-07c2-8a2cb9967d77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_832a8648-34d4-62c6-7585-89787b810cdd" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:to="loc_us-gaap_LitigationSettlementAmount_287c3286-b769-ce4b-45fb-5caef047aea9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_8f04eb90-8ce0-6eca-53eb-76b29552721f" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:to="loc_gale_LossOnWarrantExchange_8f04eb90-8ce0-6eca-53eb-76b29552721f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_e015c137-2688-2671-ea53-ff539f6b64b3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_e015c137-2688-2671-ea53-ff539f6b64b3" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_1f31ec91-1628-db92-3109-76b294b034ed" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_635b5b86-b9ab-e949-79a2-ce2ff4a8c847" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_1f31ec91-1628-db92-3109-76b294b034ed" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_311af4a2-f075-1e80-40f2-b85400721efa" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_311af4a2-f075-1e80-40f2-b85400721efa" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_20e5461b-32ea-98f3-95d9-101d9685c5a4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_78cd6ad1-8446-3c28-5468-baa1f29cdaac" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_20e5461b-32ea-98f3-95d9-101d9685c5a4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_78cd6ad1-8446-3c28-5468-baa1f29cdaac" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_9fb03578-f6c4-1b39-8db4-c6a1d99df45c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_20e5461b-32ea-98f3-95d9-101d9685c5a4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_9fb03578-f6c4-1b39-8db4-c6a1d99df45c" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_81c8f6e6-f17b-1484-8963-b3f81d593d27" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_81c8f6e6-f17b-1484-8963-b3f81d593d27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_4ebca9a0-a1af-cff3-9b4f-76b294c13e83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_d39e6781-80ba-8a9a-6ada-0a70854d4ef6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_254a2ea6-203e-6d58-1c91-7d777f7fa7f6" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_d39e6781-80ba-8a9a-6ada-0a70854d4ef6" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1463031c-a621-f194-7fe5-9c7c8d74db5b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1463031c-a621-f194-7fe5-9c7c8d74db5b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_579adfb5-ffb2-24d2-112e-563b1f113011" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8548c10b-62d4-7ad1-6b4b-61caa10c4389" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_579adfb5-ffb2-24d2-112e-563b1f113011" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8548c10b-62d4-7ad1-6b4b-61caa10c4389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_722fdbe5-74cc-ea41-59b5-38956b775e81" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_579adfb5-ffb2-24d2-112e-563b1f113011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_722fdbe5-74cc-ea41-59b5-38956b775e81" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_707d942f-1d32-04d4-698e-76b294b6726a" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_579adfb5-ffb2-24d2-112e-563b1f113011" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_707d942f-1d32-04d4-698e-76b294b6726a" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_0e844e8a-3b25-a68d-3f38-76b294af9e6e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_579adfb5-ffb2-24d2-112e-563b1f113011" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_0e844e8a-3b25-a68d-3f38-76b294af9e6e" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>gale-20160630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20160630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20160630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20160630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20160630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20160630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20160630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20160630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20160630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20160630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="gale-20160630.xsd#NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20160630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20160630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20160630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20160630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20160630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20160630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20160630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20160630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:href="gale-20160630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20160630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20160630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20160630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20160630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20160630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20160630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_78A529DF7374770D8C4770C7640B3DBE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:to="loc_us-gaap_SubsequentEventMember_78A529DF7374770D8C4770C7640B3DBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:to="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:to="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:to="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_E0616F4FCF543FFAB2FB70C7640CFA72" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:to="loc_gale_SeniorSecuredDebenturesMember_E0616F4FCF543FFAB2FB70C7640CFA72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:to="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:to="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B6087BE361C77759290870C7640CADE7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:to="loc_us-gaap_MinimumMember_B6087BE361C77759290870C7640CADE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12E00D743BF889D5CF3270C7640CB8D0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:to="loc_us-gaap_MaximumMember_12E00D743BF889D5CF3270C7640CB8D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F86ABD1F76B0D85B532570C7640C6DF4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F86ABD1F76B0D85B532570C7640C6DF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_C7E36128383E21F7CC8470C7640CB8DC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_C7E36128383E21F7CC8470C7640CB8DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRestrictionofFundsPeriod" xlink:label="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_457FA6C0907CAC5495DC70C7640D3438" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_457FA6C0907CAC5495DC70C7640D3438" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_460561C268910DCEC88570C764000634" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:to="loc_gale_ZuplenzMember_460561C268910DCEC88570C764000634" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:to="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:to="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BEDCBED34DAA59BB8F1370C764017C82" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:to="loc_us-gaap_CommonStockMember_BEDCBED34DAA59BB8F1370C764017C82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C8B4FBF79B5A3158CE7F70C76401A18E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_Goodwill_C8B4FBF79B5A3158CE7F70C76401A18E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:to="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_CD587877D8D91D41719970C76425F874" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:to="loc_us-gaap_SeniorNotesMember_CD587877D8D91D41719970C76425F874" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_40C65E54DE404260327E70C76425E780" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:to="loc_gale_SeniorSecuredDebenturesMember_40C65E54DE404260327E70C76425E780" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:to="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:to="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B04626C89F96CA2B200070C76426705F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_CommonStockMember_B04626C89F96CA2B200070C76426705F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:to="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:to="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:to="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_3E320D659BC03443297F70C763621C84" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:to="loc_gale_CommercialBusinessSegmentMember_3E320D659BC03443297F70C763621C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7C807E47B1CBBC324FB170C763638B2E" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7C807E47B1CBBC324FB170C763638B2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:to="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LegalExpensesMember" xlink:label="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:to="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_71BD66C3A15982F0798A70C76371BF10" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:to="loc_gale_CommercialBusinessSegmentMember_71BD66C3A15982F0798A70C76371BF10" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralandZuplenzMember" xlink:label="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:to="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:to="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:to="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_25FE99448F40E67EDCA470C7635DA035" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:to="loc_gale_CommercialBusinessSegmentMember_25FE99448F40E67EDCA470C7635DA035" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9741DA2291C39DC1C67170C7635E2EAB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9741DA2291C39DC1C67170C7635E2EAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28B5BFA26469B1A0F41E70C7635EC399" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28B5BFA26469B1A0F41E70C7635EC399" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_F7B505356D93CA84A62F70C7635E0C8F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_ShareBasedCompensation_F7B505356D93CA84A62F70C7635E0C8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_538FEA060C9044EB4FD070C763F583BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_538FEA060C9044EB4FD070C763F583BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:to="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:to="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:to="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:to="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_946CD086C348E9307A5A70C763DE07C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:to="loc_us-gaap_SubsequentEventMember_946CD086C348E9307A5A70C763DE07C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentsforLegalSettlementsPaidbyInsurance" xlink:label="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C18AE85951432D94A54B70C763D8773C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:to="loc_us-gaap_SubsequentEventMember_C18AE85951432D94A54B70C763D8773C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_4BD004CA59D22261537270C763D8FD6F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:to="loc_us-gaap_ScenarioForecastMember_4BD004CA59D22261537270C763D8FD6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_01A04347CF9A3AECE2E070C763D8FC0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_01A04347CF9A3AECE2E070C763D8FC0D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_7FD334DADA85F9DB0A7370C763D8AFD0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_7FD334DADA85F9DB0A7370C763D8AFD0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_EDC5A560B89A36E4271770C763D8D22B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_LitigationSettlementAmount_EDC5A560B89A36E4271770C763D8D22B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_F2334DE8C717A0595B4370C763D8F336" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_F2334DE8C717A0595B4370C763D8F336" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_3E7341FFF175030E65AB70C763D9BECD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_3E7341FFF175030E65AB70C763D9BECD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:to="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:to="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:to="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D03C546622A721DF330970C76385CF7B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:to="loc_us-gaap_MinimumMember_D03C546622A721DF330970C76385CF7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9D8283153D853393D98070C763855D6B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:to="loc_us-gaap_MaximumMember_9D8283153D853393D98070C763855D6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:to="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:to="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:to="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_80EE4BAD7B447B60D30170C763853320" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:to="loc_gale_AbstralMember_80EE4BAD7B447B60D30170C763853320" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_E85B558241E7399B342770C763858F78" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:to="loc_gale_OrexoMember_E85B558241E7399B342770C763858F78" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentofMilestonePayment" xlink:label="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:to="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_91A405132A52009D168970C763E98277" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:to="loc_us-gaap_SubsequentEventMember_91A405132A52009D168970C763E98277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:to="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:to="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:to="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:to="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:to="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7A4701EF8B38359484B270C763EACC91" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7A4701EF8B38359484B270C763EACC91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68971E2B5B07E1B112B970C763EAA0F9" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68971E2B5B07E1B112B970C763EAA0F9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DentInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:to="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:to="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:to="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:to="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E3C19F09B10A115A358E70C763A2C96B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:to="loc_us-gaap_MinimumMember_E3C19F09B10A115A358E70C763A2C96B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_767CEF46DCB2C69E5E4770C763A2408A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:to="loc_us-gaap_MaximumMember_767CEF46DCB2C69E5E4770C763A2408A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4CE92556A965D7A8854870C763A2741E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4CE92556A965D7A8854870C763A2741E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_629F9E25772E4DCBF79270C763AA2BDE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:to="loc_gale_CommercialBusinessSegmentMember_629F9E25772E4DCBF79270C763AA2BDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:to="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:to="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:to="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:to="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:to="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:to="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_797990DC01FF9A7E5F2E70C763CD40BA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:to="loc_us-gaap_CommonStockMember_797990DC01FF9A7E5F2E70C763CD40BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0672C963D180182D932670C763CDDD44" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:to="loc_us-gaap_WarrantMember_0672C963D180182D932670C763CDDD44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B0E6ADE4F97A78D1F6F870C763CD6382" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B0E6ADE4F97A78D1F6F870C763CD6382" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FAA85E077D14A7033FC070C763CD023E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FAA85E077D14A7033FC070C763CD023E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1649FECFC91C8C4409C970C763CDBD2E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1649FECFC91C8C4409C970C763CDBD2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1871B98FE4A46DF7DB9970C763CDD92D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1871B98FE4A46DF7DB9970C763CDD92D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommonStockAdditionalSharesAuthorized" xlink:label="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7857E7E916A65F0945DE70C763CE4E21" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_SharePrice_7857E7E916A65F0945DE70C763CE4E21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01007C889B83263A117870C763CED7CA" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01007C889B83263A117870C763CED7CA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45435868056C57203E5F70C763CE6FDC" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45435868056C57203E5F70C763CE6FDC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_600079A19208C45E023F70C763CEECF4" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_600079A19208C45E023F70C763CEECF4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6438CB3BBC9731FF335C70C763CECDA0" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6438CB3BBC9731FF335C70C763CECDA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:to="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:to="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_424BFF8A4692A45CFEEA70C76354D0E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:to="loc_us-gaap_MaximumMember_424BFF8A4692A45CFEEA70C76354D0E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_937B4D36FD75EDABEC3F70C76355BC51" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:to="loc_us-gaap_MinimumMember_937B4D36FD75EDABEC3F70C76355BC51" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermAxis" xlink:label="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermDomain" xlink:label="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:to="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80_default" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermDomain" xlink:label="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:to="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheOneMember" xlink:label="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:to="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheTwoMember" xlink:label="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:to="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:to="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:to="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:to="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E40AC2E80CE2B4DB5F9A70C763557845" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:to="loc_us-gaap_CommonStockMember_E40AC2E80CE2B4DB5F9A70C763557845" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:to="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_B9068A479EFABF245FDE70C76356AB2F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:to="loc_gale_SeniorSecuredDebenturesMember_B9068A479EFABF245FDE70C76356AB2F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OxfordFinanceLLCLoanMember" xlink:label="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:to="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_134DB2C1E29A5C0B3FB670C763564473" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:to="loc_us-gaap_SubsequentEventMember_134DB2C1E29A5C0B3FB670C763564473" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FCF75739E07F1253B8F770C76356D96A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FCF75739E07F1253B8F770C76356D96A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3E16909B8EEBEB57A82170C76356F502" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3E16909B8EEBEB57A82170C76356F502" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_93B37822EF6144792CDE70C763564010" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_93B37822EF6144792CDE70C763564010" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_58DA697BEA97E2EDDD0770C763565F71" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_58DA697BEA97E2EDDD0770C763565F71" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_E9C7E8CDF70FB6FC3ED970C76356A0B9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_E9C7E8CDF70FB6FC3ED970C76356A0B9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DentInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DentInstrumentOriginalIssueDiscountPercent_9203C52183B1D2B2323770C7635621E1" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DentInstrumentOriginalIssueDiscountPercent_9203C52183B1D2B2323770C7635621E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F920F8B8808F37E4F95A70C76356842C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F920F8B8808F37E4F95A70C76356842C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E1F0275763379B4DD22370C76356338E" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E1F0275763379B4DD22370C76356338E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_EF776F8B119C7C17BD0070C76356C8B2" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_EF776F8B119C7C17BD0070C76356C8B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F5F1ECFC70AAAE9E29270C763561256" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F5F1ECFC70AAAE9E29270C763561256" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest" xlink:label="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_D670141057CEDFF0A50E70C76356B1FD" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_D670141057CEDFF0A50E70C76356B1FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_307CA758CB740B805F6470C763562396" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_307CA758CB740B805F6470C763562396" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_8DAAD3EC2BB150FA8D8470C763572137" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightTerm_8DAAD3EC2BB150FA8D8470C763572137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_69A5C1AAB9CF7ABECDCE70C76357135A" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_69A5C1AAB9CF7ABECDCE70C76357135A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_56FC627D3969328962D070C76357F34C" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_56FC627D3969328962D070C76357F34C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_B6059A46DA9B4EDD147770C76357273D" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_B6059A46DA9B4EDD147770C76357273D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockMaximumConsiderationReceivedPerTransaction" xlink:label="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_E242A843A1703B9E647070C763BAE5CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_E242A843A1703B9E647070C763BAE5CB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_4D0C4018651D20E9967470C763BA6A41" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_4D0C4018651D20E9967470C763BA6A41" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_01A6218B789C961232B170C763BAEF60" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_01A6218B789C961232B170C763BAEF60" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_8C127F2954895B8FDB2C70C763BA88E4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_8C127F2954895B8FDB2C70C763BA88E4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_03453305310789EC4D0870C763BACF09" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_03453305310789EC4D0870C763BACF09" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_C2483E5568797B32485270C763BA685D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_C2483E5568797B32485270C763BA685D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_82605FBFF759686842DA70C763BAB038" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_82605FBFF759686842DA70C763BAB038" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_BC45024133843A34E9EF70C763BF50CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_BC45024133843A34E9EF70C763BF50CD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_41816523E10A54959A3D70C763BF08BA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_41816523E10A54959A3D70C763BF08BA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7EB71BDC8411FC8C004870C763C02406" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7EB71BDC8411FC8C004870C763C02406" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_CA09BA064C56F534D10070C763C0A85F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_CA09BA064C56F534D10070C763C0A85F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_0A98C162B0B419FBAEFC70C763C0FA70" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_0A98C162B0B419FBAEFC70C763C0FA70" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_DA78E41813660C4850D870C763C0001A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_DA78E41813660C4850D870C763C0001A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_2A100EA6BC7D5AD771D070C763C0483F" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_2A100EA6BC7D5AD771D070C763C0483F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:to="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:to="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:to="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:to="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6ED477FA0BC3BAC40DDD70C763C0F46B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:to="loc_us-gaap_MaximumMember_6ED477FA0BC3BAC40DDD70C763C0F46B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:to="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="arc" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gale-20160630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:to="lab_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B_terseLabel_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted, number of shares (in shares)</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B_label_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B_documentation_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:to="lab_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, expected volatility rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, expected term (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, risk free interest rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, expected dividend rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants granted (usd per share)</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from continuing operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:to="lab_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Insurance Settlements Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in continuing operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Assets Held-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:to="lab_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in discontinued operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in continuing investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:type="arc" />
    <link:label id="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09_negatedTerseLabel_en-US" xlink:label="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling costs paid for sale of commercial assets</link:label>
    <link:label id="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09_label_en-US" xlink:label="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments on Disposal of Productive Assets</link:label>
    <link:label id="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09_documentation_en-US" xlink:label="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments on Disposal of Productive Assets</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PaymentsonDisposalofProductiveAssets" xlink:label="loc_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:to="lab_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for commercial assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4_totalLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in discontinued investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:type="arc" />
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057_terseLabel_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057_label_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Exercise Of Common Stock Warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057_documentation_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of common stock warrants.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:to="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued in connection with ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:type="arc" />
    <link:label id="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A_negatedTerseLabel_en-US" xlink:label="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Minimum cash covenant on long-term debt</link:label>
    <link:label id="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A_label_en-US" xlink:label="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Financing Activities</link:label>
    <link:label id="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A_documentation_en-US" xlink:label="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Financing Activities</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_IncreaseDecreaseinRestrictedCashforFinancingActivities" xlink:label="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:to="lab_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD_label_en-US" xlink:label="lab_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:to="lab_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343_negatedTerseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:to="lab_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:to="lab_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:type="arc" />
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660_terseLabel_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2016 Warrants [Member]</link:label>
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660_label_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">January Two Thousand Sixteen Warrants [Member]</link:label>
    <link:label id="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660_documentation_en-US" xlink:label="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">January Two Thousand Sixteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:to="lab_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2015 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369_label_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:to="lab_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="arc" />
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600_terseLabel_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2013 Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600_label_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600_documentation_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:to="lab_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="arc" />
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702_terseLabel_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2012 Warrants [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702_label_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702_documentation_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:to="lab_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="arc" />
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012_terseLabel_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012_label_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012_documentation_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:to="lab_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2_label_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:to="lab_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2010 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08_label_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:to="lab_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:to="lab_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Exercised</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Exercised</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Exercised</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:to="lab_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uses of Estimates in Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:to="lab_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and In-Licensing</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:type="arc" />
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94_terseLabel_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94_label_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94_documentation_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:to="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:type="arc" />
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7_terseLabel_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7_label_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7_documentation_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs [Policy Text Block]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:to="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement Payable and Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:type="arc" />
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:to="lab_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89_label_en-US" xlink:label="lab_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:to="lab_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:to="lab_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:to="lab_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="lab_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:to="lab_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="arc" />
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0_terseLabel_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0_label_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:label id="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0_documentation_en-US" xlink:label="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Debentures [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:to="lab_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="arc" />
    <link:label id="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A_terseLabel_en-US" xlink:label="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A_label_en-US" xlink:label="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A_documentation_en-US" xlink:label="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:to="lab_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:to="lab_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1_label_en-US" xlink:label="lab_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:to="lab_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3_label_en-US" xlink:label="lab_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:to="lab_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA_label_en-US" xlink:label="lab_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:to="lab_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="lab_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for interest only payments</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307_label_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307_documentation_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:to="lab_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments at the fixed coupon rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A_label_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed</link:label>
    <link:label id="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal That Could Be Redeemed</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:to="lab_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption period (days)</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C_label_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Number of Days, Maximum</link:label>
    <link:label id="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Number of Days, Maximum</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:to="lab_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount to the prior trading day&#8217;s volume weighted average price</link:label>
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C_label_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</link:label>
    <link:label id="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:to="lab_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:to="lab_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash final payment percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:to="lab_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for principal and interest payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:to="lab_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash facility fee percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:to="lab_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares availabe from warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of average market price used for warrant exercise price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:to="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="arc" />
    <link:label id="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949_terseLabel_en-US" xlink:label="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dent Instrument, Original Issue Discount, Percent</link:label>
    <link:label id="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949_label_en-US" xlink:label="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dent Instrument, Original Issue Discount, Percent</link:label>
    <link:label id="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949_documentation_en-US" xlink:label="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dent Instrument, Original Issue Discount, Percent</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DentInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:to="lab_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653_label_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:label id="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Covenant</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:to="lab_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Placement Agent Fee, Percent of Funds Received</link:label>
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA_label_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Placement Agent Fee, Percent of Funds Received</link:label>
    <link:label id="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA_documentation_en-US" xlink:label="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Placement Agent Fee, Percent of Funds Received</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:to="lab_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="lab_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:to="lab_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:to="lab_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:to="lab_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="arc" />
    <link:label id="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD_terseLabel_en-US" xlink:label="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD_label_en-US" xlink:label="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD_documentation_en-US" xlink:label="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:to="lab_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="arc" />
    <link:label id="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2_terseLabel_en-US" xlink:label="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2_label_en-US" xlink:label="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2_documentation_en-US" xlink:label="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:to="lab_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="arc" />
    <link:label id="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8_terseLabel_en-US" xlink:label="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8_label_en-US" xlink:label="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8_documentation_en-US" xlink:label="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:to="lab_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982_terseLabel_en-US" xlink:label="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982_label_en-US" xlink:label="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982_documentation_en-US" xlink:label="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:to="lab_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18_terseLabel_en-US" xlink:label="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18_label_en-US" xlink:label="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18_documentation_en-US" xlink:label="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:to="lab_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92_terseLabel_en-US" xlink:label="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92_label_en-US" xlink:label="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92_documentation_en-US" xlink:label="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:to="lab_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7_terseLabel_en-US" xlink:label="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7_label_en-US" xlink:label="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7_documentation_en-US" xlink:label="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:to="lab_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="arc" />
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB_terseLabel_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB_label_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB_documentation_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:to="lab_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the contingent purchase price liability</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:type="arc" />
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF_terseLabel_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense)</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF_label_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Income Expense</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF_documentation_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense).</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:to="lab_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:type="arc" />
    <link:label id="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4_terseLabel_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4_label_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4_documentation_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:to="lab_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5_label_en-US" xlink:label="lab_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:to="lab_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:to="lab_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957_label_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:label id="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:to="lab_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0_negatedTerseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:to="lab_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705_label_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:to="lab_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customer and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations,Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:to="lab_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="lab_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement insurance recovery</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets of discontinued operations, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:to="lab_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:to="lab_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:type="arc" />
    <link:label id="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664_terseLabel_en-US" xlink:label="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664_label_en-US" xlink:label="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664_documentation_en-US" xlink:label="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:to="lab_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2_label_en-US" xlink:label="lab_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:to="lab_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064_label_en-US" xlink:label="lab_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:to="lab_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:to="lab_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement payable</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:to="lab_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:to="lab_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:to="lab_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:to="lab_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8_label_en-US" xlink:label="lab_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:to="lab_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:to="lab_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="lab_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:to="lab_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 275,000,000 shares authorized, 182,996,385 shares issued and 182,321,385 shares outstanding at June 30, 2016; 162,581,753 shares issued and 161,906,753 shares outstanding at December 31, 2015</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:to="lab_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:type="arc" />
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9_negatedLabel_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9_label_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit Accumulated During Developmental Stage</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9_documentation_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deficit accumulated during the developmental stage.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:to="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:to="lab_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:to="lab_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="arc" />
    <link:label id="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E_terseLabel_en-US" xlink:label="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E_label_en-US" xlink:label="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:label id="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E_documentation_en-US" xlink:label="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral Rights, Net [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:to="lab_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B_terseLabel_en-US" xlink:label="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B_label_en-US" xlink:label="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:label id="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B_documentation_en-US" xlink:label="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz Rights [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:to="lab_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="arc" />
    <link:label id="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994_terseLabel_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994_label_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:label id="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994_documentation_en-US" xlink:label="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Business Segment [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:to="lab_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge from classification as assets held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current assets of discontinued operations, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities of discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Excluded from Net Loss</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3_label_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3_documentation_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:to="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:to="lab_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:to="lab_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:to="lab_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="arc" />
    <link:label id="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8_terseLabel_en-US" xlink:label="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:label id="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8_label_en-US" xlink:label="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:label id="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8_documentation_en-US" xlink:label="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:to="lab_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7_terseLabel_en-US" xlink:label="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7_label_en-US" xlink:label="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7_documentation_en-US" xlink:label="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:to="lab_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less selling costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale, net of selling costs</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Net</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Net</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Litigation Settlements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock are Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Are Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additional channel obligations</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Additional Channel Obligations</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Additional Channel Obligations</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774_negatedTerseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:to="lab_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="arc" />
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC_terseLabel_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC_label_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC_documentation_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:to="lab_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Senior Management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding common stock options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting periods of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="arc" />
    <link:label id="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing price of the Company's common stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:to="lab_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:to="lab_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="arc" />
    <link:label id="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC_terseLabel_en-US" xlink:label="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Expenses [Member]</link:label>
    <link:label id="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC_label_en-US" xlink:label="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Expenses [Member]</link:label>
    <link:label id="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC_documentation_en-US" xlink:label="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Expenses [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LegalExpensesMember" xlink:label="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:to="lab_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="arc" />
    <link:label id="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F_terseLabel_en-US" xlink:label="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral and Zuplenz [Member]</link:label>
    <link:label id="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F_label_en-US" xlink:label="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abstral and Zuplenz [Member]</link:label>
    <link:label id="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F_documentation_en-US" xlink:label="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abstral and Zuplenz [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AbstralandZuplenzMember" xlink:label="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:to="lab_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="arc" />
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B_terseLabel_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of cancer patients affected by inadequately controlled breakthrough cancer pain (BTcP) (in percent)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B_label_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:label id="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B_documentation_en-US" xlink:label="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Cancer Patients Affected by Inadequately Controlled Breakthrough Cancer Pain (BTcP)</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:to="lab_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee contingently due to third party</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success fee, as a percentage of consideration received, contingently due to third party (percent)</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability, Percentage of Consideration</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Liability, Percentage of Consideration</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retention fees contingently due (as percentage of consideration received)</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="arc" />
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C_terseLabel_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C_label_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</link:label>
    <link:label id="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C_documentation_en-US" xlink:label="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:to="lab_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:to="lab_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:to="lab_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:to="lab_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="arc" />
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE_terseLabel_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE_label_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE_documentation_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:to="lab_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restriction of funds, period (in days)</link:label>
    <link:label id="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5_label_en-US" xlink:label="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Restriction of Funds, Period</link:label>
    <link:label id="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5_documentation_en-US" xlink:label="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Restriction of Funds, Period</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRestrictionofFundsPeriod" xlink:label="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:to="lab_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="arc" />
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7_terseLabel_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients diagnosed with breast cancer patients annually at high risk of disease recurrence</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7_label_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually At High Risk of Disease Recurrence</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7_documentation_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually At High Risk of Disease Recurrence</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:to="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="arc" />
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC_terseLabel_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients diagnosed with breast cancer, annually</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC_label_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually</link:label>
    <link:label id="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC_documentation_en-US" xlink:label="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients Diagnosed With Breast Cancer Patients Annually</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:to="lab_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="arc" />
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6_terseLabel_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Highly-liquid debt instruments maturity days</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6_label_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6_documentation_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:to="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D_label_en-US" xlink:label="lab_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:to="lab_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:to="lab_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:to="lab_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99_terseLabel_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prompyt pay discount, percent of gross sales</link:label>
    <link:label id="lab_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:to="lab_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New warrants issued during period (in shares)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:to="lab_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:to="lab_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:to="lab_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring channel inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:to="lab_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="lab_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="arc" />
    <link:label id="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock Term [Axis]</link:label>
    <link:label id="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915_label_en-US" xlink:label="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Term [Axis]</link:label>
    <link:label id="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915_documentation_en-US" xlink:label="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock Term [Axis]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermAxis" xlink:label="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:to="lab_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="arc" />
    <link:label id="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock Term [Domain]</link:label>
    <link:label id="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80_label_en-US" xlink:label="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Term [Domain]</link:label>
    <link:label id="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80_documentation_en-US" xlink:label="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Sale Of Stock Term [Axis]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermDomain" xlink:label="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:to="lab_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="arc" />
    <link:label id="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche One [Member]</link:label>
    <link:label id="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2_label_en-US" xlink:label="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche One [Member]</link:label>
    <link:label id="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2_documentation_en-US" xlink:label="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche One [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheOneMember" xlink:label="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:to="lab_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="arc" />
    <link:label id="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche Two [Member]</link:label>
    <link:label id="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6_label_en-US" xlink:label="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche Two [Member]</link:label>
    <link:label id="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6_documentation_en-US" xlink:label="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Tranche Two [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheTwoMember" xlink:label="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:to="lab_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:to="lab_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:to="lab_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE_terseLabel_en-US" xlink:label="lab_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:label id="lab_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE_label_en-US" xlink:label="lab_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:to="lab_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="arc" />
    <link:label id="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8_terseLabel_en-US" xlink:label="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC Loan [Member]</link:label>
    <link:label id="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8_label_en-US" xlink:label="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC Loan [Member]</link:label>
    <link:label id="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8_documentation_en-US" xlink:label="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Finance, LLC Loan [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_OxfordFinanceLLCLoanMember" xlink:label="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:to="lab_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="lab_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise period (in years)</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:to="lab_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Contingent Payment of Principal and Accrued Interest</link:label>
    <link:label id="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291_label_en-US" xlink:label="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Contingent Payment of Principal and Accrued Interest</link:label>
    <link:label id="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291_documentation_en-US" xlink:label="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Contingent Payment of Principal and Accrued Interest</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest" xlink:label="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:to="lab_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserved for future issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9_label_en-US" xlink:label="lab_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:to="lab_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="arc" />
    <link:label id="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944_terseLabel_en-US" xlink:label="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum consideration received on transaction under Purchase Agreement</link:label>
    <link:label id="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944_label_en-US" xlink:label="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Consideration Received Per Transaction</link:label>
    <link:label id="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944_documentation_en-US" xlink:label="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Consideration Received Per Transaction</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SaleOfStockMaximumConsiderationReceivedPerTransaction" xlink:label="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:to="lab_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowable ownership interest under Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="arc" />
    <link:label id="lab_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA_terseLabel_en-US" xlink:label="lab_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual salary</link:label>
    <link:label id="lab_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA_label_en-US" xlink:label="lab_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officers' Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:to="lab_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="lab_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:to="lab_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:to="lab_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:to="lab_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:to="lab_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:type="arc" />
    <link:label id="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0_label_en-US" xlink:label="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Warrant Exchange</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0_documentation_en-US" xlink:label="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on warrant exchange.</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:to="lab_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:to="lab_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share, continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share, discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:to="lab_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD_label_en-US" xlink:label="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:to="lab_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:to="lab_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:to="lab_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC_label_en-US" xlink:label="lab_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:to="lab_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705_label_en-US" xlink:label="lab_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:to="lab_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="arc" />
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658_terseLabel_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658_label_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658_documentation_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:to="lab_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="arc" />
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38_terseLabel_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38_label_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38_documentation_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:to="lab_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="lab_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25_terseLabel_en-US" xlink:label="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, additional shares authorized</link:label>
    <link:label id="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25_label_en-US" xlink:label="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:label id="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25_documentation_en-US" xlink:label="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Shares Authorized</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_CommonStockAdditionalSharesAuthorized" xlink:label="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:to="lab_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2_label_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:to="lab_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="arc" />
    <link:label id="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E_terseLabel_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E_label_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E_documentation_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:to="lab_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="arc" />
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894_terseLabel_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Available for Issuance, Shares, New Issues</link:label>
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894_label_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Available for Issuance, Shares, New Issues</link:label>
    <link:label id="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894_documentation_en-US" xlink:label="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Available for Issuance, Shares, New Issues</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:to="lab_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:to="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B_label_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B_documentation_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:to="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E_negatedLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of the contingent purchase price consideration</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Zuplenz rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="lab_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:to="lab_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:to="lab_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="arc" />
    <link:label id="lab_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:to="lab_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:to="lab_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:to="lab_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0_label_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:to="lab_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="arc" />
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC_terseLabel_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC_label_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</link:label>
    <link:label id="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC_documentation_en-US" xlink:label="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:to="lab_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89_terseLabel_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89_label_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89_documentation_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 1 [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:to="lab_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="arc" />
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019_terseLabel_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019_label_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:label id="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019_documentation_en-US" xlink:label="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Litigation, Opt Out Settlement, Case 2 [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:to="lab_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="lab_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99_label_en-US" xlink:label="lab_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:to="lab_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the insurance carriers</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="arc" />
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33_terseLabel_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option cancellation in period (in shares)</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33_label_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled in Period</link:label>
    <link:label id="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33_documentation_en-US" xlink:label="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled in Period</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:to="lab_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:to="lab_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="arc" />
    <link:label id="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C_terseLabel_en-US" xlink:label="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements, paid by insurance</link:label>
    <link:label id="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C_label_en-US" xlink:label="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements, Paid by Insurance</link:label>
    <link:label id="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C_documentation_en-US" xlink:label="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements, Paid by Insurance</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PaymentsforLegalSettlementsPaidbyInsurance" xlink:label="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:to="lab_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the company in cash (paid in July 2016)</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, issuance of common stock, value</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Value</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="arc" />
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE_terseLabel_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, issuance of common stock (in shares)</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE_label_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Shares</link:label>
    <link:label id="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE_documentation_en-US" xlink:label="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Issuance of Common Stock, Shares</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:to="lab_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="lab_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:to="lab_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="arc" />
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774_terseLabel_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774_label_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774_documentation_en-US" xlink:label="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sentynl Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:to="lab_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="arc" />
    <link:label id="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483_terseLabel_en-US" xlink:label="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483_label_en-US" xlink:label="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483_documentation_en-US" xlink:label="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:to="lab_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="arc" />
    <link:label id="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7_terseLabel_en-US" xlink:label="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:label id="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7_label_en-US" xlink:label="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:label id="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7_documentation_en-US" xlink:label="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monosol Rx, LLC [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:to="lab_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="arc" />
    <link:label id="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC_terseLabel_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:label id="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC_label_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:label id="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC_documentation_en-US" xlink:label="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Midatech Pharma PLC [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:to="lab_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:to="lab_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="arc" />
    <link:label id="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D_terseLabel_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D_label_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D_documentation_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:to="lab_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="lab_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:type="arc" />
    <link:label id="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274_terseLabel_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274_label_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274_documentation_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:to="lab_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD_terseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for Phase 3</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD_label_en-US" xlink:label="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD_documentation_en-US" xlink:label="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:to="lab_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Abstral rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="arc" />
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254_terseLabel_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining cash held of Abstral rights</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254_label_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254_documentation_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:to="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E_terseLabel_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated year of licensed patents expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E_label_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E_documentation_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:to="lab_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Future Milestone Payment, Monosol Contingency</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Future Milestone Payment, Monosol Contingency</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Future Milestone Payment, Monosol Contingency</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E_label_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E_documentation_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:to="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9_label_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9_documentation_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:to="lab_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="arc" />
    <link:label id="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB_terseLabel_en-US" xlink:label="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of Milestone Payment</link:label>
    <link:label id="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB_label_en-US" xlink:label="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Milestone Payment</link:label>
    <link:label id="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB_documentation_en-US" xlink:label="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of Milestone Payment</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PaymentofMilestonePayment" xlink:label="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:to="lab_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="arc" />
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C_terseLabel_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Number Of One-Time Future Cash Milestone Payment</link:label>
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C_label_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Number Of One-Time Future Cash Milestone Payment</link:label>
    <link:label id="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C_documentation_en-US" xlink:label="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Number Of One-Time Future Cash Milestone Payment</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:to="lab_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF_label_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Consideration Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:to="lab_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Upfront Payment Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE_label_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Upfront Payment Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Upfront Payment Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:to="lab_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C_label_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Receivable Under Agreement</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Receivable Under Agreement</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:to="lab_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Threshold, Net Sales</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83_label_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Threshold, Net Sales</link:label>
    <link:label id="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Contingent Consideration Threshold, Net Sales</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:to="lab_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Net Sales Contingency Threshold</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Net Sales Contingency Threshold</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Net Sales Contingency Threshold</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B_label_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:to="lab_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C_label_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</link:label>
    <link:label id="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:to="lab_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="arc" />
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E_terseLabel_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E_label_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:label id="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E_documentation_en-US" xlink:label="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shareholders Securities Litigation [Member]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:to="lab_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="arc" />
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2_terseLabel_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable by the company in common stock (paid in July 2016)</link:label>
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2_label_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock for Litigation Settlement</link:label>
    <link:label id="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2_documentation_en-US" xlink:label="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock for Litigation Settlement</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:to="lab_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917_label_en-US" xlink:label="lab_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="lab_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:to="lab_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:to="lab_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:to="lab_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:to="lab_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation for directors and employees</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:to="lab_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:to="lab_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Cancelled</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20160630.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2_label_en-US" xlink:label="lab_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:to="lab_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19_label_en-US" xlink:label="lab_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:to="lab_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:to="lab_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:to="lab_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86_label_en-US" xlink:label="lab_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:to="lab_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686_terseLabel_en-US" xlink:label="lab_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686_label_en-US" xlink:label="lab_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:to="lab_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:to="lab_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:to="lab_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:to="lab_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37_label_en-US" xlink:label="lab_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:to="lab_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gale-20160630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20160630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20160630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20160630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20160630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20160630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20160630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20160630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:href="gale-20160630.xsd#DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20160630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:href="gale-20160630.xsd#LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20160630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20160630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20160630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20160630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20160630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20160630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="gale-20160630.xsd#NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20160630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20160630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20160630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20160630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20160630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20160630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20160630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20160630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20160630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20160630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20160630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20160630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:href="gale-20160630.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20160630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20160630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20160630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20160630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20160630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20160630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_D87424FF20F8FD58D34770C763F211B9" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E62D2B5DF3C86C089C2670C763F2795E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:to="loc_gale_ContractResearchPayable_FFE5CF0D5D3E66CA08A970C763EF44FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0306965CF4A0B9C0D5DB70C763EF8BE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_122D5A9FC0E94AA6F6A170C763EFC024" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:to="loc_us-gaap_InterestPayableCurrent_78A1E49229ADB935679170C763EF3799" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_94B980D94FB98649CF6770C763EFBD88" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84A9ADBB165002E1FE8E70C763EF962C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F7F257C24ED48E39799270C763F19DC1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F7F257C24ED48E39799270C763F19DC1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_12367F117362ED0BB03570C763F1EC06" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B8C4B1093C1CEBA15B4770C764153443" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B8C4B1093C1CEBA15B4770C764153443" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_00A7D3AD23E9455737A870C764159BD7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D3141066A56A1A04F1B670C7640B0931" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D3141066A56A1A04F1B670C7640B0931" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D53BF038D7F6E3F801FE70C7640B6796" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_78A529DF7374770D8C4770C7640B3DBE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0E6AD2067DAB8F69F68170C7640B7C84" xlink:to="loc_us-gaap_SubsequentEventMember_78A529DF7374770D8C4770C7640B3DBE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6FE7527586A57CC8D05470C7640B2AAF" xlink:to="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6F5CA1FF265E592B15D770C7640B3BD9" xlink:to="loc_us-gaap_CommonStockMember_26C3A1542027928D8AE370C7640BE644" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_FA0742E60F999A2EBB8A70C7640B1010" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_E0616F4FCF543FFAB2FB70C7640CFA72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94CFEA3D0AFEDDB31A0670C7640B7039" xlink:to="loc_gale_SeniorSecuredDebenturesMember_E0616F4FCF543FFAB2FB70C7640CFA72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_08844A3C32583B634BF470C7640C241A" xlink:to="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B6087BE361C77759290870C7640CADE7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:to="loc_us-gaap_MinimumMember_B6087BE361C77759290870C7640CADE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12E00D743BF889D5CF3270C7640CB8D0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_723A35A71EE369AA5FD570C7640C5A5A" xlink:to="loc_us-gaap_MaximumMember_12E00D743BF889D5CF3270C7640CB8D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A38A4697FD14ACFFC5AC70C7640CCD09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1157C4EC1CA29D7FC83170C7640C2705" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_CAB97E10ECE1FA268A9470C7640C95FE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_43DF602F1C9C7EB3966870C7640B89E6" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F86ABD1F76B0D85B532570C7640C6DF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F86ABD1F76B0D85B532570C7640C6DF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_C7E36128383E21F7CC8470C7640CB8DC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_C7E36128383E21F7CC8470C7640CB8DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_4E962FC579E0FD78A7F670C7640C756D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6A342FB2EDBCACE75CFB70C7640CDA66" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRestrictionofFundsPeriod" xlink:label="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_DebtInstrumentRestrictionofFundsPeriod_BA60C5E3C585460901EF70C7640C51D5" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnuallyAtHighRiskofDiseaseRecurrence_CD92D0E291007E6A2A0870C7640C0FE7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually" xlink:label="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_NumberofPatientsDiagnosedWithBreastCancerPatientsAnnually_9322848D95EDD30D5DC970C7640C40EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_A004C781CEFE151C487A70C7640CF75C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_90C48FEB8316C7BD05D370C7640C47C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryNet_D8E643C48EC67CF9887B70C7640D8C8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryWorkInProcess_4C3155A865E9F32D584870C7640D25FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_InventoryFinishedGoods_19398CFC1C374359342670C7640DE8D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_737A56BA3437728FFB0270C7640D86D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_SalesDiscountsServices_3D6CA905A0E40D79E40070C7640D6F99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9441C1618916AAD9F2E870C7640D8DBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4DA96F6FD4B630B52FF670C7640D258B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_46DF157DC183015C2AF270C7640D2EC1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_B84A3DA617DDB5475A4870C7640D5FE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_457FA6C0907CAC5495DC70C7640D3438" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_FBD31B9638A5FF04041070C7640C2AF1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_457FA6C0907CAC5495DC70C7640D3438" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5B5B1E216E87BF09B56F70C76412AB8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_UseOfEstimates_ACE212B22D575D056C2970C76412098F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_41FB7E4C16A716876B3770C764129FEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3684303DD317A9CA642D70C764129A59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ED408CDF2F66BD98F24970C764122A89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3790E04AB82AD10FD1AB70C764125455" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_328FF039C6365BBB61A170C7641282CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_03962801C745E95813B270C764125EB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_239AE1E57462573FA91B70C764121AB6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0B5BFE883D7A0A2F1DD470C764123D8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_EFA7A33BB23906BDE89670C7641263CD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_0020DBB15C9A6F6A404370C76412AB94" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_7CA613A477D45863DE7B70C7641255E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_A1FBE26D63EAA3A16C8D70C764133F9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_E3AF0727371D2E5C21B970C764137ACF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F57BEEA73B6E6759277F70C764139460" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_D27F105645780847404070C76413967E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9A8338C0C0F3B9B0188170C764132A80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_28479960096F37372AC270C764139E70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39B2DF4A5B371171840470C764130895" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_584C939F0EEEAB9F4FDE70C76413E67E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7A3112AC56A2559B708F70C764131439" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_DB69C0CACA307008DCB670C764137BC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E56843A8A5B3670A75670C76412AC4D" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_13D61BC8185E5CC4EF4170C76413F8A6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A5BDAD67895C6CD95E8170C7640513C7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47B7F391B97EBA173FAE70C76405B6C0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_09BB9DF1D6AE41914D0E70C7640078CA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_09BB9DF1D6AE41914D0E70C7640078CA" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42E276675ABA39D6254170C76400867B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_460561C268910DCEC88570C764000634" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4EEFCA9F3770733ABCBC70C764005422" xlink:to="loc_gale_ZuplenzMember_460561C268910DCEC88570C764000634" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_E487DE12155168CACAEE70C76401E0A8" xlink:to="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BEDCBED34DAA59BB8F1370C764017C82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2E2E50D4BDABA454B0C470C7640142CC" xlink:to="loc_us-gaap_CommonStockMember_BEDCBED34DAA59BB8F1370C764017C82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0EB5511F3E34C5A9B9B070C76400D44E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7C70E54859CB7D7085A470C76401BAA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_BC43987754DB26E738BB70C76401A205" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_14C357103D0F3A8536BC70C76401820F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7E3AFFBDDEC0355A593D70C7640177AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E2247FC1A4C99A837F2F70C764011D93" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_654767B91F2C55B2BF8C70C764012380" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C8B4FBF79B5A3158CE7F70C76401A18E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_Goodwill_C8B4FBF79B5A3158CE7F70C76401A18E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6C901C2057F667EC8A3A70C7640188A9" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_F6070CE55522DD6A779B70C7640131DF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6CDCFC67372FD772443B70C764038B4E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6CDCFC67372FD772443B70C764038B4E" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_AA101A3F759E3B2973DE70C764035F91" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:to="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F54AA8862CC92718980770C7644C47DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B76FB3BFB58BAC9721B670C7644C95F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_57A24C78812E6AD1939070C7644C8359" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D7ECB02EED80A5D1E82E70C7644CFAEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_44AC42F728956051388F70C7644C91F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9F2761CD34E18633C13270C7644CD791" xlink:to="loc_us-gaap_AssetsCurrent_854F48921ECCF36EA4BD70C7644CEB1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8CBF8F3A3B8B11CE56B170C7644C0AFC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_gale_InProcessResearchDevelopment_3F5DD8033070FC7C9EDA70C7644D1EC1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_gale_GALE401rights_F9F7373398C47E1F0C2470C7644DC664" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_us-gaap_Goodwill_C943001F42C16A43418970C7644DA1A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_B48D900DBE324A36E0A970C7644D3084" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D1FFA4B92D7CE83F4DD270C7644C3DD4" xlink:to="loc_us-gaap_Assets_FA32ED6B9C310FCAC5DD70C7644D3064" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25EE2A4E31D5D3B9145270C7644C77B2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_AccountsPayableCurrent_A6FAC8CE98D164F9833A70C7644D12C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_109ACEE6E0DC281169E970C7644D84E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_LitigationReserveCurrent_B684A5CE606FB7BEF0CB70C7644D6D9C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_C2F5B6707E01F67812E670C7644D19A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_LongTermDebtCurrent_FADD4A2FD95FA946A6A470C7644DB60A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1FBE03A094679499C15570C7644DFD91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6292557C16635A1900FA70C7644D98B7" xlink:to="loc_us-gaap_LiabilitiesCurrent_4F27B6B43E7666E2DA1070C7644DC230" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_DeferredTaxLiabilities_8B2AD472572085FA958270C7644D2D56" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_63D6409B6FA3C3CAC0D870C7644D7981" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_Liabilities_E50E2CDAF12B55FD846D70C7644E0DB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_E59E428CEDB99769C0FE70C7644E050A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_us-gaap_PreferredStockValue_B880B6572CFC08BD16A170C76453D724" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_us-gaap_CommonStockValue_52CB89CFB261935AFF4570C7645316FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3580D1A9DDC786DC0E8C70C764539C82" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_E648E8679A9C91136EBF70C76453E3A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_us-gaap_TreasuryStockValue_64F7BD90706CA1F3DD0570C76453A6C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_03EE0FFFCCBD01D73F1770C764537ECE" xlink:to="loc_us-gaap_StockholdersEquity_1EDFDFCB43F8346961C970C76453A196" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A69E5588F71E22B3EE7C70C7644D19E3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1EAA4DB3CA78B669B5670C764536393" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DBC2305BDA3CF54B5E1A70C7642E9AD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_C33300440EB986BECA3470C7642EA258" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6B45B6A9521E9D2B0FF270C7642EADA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5F06BAB73C66AAA1181F70C7642E898A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_05B6B05DB43D23B2A21C70C7642E3A4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F0FD616BD28694AD924670C7642E3018" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_CommonStockSharesIssued_91786D88F60008849A4370C7642E8DF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_E111DFF65BF611A335F270C7642E260A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B5BED14F5E6F4763BBBF70C7642D4C59" xlink:to="loc_us-gaap_TreasuryStockShares_B669546C1F5F23F997D770C7642EF72B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_F88FA701FC23E7BB4FBD70C7642592AE" xlink:to="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8B83F65B6E0A844563F070C76425FD94" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_CD587877D8D91D41719970C76425F874" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94F8472D1EA5FA389F1370C764255C48" xlink:to="loc_us-gaap_SeniorNotesMember_CD587877D8D91D41719970C76425F874" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_704E9CA446E759090D3B70C76425FFB7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_40C65E54DE404260327E70C76425E780" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ACB3A128D8FDBF66BC3870C76425A374" xlink:to="loc_gale_SeniorSecuredDebenturesMember_40C65E54DE404260327E70C76425E780" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D764F157BF1D7D02516170C764258F3C" xlink:to="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_B04626C89F96CA2B200070C76426705F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_CommonStockMember_B04626C89F96CA2B200070C76426705F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_23CC2DED7BA948FBEE8870C76426502B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_RetainedEarningsMember_57A770A077F9C0EB345070C76426FB73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C3885798177BC0EEA43370C7642646C5" xlink:to="loc_us-gaap_TreasuryStockMember_E33A5427BCBE968EEB3270C76426019A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6903FE9783789CF53B0C70C764259917" xlink:to="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AE063E6C442FE4622D4170C76426B71B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_SharesOutstanding_F2F7076A469CD6C1108470C76426692F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0230DAA133AB716F324870C764265C22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_A75802965DC45375B3EF70C76426149B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_AB732EED6777D6A057E270C764262DD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6CDEEF89B46C1802F9DF70C76426AEE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0540DEF38FB54AFE1A9B70C764261BD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_99B3A6AAEB9DA810227070C76426BDE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_C7B1BB2D56064EB7C3F170C76426FC6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_569FFC23B98576689E9870C76426FDDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B298F90476E6B2C5523F70C764263C31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_F130A0C3D9C80CF0D3B770C764268C69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2E3AC5237A751404D97270C7642623ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_NetIncomeLoss_846BD1B41892BEA9683370C76427946F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_SharesOutstanding_F526738FE8EB25796D7D70C764275C75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3B546AF742F12865077E70C764260F65" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05922DC7A3A3EAF62E8070C76427DDD3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_B644FBE07248A7CD76CB70C7641DA42C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8ED701628D3FE6D6C6AD70C7641D4598" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:to="loc_us-gaap_ShareBasedCompensation_B19CF3EF7153F0109FA070C7641D4BE9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_1F408574215065D276DE70C7641D234E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_41B8179F31B54CB93D5570C7641D7ED0" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_1365A34D29101C3BC5E670C7641D0EEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78A6AFF11BA4594E020870C7641DE1C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable_DF62A23024CDDC02156770C7641D0249" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_0290F1B6A3EDEEAB45F470C7641D2144" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_62DBBBAD33830474526170C7641DF936" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C150CBA253D62DEAF8D970C7641D839F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4851A72C1162D38A84F370C7641D1D0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_51D1B73FE7E6CE63F6AA70C7641E7180" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_789676ED2E92875D201770C7641E7555" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_IncreaseDecreaseInAssetsHeldForSale_143AC6F4A290381AF21D70C7641EAC85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_42C4B657061E6518B35170C7641E1C6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_F1DDBADFD2DAED2244F570C7641DBB36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9CC662774A52B2BCFA6A70C7641EAC0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8B4BC7868CB44180166770C7641E27B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_818E606101C340D5313270C7641EF48C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentsonDisposalofProductiveAssets" xlink:label="loc_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_gale_PaymentsonDisposalofProductiveAssets_F675FD2DCB520FD2D9F270C7641E6B09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_01DD7C7E834B20FC0C3870C7641EFE13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_A8ECFD3320A06FD3B58870C7641ECFF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53C322BC97F715C571A970C7641ECB04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33D360A8110B72C55D6570C7641E0EDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1A65DC524097A08FCE3B70C7641E83D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0CD2F9C8D8D0C8DA93DB70C7641ED7D4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_B2D962F625ABAA7830CE70C7641EE057" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_69333DE5AC3C8BB80E3470C7641EB200" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_C3D111F875F14424013A70C7641E9B28" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_IncreaseDecreaseinRestrictedCashforFinancingActivities" xlink:label="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities_E61100B67677171D568D70C7641F653A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_AFF833A6DC3A8A41DFBC70C7641F1FA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_CEAA3FA439846143DE0870C7641E6EE6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F57041AF92E9AB11C95170C7641F16D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_60B706EEEF76DEC9F01F70C7641FF976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D17D3F93B7B6B542492970C7641FB30F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AA8D2BE9DCD0F0B2F63670C7641FD198" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_788F748FCF83BF32F44370C7641FCB16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7E17B5D2F4EA31ECDE5770C7641F5AA4" xlink:to="loc_us-gaap_InterestPaid_5519B4502B5D3D40710470C7641F0DAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_271C3B8AE8DA41DA713470C7641DA550" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_499502437F98A5188CFE70C7641FD850" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_14B444CA2320C971995170C7641F1F14" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_D877CBA0E591BF615F3D70C7641F8343" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_672733AAC03A6EC344CF70C7642A2337" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_FCD22EA471D4C857886370C7642A916C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:to="loc_us-gaap_CostsAndExpenses_ED3032FD6E107A5E12C670C7642A109A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4805D7854E01B7DC172170C7642A7BA9" xlink:to="loc_us-gaap_OperatingIncomeLoss_68C523ADD30397EFD44D70C7642A54E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="loc_us-gaap_LitigationSettlementAmount_C4CC3B67DD1426B3ACF970C7642AD2CC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="loc_gale_LossOnWarrantExchange_F79BAB4707D51152C31570C7642A64E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_B9F935ADAE3C02E0C61A70C7642A6AFE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_98BB0C7CB9C66A0D404870C7642AB3D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0DAE2D4CAD58E626AF0C70C7642AC30F" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_CEF94DE73F9829E5F9E270C7642AC202" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_E7AB870D7866999CCA7C70C7642ABB53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6FF51599272430EC0C7170C7642A07A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_NetIncomeLoss_0B76C28C30BCC0A775A170C7642A76B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_082C4CE1139AE8F58F0670C7642A4C1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_EA9555725524295D152070C7642BF8B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1FD85C152E11703E497670C7642AC88E" xlink:to="loc_us-gaap_EarningsPerShareBasic_91ECAC9A48FF35D0626370C7642B6C70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_561A2832737EA062A5A870C7642B4AFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3242DA7285310DCCA5A370C7642A34CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3F5AFE83858F7ECEB50A70C7642BBBE7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4AA694DF588E1E3D189D70C76367CF1D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4AA694DF588E1E3D189D70C76367CF1D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_E29299C482A9F241036070C76368D4CE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralRightsNetMember" xlink:label="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:to="loc_gale_AbstralRightsNetMember_8656B6F4B64450F40BFE70C76368190E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzRightsMember" xlink:label="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C00A1CB0ECC1957DEEF070C763688606" xlink:to="loc_gale_ZuplenzRightsMember_D2D673269C305E0AAD5470C76368C95B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4CD81A7A60345CAAF9A570C763684176" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51F465AFED9CF24D942070C76368801B" xlink:to="loc_gale_CommercialBusinessSegmentMember_91B50142BE1ED8FB0CF670C763685994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BFF3245523E00755153770C763688395" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_CD42E552E68AA1D5A91270C76368372F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_DC1B9852165FFC8E239E70C763680E5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_797AF1FF0E7FCBED190770C7636899CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_464A1EA9286B886EC8FD70C76368436D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_D63FF29A7C6FE6A1367770C76368B17D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_04C93FA377E4AC8FA1AB70C76368345D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_CC1B1F0F04793160D4EF70C76369107C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_41A471A7ECAC376656B070C76369AFE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_BF490616097539D549D470C763691691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_DBD394D55D21FC10DD5270C76369F979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_40FF48AC3917BDD4DB6070C763687109" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_35BDEEBE8818DEBCDFCB70C763698559" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C749192975469EE1BE4F70C76362F50C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C749192975469EE1BE4F70C76362F50C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2265D7217D0B2BB1D5DA70C76362DA45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_3E320D659BC03443297F70C763621C84" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9E50AD3F0B03480BE13C70C763624D25" xlink:to="loc_gale_CommercialBusinessSegmentMember_3E320D659BC03443297F70C763621C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1BE241D3DC1FB4D9AFCA70C763625191" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2EAED64494CF0C0AF87070C76362A062" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations_2A6927BC4CC755B3FCFD70C76363686C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2712F75A5A28A028775070C76363336A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_95B20685150F4EE153A470C76363B3B1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment_42758037BB547EF0394870C763631774" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4C7F9BEE3809736B61EA70C763638AFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_BBCD644A5739656FC66470C76363BF6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7C807E47B1CBBC324FB170C763638B2E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7C807E47B1CBBC324FB170C763638B2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0F3C92AA24629E9A60AE70C763622BA0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87F7BA7DDC864CBB45F870C76363ABD9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C3DF6293164520F74E7C70C763702815" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C3DF6293164520F74E7C70C763702815" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:to="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_0A18B6F480CA810D37E270C7637097B9" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LegalExpensesMember" xlink:label="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_13BE023023048044A79D70C763712CD4" xlink:to="loc_gale_LegalExpensesMember_F662063610DA0EA50F9F70C7637179AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_EDE558567DAAAB1E3DA470C76371C8B9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_71BD66C3A15982F0798A70C76371BF10" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:to="loc_gale_CommercialBusinessSegmentMember_71BD66C3A15982F0798A70C76371BF10" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralandZuplenzMember" xlink:label="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_83911F2DD2102386B80570C763712A6B" xlink:to="loc_gale_AbstralandZuplenzMember_FB9918B68A4F71BB968F70C76371298F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_C7DF6BF0FFB8B4B1D4CE70C76370064D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_419D6FF34727792D92C370C76371383C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP" xlink:label="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_PercentageofCancerPatientsAffectedbyInadequatelyControlledBreakthroughCancerPainBTcP_67D4B1A4777BA69CDF0070C763712F6B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement_E9F54A2C3D2712D56F5970C763710EEE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue_771720D9ACF88CA1CB7F70C76371E090" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityPercentageofConsideration_E26E49DF652F39C929ED70C7637170C7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees_8E9131B4636CCBD4E54D70C7637119D4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived_9CA5C1465B8156EA97AA70C763713BCF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_82ACB65DFBFB56DF9D2C70C763712D93" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments_DED447EC1E12C644332F70C76371FA5C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_463DB138BB5611CBAADB70C7636C57EE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_463DB138BB5611CBAADB70C7636C57EE" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_42CE4BCE44CD8FB6275470C7636CF1A4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:to="loc_gale_AbstralMember_777C50491338A9D5432B70C7636C54A8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5B711515236FE63FA8BF70C7636C97E1" xlink:to="loc_gale_ZuplenzMember_C8FE89CA22694AA5098570C7636C4FA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_882B8877EB51E40C71AC70C7636C42B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_E58BFD3D7F95C5563CA370C7636C3E6A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_5BA6298077FC22314FDF70C7636C7B3B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet" xlink:label="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_84286AF999905752FA3570C7636C2B1E" xlink:to="loc_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet_B1E30525148631EA8C2B70C7636D35D5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4F48AD41D63ABF8811A970C763760106" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AF09E8CB00D94B8E389770C763760C72" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_958301E6C94B9863435270C7635D0C7E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_958301E6C94B9863435270C7635D0C7E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2C27178CE3E88966FD6470C7635D66E3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_25FE99448F40E67EDCA470C7635DA035" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_73F3C69D0F4F811ACC2370C7635D31A2" xlink:to="loc_gale_CommercialBusinessSegmentMember_25FE99448F40E67EDCA470C7635DA035" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_AC36761B907991132C3170C7635D3B53" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_F40C35A30F1D68F1DAF870C7635D9603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9741DA2291C39DC1C67170C7635E2EAB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9741DA2291C39DC1C67170C7635E2EAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28B5BFA26469B1A0F41E70C7635EC399" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28B5BFA26469B1A0F41E70C7635EC399" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_F7B505356D93CA84A62F70C7635E0C8F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_ShareBasedCompensation_F7B505356D93CA84A62F70C7635E0C8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03A0421045BBD7C0F19E70C7635E2E43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_160A7C56565234E9BB8F70C7635D4C66" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A0CF129738AA2B5DF90E70C7635E9C50" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C8DE1438087F58DDAC7470C7637382E4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C8DE1438087F58DDAC7470C7637382E4" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1C68FCF8AC92A0313FFF70C7637376A6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="gale-20160630.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_EntityRegistrantName_56A67122EA3258A2E7BB70C7645DECF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_TradingSymbol_D29996A6208503D5D53F70C7645DDB19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_EntityCentralIndexKey_C1E0684A1047284DAFE970C7645DE8A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_CurrentFiscalYearEndDate_C3F3BCA85F47242D978C70C7645DE6AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_EntityFilerCategory_BD7333370A6258DEA9E470C7645D5F86" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_DocumentType_318CF2DB1AC3A10BF48370C7645D2686" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_DocumentPeriodEndDate_24E950B408D9ABFCD25370C7645D91EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_DocumentFiscalYearFocus_AF5444A183DFBCB9EB7F70C7645EF442" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_DocumentFiscalPeriodFocus_EB28B3FE86989BFBB88D70C7645EA991" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_AmendmentFlag_E08884C9F0208FFF864E70C7645E8C37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1EC5CBA5BBBFE2417B4C70C7645DF356" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_CA10C7368E3932E5928A70C7645ED8B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9899F7216F7D5429EA6770C763FD9A04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9899F7216F7D5429EA6770C763FD9A04" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8548B63EE4D1D4615B0E70C763FD5537" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_286B116EA374345A372E70C763F9BFD2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_738A68B5E811EB288E0870C763F95DC0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3FACBB250F6156F91B8E70C763F9D7E6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2FF2D7D33C0857BC0E1F70C763F997AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B0B982C14E045C2446C070C763F9E783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_99A4E1BD3061F517416E70C763F954A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_12FEC01D4A3472000DBB70C763F9F51E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5F697BC8195D611E979570C763F93CCB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DEF31B97CFC3DA9A6F4870C763F9AB00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23985BF145F900E157C170C763F9DD0F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0EBEE8134B1504A69DB670C763FA10AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_B8A70BC95CABD88AF38D70C763FA0119" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4FF7B60ECCB65C93A5CF70C763F9D209" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_14A3073875529C80EBB170C763FA4DE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A0A6978B02DB3C37CD2970C763F90F22" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_D5B75E3B450E00AD2D7570C763FA2EDD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_9CA0CC24BEAFEC05344E70C763FA64EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_EF7E1C95A72451DA32B170C763FADE17" xlink:to="loc_us-gaap_EquityFairValueDisclosure_FA21048EB06F9F47C66770C763FA769B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_09D0C215E1125806794F70C763F446E8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_09D0C215E1125806794F70C763F446E8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_590B05A3F2F94C41984870C763F4F432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_538FEA060C9044EB4FD070C763F583BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D408344AFB7CE48053D70C763F5FCB8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_538FEA060C9044EB4FD070C763F583BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_A8742FDD8026AA2833FE70C763F451A8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6FC5925235731185D8EE70C763F535B9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_73235D8E596D51F8CB4470C763F550B4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_AFFF3E9F864A768AF3DE70C763F5382E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36587B58DE1DF2FF307E70C763F5C74D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7A1DB2E769E559EF01DE70C763F52F4E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_EC705D60568CBADA433570C763FCDB1B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EC705D60568CBADA433570C763FCDB1B" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C32EAF481D00B8093C8070C763FC2EA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_EC705D60568CBADA433570C763FCDB1B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6690A08A4A2C13377C8C70C763FCEDEE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AEA2A6224D1CA09BA9E370C763DE0B93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AEA2A6224D1CA09BA9E370C763DE0B93" xlink:to="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_72B604E18BBD26A03C5B70C763DE680D" xlink:to="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_77FC62CFFC9B77826B2070C763DE5389" xlink:to="loc_us-gaap_SettledLitigationMember_26AFF1C69ADD9EDD2C9C70C763DEEF46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_303C4BB8BFC1B824CC0370C763DEE003" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6F6977EE0DCB4C9B8FF670C763DE304A" xlink:to="loc_us-gaap_ScenarioForecastMember_841AEBC55F9F957CF0E270C763DEE1E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7AF1004EDE498564673070C763DEC1E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_946CD086C348E9307A5A70C763DE07C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_32488019F0F056355BA070C763DE4167" xlink:to="loc_us-gaap_SubsequentEventMember_946CD086C348E9307A5A70C763DE07C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_8A9B653537785EE908C670C763DEAB1B" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_78424FC70B9FAE77B4C470C763DFFEE0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_C6E2E10DCBA7AB8E3DE470C763DFF0AC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase1Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase1Member_C743EFC7CBD4FFBC034270C763DF8C89" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SecuritiesLitigationOptOutSettlementCase2Member" xlink:label="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6AF947AD34037AF8525F70C763DE2A03" xlink:to="loc_gale_SecuritiesLitigationOptOutSettlementCase2Member_7DA1B61C796C1DCC5C1270C763DF8019" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61E36534DC08ED7BC20C70C763DE815C" xlink:to="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_LegalFees_BB637CCE54BF2A62537F70C763DF9B99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_83B670988E4BB7E682BD70C763DF0C9D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod" xlink:label="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod_5376E000BAEEE13DEBC270C763DF8E33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_LitigationSettlementAmount_FECF9D6CBB3E37373C0970C763DF6016" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentsforLegalSettlementsPaidbyInsurance" xlink:label="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_PaymentsforLegalSettlementsPaidbyInsurance_80D79B507D6707F8439B70C763DF6D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_D9D8B739ECF599696BE370C763DF6381" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockValue" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockValue_F1312EC867FAE579721D70C763DFBE12" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LitigationSettlementIssuanceofCommonStockShares" xlink:label="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_72ED1ADB6D36595F597370C763DFF6C3" xlink:to="loc_gale_LitigationSettlementIssuanceofCommonStockShares_05581AE33A0EB0E421C470C763DFE7FE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BBAA116CE36CD7B7F1FF70C763E3B483" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62EBD941B5F0D6DE572270C763E357EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2C915F06334E9A21EFF70C763D7D4F4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2C915F06334E9A21EFF70C763D7D4F4" xlink:to="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_B9B7A08CCDB7F8BF074370C763D815C3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C18AE85951432D94A54B70C763D8773C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11C92F2E6FAC5A8F470070C763D8F878" xlink:to="loc_us-gaap_SubsequentEventMember_C18AE85951432D94A54B70C763D8773C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5943114D92D021F4740270C763D8D0B1" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_4BD004CA59D22261537270C763D8FD6F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2775A479B027FE420AC070C763D846D2" xlink:to="loc_us-gaap_ScenarioForecastMember_4BD004CA59D22261537270C763D8FD6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_1CFB93E5069B124CF15F70C763D80711" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_01A04347CF9A3AECE2E070C763D8FC0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember_01A04347CF9A3AECE2E070C763D8FC0D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember" xlink:label="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_7FD334DADA85F9DB0A7370C763D8AFD0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember_7FD334DADA85F9DB0A7370C763D8AFD0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ShareholdersSecuritiesLitigationMember" xlink:label="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_4A9B1BB2AA15EA885F2070C763D85C4C" xlink:to="loc_gale_ShareholdersSecuritiesLitigationMember_67B6ADDE8AB0D57D8D6570C763D8B07E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ABA67EEB465F5FE2445F70C763D7D951" xlink:to="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_EDC5A560B89A36E4271770C763D8D22B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_LitigationSettlementAmount_EDC5A560B89A36E4271770C763D8D22B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_F2334DE8C717A0595B4370C763D8F336" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_F2334DE8C717A0595B4370C763D8F336" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_3E7341FFF175030E65AB70C763D9BECD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_3E7341FFF175030E65AB70C763D9BECD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_IssuanceofCommonStockforLitigationSettlement" xlink:label="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_C039590FAE8F0EF9D68670C763D8FD4E" xlink:to="loc_gale_IssuanceofCommonStockforLitigationSettlement_799592EFE9139557D11D70C763D9EBB2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C738D08B58B379C2073F70C763E1F020" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C738D08B58B379C2073F70C763E1F020" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_80D947F09D21EC2757EC70C763E12FAA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6C8221578572E4E3DE2370C76388B2B3" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_2C9FA94972045816449770C76389A2FE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31B29F2D9B1E5D69221270C763840D4A" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31B29F2D9B1E5D69221270C763840D4A" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_6C78DFFC6423AB3A812C70C76384F4FE" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SentynlTherapeuticsInc.Member" xlink:label="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_SentynlTherapeuticsInc.Member_D01E24BFC9802AFEE8E970C76384E774" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MonosolRxLLCMember" xlink:label="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_MonosolRxLLCMember_1C8506677813E9F97B0C70C76384E6A7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MidatechPharmaPLCMember" xlink:label="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_05B8F61CB186D941784170C7638422D1" xlink:to="loc_gale_MidatechPharmaPLCMember_A8A8618A08E5A3A20F6270C763849EEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CEF7A2FB617D8F27035B70C7638416FE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B08EC913F332AA6CD57D70C7638421C9" xlink:to="loc_us-gaap_DistributionRightsMember_EBEE224ADF93B301A56970C7638484FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_07AFE9658378A299955870C763858F92" xlink:to="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D03C546622A721DF330970C76385CF7B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:to="loc_us-gaap_MinimumMember_D03C546622A721DF330970C76385CF7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9D8283153D853393D98070C763855D6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_09097237D07EF86BF83770C763859049" xlink:to="loc_us-gaap_MaximumMember_9D8283153D853393D98070C763855D6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_26E00B5838DCC0132E2970C7638504F9" xlink:to="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_C451CFC8C1EF6340284170C763851379" xlink:to="loc_gale_MDAndersonCancerCenterMember_56B11023F33969230F1070C76385478D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3B9628D887468D59E6F270C76385C183" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AbstralMember" xlink:label="loc_gale_AbstralMember_80EE4BAD7B447B60D30170C763853320" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:to="loc_gale_AbstralMember_80EE4BAD7B447B60D30170C763853320" xlink:type="arc" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB720FCEDF59EB1B7F4570C763851B1F" xlink:to="loc_gale_OrexoMember_0DEC10C8EECA96B2CC1F70C76384C483" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_FCAA05D4FC73803793D570C763841ED7" xlink:to="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_AnnualMaintenanceFee_059A6D967C462489861E70C763850274" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FutureMilestonePayment_E772C6BDFA1366F5299870C7638544AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_FA929B6EB64C7DDFD57870C763859D14" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_267292678039B820ED9670C763854254" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_379C370441DCB9C7E5DB70C76385608E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A747F818F8A4D6C5889670C76385212C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_48509F10237B484FF87370C76385EF39" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_424BEB370889C900491070C763866C41" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredFutureMilestonePaymentMonosolContingency_E953DCECB5844C6C1F5670C76386224F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_2B30D184825C3D72D71470C76386DCE7" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C36D16E0F8E77092EAEC70C76386B47E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_F5F15391337073C1FD0670C763867DF9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PaymentofMilestonePayment" xlink:label="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PaymentofMilestonePayment_2070FC05785B8F6127BD70C76386C5FB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment" xlink:label="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_LicensingAgreementNumberOfOneTimeFutureCashMilestonePayment_9956F49B5663FFAA5C1770C76386DD1C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementConsiderationReceivableUnderAgreement_C54169A855274AF2BA5B70C7638613FF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement_A68F107E25EA6FB5B6EE70C76386E5FE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement_EAADAB0E435B44DEC08070C76386AF4C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementContingentConsiderationThresholdNetSales" xlink:label="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementContingentConsiderationThresholdNetSales_C9F330944769580C0B8970C763863C83" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationNetSalesContingencyThreshold_89F489A0C0E6D53DF59D70C763860522" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFee" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFee_797557D6C50666E8D37870C76386367B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived" xlink:label="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_16987F6F8D220EA1090E70C763851BC7" xlink:to="loc_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived_5B72677A87AA7CAA70F370C76386A56C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4BB16C3092FFCC3F3AFA70C763EC2362" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4BB16C3092FFCC3F3AFA70C763EC2362" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_FA96883E83786AE1119D70C763ECC9B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EAED89B6625F6B13013970C763E8C9CA" xlink:to="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B6A5604A9DF89F050A4170C763E980E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42ACCD2C3F0B1D19907670C763E9A78C" xlink:to="loc_gale_SeniorSecuredDebenturesMember_AD19D6108EF22986150370C763E930E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BA7C57F9754DCDB94F3770C763E9D9D0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_91A405132A52009D168970C763E98277" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_AD771F84E58529BA2A7470C763E9BEFC" xlink:to="loc_us-gaap_SubsequentEventMember_91A405132A52009D168970C763E98277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0BEB6C457DC9F53B12B70C763E9DEEE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:to="loc_gale_FirstTrancheMember_769C8C12B985515949C970C763E9608A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4745E6B6AC213BD03FDD70C763E9F831" xlink:to="loc_us-gaap_SeniorNotesMember_B5783D685260618472AA70C763E926D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_A81B9EDDF7A655A8C2EE70C763E98DC1" xlink:to="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F4673D2704E6D7E3A56970C763E962C3" xlink:to="loc_us-gaap_MaximumMember_93EC5F3B36362630916E70C763E9CEAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5658F36019B975C9727270C763E95912" xlink:to="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_F8CDEB7FC17E05A1411F70C763E990CF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_F3581E387B9209DBC14670C763E90307" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC1DDF96F4693694905570C763E995B0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_77FA739CD707D7BCF82670C763EABB4A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentRedemptionNumberofDaysMaximum" xlink:label="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentRedemptionNumberofDaysMaximum_829D9CC64C636B99675A70C763EA598C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6188930777C2E05A360270C763EA0B25" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate" xlink:label="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate_F5884FA2405E86ED119370C763EAA20C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7A4701EF8B38359484B270C763EACC91" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7A4701EF8B38359484B270C763EACC91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68971E2B5B07E1B112B970C763EAA0F9" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_68971E2B5B07E1B112B970C763EAA0F9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_ClassofWarrantorRightTerm_67EEBE44C7E5F031161E70C763EAD684" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_F2F4B762B227901675FC70C763EA3552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentTerm_62F0093560C7BD557A0470C763EA5FB9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_B947F2B1B64FE65DBA5870C763EA264D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DDDC45A0F734BBA03E9F70C763EA7BE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_CD260FBB37BE6D5D02BB70C763EAA9D6" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_71E4B572C8114490B3B470C763EA448F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DentInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DentInstrumentOriginalIssueDiscountPercent_DD36B0E4F6258952A8CD70C763EAC949" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E6F061E7D2AC883250A670C763EA8DCD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_5A70156D6D8F75BD808A70C763EA8653" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43E137AB3E6B56EBF09370C763E946D5" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_48F7811B905B4DC5A4B770C763EA33FA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1D2047BA1EE757CD359D70C763927FD5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1D2047BA1EE757CD359D70C763927FD5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2951078FC21919BAB5F570C7639275F3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3BBCF14842F6E2BCD07D70C7638B8C69" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1333E63DA937CEAA4B0F70C7638BC87E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:to="loc_us-gaap_WarrantMember_1ED16F8974AB4500AE5070C7638BCE89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_65D5F348F52DB37EBC2670C7638BF45F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FF0DB81CA6D4245ED22070C7638B1E79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6F0EEFBAE5D62A981B4770C7638B196E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F73F8C64EB46385AD0EC70C7638B1F22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BF1C411FA2D8925AA22B70C7638B47A8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88F6769D78BB48D9DAB670C7638E8585" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88F6769D78BB48D9DAB670C7638E8585" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B0704FD4824E4214E57E70C7638EA156" xlink:to="loc_us-gaap_NetIncomeLoss_E9E3E21ACBAC7D88543670C7638E8B7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88F6769D78BB48D9DAB670C7638E8585" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_A70A14F2116CA425339170C7638EE967" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04F761E3656460942D4170C7638EAE8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88F6769D78BB48D9DAB670C7638E8585" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8EDC0388087D9C116EBE70C7638ED035" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_486EA20B004A9D67DFF870C7638F5DF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_48E88DB4868C12C0709E70C7638E038E" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_54D3EA1E4AE93C2CA74570C7638F9921" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88F6769D78BB48D9DAB670C7638E8585" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC2794C88D7567E7D74270C7638F202F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B5A326139B28BAD6F86970C763907231" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B5A326139B28BAD6F86970C763907231" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_854B01DD7D2F05731C2570C763901750" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B5A326139B28BAD6F86970C763907231" xlink:to="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_BEF50311ABA3CA669AA370C76390CDC3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_F0111631AAFEDEC45C5E70C76397C3D3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F0111631AAFEDEC45C5E70C76397C3D3" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2F50767F293497A48FA870C763970299" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_3276BC4F6674A7E4FFD170C763947013" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:to="loc_gale_MiscellaneousOtherIncomeExpense_4738369A7B833F9A7B6C70C76394CECF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E358D7BE0ADDCD49E0BA70C763947059" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2092E905EC491985FEC370C76394ABE4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_3949B86B09083EE6237470C76395AD81" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_3949B86B09083EE6237470C76395AD81" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5A10C0AE1D91F318030F70C76395DDBA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_CF30630F7C81419DBF7270C76379C62B" xlink:to="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_E1BE0A680719EF0EA51F70C76379949E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BBC62D73A3E64165018270C76379A841" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_6D7AC5AE5ABE30A3F89370C7637A896B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_968528D794EECB88844170C7637A380C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_4108F83B193A4E7087F270C7637AA0F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23957E622B72ABA237F370C7637A8DF9" xlink:to="loc_us-gaap_AccountsReceivableMember_4E9BA7CB4F93228FA74870C7637AB913" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_30DDDE907330571A065370C7637A6684" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerOneMember_07527CD23D6D56E17DA370C7637AA7CD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerTwoMember_6AC82C852363C303A62B70C7637A1EF2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerThreeMember_48D6103A419D9391209E70C7637A3AC8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerFourMember_CF264DBBFBBB5F5EA21870C7637A7982" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_76F8B93533D3C11CBDE270C7637A6C36" xlink:to="loc_gale_CustomerFiveMember_EDE9D2CCE80F01DF5C3A70C7637ABC18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1098D1C46DA85D6AF85E70C763790604" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofCommericalProducts_95CD2690A2761CFD283170C7637A9F92" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofDosingStrengths_63253C2F7CCF5C7CC00670C7637A45E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_BDDD632C1A0D8AEA41BD70C7637A6189" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9C8F126807C0ABBEEC8B70C7637A8597" xlink:to="loc_gale_NumberofTopPerformingPharmacies_5EF334EF82B69DD1F41B70C7637ACEDB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_DCAF7978A36759CBB9B170C7637D60B5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_DCAF7978A36759CBB9B170C7637D60B5" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_D1F0A29D44383031ACAF70C7637D6D72" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_1A5E9B213B34B75928FD70C7637C043F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_1A5E9B213B34B75928FD70C7637C043F" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59ED1118A0C71A1A69BD70C7637C0553" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7D7484FC9191E26902C370C763AE7EE4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7D7484FC9191E26902C370C763AE7EE4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394AD52D7F226CF4430D70C763AEFC73" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D3955EADF41D660448F270C763A161ED" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D3955EADF41D660448F270C763A161ED" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3E5A6F7986CEDAAF6F4470C763A2E8C1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D5E12AC73BD493F27B1470C763A21A02" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_765340A30B97324FE8F570C763A2ABBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6AE55ABB1E150FC156F670C763A26D24" xlink:to="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E3C19F09B10A115A358E70C763A2C96B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:to="loc_us-gaap_MinimumMember_E3C19F09B10A115A358E70C763A2C96B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_767CEF46DCB2C69E5E4770C763A2408A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3595B4CCB8FECA09F0CB70C763A2C7B6" xlink:to="loc_us-gaap_MaximumMember_767CEF46DCB2C69E5E4770C763A2408A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E9853B84B554BC4CEA6A70C763A27406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75F40D3960F4EDEE3E9D70C763A222CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_C60E1E890876690EC10070C763A20498" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43FADBE5B44E0F815BAA70C763A22A4A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_97936F941C5EC2A58BF370C763A2ED8A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_DA03C3789D264786DAB470C763A2A1F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4CE92556A965D7A8854870C763A2741E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4CE92556A965D7A8854870C763A2741E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_49D55F9C676829E7AA3470C763A2FC1A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_8F73BBA409D05FC62FD870C763A35FEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32D2E4D2D4E3AE555D5970C763A37A41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81A1B49E26C17EB5927670C763A3134C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_714E516DEAA7DB8E51DD70C763A3C428" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B154CE67CFEE1480B8EF70C763A3CA03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4F4E668FA74F886FE2CE70C763A39C4E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FABD10A398AC1C65E0AA70C763A29313" xlink:to="loc_gale_ClosingPriceOfCommonStock_795F6BAD09CE83D8C00570C763A3346C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8398ED71E2316C673D6370C763A9C5C6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8398ED71E2316C673D6370C763A9C5C6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_C2E2DB80143C159D83D470C763A9E87C" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_811A9C34E519B04D0CF070C763AAA00E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_B31F1DBBA012636AF5BE70C763A980CF" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_25D03B131D2F83E90E9B70C763AA0BF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_186192424266EF21B0DE70C763AABA05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommercialBusinessSegmentMember" xlink:label="loc_gale_CommercialBusinessSegmentMember_629F9E25772E4DCBF79270C763AA2BDE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5AF6930C13E27D931E0E70C763AA610F" xlink:to="loc_gale_CommercialBusinessSegmentMember_629F9E25772E4DCBF79270C763AA2BDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_169FF7C2436B43ABECFC70C763AAEE85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_816BF3F53F7BC0DB429870C763AA3789" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B0C7681D64EF2B25726170C763AA811B" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E4127F0CDA8FD0A6C06670C763AAA06F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1CB671C7A3798FEB30B770C763A983CD" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5FEFFCAF2D4052DC98B070C763AA30D9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D318F9CEC34C07D853DB70C763AACD1B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8D76E0DFF52EC6270D3D70C763A64FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8604468994F945AD39A970C763A61033" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_73A5C1067C83AF05DABE70C763A6D22D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4026C8FE212E10D9692570C763A67818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1636AC6435F3C3AA325370C763A60224" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1DD7F516619F03FFE80570C7639B5830" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B4A0EF630D7CFD67BE7070C7639BA6BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A03D22D1FB045ECA9AD070C7639B3EF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_E0119518B9C38F08942170C7639B0923" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54FBB78280D37543F9C470C7639B46F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BA5FDB91EA17FFFBADF470C7639B651D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B0CC7C6A52F4E4FC71F170C7639B701D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_EB01CB6696C6D54C512F70C7639B5323" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_EEF3CACAF51A0A0D5E2C70C7639B1601" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05232F0AA9BCC977223E70C7639B162C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_23AA3E21189E8C2214E270C7639C46FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_75BF7905365FB259D76F70C7639BD44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4F501DBB978B290C4DBD70C7639CAE7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_AC77099B4CD690307AAE70C7639C5041" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FFC2DE7023B36D03192F70C7639CB063" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_69D5B03DB8FD4BBD53BE70C7639C5512" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28264F1BBE35159A929870C7639C90EE" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_5D4772F74DFCF5AE761070C7639C8E32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_EC7936AE163FB3B48C3170C7639C2DFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4D6BD95FB90788AF911270C7639B256D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_FAF4C4811CF6DEBB529770C7639D82BB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C022361C2D722A08A79670C763AC68FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C022361C2D722A08A79670C763AC68FF" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C2C9C10253FD215AB81B70C763AC4A7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C022361C2D722A08A79670C763AC68FF" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_A5DE7841F4A4D81F1E0B70C763ACD8B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C022361C2D722A08A79670C763AC68FF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6A3C6B855CC11A1E6AB370C763AC91E2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_977568EC48DBEA8C2A4670C763D42E07" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_977568EC48DBEA8C2A4670C763D42E07" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C4257826BFD814B1E58770C763D43BA3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_31DFEE5968157E82D66370C763CC1264" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31DFEE5968157E82D66370C763CC1264" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7A9E7E8A223A4B70EBD070C763CDC56C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54CDBF37371BC36F662B70C763CD95DF" xlink:to="loc_us-gaap_OverAllotmentOptionMember_440F40EF790EB365604370C763CDC6B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9CFF8F2BC3AD50D7D21D70C763CDB0CC" xlink:to="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:to="loc_gale_LincolnParkCapitalLLCMember_9C47ADD3986369057AA570C763CD6658" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_62F3FF07E9A145DB409670C763CDA705" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_6D1BD3E7CF8A4A240C8970C763CDAC38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_938EA6997156CFC38DA570C763CD5926" xlink:to="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_797990DC01FF9A7E5F2E70C763CD40BA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:to="loc_us-gaap_CommonStockMember_797990DC01FF9A7E5F2E70C763CD40BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0672C963D180182D932670C763CDDD44" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2A9B8CEC8D490542B3A570C763CDE875" xlink:to="loc_us-gaap_WarrantMember_0672C963D180182D932670C763CDDD44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32E0BDC836A7B3AF16D570C763CC45EB" xlink:to="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B0E6ADE4F97A78D1F6F870C763CD6382" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B0E6ADE4F97A78D1F6F870C763CD6382" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FAA85E077D14A7033FC070C763CD023E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_FAA85E077D14A7033FC070C763CD023E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1649FECFC91C8C4409C970C763CDBD2E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1649FECFC91C8C4409C970C763CDBD2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1871B98FE4A46DF7DB9970C763CDD92D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1871B98FE4A46DF7DB9970C763CDD92D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommonStockAdditionalSharesAuthorized" xlink:label="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_CommonStockAdditionalSharesAuthorized_F1867824559C73F6FC8A70C763CE3C25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_A63EB2F4D48BEFB3549E70C763CEC227" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_PurchaseAgreementTerm_A934B67CEC14D4C5801C70C763CE05A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_0B926B4AB256CE4321CC70C763CEB599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7857E7E916A65F0945DE70C763CE4E21" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_SharePrice_7857E7E916A65F0945DE70C763CE4E21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01007C889B83263A117870C763CED7CA" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01007C889B83263A117870C763CED7CA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_F41EC78AE1DCE2CF056F70C763CE0585" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_E0A43D158BAD6C4CA02370C763CEF58B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_NumberofSharesPerUnit_53FA8C73BC959EE5D49270C763CE410E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45435868056C57203E5F70C763CE6FDC" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45435868056C57203E5F70C763CE6FDC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_StockAvailableforIssuanceSharesNewIssues" xlink:label="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_StockAvailableforIssuanceSharesNewIssues_AA6BA362A5CC0EB855AD70C763CE4894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_600079A19208C45E023F70C763CEECF4" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_600079A19208C45E023F70C763CEECF4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_F7EC67A6EFCE82D9BF9170C763CE9A33" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_16C947B101CCB76A0F7D70C763CE051B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6438CB3BBC9731FF335C70C763CECDA0" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6438CB3BBC9731FF335C70C763CECDA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34695788CDE7E058BC7170C763CE883A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B93C01D138D7E0F4083A70C763CD986F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7E45A6E68C2079D5B69470C763CE4B97" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_56BD7F36123DCFF54DB070C763C7604D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EB18509846DB8EF6303D70C763C752EF" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_02611E3A1C3E7158B76C70C763C79CAC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_8D483DBE8D06D3C3C5C770C763C776E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8C5C306F3D229BCD638170C763C66713" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B98435D5854A5B70937170C763C769C8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5708585156E4B554603770C763D28A67" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5708585156E4B554603770C763D28A67" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_8DCEA65BB1C9C8942A5B70C763D25A52" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_C5E6A5A1632E0754713870C7635A05CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_C5E6A5A1632E0754713870C7635A05CB" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_31B8797C6078C159B88070C7635A33D3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_405672DFCECB82173AC670C763536377" xlink:to="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2711A0FE11CD85CDBD8D70C76354240C" xlink:to="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_424BFF8A4692A45CFEEA70C76354D0E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:to="loc_us-gaap_MaximumMember_424BFF8A4692A45CFEEA70C76354D0E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_937B4D36FD75EDABEC3F70C76355BC51" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_DED514339BF61180F76F70C763546036" xlink:to="loc_us-gaap_MinimumMember_937B4D36FD75EDABEC3F70C76355BC51" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermAxis" xlink:label="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTermDomain" xlink:label="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SaleOfStockTermAxis_6E594259418861ABFB8A70C763557915" xlink:to="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheOneMember" xlink:label="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:to="loc_gale_SaleOfStockTrancheOneMember_280C967842E361C11FA870C76355DBD2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockTrancheTwoMember" xlink:label="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_SaleOfStockTermDomain_979FC9BBD3C95E137BF870C763551F80" xlink:to="loc_gale_SaleOfStockTrancheTwoMember_B1FA0528E073D35E926C70C7635502A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1B4D6AAF384D2A864F9770C763552BF1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D7D25B19DC8854C6F23070C7635519A5" xlink:to="loc_us-gaap_PrivatePlacementMember_E5C5E73207323D22D6F070C763556180" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EA07D7234C6FAF371E3570C763556AA6" xlink:to="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E40AC2E80CE2B4DB5F9A70C763557845" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71569C6316320532273470C76355665D" xlink:to="loc_us-gaap_CommonStockMember_E40AC2E80CE2B4DB5F9A70C763557845" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_195619F184C785ED4B0770C7635527D9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_EA954241F07787D2F18470C763555F38" xlink:to="loc_us-gaap_ProFormaMember_6E1A47A5713F1C2746BB70C763557DEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3CA9322DA1BF96107C5D70C76355C17F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeniorSecuredDebenturesMember" xlink:label="loc_gale_SeniorSecuredDebenturesMember_B9068A479EFABF245FDE70C76356AB2F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:to="loc_gale_SeniorSecuredDebenturesMember_B9068A479EFABF245FDE70C76356AB2F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_OxfordFinanceLLCLoanMember" xlink:label="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1A6E9E190419E17067E070C7635691DB" xlink:to="loc_gale_OxfordFinanceLLCLoanMember_B141059C993B8D6B155370C7635613E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9324A9112DF750AC410A70C76356E96F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_134DB2C1E29A5C0B3FB670C763564473" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_848B8F2554D200A85F6370C763564650" xlink:to="loc_us-gaap_SubsequentEventMember_134DB2C1E29A5C0B3FB670C763564473" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5890C78E1AE7312CCFB170C76354AA35" xlink:to="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FCF75739E07F1253B8F770C76356D96A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FCF75739E07F1253B8F770C76356D96A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3E16909B8EEBEB57A82170C76356F502" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3E16909B8EEBEB57A82170C76356F502" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightIssuedDuringPeriod" xlink:label="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_93B37822EF6144792CDE70C763564010" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightIssuedDuringPeriod_93B37822EF6144792CDE70C763564010" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_58DA697BEA97E2EDDD0770C763565F71" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_58DA697BEA97E2EDDD0770C763565F71" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExercisePeriod" xlink:label="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightExercisePeriod_EAB04755EDEA69CAFC8D70C763563B20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_E9C7E8CDF70FB6FC3ED970C76356A0B9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_E9C7E8CDF70FB6FC3ED970C76356A0B9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DentInstrumentOriginalIssueDiscountPercent" xlink:label="loc_gale_DentInstrumentOriginalIssueDiscountPercent_9203C52183B1D2B2323770C7635621E1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DentInstrumentOriginalIssueDiscountPercent_9203C52183B1D2B2323770C7635621E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F920F8B8808F37E4F95A70C76356842C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F920F8B8808F37E4F95A70C76356842C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E1F0275763379B4DD22370C76356338E" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_E1F0275763379B4DD22370C76356338E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_EF776F8B119C7C17BD0070C76356C8B2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_EF776F8B119C7C17BD0070C76356C8B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F5F1ECFC70AAAE9E29270C763561256" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5F5F1ECFC70AAAE9E29270C763561256" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest" xlink:label="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentContingentPaymentofPrincipalandAccruedInterest_1544D2E090E48744E87370C763567291" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPrincipalThatCouldBeRedeemed" xlink:label="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_D670141057CEDFF0A50E70C76356B1FD" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentPrincipalThatCouldBeRedeemed_D670141057CEDFF0A50E70C76356B1FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_307CA758CB740B805F6470C763562396" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_307CA758CB740B805F6470C763562396" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_8DAAD3EC2BB150FA8D8470C763572137" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_ClassofWarrantorRightTerm_8DAAD3EC2BB150FA8D8470C763572137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_69A5C1AAB9CF7ABECDCE70C76357135A" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_69A5C1AAB9CF7ABECDCE70C76357135A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentCovenantLiquidityCovenant" xlink:label="loc_gale_DebtInstrumentCovenantLiquidityCovenant_56FC627D3969328962D070C76357F34C" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentCovenantLiquidityCovenant_56FC627D3969328962D070C76357F34C" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived" xlink:label="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_B6059A46DA9B4EDD147770C76357273D" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived_B6059A46DA9B4EDD147770C76357273D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A03F1E1AC293E847071B70C76357751F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_SharePrice_9F0D60B42183A24366FD70C76357AEA9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SaleOfStockMaximumConsiderationReceivedPerTransaction" xlink:label="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction_2825132FF859601553B370C763570944" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_B3310C6F642E7012B80470C76357D775" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5941E49513606E75E88570C763565455" xlink:to="loc_us-gaap_OfficersCompensation_DD37943E5A487E8D409970C7635722AA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_732181022F0B515BF0A970C763C449BD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_732181022F0B515BF0A970C763C449BD" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_05A757BA6423446D155070C763C4EF52" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32D1C3A75EFC5E4E150170C763B55EEE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3633E1453272A5CE370270C763B57B79" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_6FBD92A4A2E879EBBF2F70C763B60660" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_6122EEBD85F91BE3799570C763B6A369" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7B05E303FD28291FD77F70C763B66600" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_1DEBE7A5C3809DE6A97D70C763B6C702" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_86B9E81B29AB22663CA770C763B68012" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_CC4DD13B237A8D630B0770C763B65EA2" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_FE081EF509DD1EC8C0CF70C763B5B79E" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_3AFB1905BA7FF54C4DF370C763B60D08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_16A8F877EA4CEB85ECC870C763B519EA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_83D736584EBB282CF2AB70C763B64395" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_CBBCB137D899967F4CA670C763B60A8E" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueofWarrantsGranted_1506430E10F20BF0CC8770C763B69B77" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsExercised" xlink:label="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueOfWarrantsExercised_05822761AAA98CDF43F870C763B63ABA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_9D99A85311541BCB4FDA70C763B6CD2A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_621777D23450E3733CE670C763B69173" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_20D45B4430BEF98C928370C763B6E6CE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C21CA7B9BE8081BFF63970C763BA7F5D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C21CA7B9BE8081BFF63970C763BA7F5D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_795DCB050E2965993F8B70C763BA3A63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_E242A843A1703B9E647070C763BAE5CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_E242A843A1703B9E647070C763BAE5CB" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_4D0C4018651D20E9967470C763BA6A41" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_4D0C4018651D20E9967470C763BA6A41" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_01A6218B789C961232B170C763BAEF60" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_01A6218B789C961232B170C763BAEF60" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_8C127F2954895B8FDB2C70C763BA88E4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_8C127F2954895B8FDB2C70C763BA88E4" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_03453305310789EC4D0870C763BACF09" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_03453305310789EC4D0870C763BACF09" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_C2483E5568797B32485270C763BA685D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_C2483E5568797B32485270C763BA685D" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_82605FBFF759686842DA70C763BAB038" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_38A4EE1003A96355D56C70C763BADFAC" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_82605FBFF759686842DA70C763BAB038" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_E144EDA9126D53EA1D2B70C763BAFD7A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantStrikePrice_F7E3B41F08B335AB280670C763BBFED8" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_17F0D5276695E0302F4E70C763BB2664" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_36DC6D589340600A196E70C763BB186B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_FCE8DE0D27BF5BD6CF2570C763BBB5E9" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_AAD8F9F9A4D250203D1570C763BBD7B0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_62011BBB04F037BB6EEE70C763BF8340" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_62011BBB04F037BB6EEE70C763BF8340" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9D5470B85824F56C4BA970C763BF5CA1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_JanuaryTwoThousandSixteenWarrantsMember" xlink:label="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_BC45024133843A34E9EF70C763BF50CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_JanuaryTwoThousandSixteenWarrantsMember_BC45024133843A34E9EF70C763BF50CD" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_41816523E10A54959A3D70C763BF08BA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_41816523E10A54959A3D70C763BF08BA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7EB71BDC8411FC8C004870C763C02406" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_7EB71BDC8411FC8C004870C763C02406" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_CA09BA064C56F534D10070C763C0A85F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_CA09BA064C56F534D10070C763C0A85F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_0A98C162B0B419FBAEFC70C763C0FA70" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_0A98C162B0B419FBAEFC70C763C0FA70" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_DA78E41813660C4850D870C763C0001A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_DA78E41813660C4850D870C763C0001A" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_2A100EA6BC7D5AD771D070C763C0483F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_2A100EA6BC7D5AD771D070C763C0483F" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_153C786937C9F5ED404A70C763BF0B53" xlink:to="loc_gale_ConsultantWarrantsMember_DB298F219BEA2224BA4E70C763C0DCB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:to="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_C83EE1A3C795F2F94A5070C763C0F441" xlink:to="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:to="loc_us-gaap_MinimumMember_FCBAC21F14D99C6E4CEF70C763C0AEE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6ED477FA0BC3BAC40DDD70C763C0F46B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_DB7FA9D01A07B7EAB00E70C763C01026" xlink:to="loc_us-gaap_MaximumMember_6ED477FA0BC3BAC40DDD70C763C0F46B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_BA8E7CD29EF382938DBE70C763BFF9D2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_76B55256FBFFBD61D2EB70C763C017FA" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_184AA2A20AB2B102868370C763C09DC1" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassofWarrantorRightGranted_FE73D0488F08EBFB095870C763C0CA3B" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantOrRightExercised" xlink:label="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassOfWarrantOrRightExercised_C262707F8BE48C2B629670C763C05957" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassofWarrantorRightExpired_7F003C3A32B6CA7EC15170C763C049C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6BCFE3271CE130AEEE6A70C763C0B100" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_327CC150CF5F1C57AAF870C763C0332F" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_65F9BCAFCC3D607EA87070C763C03705" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C946E227B46D79DE8D1F70C763C268C9" xlink:type="locator" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C946E227B46D79DE8D1F70C763C268C9" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_D6681E4B9D7EC95B0D7670C763C20AA0" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C946E227B46D79DE8D1F70C763C268C9" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_0461E8CE048DAF4B381A70C763C37D65" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_C946E227B46D79DE8D1F70C763C268C9" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_44625C524BC7CE04DFA570C763C36BF4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_CE367F6645058FF67A3F70C763B1D016" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_609559A9421242A4CDB570C763B117E6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6B2342201932F9B8945A70C763B1EBC8" xlink:to="loc_us-gaap_SubsequentEventMember_FEAE7035D46081E86A5A70C763B1D8FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C1A57224EF84F9D98CF870C763B10F94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E82130C7D21D3D0BC04A70C763B1A8BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DEC6BE553FDAAC5E4A3570C763B1B691" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_gale_WarrantsGrantedNumberofShares_5C8D413C0697E346C07D70C763B12C1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A9A55A51B9A5EFA0296A70C763B19C88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20E881FAC7BE04EA0EEA70C763B18C52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_60CE8EB8EE1845CCEA1B70C763B16735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_FFA10ABDA505EBFB661970C763B130E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_3171B812C7764FA5024570C763B220A6" xlink:type="arc" />
    <loc xlink:href="gale-20160630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_52B347813E94EEBCB19D70C763B1AC43" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_E9B6D970BB75C5D9691470C763B212FD" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>logo-verticala10.jpg
<TEXT>
begin 644 logo-verticala10.jpg
MB5!.1PT*&@H    -24A$4@   ?0   &0" 8   !8LY+&    &71%6'13;V9T
M=V%R90!!9&]B92!);6%G95)E861Y<<EE/   4X])1$%4>-KLG?E[(\=YYZMA
M97\-_,ORFN<)QE<2)YO!))O=)'ZR!./(DJR+M Y;LJT!)8^L>TA9IV-GP,2.
M-))E<BSYT&$!E*S1+7*DD2Q9<8C9W/8F ]FQX\0'D>?AN;\(^P<$M55] %W5
M57T #: ;_'ZD'H! -X[N1G_K6_6^;Q$"
M
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MD#__K]/[7OC)&A/=-5/,3>&V(]8=X6Y'L-OW:=NMT]8=[_CYC4]EV;JYUOH
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MKO^%UW/F7.3-IBOZG;;G'E=UEPOW;6$W-,*NZX*/$C@GZ[DJ(MZ@ 0X=W>T
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M$O(FS8G.6^&.50[=(X)!X]RJ+GCW8ZK> (V+%SY3MX%SFH(RJBYVZ#D $'0
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M MU4/$Z\Z[D_%]&]7EOL*75]WZ9W#G1B%I1QN7TJIZ_AO ( @@Y /\5\9JG
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M3Y75HOZM3[M$735&+OY-FR$CXIL!8^JZP+=>!,ZIW7G!4^;5+>+(00< @@Y
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M]5N>UHCZ#8ZHJ]/1@@+GFA$"Y[I(=Z-:-^]I0-2W[CZ[KG?G+A&7Z[<C* X
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M?_]L1T[=X]C-]VFPAML[A5Z/CWR%':-FT7;GO%%WD#GXNDO,>9K:>N!L:NY
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MC?&%UY@H\S%K.YB-: O.U"U'3RK;QS\66J#&[_W+K%G!S>I2+Z@=LRVTO(?
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MNK>A5/W:K?6;]N*L[[KO64]Z????;B%NTIK7G>L$7"_FYM]-;PE8YM(AY@!
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M:Y=;]=YKI-E4I(]IG+1B/77N>C-$P%QP65E7-+Q84.9C7\NQQW(1Q!QCYP!
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MNN5^9VQQE4K!JH+FY-QU&G+"%W.]^LXW9T6W3<FD1LSYL\?9YT.)5P @Z "
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MK$U;:U85:Q>DOS%V#@ $'0#08U&OD+!5VY1!<TTQ(.[L>V0Q7\($+ ! T $
M_1%U[M*KH3=P!\U13Y>[6] ;<.< 0- ! /TE>#S=*^KUW=?OE-WW ==]3, "
M  0= -!GE\Z%=RKB9JI MX++G6,"%@ @Z "  8BZOI*<&GG\/,=NLO:?\W#G
M $#0 0"#$_4*<<_,YD]5X\XQ 0L $'0 0 )$G;OT6HCUY'6<@C((A , @@X
M2 A!07)5Q6.\H$P5[AP "#H (#DNO6Z+N@YY_#QK"SK<.0 0= ! PD2=N_#Y
MD [=<>=5[#D (.@ @.2).D\]JRB>4A64P00L $#0 0 )9EX2\)HB):V&"5@
M@* # )+MTN69V:J*=5:QIP" H , DB_J==(N.O,6]@@ $'0 0'I%G;OP:!.Y
M
M
M
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M#ETU" !@KY&UG<UDBH7=N0@V<#@!
M
M
M
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M^7TEB;)&I/(A2H;6B7I<E9N"U3UP_5A-Z'FKT@?=>#H_?JIB.<ZX>5J8(YJ
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M]6%?ZWXG_88W&I=[>=VT)VXY2/2%A@
M
M                                                   8$OZ_  ,
4XT7\[_IA+3      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>logo-verticala11.jpg
<TEXT>
begin 644 logo-verticala11.jpg
MB5!.1PT*&@H    -24A$4@   ?0   &0" 8   !8LY+&    &71%6'13;V9T
M=V%R90!!9&]B92!);6%G95)E861Y<<EE/   4X])1$%4>-KLG?E[(\=YYZMA
M97\-_,ORFN<)QE<2)YO!))O=)'ZR!./(DJR+M Y;LJT!)8^L>TA9IV-GP,2.
M-))E<BSYT&$!E*S1+7*DD2Q9<8C9W/8F ]FQX\0'D>?AN;\(^P<$M55] %W5
M57T #: ;_'ZD'H! -X[N1G_K6_6^;Q$"
M
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MD#__K]/[7OC)&A/=-5/,3>&V(]8=X6Y'L-OW:=NMT]8=[_CYC4]EV;JYUOH
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MKO^%UW/F7.3-IBOZG;;G'E=UEPOW;6$W-,*NZX*/$C@GZ[DJ(MZ@ 0X=W>T
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M$O(FS8G.6^&.50[=(X)!X]RJ+GCW8ZK> (V+%SY3MX%SFH(RJBYVZ#D $'0
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M MU4/$Z\Z[D_%]&]7EOL*75]WZ9W#G1B%I1QN7TJIZ_AO ( @@Y /\5\9JG
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M3Y75HOZM3[M$735&+OY-FR$CXIL!8^JZP+=>!,ZIW7G!4^;5+>+(00< @@Y
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M]5N>UHCZ#8ZHJ]/1@@+GFA$"Y[I(=Z-:-^]I0-2W[CZ[KG?G+A&7Z[<C* X
M"#H 2B%_Z@?%B1,_7&<"5>;3F=I.TTP?VYAYGRCFYW Q=ZJ_D99P&_IH=H6(
M.V9=^7QY;.Y9M:@_8XKZK.#2?0+E/,+>[*"4K%_7NR;P+5S@7%,UP]JDQYU+
M%>(HID\%H&,P?2H83A&OG.'E6.>8^!YA8I%MN;^FV8QML+^F-B_[=4%T1CYT
M+Y_#?(UMDW4+M!'DS!6/!03/E<<^\SS9?N"RBD?4G[VQ,GKY0_QNN6U7A3E5
M_>=2%Z9JI>&W<^9@%^9J)QW.P6ZNHR@HX^2?2UWLLCMWWP( X-#!'A7RQ[Z?
MG?CF_RDQA[C.EJ/,+6:EH"V>)C:U>?G[93'G4>R2,P\2<9]N>*)[CK1%_?87
MU4[]N9LJ[#/.JKO:0Y2$E2/BE8%OFHCUV +GQ)2UT4\\S,?.\]H*<<1Y"*EK
M $#0P=X6\F_\0V[BX7\L,S%XFRV6D MSC)L"9HY3;U[QFZ*8GWU/T73$ALN9
M9U3N/$CHB3=XCOAM0\IC=ZVH1?UY)NI613E-5WO,@7,QS\&^53J_*GVEO+?,
M*_%)7<,Y#0 $'>PM(7_H;W,37_T[+N0\V*WH4\+4$O./_Y97S%MUV47Q-=R/
M98R0#MT(&2CG<NJ?/:D1]9M=HJX+D(L8.*=;+]Z(>-7X>4$IXFYW3M3/ 0 @
MZ&"(&5_ZWX7QXW^]1ATA;VJBKJW[EIA?E6](8KYH._/(+MS[&"'**G)$V=TN
M.7CFU#_WLEK47W!$71<0%S%PCO8A<$Y5(8[22>_\YRJ7CG,;  @ZV!M"_J6U
MPO@#U35WZAG532IB_5W9O/IW#FX6?UL6<QYT-N>-7,\H<L[#+;[!<T00<-6V
MY?$_/:46]1=OX:*^( PA"-WL344]=YV;]YF#W6\[3]>\3\4YU0QKQ)YAK27F
M4B&9EDV'0P< @@Z&6\CO?;,X?NPO>>I9.X?<Y<)I4SE12&7S4[\[*[^6+>:6
M>(9.1_-S[B1**5AI;%U8OSQ>>FU:*>HO'2FQ[U4)=..TP\ Y&B%P+MB]BP5E
M/OZ-?& A&?DQZ#D D4':&DBNB/_9MWF0VC030Q[DEFLU/[EP9.P_FNUF*=<9
MH[4.6=J\X??F)2'GD=9<S*=%,1?%UPA5UM53WI6(W>MRUSOQW[8]5E\>__/7
MZUN?/]<S#KVS<F1V9'J)KU844]4(T?_M:D 0*8V-M)TQ%:KA47$[+K"95CJ:
M^CW:+]_8OO\CXF<WYS]7%Y*A*F&WWK.!7P  <.@@[4+^IZ>RXT=?Y8Z4CX^7
M33&G/NE5KJYVVVW.;M[P^RHQ7_.*.=$'PLGW,V&W\1-_Q;:"6R<\;6YM_(MO
MY%7[9G=U;I8VFQ4:MI)<F"(U\<[!K@B(HP=TA61$$6\U,.KLWPI^"0! T$%*
M&?OL:F[L3TZ6F*BLFZEGU,DAU\RWW4JA$M*X9C=O^D!%(^9MD0QTX21$=SL)
MV(;X!<))CPGK\)Z)M?%[WE2+^LGY63Z<0*,$Q,4>.">-Y;?744S(8H^?^Q:2
M$<;.9W??N!,.'0 (.DB=D-_^8F[LCI?*IB-O6D+>JDU.I8AUJKW/2[G.;!WY
M0UG,\VHQ)QXQ-Y3CZ.U .55#0!D\1XQ0A6D,HA!](HGZL>_ZB[I<QYVZQ]+E
MO\.X^8# .>W8O3K"??3*K^?8$SEO#KI4YK4=,+>Z^_J=5?PJ ("@@S0)^=RS
M^;%;GVOGD$O"39LJ,6H2X@V ,ZN_;=U:6 TGYA%2U#)1@N,T@7+.^Q(_\2?B
M\+:UO=7]?O]?J47]Y5MGS4 Y=QUWN8M<V67>#)A+O=,YV!5=[M2N#N=UX=XR
MK]:X>2N(<>1#]Q9&SCVV/G+>?7G\6@" H(,D"OE-)PIC-S_-H]7/,!$H"M7'
M9%%7NO&F5\QO_Z.:1LRSG@_@%P@7MKPK(5(@7-@RL<3U?B1,P)WEU!^HJD7]
M%2[JS9JS#]OE7J.,K<MI9TUOKTBH.=B;]>WC'Y.ZREWYYW*95Z_(S^^^?D?#
M=9P6V9)CC:JUD0L?@*@# $$'B1'R3S\Q/7;]DVO2]*6*'&C1]6E%W:K^=G#K
MKC^6Q;R@%//.)E)1=M$;GL>(SU@Y\0F$TT3"$UG4F5-?/*T6-4JFS.(YKOWG
MJ>,>.(;>#'#W)$PIV:KBL^4];ES9U4ZKN]^^H](ZAN<<*[;GHL^8C9J1Z26(
M.@ 0=#!(1J\I%T</5]:9,*]80JZ(4->Y<%>>.15SSYF8-Z>V/ONANB3F15]G
MG@F1CI8)'Z7N%682/'&+;RX[D;K>):=^_*\]HK;[ZFT-<RYUWL"1NLP["YP+
M64K6.[:N+RA# PK)B%WM_-@=E?97EC6$UD8O^0I$'0 (.NBKB'_RD>SHH4>+
MH\7'A-0S;Y=M4U&X1"'J5'#K9BG7K<^?UU"(>5GY@72!:4'.G 1MHPJ$(]IQ
M]'8@G+MZG$] '5$$RCWX-UY1?^UV<^C!W?WNB#!M!M1Q#YO>IOA;F(-=#HC[
MV-<*WDE7%(5D"%E@[KSN.E9S=E=[JP%F]:)8WW_THU^=QB\, ,5E#KL Q"KD
M5WS-GH<\<\2\ #MN-Y/QSF*6D1UQ1O&8>SWS-2K;7[Q(5?UMCMTLZL7<$0?G
M/3)MH7!_MM;?&='-9]J?S5!])_,^:3_F_=S6^_E^-V)'U)/V9U3DP;/7:+!_
MIC9O_ -/SO?(N?=9*7H9WEU--"5J24#/@::7@1#?WH6=1XO"]80);XD)]E%W
MPXQZN_/KK#&RO_7YSSF68Z]WANV/;/MX9=K'J7V\9G>>OKZ"7QP <.@@;B&_
M],'<Z.4/.<5@CK(+=M:O&Y<JN]N;)"#O7"?F9:V8RZ+N$B$C=.2Z% @71NPR
MND X32 =T;MZ,=7-:(VI3WS][W,>IVX&E=E._3_5 7"Q!,YYN^JKBKU^0%OF
ME;3<N7P\CPK3V H-$.*.9RB/?O*1(GYY $#004R,7+R8&YU9LE+/FE(Q&$VT
MM).&1E5I4E01G&7=7]J^=\:_+KM.R!5CXD;&B)C"%E!%3@Z$(T03"$=\MC4T
MD[DH7YLY<6-EXN%_S'I%_<Z&&2A'G4 Y=0!<5X%SU%,YSELACA>4(8I",NUN
M^ ISYU67.R\0LZQMV,I[3-0//091!P""#KH6\PL>*'$AI^[4,Z5 ZP+@FN*D
M*MJ(]^;L]OV7>$JY!HJY6PPS 8*=,2(&L\44"-<2>=VB</@MP2=YTZD_\CVO
MJ/-*:Y3.L/W94+MO=YZY(ATMZASL5*P0-WKY5W/LP:S;G5-Q/)U_OGF%.Y=F
MO0L,8"R/7E,NX=<(  0== .EJZ9@J,=&7<5?- %70:)NW9_=_O+E%5G,B17)
M'D+,2< TIR2@^YQXQYT)"3?SFKU>I$ XX@F$,^\;Q%"(O_D/3^U:FWCL^UY1
M_\Y==3/ZO=EL:-UV1Q'QRL<EATX+^C*OYK^S9B!?VYUS9U[PGXY6N\^/CAZN
ME/&#!!!T #ID]]7;:I9@: .>U/77J=?%4]LINL3"=)C;QS^F$_-\*&>N'-<F
M'::M1>NB5T['FE&Y;U5W/-'7A/=6E[-$_?%_\HKZFW=SH9VR2^,J&E5BY3A/
M'7>JJA#7E+>K[SQQN"[J.9GT%))I"WR5G3NMJGYFFIIAN_-68"*1JO3Y'S,C
M8Q3'KGL2H@X@Z !T*>JS[A0I3Y>LGZ@K9TOCCK(YM?W@E:L=B3DAVG*LAK)0
M#-%/KD+\@N=(X#BZ)Q".1 B$:SE\S1B]^)IF9;R)\C\'B[I[2*.CP#F/VU?-
ML)87&P3NKG8I$(YG11 CYQX6$::PE1=](ZHX=N-3$'4 00>@"U&OF!=I>[R<
MZL;"J2;J713U!A.2J>VO?U(A$F:.>2Y8S!7I<,HN7!+HQ'V#YXC/[&E"$!WI
M/A N1./!JJS&1'WYC%[4"6EXA+;[P#FAH,SH90]E6Q7B")$+R1QGYTO+S8^<
M<XR[\R/A>D6,@#0\8HGZ+4^7Q^:>S>*7"2#H '0JZN9$(4U]6IJR0IPPGLO%
MYN#.(X=JRO=X\^X9MKR3W3W(%AY056%+72OHH2=7"1@+#Y76IG/<,07""5T&
M*H%O_<V$U%B;>*+F+^J.P(8,@ L(G*MZW+GEQN4RK[7=4[>5I(^UZ$U3\VM$
MD3#!B$7>L!F[]3F(.MA3H+ ,B)61#]]?-B^HKH(IAEQR55E\I74QGMHI7U.-
M])Y65WR!$',L>9*]?D$L$L.=MJY0C/MQ<1TC(Q>[412^D0KFM+=U%8K):,;4
M,_[C]X9FFM>08_DUL_C,)WZKH=A?ZHEK0O5>$$]0X<Z+MX@%92Y]L&3/9R_%
M59"IW5.?J;K<.3]>9XA4-,931,958$8L#N0^KAGQ&%G/U]C?4]OW7X*YU0$<
M.@"1G?IKM\^V:HH[LW1139>NNNSKH<CO^>;=#;:LLJ6T^YV[IG9?OX,/.T^Q
M"_H\6U:9 -6U A6VJS="?7=#YR0)"9ANE40)A-,X]-9C5O?[4S_4.?5YSXZD
M&I>N#)QK'3]5;\JDHI#,DEO,;3NQJ,[UU\Q'[YNM8+AZ8\1],';7"IPZ@* #
MT!'NB4):-=AU^>@>82^.'GHLUW7#XM7;J[NO?&9I]^3\S,[JW'YV<6<+#\8R
MEBSW2GPF5U$$PA$CW%AV4'UWMZ@3TFT@G.BN/1UNMJ@__2\J4:\0;Y6VMK"[
MN^/_4YWN9M5Q;U85V^=;D[!8PLX=\H+02W#.L6GV^0J*>NTA,PR(8BA#N;Z9
M 3#VV9,0=3#TH,L=](21\\R:XNMF36Y7E[OATTWMZIY>V'GB<*G7GW'TDX\4
MS-SGC'' [J;/JKO:-77F,][A R-*;7J?4K%&8*^ $;X>.R'5S2M^<TIYG/PF
MM"$DS.O/[KY\:Z6U3_EL:)2<,5,1VXVW&=:X$C,6SCW&SXV<;[UV95>ZJP:_
MH5M766>_87:___F%-?PZ 1PZ %$<\K=Y37%B%36AXNQ<_E7ES,>/].,S[CQY
M;94W''8JGYK9>?QJ*]B."12? (8)0"UH3G1MD1E5][C;P1/B[3HGI(M ."*Y
M=:FMSAHM$\_\2"G:OD[=<>O^@7.R0!:D0C)5CYB?<ZQDSJ865*^]HZI]VK1$
M<_K5\:.O8OI5 (<.0$=._=S[\O;L65+0F":HK'U_=N=;GZZX7VO?J^MENSOX
M-!^[W;CX/3UU6V,WG<C:U<OR[#--LJ7052!<)GALWA#&@CMUZ$39X&#_5S8N
M?_]L1T[=X]C-]VFPAML[A5Z/CWR%':-FT7;GO%%WD#GXNDO,>9K:>N!L:NY
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MC?&%UY@H\S%K.YB-: O.U"U'3RK;QS\66J#&[_W+K%G!S>I2+Z@=LRVTO(?
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MNK>A5/W:K?6;]N*L[[KO64]Z????;B%NTIK7G>L$7"_FYM]-;PE8YM(AY@!
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M:Y=;]=YKI-E4I(]IG+1B/77N>C-$P%QP65E7-+Q84.9C7\NQQW(1Q!QCYP!
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MNN5^9VQQE4K!JH+FY-QU&G+"%W.]^LXW9T6W3<FD1LSYL\?9YT.)5P @Z "
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MK$U;:U85:Q>DOS%V#@ $'0#08U&OD+!5VY1!<TTQ(.[L>V0Q7\($+ ! T $
M_1%U[M*KH3=P!\U13Y>[6] ;<.< 0- ! /TE>#S=*^KUW=?OE-WW ==]3, "
M  0= -!GE\Z%=RKB9JI MX++G6,"%@ @Z "  8BZOI*<&GG\/,=NLO:?\W#G
M $#0 0"#$_4*<<_,YD]5X\XQ 0L $'0 0 )$G;OT6HCUY'6<@C((A , @@X
M2 A!07)5Q6.\H$P5[AP "#H (#DNO6Z+N@YY_#QK"SK<.0 0= ! PD2=N_#Y
MD [=<>=5[#D (.@ @.2).D\]JRB>4A64P00L $#0 0 )9EX2\)HB):V&"5@
M@* # )+MTN69V:J*=5:QIP" H , DB_J==(N.O,6]@@ $'0 0'I%G;OP:!.Y
M
M
M
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M#ETU" !@KY&UG<UDBH7=N0@V<#@!
M
M
M
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M^7TEB;)&I/(A2H;6B7I<E9N"U3UP_5A-Z'FKT@?=>#H_?JIB.<ZX>5J8(YJ
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M]6%?ZWXG_88W&I=[>=VT)VXY2/2%A@
M
M                                                   8$OZ_  ,
4XT7\[_IA+3      245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pipeline8092016.jpg
<TEXT>
begin 644 pipeline8092016.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!T17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  *@ @ $     0   FJ@ P $     0   5,
M    _^T .%!H;W1O<VAO<" S+C  .$))300$        .$))300E       0
MU!V,V8\ L@3I@ F8[/A"?O_B!^A)0T-?4%)/1DE,10 ! 0  !]AA<'!L B
M &UN=')21T(@6%E:( ?9  ( &0 + !H "V%C<W!!4%!,     &%P<&P
M                  #VU@ !     -,M87!P;
M                                        "V1E<V,   $(    ;V1S
M8VT   %X   %G&-P<G0   <4    .'=T<'0   =,    %')865H   =@
M%&=865H   =T    %&)865H   >(    %')44D,   ><    #F-H860   >L
M    +&)44D,   ><    #F=44D,   ><    #F1E<V,         %$=E;F5R
M:6,@4D="(%!R;V9I;&4              !1'96YE<FEC(%)'0B!0<F]F:6QE
M
M      !M;'5C         !\    ,<VM32P   "@   &$9&%$2P   "X   &L
M8V%%4P   "0   ':=FE63@   "0   '^<'1"4@   "8   (B=6M500   "H
M  )(9G)&50   "@   )R:'5(50   "@   *:>FA45P   !8   +";F).3P
M "8   +88W-#6@   "(   +^:&5)3    !X   ,@:71)5    "@   ,^<F]2
M3P   "0   -F9&5$10   "P   .*:V]+4@   !8   .V<W9310   "8   +8
M>FA#3@   !8   /,:F%*4    !H   /B96Q'4@   "(   /\<'103P   "8
M  0>;FQ.3    "@   1$97-%4P   "8   0>=&A42    "0   1L=')44@
M "(   209FE&20   "@   2R:')(4@   "@   3:<&Q03    "P   4"<G52
M50   "(   4N87)%1P   "8   5096Y54P   "8   5V %8!80!E &\ 8@!E
M &, ;@#] "  4@!' $( ( !P '( ;P!F &D ; !' &4 ;@!E '( 90!L "
M4@!' $( +0!B &4 <P!K '( :0!V &4 ; !S &4 4 !E '( 9@!I &P ( !2
M $< 0@ @ &< 90!N .@ <@!I &, 0QZE '4 ( !H .P ;@!H "  4@!' $(
M( !# &@ =0!N &< 4 !E '( 9@!I &P ( !2 $< 0@ @ $< 90!N .D <@!I
M &, ;P07!# $,P0P!#L$3 0]!#@$.0 @!#\$0 0^!$0$, 0Y!#L ( !2 $<
M0@!0 '( ;P!F &D ;  @ &< Z0!N .D <@!I '$ =0!E "  4@!6 $( P0!L
M '0 80!L .$ ;@!O ', ( !2 $< 0@ @ '  <@!O &8 :0!LD!IU*  @ %(
M1P!" """<E]I8\^/\ !' &4 ;@!E '( :0!S &L ( !2 $< 0@ M '  <@!O
M &8 :0!L $\ 8@!E &, ;@#] "  4@!' $( ( !P '( ;P!F &D ; 7D!>@%
MU07D!=D%W  @ %( 1P!" " %VP7<!=P%V0!0 '( ;P!F &D ; !O "  4@!'
M $( ( !G &4 ;@!E '( :0!C &\ 4 !R &\ 9@!I &P ( !2 $< 0@ @ &<
M90!N &4 <@!I &, 00!L &P 9P!E &T 90!I &X 90!S "  4@!' $( +0!0
M '( ;P!F &D ;,=\O!@ ( !2 $< 0@ @U02X7-,,QWQF;I : "  4@!' $(
M(&//C_!EAT[V3@""+  @ %( 1P!" " PUS#M,-4PH3"D,.L#DP.U [T#N0.Z
M \P ( /  \$#OP/& Z\#NP @ %( 1P!" %  90!R &8 :0!L "  4@!' $(
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M!D0&.08G!D4 1P!E &X 90!R &D 8P @ %( 1P!" "  4 !R &\ 9@!I &P
M971E>'0     0V]P>7)I9VAT(#(P,#<@07!P;&4@26YC+BP@86QL(')I9VAT
M<R!R97-E<G9E9"X 6%E:(        /-2  $    !%L]865H@        =$T
M #WN   #T%A96B        !:=0  K',  !<T6%E:(        "@:   5GP
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MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M!@8&!@8("@@(" @(" H*"@H*"@H*# P,# P,#@X.#@X/#P\/#P\/#P\/_]L
M0P$" @($! 0'! 0'$ L)"Q 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0_]T !  G_]H # ,!  (1 Q$ /P#YD\=>
M.O&]KXW\0VUMXAU&*&+4;M$1+N9555F8  !L  < "N5_X6#X]_Z&74__  ,F
M_P#BZ/B#_P C[XE_["=Y_P"CGK]"/BE\;?AKX^^)%K\)->O)=?\ #&I^(-!:
MXU"]U*!M+T^SA"+<_89(E5H5D5V69S-A=IZ'D?N56M[-04:=TU=^5K??N?GD
M(<W->5M?\S\]_P#A8/CW_H9=3_\  R;_ .+H_P"%@^/?^AEU/_P,F_\ BZ^I
MM'\/?L[>(/#E[K$UKINDQ^?JT5X&U>9;S3HK6U7^SGL+>68M>M=3 F4[9%!.
MT")<,/0_!FG_  %TGP"='O+[28]#\1GP9]ND.K?\3&['VN-]76XM1,7MQ;EF
M"E$3]V-P9^67.IF-.*_AN]^R[_T[?/;4N.%D_M_U_7]7/A;_ (6#X]_Z&74_
M_ R;_P"+H_X6#X]_Z&74_P#P,F_^+KZHM_AI\%])?2=/U&]T34==-CKLOV;^
MW(S87%[#>(NG0W5W#<B.%&MF9@5ECW$!6<-G',_%4> H?@K8:1X4M=#COM*\
M5:JEP]CJ+75R()88&@\OS'22XMR0Z";R2H\I<,&=FDTAC:4I*,8;OLO/7\")
M8>:3;D?/O_"P?'O_ $,NI_\ @9-_\71_PL'Q[_T,NI_^!DW_ ,77(45Z7LH=
MCE]I+N=?_P +!\>_]#+J?_@9-_\ %T?\+!\>_P#0RZG_ .!DW_Q=<A11[*'8
M/:2[G7_\+!\>_P#0RZG_ .!DW_Q='_"P?'O_ $,NI_\ @9-_\77(44>RAV#V
MDNYU_P#PL'Q[_P!#+J?_ (&3?_%T?\+!\>_]#+J?_@9-_P#%UR%%'LH=@]I+
MN=?_ ,+!\>_]#+J?_@9-_P#%T?\ "P?'O_0RZG_X&3?_ !=<A11[*'8/:2[G
M7_\ "P?'O_0RZG_X&3?_ !='_"P?'O\ T,NI_P#@9-_\77(44>RAV#VDNYU_
M_"P?'O\ T,NI_P#@9-_\71_PL'Q[_P!#+J?_ (&3?_%UR%%'LH=@]I+N=?\
M\+!\>_\ 0RZG_P"!DW_Q='_"P?'O_0RZG_X&3?\ Q=<A11[*'8/:2[GK4OCO
MQP/ ]K<#Q#J/FG49U+_:YMQ40Q$#.[.,D\5RG_"P?'O_ $,NI_\ @9-_\71+
M_P B%:_]A.X_]$PU[U^S7\6_$?@"T\<Z59^*I-!LIO#NJW-K%]J$"/J@C18&
MC!(#3\83&6..!7)5M"FY1@F[^G7T9O#WI).5CP7_ (6#X]_Z&74__ R;_P"+
MH_X6#X]_Z&74_P#P,F_^+KZT\2:Y\-/B)X$TA?'-_:W/B&Q\%2WO]J&^8WB:
MH==F9K8P^:(Y)9(9Y)6C=#(00RE0"3N>*O!'[+/A[7KF;2VL]4LK+2];N;:$
MZLODWS6R0MIQ=[>^EE6>9C('C/D,X.%@C*\\BS"FM)4W?7HNGW;FSPLMU/33
M\3XO_P"%@^/?^AEU/_P,F_\ BZ/^%@^/?^AEU/\ \#)O_BZ^U_ 'PK^ /BO0
M/!\=^=*?6]:U70=]O::F_P!HDAU#4/)O+-HFO7FS#$Z@XMHF7&Y991N961?#
M7]G)?$8LM8ETNQU.'3[]ETVWUA;BPEDBO88[5Y;N6^MU2>2U:61X3<Q890=J
MG]R4\TH7<>1Z>2!8.I9/F_$^*_\ A8/CW_H9=3_\#)O_ (NC_A8/CW_H9=3_
M / R;_XNOJN'X<?L_7MK<:KIFIV T_3_ /A,(Y5O=6BANWDMX"^B;8A.#+EN
M%>)2DC##9)"GT?79/@?XC,=MK.HZ9H/AW5_^$!$L.EZEGS($M+I+YIK<32%'
MMY,1.S('B7$A!:0M(2S&FGI3?W>=O^#Z L+/K+^K'P;_ ,+!\>_]#+J?_@9-
M_P#%T?\ "P?'O_0RZG_X&3?_ !=>N:CX(\&ZI\7?"_AB[N-"\+Z3?B!M4DT_
M6/M]C:QK(YF;[5*\BB0PJ"(UFD^8J 0S;%^G_'VN?L_?&CQ5X>^(FIZK87-C
MID&N:9>:?,_]C2-!:VES=Z*%3S1(P0[;8R*<.ZQJ1E@INKCH1<?W=TTWMMV\
MM;=R88>3O[W]?\ ^!/\ A8/CW_H9=3_\#)O_ (NC_A8/CW_H9=3_ / R;_XN
MOIU?!_[/FM?"K3_$,5Q::3KNJR*TJB^ ^P7$NI^6;=H9;Q[DVL=E\WF"UD;_
M ):&<D&*N0_:/\)?"GPR/#4OPTFL#/<"^BU"'3[Y;R-6MY@()"!>7Q3S8F!!
M\T!L9V1L&1=*6,I2FJ?([W:V[$SH3C'FYNW7N>(_\+!\>_\ 0RZG_P"!DW_Q
M='_"P?'O_0RZG_X&3?\ Q=<A17H>RAV.;VDNYU__  L'Q[_T,NI_^!DW_P 7
M1_PL'Q[_ -#+J?\ X&3?_%UR%%'LH=@]I+N=?_PL'Q[_ -#+J?\ X&3?_%T?
M\+!\>_\ 0RZG_P"!DW_Q=<A11[*'8/:2[G7_ /"P?'O_ $,NI_\ @9-_\71_
MPL'Q[_T,NI_^!DW_ ,77(44>RAV#VDNYU_\ PL'Q[_T,NI_^!DW_ ,71_P +
M!\>_]#+J?_@9-_\ %UR%%'LH=@]I+N>M>#?'?CB?5[A)_$.HR*-.U1@&NYB-
MR6,[*>6Z@@$'L1FN4_X6#X]_Z&74_P#P,F_^+H\$?\AFY_[!FK?^D$]<A6:I
M0YWIV_4ISERK4Z__ (6#X]_Z&74__ R;_P"+H_X6#X]_Z&74_P#P,F_^+K[*
M^'_Q^\._"OX$>"M.EN+K6+A[CQ"+O0[:\@2TG2<0I$-3@9)',9W$QX"DX?![
MBOXL3X->/]/TJWU2]TNUU73-&\"6J:BVHN"XD@BMM0AEC61DVVR &39'YD15
MBQQ\H\U8VTFI4M+M7WV=MCK]A>.D]?\ @7/CW_A8/CW_ *&74_\ P,F_^+H_
MX6#X]_Z&74__  ,F_P#BZ^Z&^&_[,2>+-/@=](,5SI4WGQ)K,1M;>\BOS&)6
M!U?G=:D/M&H9_C6)CNB7RO6_ OP T_X/ZMJNG:M;ZCXA@DOTCF@NT$BW$.H>
M5:I';RW:2O;S6O[S<+1S\VXRH4,9=/,J,FDH/5I;=_\ AA2PM1?:7WGS7_PL
M'Q]_T,NI_P#@9-_\71_PL'Q[_P!#+J?_ (&3?_%UZ[\//&6F6GP%^*O@R[_L
M^SN;ZWTR:W=MJWUY(FI6Q,2LS;G2*-6?8@&,LS9P"/G.N^ERR<DXVL[>NB=_
MQ.:;:2:EN>M>(O'?CB+2/"[Q^(=11I=.D9R+N8%F%]=+D_-R< #)[ #M7*?\
M+!\>_P#0RZG_ .!DW_Q='B7_ ) WA3_L&2?^E]W6A\*+RST[XI>#M0U">.UM
M;76=/EFFE8)''&ERC,[LV JJ 223@#DTE",8.7+W'S-R2OV,_P#X6#X]_P"A
MEU/_ ,#)O_BZ/^%@^/?^AEU/_P #)O\ XNOT!N/VB_!OBKXM0Z/J5S/?V&BS
M>+IO[8UG4('WQ76EW-O#96LL:($MG<+Y0+NS,ZA>P/)> /A_^S3K^OZ=J6OW
M&BV6EZEI^A/>V3ZL\?V&>\$RWKQ/-?0,HB9$+*[W#QEAF$J=R^;_ &BHQO5H
MM:7TL^K]#K^JMNT)W_ ^*_\ A8/CW_H9=3_\#)O_ (NC_A8/CW_H9=3_ / R
M;_XNOK"P^'W[.=UX/\&7&L:M9:5/)J6G0:M,M^MQ=S02SLETRK'=OY2(F&;?
M9Q!!RLLV0#Y5\6_#O@/0_B-X=T_X9R64)F2 W*O=V]SIT5T;EU0F87=[&L1C
M$9D$D[8^8MM!VKTTL92G+D4._3L8SH3BN9R_$\D_X6#X]_Z&74__  ,F_P#B
MZW_"OCWQS-XHT>*7Q%J3H]Y;JRM=S$$&10006Y!KVS]K+4WO=2\+V$^O:9XM
MN-/M;A)]:L+ZSNVO)9)?-9?+M'?R+>'?Y=LDF&* G 'RK\S^$?\ D;-%_P"O
MVV_]&K6M"4:M'VG*E>_];$5$X5.6YLZC\0/'BZA=*OB34@!*X %Y-@#<?]JJ
M?_"P?'O_ $,NI_\ @9-_\77/:G_R$KO_ *ZR?^A&O:_V8-9TGP]\??!6M:[?
M0Z;86E\'FN;B588HEV,-S2.0JC/<FM:RC"FYJ-[*Y,&Y34;[L\U_X6#X]_Z&
M74__  ,F_P#BZ/\ A8/CW_H9=3_\#)O_ (NOL^U_:$\*>-QK2ZU'/=MI/@W6
M;,7GB&^C:^U::ZN;>6*V>2!8"RQA2(T5C(07PPX(GT[X:?LTW=_XJEDU'1H]
M.F3_ $%3J^);*5]&BND\IY+V+>@O7:$9CNCE"D@CQO/G?7XPO[6E;TLSI^K-
M_!._X'Q3_P +!\>_]#+J?_@9-_\ %T?\+!\>_P#0RZG_ .!DW_Q=?7<OP^_9
MLN7^'4T^IV.E6FH7$$.JHFH+/<2*UF9&EED6\D6*(W*B-C)#9LF_[A"EQY%X
MNL/"OA;XV:$GPMU*PT?ROL,IN+N6&\TVSOR<L2Z3:C&84.TG=+-L.06.W-;4
ML92F[1AK9O5=B)T)Q5W+\3R'_A8/CW_H9=3_ / R;_XNC_A8/CW_ *&74_\
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M(?\ G[UW_P "K7_Y%KW\5*M9NBOZ9M'C#,?^?OX+_(^?Q^RK\(#_ ,O>N_\
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M_F+>(O\ P*L__D.OM<5*O6L_[1KK:;-EB9O<^)A_P3^^"!_YB_B+_P "K/\
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M_P .?I>MC=_\\C4@L;O_ )Y&OS,_X>/_ !(_Z%32/^^KC_XY2_\ #R#XD_\
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MZ;J6ISSP;+Z</=6MV(?#FDWC^6MUJEK!$SS76/+AGW/AG2"60S./TNI-J\#
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M=2<73>E[Z+HKOJ73X8QSIQJ*O%J7+;WI?:=DMM'Z]#Q)?$7B#_H)W7_?]_\
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M 'T:@7I4HK.4(]CHC6GW985Y,<NW_?1J56?^\WYFH%J9:R<%V-XU9]R=6?\
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M#]E?Q /^8Y:_]^WIX_99U\?\QRU_[]O7VM12_P!=LQ_G7W(M>$F1_P#/I_\
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ME 16,<:_U@Q7\WX(M<$9=_(_O?\ F: ^$&IC_F(0_P#?+5(/A%J7_/\ Q?\
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M_P" DW_Q^I_L3'^7]?(M8+"]OS/V,'AD_P#/S_XY_P#7IX\-$?\ +Q_XY_\
M7K\<?^'B/QX_Y\M#_P# 2;_X_1_P\1^//_/GH?\ X"3?_'ZEY%CO+[_^ 6L+
MA>WYG[+?\(T0%/VC[PS]SW(]:</#A'_+Q_X[_P#7K\:?^'BGQ[P!]CT/C_IS
ME_\ C]'_  \4^/7_ #YZ'_X!R_\ Q^I_L#'>7W_\ U]CA>B_,_9H>'V_Y[_^
M._\ UZD&@D#_ %__ ([_ /7K\8?^'BGQ[_Y\]#_\ YO_ (_1_P /%/CW_P ^
M>A_^ <W_ ,?J7P_CO+[_ /@%J&%[?F?M&-!;_GO_ ..__7J0:$1_RV_\=_\
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MA^2E+GEYIV^=_P M?,5/ 2=3FFN5>37Z'T3X8O;V_P!&MKC4.9RBAW$9B$C
M8+B,LY0,>0I=MHXW'K70BHT54 51@#H!4@K\_/88X4^F"GBLRT/6GTQ:?29:
M'_P_C3UIG\/XT]:@U'TX4T4X5#+0ZI!48J1:1HAXIU-IU9FB'BGBF"GBDS9#
MZ6DI:@L__];]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BJ]M=VEZC
M26<R3JC,C&-@P#J<,I([@]1VJQ0 4444 %%%% !1110 445X7XW^,:>!/BMH
M7@S5+.ZN=)U;1=1U!FT_2K_5+M;BTN;2)!LL8YBD12=]Q>/&X* PZ, >Z4@
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MXF?'[38_CPOAZ] \,Z1\0_#%D-2;7+RWU/38KB31 ]K8VB6[QFWE,I$@^U1
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M)<RBHK78_3+_ (6Y\+O^ADT[_O\ ?_7I?^%N_"[_ *&33O\ O]_]>OST\/\
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M_A4PTW4?^?67_OAO\*R=2/<WC0G_ "LA7I4@JRNFZA_SZR_]\-_A4@T[4/\
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M/X_Y%KQYRY_\N)_^2_YGZE45^72_&#XFGKXCN_\ OH?X5*/B_P#$S_H8KO\
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MX>0?$'_H4=*_[^7'_P 77YR45]A_86$_D_/_ #/"^M3_ *2/T<_X>0_$(?\
M,HZ5_P!_+C_XNE_X>1_$/_H4=*_[[G_^+K\XJ*/[!PG\GXL/K4_Z2/T>_P"'
MD?Q#_P"A2TK_ +[N/_BZ/^'DGQ#_ .A2TK_ON?\ ^*K\X:*/[!PG_/O\6/ZW
M4[_@C](?^'D_Q%( _P"$2TGC_;G_ /BZ/^'D_P 1?^A2TG_ON?\ ^+K\WJ*7
M]@8/_GW^?^8_KE3O^"/TA_X>4?$;_H4M)_[[G_\ BZ7_ (>4?$;_ *%+2?\
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MQGXE_P#0J:'_ -\W/_QZO7O@Q^W[:^)_%T/AWXL:18:#87V(X-0M3((H9B<
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MDS^*M4>+;-?WALKJ:STBVU-XA;+);:AY$TLGR?O(Q&Y1]V:_;,@,,,,CWI:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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METF37OASX@T*&00OJFG7UFLC*S*CW5M)"K,$#-M#."< G'0&OQB_X8G\6?\
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M?#GA^RU^XEU;Q"=(N;E;R:^B%O8V_P!BN%GE7["?O31@M(B\?>KKK?\ :/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847600304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galena Biopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,968,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6848138928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,590<span></span>
</td>
<td class="nump">$ 29,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">24,401<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Litigation settlement insurance recovery</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,284<span></span>
</td>
<td class="nump">53,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GALE401rights', window );">GALE-401 rights</a></td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">5,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,778<span></span>
</td>
<td class="nump">82,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement payable</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">23,157<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">5,925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,224<span></span>
</td>
<td class="nump">57,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">5,418<span></span>
</td>
<td class="nump">5,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent purchase price consideration</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">53,457<span></span>
</td>
<td class="nump">68,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 275,000,000 shares authorized, 182,996,385 shares issued and 182,321,385 shares outstanding at June 30, 2016; 162,581,753 shares issued and 161,906,753 shares outstanding at December 31, 2015</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">314,639<span></span>
</td>
<td class="nump">296,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeficitAccumulatedDuringDevelopmentalStage', window );">Accumulated deficit</a></td>
<td class="nump">290,487<span></span>
</td>
<td class="nump">279,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
<td class="num">(3,849)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">20,321<span></span>
</td>
<td class="nump">13,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 73,778<span></span>
</td>
<td class="nump">$ 82,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeficitAccumulatedDuringDevelopmentalStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deficit accumulated during the developmental stage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeficitAccumulatedDuringDevelopmentalStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GALE401rights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>GALE-401 rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GALE401rights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6846848160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">182,512,117<span></span>
</td>
<td class="nump">162,581,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">181,837,117<span></span>
</td>
<td class="nump">161,906,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847907024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,175<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
<td class="nump">$ 11,618<span></span>
</td>
<td class="nump">$ 13,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">6,642<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,292<span></span>
</td>
<td class="nump">9,083<span></span>
</td>
<td class="nump">18,260<span></span>
</td>
<td class="nump">17,995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,292)<span></span>
</td>
<td class="num">(9,083)<span></span>
</td>
<td class="num">(18,260)<span></span>
</td>
<td class="num">(17,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnWarrantExchange', window );">Change in fair value of warrants potentially settleable in cash</a></td>
<td class="nump">14,392<span></span>
</td>
<td class="num">(4,267)<span></span>
</td>
<td class="nump">10,520<span></span>
</td>
<td class="num">(3,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(519)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change In Fair Value Of Contingent Purchase Price Consideration</a></td>
<td class="nump">5,497<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">5,327<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="nump">17,570<span></span>
</td>
<td class="num">(4,391)<span></span>
</td>
<td class="nump">13,436<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="nump">8,278<span></span>
</td>
<td class="num">(13,474)<span></span>
</td>
<td class="num">(4,824)<span></span>
</td>
<td class="num">(21,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(2,889)<span></span>
</td>
<td class="num">(2,186)<span></span>
</td>
<td class="num">(6,280)<span></span>
</td>
<td class="num">(4,417)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,389<span></span>
</td>
<td class="num">$ (15,660)<span></span>
</td>
<td class="num">$ (11,104)<span></span>
</td>
<td class="num">$ (26,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per share, continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Basic and diluted net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic and diluted</a></td>
<td class="nump">182,034,593<span></span>
</td>
<td class="nump">161,383,398<span></span>
</td>
<td class="nump">180,703,456<span></span>
</td>
<td class="nump">148,647,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted (in shares)</a></td>
<td class="nump">185,477,330<span></span>
</td>
<td class="nump">161,383,398<span></span>
</td>
<td class="nump">180,703,456<span></span>
</td>
<td class="nump">148,647,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on warrant exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847808832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th">
<div>Senior Notes [Member] </div>
<div>Senior Secured Debentures [Member]</div>
</th>
<th class="th">
<div>Senior Notes [Member] </div>
<div>Senior Secured Debentures [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,581,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2015</a></td>
<td class="nump">$ 13,513<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 296,730<span></span>
</td>
<td class="num">$ (279,383)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,772,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">20,189<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">20,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued</a></td>
<td class="num">(5,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,139)<span></span>
</td>
<td class="num">$ (1,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock-based compensation for directors and employees</a></td>
<td class="nump">$ 1,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">166,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,996,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2016</a></td>
<td class="nump">$ 20,321<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 314,639<span></span>
</td>
<td class="num">$ (290,487)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65880886&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847993280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">$ (4,824)<span></span>
</td>
<td class="num">$ (21,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(10,520)<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(5,327)<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable', window );">Litigation settlement insurance recovery</a></td>
<td class="nump">21,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Litigation settlement payable</a></td>
<td class="num">(19,900)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(589)<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operating activities</a></td>
<td class="num">(17,588)<span></span>
</td>
<td class="num">(19,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations</a></td>
<td class="nump">6,280<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Changes in operating assets and liabilities attributable to discontinued operations</a></td>
<td class="num">(839)<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in discontinued operating activities</a></td>
<td class="num">(7,119)<span></span>
</td>
<td class="num">(3,980)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(24,707)<span></span>
</td>
<td class="num">(23,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in continuing investing activities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PaymentsonDisposalofProductiveAssets', window );">Selling costs paid for sale of commercial assets</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid for commercial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in discontinued investing activities</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,056)<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">20,189<span></span>
</td>
<td class="nump">47,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of stock options</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NetProceedsFromExerciseOfCommonStockWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from common stock issued in connection with ESPP</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="nump">23,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities', window );">Minimum cash covenant on long-term debt</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(4,779)<span></span>
</td>
<td class="num">(1,914)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">15,623<span></span>
</td>
<td class="nump">45,613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(10,140)<span></span>
</td>
<td class="nump">21,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">29,730<span></span>
</td>
<td class="nump">23,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">19,590<span></span>
</td>
<td class="nump">45,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the periods for interest</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as cost of equity</a></td>
<td class="nump">5,590<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liabilities upon exercise</a></td>
<td class="num">$ (324)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IncreaseDecreaseinRestrictedCashforFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Restricted Cash for Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IncreaseDecreaseinRestrictedCashforFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NetProceedsFromExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NetProceedsFromExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PaymentsonDisposalofProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments on Disposal of Productive Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PaymentsonDisposalofProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838395408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"> Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. The Company&#8217;s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, our novel cancer immunotherapy programs including NeuVax&#8482; (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE-401 has completed a Phase 2 trial and we are advancing the asset into a pivotal trial. NeuVax is currently in multiple Phase 2 trials. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Developing hematology and oncology assets through clinical development, targeting areas of unmet medical need.  Our hematology asset is targeting the treatment of patients with essential thrombocythemia (ET) to reduce elevated platelet counts</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition of additional development programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:120px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer (i)&#160;to Galena, our wholly owned subsidiaries, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">At </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company&#8217;s capital resources consisted of cash and cash equivalents of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$19.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> not including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of restricted cash. The Company will need to continue to incur significant expenses to advance our development portfolio and will need to raise additional capital to finance such activities.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On July 13, 2016, we closed the sale to certain institutional investors of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at a purchase price per share of&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.45</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;in a registered direct offering, and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock with an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.65</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. The current unrestricted cash and cash equivalents as of the date of this filing will fund the Company's operations for at least six months.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional funding was received July 13, 2016 upon the closing of an underwritten registered direct offering of our common stock and a private placement of warrants for net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to the Company. Additional funding sources that are, or in certain circumstances may be, available to the Company, include 1) approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of restricted cash associated with our </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> sale of Debentures by amending the current agreement with the holder to reduce the minimum cash covenant as detailed in Note 4; 2) a Purchase Agreement with Lincoln Park Capital, LLC; and 3) At Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC. The Purchase Agreement and ATM are unavailable to the Company until </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75 days</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> after the closing of our July 2016 financing. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of the Company's product candidates and to support its other ongoing activities. However, the Company cannot be certain that it will be able to raise additional capital on favorable terms, or at all, which raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Litigation Settlement Payable and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions of the FASB ASC Topic 718, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and six month periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation-Stock Compensation </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774755200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent purchase price consideration during the quarter ended June 30, 2016 reflects an adjusted probability and time line for the potential approval of NeuVax associated with the Phase 2 combination trial with trastuzumab. Previously, the valuation was measured using the probability and time line of the Phase 3 PRESENT trial, which was stopped in June 2016 due to futility as recommended by the Independent Data Monitoring Committee ("IDMC").</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">See Note 7 for discussion of the Level 2 liabilities relating to warrants accounted for as liabilities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774644992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774770480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$10 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "Loan"). The Loan payment terms include </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">12</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of interest-only payments at the fixed coupon rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8.45%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, followed by </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">30</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash facility fee and a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> cash final payment and granted to the lenders </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">seven</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,186</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, which equaled a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On May 10, 2016, the Company entered into a&#160;Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.375%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> original issue discount, a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25,530,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> Senior Secured Debentures&#160;(the &#8220;Debentures&#8221;) and warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock. Net proceeds to the Company from sale of the&#160;Debentures, after payment of commissions and legal fees, were approximately </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$23,400,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The&#160;Debentures&#160;mature November 10, 2018, accrue interest at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per year, and do not contain any conversion features into shares of our common stock. The Company intends to&#160;use the net proceeds from this offering to fund the costs associated with the close down of the Phase 3 PRESENT study of NeuVax and other clinical trials of our product candidates and to augment its working capital and for general corporate purposes.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Debentures carry an interest only period of six months following which the holder shall have the rights, at its option, to require the Company to redeem up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1,100,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per month of the outstanding principal amount of these Debentures. Interest is payable at the end of each month based on the outstanding principal. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company is required to promptly, but in any event no more than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> trading days after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company&#8217;s election and subject to certain conditions, in shares of the Company's common stock. If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or B) a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7.5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> discount to the prior trading day&#8217;s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debentures but not less than the monthly payment.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Based on the recommendation of the IDMC to stop the PRESENT Trial, the holder has the right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of this Debenture funded in cash by the holder on the closing date, plus all accrued and unpaid interest. If the holder elects such prepayment of the Debentures, then the number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by the Company. The Purchaser received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the closing on the sale of the Debentures at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, maturing </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years from issuance. Additionally, the Purchasers received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.43</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. As of June 30, 2016 and the date of this filing, the holder had not exercised its right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of the Debentures. The holder's right to require the Company to prepay the outstanding principal amount expires 30 trading days after June 29, 2016, the announcement date of the recommendation of the IDMC. Therefore as of June 30, 2016 the Debentures, net of unamortized discounts, are presented as current liabilities on the condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s obligations under the&#160;Debenture&#160;can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company&#8217;s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the&#160;Debenture in cash. The Company&#8217;s obligations under the&#160;Debentures&#160;are secured under a Security Agreement by a senior lien on all of the Company&#8217;s assets, including all of the Company&#8217;s interests in its consolidated subsidiaries. Until the holder exercises its right to require the Company to prepay some or all of the loan, the Company must also maintain a minimum of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$24.0 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash, which is included in restricted cash as of June 30, 2016. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:12pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Armentum Partners, LLC (the &#8220;Placement Agent&#8221;) acted as the&#160;placement agent&#160;in the offering of the&#160;Debentures and the Company agreed to pay the Placement Agent a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the funds received from the sale of the&#160;Debentures. The Company paid half of the placement fee upon funding with the remaining payable </font><font style="font-family:inherit;font-size:12pt;">at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">such time as the IDMC recommended in favor of the continuation of the PRESENT Trial or the holder waives the Company&#8217;s obligation to prepay the Debenture as a result of the IDMC&#8217;s recommendation</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774644992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Legal Proceedings</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we agreed in principle to resolve and settle the consolidated shareholder derivative action,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00382-SI, pending in the United States District Court for the District of Oregon against us and certain of our current and former officers and directors. On April 21, 2016, the District Court of Oregon held the final approval hearing of the settlement with the derivative plaintiffs after which the District Court continued the final approval hearing until June 23, 2016 and requested the parties submit additional briefing by June 9, 2016 on the fee request by the derivative plaintiffs&#8217; attorneys.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Derivative Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval to the settlement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus costs, which will be paid by our insurance carriers. The settlement includes a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$15 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,200,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December&#160;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,&#160;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, Civil Action No.&#160;3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Securities Litigation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#8217;s fees of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus costs, which is paid out of the settlement funds. The settlement agreement provides for a payment of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> settlement payment to the class, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$16.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> was paid by our insurance carriers and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash was paid by us on July 1, 2016, along with </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">480,053</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares) paid by us on July 6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits. As of June 30, 2016 our insurance carriers paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The Company paid </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in cash and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in common stock on July 1, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In July 2016, we have resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> plus </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$150,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">291,262</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">) of our common stock, and in another case for </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of our common stock (</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,366,750</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follow as of June 30, 2016 (in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in cash  (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in common stock (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff to resolve the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney&#8217;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#8217; pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#8217; attorney&#8217;s fees. To our knowledge, we are not a target or subject of that investigation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney&#8217;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#8217;s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774733888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s Board of Directors upon its issuance. To date, the Company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company has authorized up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">275,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.0001</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;par value per share, for issuance. On July 14, 2016, shareholders approved a </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> share increase to the Company's authorized shares of common stock up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">350,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$50 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in shares of the Company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.5 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of the Company's common stock at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.00</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and the Company issued </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">631,221</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.7 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock, excluding the commitment fee shares. There were no sales of our common stock under the LPC purchase agreement during the six months ended June 30, 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with FBR &amp; Co. (formerly MLV &amp; Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in gross proceeds. The ATM is available to the Company until it is terminated by the Agents or the Company. During the first quarter of 2015, we received </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.3 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in net proceeds from the sale of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the six months ended June 30, 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On March 18, 2015 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">January 2016 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On January 12, 2016 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,772,727</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The underwriters did not exercise their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expense paid by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">59,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774894048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants issued to Consultants and Debtors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2016-2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in January 2016, March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">113.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">122.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">139.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">167.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">65.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">71.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*The March 2011 warrants expired in March 2016. The March 2010 warrants do not expire until September 2016.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,515</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(6,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,075</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us and warrants issued in connection with debt financings. On May 10, 2016 upon closing on the sale of Debentures, we granted the holder warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.51</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">77.13%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five and five tenths</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.26%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.87</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. These warrants are recorded in equity at fair value upon issuance. Additionally, on June </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upon closing on the public announcement of the interim analysis of the PRESENT trial, we granted the holder warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,000,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.43</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">106.63%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, expected term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.5</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.35%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, and a dividend rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.00%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.27</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. These warrants are recorded in equity at fair value upon issuance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Freestanding Contract<br> -URI http://asc.fasb.org/extlink&amp;oid=6513800<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 55<br> -Paragraph 63<br> -URI http://asc.fasb.org/extlink&amp;oid=6924035&amp;loc=d3e23176-110880<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90198-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838395952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The weighted-average fair value of options granted during the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.36</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.86</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share, respectively. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the Company&#8217;s options of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> with the average vesting term of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for an average of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">six years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">15%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to its employees, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, there was </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3,755,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.79</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,500,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock were reserved for issuance under the Company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares subject to outstanding common stock options granted under the plan. On July 14, 2016, the shareholders approved the 2016 Incentive Plan into which the available shares in the 2007 Incentive Plan were transferred. There are </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,923,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares available for future grants based on adjustments in the 2016 Incentive Plan. The administrator of the plan determines the terms when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">four years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">ten years</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the Company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,952</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were calculated based on the closing price of the Company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$0.47</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying options.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774728080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) (in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,034,593</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of dilutive securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">677,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,765,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,442,737</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">185,477,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838424768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance. BioVascular has advised the Company of an alleged breach of the BioVascular agreement which the Company has denied. Both parties are discussing the dispute and it is anticipated that the dispute will be resolved. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On November 19, 2015, the Company and Sentynl Therapeutics Inc., a Delaware corporation (&#8220;Sentynl&#8221;), entered into and closed upon an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) sublingual tablets product (&#8220;Abstral&#8221;). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company&#8217;s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (&#8220;Orexo&#8221;)  dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the &#8220;Orexo Agreements&#8221;).  The Company&#8217;s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. In connection with such assignment, Orexo released the Company from any future obligations under the Orexo Agreements. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities and rebates related to Abstral for a period of time post-closing.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upfront payment and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of two one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$25 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$35 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 17, 2015, the Company and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (&#8220;Midatech&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film (&#8220;Zuplenz&#8221;). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company&#8217;s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (&#8220;MonoSol&#8221;) dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  The Company&#8217;s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain rebates and channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The total potential consideration payable to the Company under the Purchase Agreement is </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$29.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, comprised of an </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$3.75 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> upfront payment upon the closing and up to an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$26 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$12 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$70 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Through a separate agreement with MonoSol entered into on December 16, 2015 (the &#8220;MonoSol License Amendment&#8221;), (i) the Company and MonoSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company paid MonoSol </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of the upfront fee payable to the Company under the Purchase Agreement and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of any future milestone payments received by the Company under the Purchase Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company&#8217;s License and Supply Agreement, dated July 17, 2014 (the &#8220;MonoSol License&#8221;).  As a result of such assignment, Midatech assumed all of the Company&#8217;s obligations under the MonoSol License.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774802224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations,Assets Held for Sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Discontinued Operations, Assets Held for Sale</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">During the fourth quarter of 2015, The Company sold its rights to its commercial products Abstral</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (ondansetron) Oral Soluble Film. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, the Company paid a success fee to the third party firm in an amount of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$900,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and agreed to pay </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of realized future revenue and payment streams. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, the Company paid a retention fee to the three employees in a combined total amount equal to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$352,000</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> or </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3%</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of cash consideration received as upfront payment in the transactions. These employees also received severance payments equal to one month&#8217;s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees who were part of the commercial business and did not accept employment opportunities at the companies that purchased Abstral and Zuplenz. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Abstral and related assets on November 19, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Sale of Zuplenz and related assets on December 24, 2015</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net proceeds from sales</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">8,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Less selling costs*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Proceeds from sale, net of selling costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">7,533</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">*Selling costs related to the sale of Zuplenz and related assets were included in accrued liabilities as of December 31, 2015 and were paid in the first quarter of 2016. All other amounts were received or paid in the fourth quarter of 2015.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$30 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents amounts related to the discontinued operations in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:490px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:298px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:77px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(588</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,614</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> respectively, in selling, general, and administrative expense in discontinued operations. of which </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:490px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772231024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Discontinued Operations </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of Estimates in Preparation of Financial Statements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">90</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the Company&#8217;s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment and Furnishings</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">three</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">five</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div></td></tr></table><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:Helvetica,sans-serif;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and In-Licensing</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Purchase Price Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Litigation Settlement Payable and Insurance Recoveries</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Litigation Settlement Payable and Insurance Recoveries </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212; There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company follows the provisions of the FASB ASC Topic 718, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Accounting for Income Taxes (&#8220;ASC 740-10&#8221;).</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the Company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">There was no income tax expense or benefit for the three and six month periods ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, the Company&#8217;s cash equivalents were invested in money market mutual funds. The Company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Effect of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">Effect of Recent Accounting Pronouncements</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Compensation-Stock Compensation </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company follows ASC&#160;820, </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Net Income (Loss) Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents and Patent Application Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6750924080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">18,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Observable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">29,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">14,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(5,327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Balance at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6582768928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774789536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Litigation Settlements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The litigation settlements are summarized as follow as of June 30, 2016 (in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Class action settlement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Derivative settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shareholders securities litigation settlements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Paid by the insurance carriers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in cash  (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Payable by the company in common stock (paid in July 2016)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total settlements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14472-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12021-110248<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14453-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12053-110248<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14394-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838438016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On March 18, 2015 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">24,358,974</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.56</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$38 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.50</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.08</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,826,923</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,653,846</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$5.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$40.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">January 2016 Underwritten Public Offering</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> - On January 12, 2016 the Company closed an underwritten public offering of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">19,772,727</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> units at a price to the public of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.10</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$21.8 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.60</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$1.42</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,779,545</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of common stock. The underwriters did not exercise their over-allotment option to purchase </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,965,909</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expense paid by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">59,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772006064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants issued to Consultants and Debtors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">15,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Outstanding, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">13,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">37,418</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2016-2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Varies 2014-2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">113.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">122.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">139.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">167.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">218.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">As of December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">2.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">74.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">76.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">65.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">47.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">71.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">January 2016 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Other Equity Financing Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">10,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">1,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">14,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">5,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Fair value of warrants exercised</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,515</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(6,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(1,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(909</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">(10,520</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">Warrant liability, June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4,075</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">3,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">9,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6768171776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and 2015, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total stock-based compensation from continuing operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">76.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">75.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table summarizes option activity of the Company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">13,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,952</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Outstanding at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options exercisable at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2.97</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849072928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net income (loss) (in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(11,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">182,034,593</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Effect of dilutive securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">677,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,765,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,442,737</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">185,477,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">180,703,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Basic net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock', window );">Common Shares Excluded from Net Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Helvetica,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.10136452241716%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">21,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">37,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">10,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">27,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">47,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744368816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents amounts related to the discontinued operations in the balance sheets (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:490px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">December 31, 2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of assets included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current assets of discontinued operations, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Carrying amounts of liabilities included as part of discontinued operations:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">1,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">2,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Total current liabilities of discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">5,925</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:298px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:77px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">3,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">6,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(1,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(588</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,614</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(8,921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Non-operating income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Impairment charge from classification as assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Loss from discontinued operations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(2,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(6,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(4,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Selling, general and administrative expense</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;font-style:italic;"> </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> respectively, in selling, general, and administrative expense in discontinued operations. of which </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;"> and </font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$4.4 million</font><font style="font-family:Helvetica,sans-serif;font-size:10pt;">, for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:490px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Helvetica,sans-serif;font-size:8pt;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Helvetica,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849429856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jul. 29, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>May 09, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May 08, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,279,000<span></span>
</td>
<td class="nump">$ 19,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,730,000<span></span>
</td>
<td class="nump">$ 23,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents', window );">Highly-liquid debt instruments maturity days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,772,727<span></span>
</td>
<td class="nump">24,358,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock purchase price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRestrictionofFundsPeriod', window );">Restriction of funds, period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Senior Secured Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock purchase price per share (usd per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightIssuedDuringPeriod', window );">New warrants issued during period (in shares)</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRestrictionofFundsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Restriction of Funds, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRestrictionofFundsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847621312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,898<span></span>
</td>
<td class="nump">$ 5,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835447680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">$ 9,264<span></span>
</td>
<td class="nump">$ 14,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">10,079<span></span>
</td>
<td class="nump">20,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">29,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="nump">14,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 6,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6847691824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="num">$ (5,497)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (5,327)<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6643268912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">$ 3,208<span></span>
</td>
<td class="nump">$ 3,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 4,703<span></span>
</td>
<td class="nump">$ 5,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850006592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt (Details)<br></strong></div></th>
<th class="th">
<div>May 10, 2016 </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 08, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 13, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 12, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentTermInterestOnly', window );">Term for interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFinalPayment', window );">Cash final payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term for principal and interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFacilityFee', window );">Cash facility fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice', window );">Duration of average market price used for warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember', window );">First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan, amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Debt Instrument, Covenant, Liquidity Covenant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member] | Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentRedemptionNumberofDaysMaximum', window );">Redemption period (days) | day</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate', window );">Discount to the prior trading day&#8217;s volume weighted average price</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed', window );">Debt Instrument, Principal That Could Be Redeemed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DentInstrumentOriginalIssueDiscountPercent', window );">Dent Instrument, Original Issue Discount, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived', window );">Debt Instrument, Placement Agent Fee, Percent of Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Average Market Price Used For Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Placement Agent Fee, Percent of Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal That Could Be Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPrincipalThatCouldBeRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prior Trading Day&#8217;s Volume, Weighted Average Price, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPriorTradingDaysVolumeWeightedAveragePriceDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentRedemptionNumberofDaysMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Number of Days, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentRedemptionNumberofDaysMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentTermInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Interest Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentTermInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DentInstrumentOriginalIssueDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dent Instrument, Original Issue Discount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DentInstrumentOriginalIssueDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849776240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 06, 2016</div></th>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Jun. 24, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Payable by the insurance carriers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (26,800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember', window );">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember', window );">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PaymentsforLegalSettlementsPaidbyInsurance', window );">Payments for legal settlements, paid by insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash (paid in July 2016)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Payable by the insurance carriers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod', window );">Stock option cancellation in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement, issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement, issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Subsequent Event [Member] | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PaymentsforLegalSettlementsPaidbyInsurance', window );">Payments for legal settlements, paid by insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash (paid in July 2016)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockValue', window );">Litigation settlement, issuance of common stock, value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LitigationSettlementIssuanceofCommonStockShares', window );">Litigation settlement, issuance of common stock (in shares)</a></td>
<td class="nump">480,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LitigationSettlementIssuanceofCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LitigationSettlementIssuanceofCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PaymentsforLegalSettlementsPaidbyInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Legal Settlements, Paid by Insurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PaymentsforLegalSettlementsPaidbyInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsCanceledinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the amounts received by the insured under the terms of an insurance contract settlement. This element pertains only to insurance proceeds related to operating activities. It excludes insurance settlements classified as investing cash flows, for example, insurance settlements related to fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772253136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Schedule of Litigation Settlements) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Payable by the insurance carriers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember', window );">Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember', window );">Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember', window );">Shareholders Securities Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payable by the company in cash (paid in July 2016)</a></td>
<td class="nump">$ 2,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_IssuanceofCommonStockforLitigationSettlement', window );">Payable by the company in common stock (paid in July 2016)</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_IssuanceofCommonStockforLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_IssuanceofCommonStockforLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the amounts received by the insured under the terms of an insurance contract settlement. This element pertains only to insurance proceeds related to operating activities. It excludes insurance settlements classified as investing cash flows, for example, insurance settlements related to fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=gale_ShareholdersSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849240128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Nov. 18, 2014</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jul. 14, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>May 08, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAdditionalSharesAuthorized', window );">Common stock, additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementTerm', window );">Purchase Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">19,772,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,358,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofSharesPerUnit', window );">Number of Shares Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption', window );">Stock Issued During Period, Shares, Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653,846<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</a></td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock purchase price per share (usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember', window );">MLV &amp; Co. LLC and Maxim Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds', window );">At Market Issuance Sales Agreements, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds', window );">At Market Issuance Sales Agreements, Maximum Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockAvailableforIssuanceSharesNewIssues', window );">Stock Available for Issuance, Shares, New Issues</a></td>
<td class="nump">2,965,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="nump">1,779,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Maximum Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Percent of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockAvailableforIssuanceSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Available for Issuance, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockAvailableforIssuanceSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Overallotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772068256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">37,418<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">10,309<span></span>
</td>
<td class="nump">13,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Options reserved for future issuance under the Company's 2007 Incentive Plan</a></td>
<td class="nump">10,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan</a></td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">59,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836082784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Schedule of Warrant Activity) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 12,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 18,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850098608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">113.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 8 months 19 days<span></span>
</td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">122.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 2 months 19 days<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">139.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.24%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 5 months 23 days<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">167.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">9 months 22 days<span></span>
</td>
<td class="text">1 year 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">218.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">218.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836468544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Changes in Fair Value of Warrant Liability) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">$ 14,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">5,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(10,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember', window );">January 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">5,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(1,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">4,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">10,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(6,668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">3,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsExercised', window );">Fair Value Of Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_JanuaryTwoThousandSixteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772112960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Warrants Classified as Equity) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 29, 2016</div></th>
<th class="th"><div>May 08, 2013</div></th>
<th class="th"><div>Jul. 13, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>May 09, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsGrantedNumberofShares', window );">Warrants granted, number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value assumptions, expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsGrantedNumberofShares', window );">Warrants granted, number of shares (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="nump">106.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value assumptions, expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted (usd per share)</a></td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsGrantedNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsGrantedNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835700064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Allocated Stock-based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 1,278<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774618704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">76.30%<span></span>
</td>
<td class="nump">73.32%<span></span>
</td>
<td class="nump">75.63%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">5 years 9 months 4 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835659168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Additional Information) (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees', window );">Estimated annualized forfeiture rate for options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement', window );">Estimated annualized forfeiture rate for options granted to senior management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember', window );">2007 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">26,500,000<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,309,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">10,923,000<span></span>
</td>
<td class="nump">10,923,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting periods of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock | $ / shares</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to senior management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774768704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Stock Option Activity) (Detail)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Beginning Balance | shares</a></td>
<td class="nump">13,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options activity, Total Number of Shares, Granted | shares</a></td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options activity, Total Number of Shares, Exercised | shares</a></td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options activity, Total Number of Shares, Cancelled | shares</a></td>
<td class="num">(2,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Ending Balance | shares</a></td>
<td class="nump">10,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Total Number of Shares, exercisable | shares</a></td>
<td class="nump">5,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 2.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">1.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">1.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">2.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, exercisable | $ / shares</a></td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Beginning balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Exercised | $</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Cancelled | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Ending balance | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6768268848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) Table (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of the contingent purchase price liability</a></td>
<td class="num">$ (5,497)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (5,327)<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6848082256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,389<span></span>
</td>
<td class="num">$ (15,660)<span></span>
</td>
<td class="num">$ (11,104)<span></span>
</td>
<td class="num">$ (26,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">182,034,593<span></span>
</td>
<td class="nump">161,383,398<span></span>
</td>
<td class="nump">180,703,456<span></span>
</td>
<td class="nump">148,647,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options</a></td>
<td class="nump">677,279<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants</a></td>
<td class="nump">2,765,458<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">3,442,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">185,477,330<span></span>
</td>
<td class="nump">161,383,398<span></span>
</td>
<td class="nump">180,703,456<span></span>
</td>
<td class="nump">148,647,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Treasury Stock Method<br> -URI http://asc.fasb.org/extlink&amp;oid=6527216<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Call Option<br> -URI http://asc.fasb.org/extlink&amp;oid=6506649<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774629424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">27,959<span></span>
</td>
<td class="nump">33,719<span></span>
</td>
<td class="nump">47,727<span></span>
</td>
<td class="nump">33,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">21,517<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
<td class="nump">37,418<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">6,442<span></span>
</td>
<td class="nump">11,411<span></span>
</td>
<td class="nump">10,309<span></span>
</td>
<td class="nump">11,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849837776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 24, 2015</div></th>
<th class="th"><div>Dec. 16, 2015</div></th>
<th class="th"><div>Nov. 19, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement', window );">Purchase Agreement, Consideration Receivable Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement', window );">Purchase Agreement, Upfront Payment Receivable Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement', window );">Purchase Agreement, Contingent Consideration Receivable Under Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Purchase Agreement, Contingent Consideration Threshold, Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member', window );">Sentynl Therapeutics, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Purchase Agreement, Contingent Consideration Threshold, Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember', window );">Monosol Rx, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementPaymentofUpfrontFee', window );">Purchase Agreement, Payment of Upfront Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived', window );">Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement', window );">Purchase Agreement, Consideration Receivable Under Agreement</a></td>
<td class="nump">$ 29,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement', window );">Purchase Agreement, Upfront Payment Receivable Under Agreement</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement', window );">Purchase Agreement, Contingent Consideration Receivable Under Agreement</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Purchase Agreement, Contingent Consideration Threshold, Net Sales</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember', window );">Midatech Pharma PLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales', window );">Purchase Agreement, Contingent Consideration Threshold, Net Sales</a></td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementConsiderationReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Consideration Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementConsiderationReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Contingent Consideration Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementContingentConsiderationReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementContingentConsiderationThresholdNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Contingent Consideration Threshold, Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementContingentConsiderationThresholdNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementPaymentofUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Payment of Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementPaymentofUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementPaymentofUpfrontFeePercentageofFutureMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Upfront Payment Receivable Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementUpfrontPaymentReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_SentynlTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_MonosolRxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gale_MidatechPharmaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837093056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Disposal Group, Including Discontinued Operation, General and Administrative Expense</a></td>
<td class="nump">$ 2,233,000<span></span>
</td>
<td class="nump">$ 4,581,000<span></span>
</td>
<td class="nump">$ 4,614,000<span></span>
</td>
<td class="nump">$ 8,921,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement', window );">Success fee contingently due to third party</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue', window );">Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees', window );">Retention fees contingently due</a></td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived', window );">Retention fees contingently due (as percentage of consideration received)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralandZuplenzMember', window );">Abstral and Zuplenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments', window );">Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=gale_LegalExpensesMember', window );">Legal Expenses [Member] | Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Disposal Group, Including Discontinued Operation, General and Administrative Expense</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentLiabilityFromDivestitureAgreementPercentofRealizedFutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Retention Fees, Percentage of Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationContingentRetentionFeesPercentageofConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationRevenueMilestonePotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralandZuplenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralandZuplenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=gale_LegalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=gale_LegalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6849809104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Net Proceeds from Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 24, 2015</div></th>
<th class="th"><div>Nov. 19, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralMember', window );">Abstral [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Less selling costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet', window );">Proceeds from sale, net of selling costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_ZuplenzMember', window );">Zuplenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration</a></td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Less selling costs</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet', window );">Proceeds from sale, net of selling costs</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_AbstralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_ZuplenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_ZuplenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6837473936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">$ 3,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total current assets of discontinued operations, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">$ 3,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6848065328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">$ (2,889)<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="num">$ (6,280)<span></span>
</td>
<td class="num">$ (4,417)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations', window );">Additional channel obligations</a></td>
<td class="num">(656)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,666)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(468)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of certain acquired intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(442)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="num">(2,233)<span></span>
</td>
<td class="num">(4,581)<span></span>
</td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(8,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Non-operating income (expense)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge from classification as assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">$ (2,889)<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="num">$ (6,280)<span></span>
</td>
<td class="num">$ (4,417)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Additional Channel Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationAdditionalChannelObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774595824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember', window );">Commercial Business Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for acquisition of Zuplenz rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6850512624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 08, 2016</div></th>
<th class="th"><div>Jul. 13, 2016</div></th>
<th class="th"><div>May 09, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>May 08, 2013</div></th>
<th class="th"><div>Jul. 29, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,772,727<span></span>
</td>
<td class="nump">24,358,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock purchase price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExercisePeriod', window );">Warrant exercise period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCovenantLiquidityCovenant', window );">Debt Instrument, Covenant, Liquidity Covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DentInstrumentOriginalIssueDiscountPercent', window );">Dent Instrument, Original Issue Discount, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed', window );">Debt Instrument, Principal That Could Be Redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived', window );">Debt Instrument, Placement Agent Fee, Percent of Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock purchase price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightIssuedDuringPeriod', window );">New warrants issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction', window );">Maximum consideration received on transaction under Purchase Agreement</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Allowable ownership interest under Purchase Agreement</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Sale Of Stock, Tranche One [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Sale Of Stock, Tranche Two [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Sale Of Stock, Tranche One [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Sale Of Stock, Tranche Two [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Placement Agent Fee, Percent of Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPlacementAgentFeePercentofFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentPrincipalThatCouldBeRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal That Could Be Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentPrincipalThatCouldBeRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DentInstrumentOriginalIssueDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dent Instrument, Original Issue Discount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DentInstrumentOriginalIssueDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SaleOfStockMaximumConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Consideration Received Per Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SaleOfStockMaximumConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gale_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SaleOfStockTermAxis=gale_SaleOfStockTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SaleOfStockTermAxis=gale_SaleOfStockTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SaleOfStockTermAxis=gale_SaleOfStockTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SaleOfStockTermAxis=gale_SaleOfStockTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*;V"^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%     @ 1X<)2:KL&"/T 0
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M.!\4*4'+^: E)>AV/NB6$G0W'W1'";J?#[JG!$D-9*PY20AKCM8"N!:.UP+
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M-?\-AT47>.?R=DS73SE/A0T76I=II13.UZN_6^>I?T/"I_\Z/+X#4$L#!!0
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M31-,/*-_C\/Q!9C;"S"?O9C[#*4&Q*)N]QPE,K-@4PM(Q>3.B_E.(F!/7&7
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MR ]6@]=FH(C@:'_%&6G8C54P_F_&/P%02P,$%     @ 1X<)20JW><VA!
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M.K3;AB2M5YEU^4;G]-WZWT' 5I528[IV6\XT;W;8+?GUI\/7_P!02P,$%
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M<Z -/4@=@JC'E>YHT^A(BOS7!?U@:N/M^QC]NUFN2G]/!-VQYD]]E)7*-@S
MD9[(I9&O;/A!W1H2'?# &F%^P>$B)&M'2P!:\FZ?=6>>@_V28&?S&[ SX,F
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M7:,&OW>XK8IF^'2VUZ:M2F.R<,K\%WR?SL/W#?Y1'IK9#3@:\-%@[,=N(-!
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M;P5  L<Q(X)^(9M](B,8R<BZL+X;'$8_P8ZFS?M8UDT-3WM@"(J8:R8O@7O
M<1@)QR1;]:#E@1]<O9H>T[W\D5;[K*R]5]7HM]SN972G5"-UF/!1OW ?]"?7
M<)'+7=.><GU>F8\0<]&H8_]--7S8)?\ 4$L#!!0    ( $>'"4FN5.V_M@0
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MX,2),E-\[B1GG>34BQ*<.$VL$B,9+IT,WZ^9FV8*UDQ!9D PXS2Q09!&R*D
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M-[5]&J;+;+SNW-F\NQG:B_^I8?F]8_L_4$L#!!0    ( $>'"4F%9'S'H@$
M +$#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULA5/;;J,P$/T5RQ]0
M$Y*T5420FE:KW8>5JC[L/CLP@%7;P]HF=/^^O@!-JJA]P3/#.6?.^%*,:%YM
M!^#(FY+:[FGG7+]CS%8=*&YOL ?M_S1H%'<^-2VSO0%>1Y*2+,^R6Z:XT+0L
M8NW9E 4.3@H-SX;802EN_A] XKBG*SH77D3;N5!@9<$67BT4:"M0$P/-GCZL
M=H=-0$3 'P&C/8M)\'Y$? W)KWI/LV !)%0N*'"_G. 1I Q"OO&_2?.C92">
MQ[/ZCSBM=W_D%AY1_A6UZ[S9C)(:&CY(]X+C3YA&V ;!"J6-7U(-UJ&:*90H
M_I96H>,ZIC_KF7:=D$^$?"'<9]%X:A1M/G''R\+@2&S/P]FM=AYN@HA7)MZ;
M]6-'31,'+XM3N=IN"W8*0A>81#Q,F 7!O/K5%CF]1L\C/?^>OKZDKY/#]>3P
M]GN!S:7 )@ELOAHQ80XSYNY3$W:VIPI,&Z^.)14.VJ4M7:K+[7S(XYE\P,NB
MYRW\YJ85VI(C.G^R\0 :1 >^?7:SI:3S[V=))#0NA'<^-NE*I<1A/S^0Y966
M[U!+ P04    " !'APE)D\B\A:0!  "Q P  &    'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;(53RV[;,!#\%8(?$,JRG*:&+"!.4;2' $$.Z9F65A(1DJN2
ME)7\??B0%;LPFHNXNYJ9G>6CG-"\VA[ D3<EM=W1WKEARYBM>U#<WN  VO]I
MT2CN?&HZ9@<#O(DD)5F>9;=,<:%I5<;:DZE*')T4&IX,L:-2W+SO0>*THRMZ
M*CR+KG>AP*J2+;Q&*-!6H"8&VAV]7VWW14!$P(N R9[%)'@_(+Z&Y'>SHUFP
M !)J%Q2X7X[P %(&(=_X[ZSYV3(0S^.3^L\XK7=_X!8>4/X1C>N]V8R2!EH^
M2O>,TR^81]@$P1JEC5]2C]:A.E$H4?PMK4+'=4I_UL5,NT[(9T*^$.ZR:#PU
MBC9_<,>KTN!$[,##V:VV'FZ"B%<FWIOU8T=-$P>ORF.UVMR5[!B$+C")N)\Q
M"X)Y]:LM<GJ-GD=Z_C5]?4E?)X?KV>'WKP6*2X$B"13_&S%A]C/F-ONG"3O;
M4P6FBU?'DAI'[=*6+M7E=M[G\4P^X54Y\ X>N>F$MN2 SI]L/( 6T8%OG]UL
M*.G]^UD2":T+X3<?FW2E4N)P.#V0Y956'U!+ P04    " !'APE)CIPOGJ(!
M  "Q P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;(U3VVZC,!#]%<L?
M4 .A%T4$J>FJ:A]6JOJP^^S  %9MAMHF=/^^O@!-JFAW7_#,<,Z9,[X4$^HW
MTP%8\J%D;W:TLW;8,F:J#A0W5SA [_XTJ!6W+M4M,X,&7@>2DBQ+DANFN.AI
M683:BRX+'*T4/;QH8D:EN/ZS!XG3CJ9T*;R*MK.^P,J"K;Q:*.B-P)YH:';T
M/MWN<X\(@%\")G,2$^_]@/CFD^=Z1Q-O 214UBMPMQSA :3T0J[Q^ZSYU=(3
M3^-%_3%,Z]P?N($'E+]%;3MG-J&DAH:/TK[B] 3S"-=>L$)IPI=4H[&H%@HE
MBG_$5?1AG>*?_':F729D,R%;"7=),!X;!9L_N.5EH7$B9N#^[-*M@VLOXI2)
M\V;<V$%3A\'+XEBF-VG!CE[H#!.)^QFS(IA3O]@BHY?H6:!G_Z9OSNF;Z' S
M._P/@?Q<((\"^=]&C)C]@ME\:\).]E2!;L/5,:3"L;=Q2]?J>COOLW F7_"R
M&'@+/[EN16_( :T[V7  #:(%USZYNJ:D<^]G320TUH>W+M;Q2L7$XK \D/65
MEI]02P,$%     @ 1X<)25\>BJ"C 0  L0,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&ULA5/;;J,P$/T5RQ]0$T+25420FE95^[!2U8?=9P<&L&HS
MU#:A^_?K"]"DBMH7/#.<<^:,+_F(^LVT )9\*-F9/6VM[7>,F;(%Q<T-]M"Y
M/S5JQ:U+=<-,KX%7@:0D2Y-DRQ07'2WR4'O118Z#E:*#%TW,H!37_PX@<=S3
M%9T+KZ)IK2^P(F<+KQ(*.B.P(QKJ/;U;[0Z91P3 'P&C.8N)]WY$?//)<[6G
MB;< $DKK%;A;3G /4GHAU_A]TOQLZ8GG\:S^&*9U[H_<P#W*OZ*RK3.;4%)!
MS0=I7W%\@FF$C1<L49KP)>5@+*J90HGB'W$575C'^">]G6C7">E$2!?"KR08
MCXV"S0=N>9%K'(GIN3^[U<[!M1=QRL1Y,V[LH*G#X$5^*E;;+&<G+W2!B<3#
MA%D0S*E?;9'2:_0TT-.?Z>M+^CHZ7$\.-S\+9)<"613(OALQ8@XS9ONE"3O;
M4P6Z"5?'D!*'SL8M7:K+[;Q+PYE\PHN\YPW\YKH1G2%'M.YDPP'4B!9<^^1F
M0TGKWL^22*BM#V]=K..5BHG%?GX@RRLM_@-02P,$%     @ 1X<)2=U'<RRG
M 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULA5/;3N,P$/T5
MRQ^ T[2E;)5&HJP0/*R$>&"?W6226-B>8#L-^_?XDH9V58F7>&9RSIDSOA0C
MFG?; 3CRJ:2V.]HYUV\9LU4'BML;[$'[/PT:Q9U/3<ML;X#7D:0DR[/LEBDN
M-"V+6'LQ98&#DT+#BR%V4(J;?WN0..[H@IX*KZ+M7"BPLF SKQ8*M!6HB8%F
M1^\7V_TJ("+@3<!HSV(2O!\0WT/R7.]H%BR A,H%!>Z7(SR E$'(-_Z8-+];
M!N)Y?%)_C--Z]P=NX0'E7U&[SIO-**FAX8-TKS@^P33".@A6*&W\DFJP#M6)
M0HGBGVD5.JYC^K/>3+3KA'PBY#/A+HO&4Z-H\S=WO"P,CL3V/)S=8NOA)HAX
M9>*]63]VU#1Q\+(XEHO;3<&.0>@"DXC["3,CF%>_VB*GU^AYI.<_TY>7]&5R
MN)P<WOTLL+H46"6!U23PZ]J(";.?,)OLOR;L;$\5F#9>'4LJ'+1+6SI7Y]MY
MG\<S^8:71<];^,--*[0E!W3^9.,!-(@.?/OL9DU)Y]_/G$AH7 @W/C;I2J7$
M87]Z(/,K+;\ 4$L#!!0    ( $>'"4FQ"Q9THP$  +$#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;(U3RV[;,!#\%8(?$$JRDQ2&+"!.$22' D$.
M[9F65A(1DJN2E)7^??F0%+LPVE[$W=7,["P?Y83FW?8 CGPHJ>V>]LX-.\9L
MW8/B]@8'T/Y/BT9QYU/3,3L8X$TD*<F*++MCB@M-JS+67DU5XNBDT/!JB!V5
MXN;7 21.>YK3I? FNMZ% JM*MO(:H4!;@9H8:/?T(=\=M@$1 =\%3/8L)L'[
M$?$])"_-GF;! DBH75#@?CG!(T@9A'SCG[/F9\M /(\7]:<XK7=_Y!8>4?X0
MC>N]V8R2!EH^2O>&TS/,(]P&P1JEC5]2C]:A6BB4*/Z15J'C.J4_13[3KA.*
MF5"LA"]9-)X:19M?N>-5:7 B=N#A[/*=AYL@XI6)]V;]V%'3Q,&K\E3E]WG)
M3D'H I.(AQFS(IA7O]JBH-?H1:07_Z9O+NF;Y' S._P/@>VEP#8);/\V8L(<
M%LSFCR;L;$\5F"Y>'4MJ'+5+6[I6U]OY4,0S^817Y< [^,9-)[0E1W3^9.,!
MM(@.?/OLYI:2WK^?-9'0NA#>^]BD*Y42A\/R0-976OT&4$L#!!0    ( $>'
M"4G/2&?BHP$  +$#   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(53
MVT[C,!#]%<L?@-,TI:LJC41!"!Y60CSL/KO)Y")L3["=AOW[]24)+:K@)9Z9
MG'/FC"_YB/K-M "6?$BAS)ZVUO8[QDS9@N3F!GM0[D^-6G+K4MTPTVO@52!)
MP=(DN662=XH6>:B]Z"+'P8I.P8LF9I"2ZW\'$#CNZ8K.A=>N::TOL")G"Z_J
M)"C3H2(:ZCV]6^T.F4<$P)\.1G,6$^_]B/CFD^=J3Q-O 024UBMPMYS@'H3P
M0J[Q^Z3YV=(3S^-9_3%,Z]P?N8%[%'^[RK;.;$))!34?A'W%\0FF$39>L$1A
MPI>4@[$H9PHEDG_$M5-A'>.?;#O1KA/2B9 NA%]),!X;!9L/W/(BUS@2TW-_
M=JN=@VLOXI2)\V;<V$%3A\&+_%2LMEG.3E[H A.)APFS()A3O]HBI=?H::"G
M/]/7E_1U=+B>'&Y^%L@N!;(HD'TW8L0<9LSMER;L;$\EZ"9<'4-*')2-6[I4
ME]MYEX8S^807><\;^,UUTRE#CFC=R88#J!$MN/;)S8:2UKV?)1%06Q]N7:SC
ME8J)Q7Y^(,LK+?X#4$L#!!0    ( $>'"4F9<87TI $  +$#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;(53RV[;,!#\%8(?$,JR4J>&+"!.4;2'
M D$.[9F65A(1DJN2E)7^??F0%+LPFHNXNYJ9G>6CG-"\VA[ D3<EM3W0WKEA
MSYBM>U#<WN$ VO]IT2CN?&HZ9@<#O(DD)5F>99^8XD+3JHRU9U.5.#HI-#P;
M8D>EN/ES!(G3@6[H4G@17>]"@54E6WF-4*"M0$T,M ?ZN-D?BX"(@)\")GL1
MD^#]A/@:DN_-@6;! DBH75#@?CG#$T@9A'SCW[/F>\M O(P7]:]Q6N_^Q"T\
MH?PE&M=[LQDE#;1\E.X%IV\PCW ?!&N4-GY)/5J':J%0HOA;6H6.ZY3^[(J9
M=IN0SX1\)3QDT7AJ%&U^X8Y7I<&)V(&'L]OL/=P$$:],O#?KQXZ:)@Y>E>=J
ML]N5[!R$KC")>)PQ*X)Y]9LM<GJ+GD=Z_C%]>TW?)H?;V>'#QP+%M4"1!(K_
MC9@PQP7S^9\F[&)/%9@N7AU+:ARU2UNZ5M?;^9C',WF'5^7 ._C!32>T)2=T
M_F3C ;2(#GS[[.Z>DMZ_GS61T+H0[GQLTI5*B<-A>2#K*ZW^ E!+ P04
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M/C;I2J7$83\_D.65EO\!4$L#!!0    ( $>'"4ESF"*3HP$  +$#   9
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M(UIWLN$ &D0+KGURLZ6D<^]G320TUH<_7*SCE8J)Q6%Y(.LK+?\"4$L#!!0
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M$@F-"^&#CTVZ4BEQV,\/9'FEY3]02P,$%     @ 1X<)2=B%1;^P @  PPL
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M(4'LXATFX>))&52QVX8B=O4>E'#WA(1U"%+$;M^#$JZ?0%@'Z[6,&<"#$AQ
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MPI0;I2PX^^0FQZASCW0).#36;^_<7L=[&P.K^OD5+K^"\@-02P,$%     @
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M*T4'KYJ802FN_QY XKBG*SH7WD336E]@1<X67B44=$9@1S34>_JPVATRCPB
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M]/[]K(F$UH7PT<<F7:F4.!R6![*^TNH/4$L#!!0    ( $>'"4D6P#J)P@$
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MNNL3IEPC6G#VR5U&2>L>Z1)(J*W??G%['>]M#"SV\RM<?@7%'U!+ P04
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MA#L?FW2E4N*PGQ_(\DK+_U!+ P04    " !'APE)5[=@BYL#  "&$0  &0
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MWC^?.9'0N1 N?6S2'Y42A\/Q?<R/M/X$4$L#!!0    ( $>'"4F9:/">: ,
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MA@"+%U$"W#TK)\\J@$46Z3 $<+3RXFDU@*.%'W^M'&%+]V%<6?CUU<H!M@9
MD44:NSM7MIXXPP;IJ_SL:S_Q[&OEY-G+6^>-5>#Y(C) PJV</,O),\B$R<FS
MGTA>)"<O M:\YXOHESV#X-VF<.F:_;B[WGJ;^E1UTV[L?'7>P7_2PZ;R3]=7
MZF$][<._E5DNCMG>_94U^[QJO9>ZZ^IRW%G>U77G^GZ%7ZSO'5RVG4\*M^N&
MP[@_;J;=^.FDJX^7'Q?F7SB6_P-02P,$%     @ 1X<)2>9H8I'J P  OQ4
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MP-M5#6Y915J'XOW2?06+-0@E1"%^5;AG5^^.-+\AY$,.?NR6KB\]X!ION91
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M;*4TPM+311%'>SMGC@^=V!IW6]I[%2:O\&#DX3Q(CM-L\Q]02P,$%     @
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MF0O6]"&^UY3OYEJU^GHQ_R2A#7,'0!L AX ACSL V0#T$8 G [ -P/=FB&Q
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M+]1CJ@IG3C%F(&A[.91U)\/\'U!+ P04    " !'APE)F+?9Y_X!  !8!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6R-55MOVC 4_BM6WEO;N9"
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MOJ_<4S7WH2D/_B'AZ4GEXG]02P,$%     @ 1X<)2;!"_O.4?0  OOP! !0
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M#X-OG24WV1H.+VWB!A $9"15M$T>DYMU _GA]Q)A?>#LS/#'84S'5*^3K(P
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MV7J/=#^W[])+<?LVHA,XM&6Q7B=E=8"^'#=#Q\X_:X[FN$>^_D.*8G"Z/$U
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MUD7E^3#7VJ:XL^.Z;\54PX#;*,,&Z[K@1QKO'8]S&8YS#3.T_T(SD*KH/WV
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MA@(7JL_>-6O5\1JL? BH&(I"A;P7U9'G.T'X2TF")K$)P$)^QP-0^;G&<9F
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MQ(WCXOV<'#,;]ZE+TKFW9>%^ H@XP9F>=76(L)9HZZZDYPR5CL!U)9_X"I<
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M_AF.Z9_^A( ]PT&0Y,C_&W86GQ?1>JV=-;7.I.BFFJR*SDM;BV$]@B>1''5
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MP"\G#CD,M7;FP+([1(%[IC8LL0+)7^\]YV]_>8H(C"WGQJ#D"*&5OYCQ#&=
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MWSONO[/H9D:]PX@-7-DS:L=[:()X;:/0)HR4 5HF $XT452+74"XX_GCX_Z
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M=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @ 1X<)24AU!>[%    *P(   L
M             ( !)@(  %]R96QS+RYR96QS4$L! A0#%     @ 1X<)2:KL
M&"/T 0  _R   !H              ( !% ,  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 1X<)26M#+AU7 P  VPT  !
M     ( !0 4  &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !'APE)2"'_
M_3\!  !I P  $0              @ '%"   9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " !'APE)F5R<(Q &  "<)P  $P              @ $S"@
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $>'"4EK%/J71P(  'P*
M   -              "  700  !X;"]S='EL97,N>&UL4$L! A0#%     @
M1X<)20JW><VA!   O1$   \              ( !YA(  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( $>'"4F%7K?]4@(  /4'   8              "
M ;07  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !'APE)
MOQ)B<O@#  "N$P  &               @ $\&@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ 1X<)213_05D= @  &@<  !@
M     ( !:AX  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M $>'"4FH&C2G1 0  ,<3   8              "  ;T@  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !'APE)GIDASD8#  #D#0  &
M            @ $W)0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ 1X<)2:Y4[;^V!   ^Q@  !@              ( !LR@  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $>'"4F%9'S'H@$  +$#
M   8              "  9\M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !'APE)D\B\A:0!  "Q P  &               @ %W+P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 1X<)28Z<+YZB
M 0  L0,  !@              ( !43$  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( $>'"4E?'HJ@HP$  +$#   9              "
M 2DS  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 1X<)
M2=U'<RRG 0  L0,  !D              ( ! S4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !'APE)L0L6=*,!  "Q P  &0
M        @ 'A-@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( $>'"4G/2&?BHP$  +$#   9              "  ;LX  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 1X<)29EQA?2D 0  L0,
M !D              ( !E3H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !'APE)?(/CFZ(!  "Q P  &0              @ %P/
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $>'"4ESF"*3
MHP$  +$#   9              "  4D^  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ 1X<)2;KT]."E 0  L0,  !D
M ( !(T   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !'
MAPE)V(5%O[ "  ##"P  &0              @ '_00  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $>'"4E8%G1?L $  !8$   9
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M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 1X<)21;
M.HG" 0  >P0  !D              ( !8DP  'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " !'APE)X(:#$,(!  ![!   &0
M    @ %;3@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M $>'"4F @X1:L0$  !8$   9              "  510  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ 1X<)29<(Y1RC 0  L0,  !D
M             ( !/%(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !'APE)5[=@BYL#  "&$0  &0              @ $65   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $>'"4EZ4P25GP$
M + #   9              "  >A7  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ 1X<)29EH\)YH P  SA(  !D              ( !
MOED  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !'APE)
M!-_KH#\"  !&!P  &0              @ %=70  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( $>'"4GPS[6R^ $  -0%   9
M      "  =-?  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ 1X<)22;68KDR!   \A4  !D              ( ! F(  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !'APE)7=OD\)$#   "$P
M&0              @ %K9@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( $>'"4F#6U47LP(   ,+   9              "  3-J  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 1X<)25,V6-R#
M!   /Q@  !D              ( !'6T  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !'APE),C-WH>8!  !S!0  &0
M@ '7<0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $>'
M"4E+GJO6)00  .T8   9              "  ?1S  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ 1X<)2>9H8I'J P  OQ4  !D
M         ( !4'@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " !'APE)C0FFS<D#   "%0  &0              @ %Q?   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $>'"4FAHU)HQ0(  +L+
M   9              "  7&   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ 1X<)21I9.6:! @  2 D  !D              ( !;8,
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !'APE)?Q*O
MI4<"  #>!P  &0              @ $EA@  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( $>'"4GX"LY>X (  !,,   9
M  "  :.(  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M1X<)207KXT_! @  V0H  !D              ( !NHL  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !'APE)"77(AOP!  !O!0  &0
M            @ &RC@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( $>'"4GKQC(PQ (  $$*   9              "  >60  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 1X<)28M<2 5? @
M+P@  !D              ( !X),  'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !'APE)7!W'CZ<"  #F"P  &0              @ %V
ME@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $>'"4D/
MKLIZH (  "4*   9              "  529  !X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ 1X<)29BWV>?^ 0  6 8  !D
M     ( !*YP  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $>'"4FP0O[SE'T  +[\ 0 4              "
M 8*L  !X;"]S:&%R9613=')I;F=S+GAM;%!+!08     /P _ "L1  !(*@$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>295</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Discontinued Operations, Assets Held for Sale (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Legal Proceedings, Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Warrants</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Discontinued Operations, Assets Held for Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Business and Basis of Presentation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LongTermDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Legal Proceedings, Commitments and Contingencies (Schedule of Litigation Settlements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesScheduleOfLitigationSettlementsDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Schedule of Litigation Settlements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail</Role>
      <ShortName>Warrants (Schedule of Warrant Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Warrants (Changes in Fair Value of Warrant Liability) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants (Warrants Classified as Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Allocated Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail</Role>
      <ShortName>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation (Stock Option Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Other Income (Expense) Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails</Role>
      <ShortName>Other Income (Expense) Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail</Role>
      <ShortName>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LicenseAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Discontinued Operations, Assets Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Discontinued Operations, Assets Held for Sale - Net Proceeds from Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleNetProceedsFromSaleDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Net Proceeds from Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleCarryingAmountsOfAssetsAndLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleComponentsAttributableToCommercialBusinessDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DiscontinuedOperationsAssetsHeldForSaleSignificantOperatingNonCashAndCapitalExpendituresDetails</Role>
      <ShortName>Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gale-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gale-20160630.xml</File>
    <File>gale-20160630.xsd</File>
    <File>gale-20160630_cal.xml</File>
    <File>gale-20160630_def.xml</File>
    <File>gale-20160630_lab.xml</File>
    <File>gale-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001390478-16-000134-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-16-000134-xbrl.zip
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MR=WL@??YD8SPN]$.H$3+)4+$RA!9])@9BV0!BE*8 BA_D"D4:[^E'HP$YZY
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MTD@@TVY/[B:]-'A@FH_PJ0=J<)_>"Q'+&$1_/[\T:JRQP01%8RF1-.F_PH[
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M;M29BB^R>,U\, 5/S(MKBX) H:E G%:68X.Y4":6%[[,"UJ-@J2^$F9<8:Z
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MP@E$8YDXL]16EW>FX0%'(,"L1K/W\#$;CWM9&NX&05IK]&W/D,K0B 0+-OC
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MI*S,>RU&AZ?SIA;K"(VRJ<@Z*$<\5DXI6@;;7$\'GU/Q=AWT2^-7*Z\6*!5
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M$1)S@87G&(% Z1B+$QZEUI79R+\J@ME*2GRVMW ;')O*_J+73"E'C.6.$1W
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MQ*-6'"U/:6/$.*(<N&4V8B2M*5U2'S&M=4FI7EGJ<EIR;%R<$IBS><RE.88
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MLU@0KK#D= /(U26$.X.[4;*)!T\^8,N-HYY' +O,H#KM**L=P:D(QQ#^R</
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M41[&TVA4S>':-1F6.R!7#6)1H#/#8!3@*F_-L/QFBM@AVSM@PO26GE &,SC
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M9#L6<#VKJIX(6,$-L80P:A#_L TDPR@:J8:-+87JN^Z>+KO8DJ\8RAXG@4_
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MR_9=YH)/#(+,M V?@"HI=VN"/'NE4_U\M^DAAZ+3Q($;^-P3"&Q=PPVHYQN
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M.!I9O1:IZK4&M[QX97MV.G_Q]^C6"_(S*_+]W%LO6#?"8 87&'/8GV#=M5[
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MNQ']WVTU^:>_4/Q9-#:\('1>KIY[FX"D>@ZT!J0&Y/D DM\04P-2 U(#\CP
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M Y3@G:Z@ZK_G(/'N "GPKL&'VU);W'P8?(/'1=\E-JIZ0@#<\"',X(<49-)
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MMU)FU1<9]:KR25IK7WU7%N$7C9O5=?#T?M'X8A+FN;PT5B52JO-$420U+ZH
M%OTQYKELH5T^)$FOB_?+A/Y9FMQ%JFPA'&=E9>BR.\8,P!</2XLQEJU]_E%6
M<-U&T;0L&,C#8:T_GUQOEH=W,JM?5765E2?S:1:-B]+15-J@R2Q*BS4O/EK;
M8]EL ;Y@%&?#N5I@UOHER\XKC4?HXKZ>.=9>-")8/3I9TO&45)4=LF7[]2PM
M6B;+ Y\]/&?Q,(9GJ[HJ^S;+Y3,>0LG(V7R<+TMTX",3U<@#^%1F1M2;>,FO
M6'N4*E6!3S_&2<7@Y9NKA0; YM' +4I4[&%>8_9%4X4\S.=YU<=JL8(\5=VG
M989&T9GE\S!/;N%SB^KILK1Q&,6/JC-+\8EL?CM+9$\454B=#.=5C71+L4V8
MMX#@:1?D5.L8NZT1R6=5VK/H(_,5! 'L=+K24,8>A[>A;-2R:/@ANW&/JSXV
MJ_N_:D5P>5CEI)_RB!9;K;<'%8NN &7U%9 ''I-%93O3$2RJZ/<IZS14,=8Z
M)\AZO&JQ8$))2B][<,936>)4TNY6EA<5;3;+)C]U?E&]<HK^)*.5SZ71?=G<
MI9@24LTN&L8I[$@V5QM&2B"#U%$M8. 3M[)"==GWY#;*G^1IU?J)+YN&M"RF
MWO*SZ)LS5*--GJ+Q6/X+GXO30?(T!5(]Q+.JGD_Y[3<#MQ3S9757-)F-DV?9
M@F:5(5?944T4"&<SD$*#4M44;ZC199!(/.22'R?)]'G)Y&4/+"5\X\GM' Y0
MELT4A9(K:VAK9MKHE0-(2]2&?I\F3W#F]U'1;JNJ,1OD87H?J:HX6/Y_1<.R
M:FP=+KIEVBO47:5E7[2EC*H$Z;+'W<HI*9D<+L)0ZA@?U!R?4H 4+\F_JVDY
M2LY52B*N-6V2LBR<1: 4AE5[F+J\E.0MYD65_!UX=DW<%YT+)5SE4LLFZ&6=
M:-W6DGQ9?3LL<)(H(3%+9;[^,"JD6]4V;H!XK5U<314LE$!9LEJ&XG9*[GA5
M5LNJK+]*<?E<=1*NQ-2J[ UE17TX&J3A]#Y:$<9RS($4%J6Q*#=73 "I9HTM
MMJBV6VZRKJ?WL 'W5D@;]K:WCI&O+-LSUS1.:4O/IRKP"1N=R4$0<HW+<7)@
MDX[A)$ -3:*%7(&WCE63>6E-C.2D"+GIU=:-F1+YTE IUP!RK[3$KQ8-*H&Y
MBWVI4N3RSS>#3W>59+N37FPYU@4VMS!9JGVM6RI7 WN:Q]?_;SS\77K!JD$=
MF"E7@R_P,:ETOJ1)7IH3DH#V'5!YI/;ORN]3CZBJC14-0/J#=:_>4<"T_&N%
MW[LTG(^*P[B5'H7LVJ(8>Q*J<5@UFLV M\>Y&NJG]BOG<JCF?DIQ+HRXY;M&
M8'+<RQ_NY"RG<F'M%)<$B;Z74_>*05A+[,H^>V-@NZ'<XD(95<W'[M-P4G"#
M'.,U"7]7(^- 4A3WX>HL2Y<)5)PB@/0FYNEPT0A5=L291HLA<J/H,<F+WU8.
MOCQWJ:7GN>2H-4ZXDJ/.@+A7"W&T^MFB2X[D*<GLFUAPMIQ\H ZA**6>*A@O
M!I#)VO'%M!1I8^TQ(*QER,=!PSG6QGH VA[DP,G'Z--4$J.8_7'X\"T>V-CP
M?-OR.*.VRTW+J(9ON0C[WIN>W+-"Q\'/2=;WU*W5+X037@R36G20D!/RY!^N
M"F$/8"IK_E<^&JM#'\1Y-,D6LAXD>9R,9,0!6'_:V0S&RYB8LR<D5F$TE?6<
MJ5(*O\79[ZZ:921_V@,YMO -WT4FQ<(BR!84^R5R+(>YPGGCR*F13O%N0;N!
M)%[/( I6!E55<^F4T)^!YIC*WJSCYZ7NK'F(H%,RL.'5C*RI&EJQMHMRFE5:
MLD UYJUH0EP,>EOTZ6I.BJOW(9O(81.R267943T<5UXM^.6/A?5>380KS+HG
M4'_A]/=%8U"IQ!2;%!9S;>9F:3Z,GXO$LTC.])S4FKUU?P"GFT2[:3S9.K6+
M\;0;I^U-YKEL75YKG]KVT.+CA2U3S+I;=%(/50>+VAM4PZ+G8B!BK80H56WW
MB@&"<JAH]7QL_%3[,)A)HVCQ)_23=$^*P9JPR,+^EF&O]+%P>.J,)!TWN:#H
MNY3O8!]$16] J20BU610#F2K)@D>Q:$KF-CT8<6/P*,;YL0I_.W/J4=KIO-7
M1!N5RIKN*9O-PMN.,-NP9WG"(1XSK  YCF/XU?QU9#GDQ//7S\] >/6E;]";
M7ZHI7H7.K#-!OUIS*;R_-5H=+P"M?-1%@U'5=ZL8@ESJ*5ARV7U<71WEJMN4
M4HM/,@P$&C>+1W&8JGLL>ZQFPT;I8DA\%8]:/&\9XXC&RH'-%[W&EG1Y5T;L
M9J%0%QX>Z*#CYC<R)(2P7.(RC$W7-4W3HX7<<*DPA-6[W.CC"/::U9C(Q) H
MG<@YH]OKZR^8I?9>>J^SZ3]/![^$SX/B)HJH>%8U3 'D0#((P78)I^4<CV$Q
M/'IYLZ.,X<_?96BM-/7!-?_9O5J;1"OCR>4XH:KW,4@F5> ]E_\L!Q7=)FF:
M/"TFTZ5@TN<R./40]36BJ<_^[3_(77SX&0CXH6S5*']>]G('%E]*[^Z_'_70
M)51:[OF#4B]*3X#1?)U,Q\_5IK+J^NPN_BX[VB;SF;Q$5/'4/@Y0W%#VQSY\
MFZ(M7G$YT?WS21]-09='$T[DA*__6430E[-YBCR2XN#*&8^+H?!J>O-C<753
M7.-_:N^!*;E8B0J5(RU?*> ,TJ('+N[A> N'Z2X<%GU(Y2Q*%=CO8?GLI@_^
M+#=0W".4XD3N0 U\603D%U*V^P7(N$@/(O/Z6=[ /X5IJH80R;N4>3I\D'U<
MYS/Y:P_\)? 5$CW$1[:U&Y;^M_2]P=".,WF3(>\!>QH$<T/-/@1DH;.C_YZ'
MXZ@?Z. >A.3U"*R=4,;T[J,J_K2@?N.8X"\R7E^ :50J,?FSPIFZ[);6$S+J
MLZL6TPW2:"$?ZW,(:\)8=1!<1G!6\-R1+]6K]7C2W(V3&,+M1[EJ$B_]\]H@
MKR^5G+(KZ[B\%:K23BM!)F=WS--L'A;3?)93FJLO [=R=*4D1 ^8XC?$[$4A
M)6E\K]A7Y72H1%7)W#*W+5=U'CU)-W;%2%^-_+]&4XE_=<IP^N"-PK'*H9Y+
M#E F?BV.O/X>%4'^L<C$.:56PS>]#J9::+8:X_[O;$5XW@Q^5;)5W=$O$@LJ
M)E>)"QFHCO(A2XHN*7A5#C*O#4J37Q"7^<^2ID5J@,R:NRHN&=2(N^^Q#&:-
M^S#<_X#)%>UK7*WR$=LHL7Q-&>O1TDXOY17X[^%PF,ZCI7$/ J3[%5I]B(X9
M[$/:?46$H!PFH-*HRGL<^!DT=I'P$BD"9(4HWFQAK5Z?2*),%1,N*3G/BHCI
MM,ZEBBWSASA;#D&HQB87Q:)JXE.6)<-8A3&6 ^G&,M]SE#PM,I:^*'R3P9??
M_*_^K]]@6?/1<Y':-?][^+V6>S<$-2BK?XJ4T\5VJOR_H;0;1FK^9ECD2(7S
M<I:EC.HFZ>^J""*<Q7GIX,DD@_MHJF(OR^'$('-FL,B>1NEJ0^. YOQ+9*LF
M)#+';PG<(IRB\D-4QES\O?+L[Q8S59=60]$I42)A/"Z"]"H-4.XT4U:$NFA4
MLZZOBA1E-=EZ_:H=]!M8+;VIHS^@*]3;D&\I/Q2%*NAMM;8728K+0Y"!CI+X
M:L)G42!>!K(B-11D$(4R<5%]RVV8%6-1-G[739.$Y\^8;PQC"]F?53P_*E)?
MX?5\_'PUN)TO$@5D,".7^5N3I*@VZWA(L%I4_@".00_LGZ=A,=\^?,Y*BZDF
M&$;1.'Y4,W(4QB=*$D@-*WW>5:/L2K)^<8NXS(6M?:@$4-7%)$FO*HRTY6M$
MXUKZ;2TYMO*'%KF8(*969C-M,RD_W:WZ9?(["H.Z7'GK<I?/EL)P=;X5?*A,
MHB_>5 U]+.DF0QMY&4O+,C6G=F#_V -WF/W$"2L_K#KJ*O11TID,9) ;Y-YC
M,IY/HD%Q%R<W7;Y/Q4: =(\E5Q41$6RL<AV\Y/S8B[]Z(K*4@9[EGE98>2MQ
MUA-UG@L%#BI7V6&5\[+"ABM!IGA9FBKE5/Y<@X;*TIE$^<J7--2Z_%)5=0)?
M.(SJZ%_7[&4!N7R'TF7CYSIB-NC*NKDBA:8TSY=)5/5G=1.Z>D/:[R1+=^KV
M2"HK.":RIJY>/O')^\55&95Y,BN\D](K^5;4,=98YJ&HL"M,R"T6HPIO+GM:
M@?FY**B8R=LGR9A[VV.@I!=,IMRM,KE$I6,^UY=7;E/Z6P549=&'FA$I#>#"
M"2[*-.;3LH5/8=HME$?YH%)WJ *-8B]5D&&5Y6LJ8CI7/K<TR@LHU]2:_/LB
MPE/6-94OEU^X'"<,;EVQ/S!&2EHM!%&4RI2T4D0OB;4P8=0]5;G+A<M05&-4
M >>28.59%:*C"D^FRSJL'JY2>AT<7M)672C762"IBN 6P:2ZP#KA30NZ8:B/
MFY;B@A9VVL/M9 \G)4,Y921%XD FA=P,[$55\OBY$#=?EO'P-\.22[-UI5>$
M].^G(.R&45W$*/3&$_A;.'[.XG(&^30:8*N<OW="WC5N: ^3UMLGFB]JOQ<7
M:K$J;P<67]-$HS*;NB! D<9X4KVT&B7XMEC;_]Y['3N_)_H^BZ6@(D:;)[?"
M$ 5U5GBI?BFY6?6KI:?1G?1NVP8]KFL\&1.5<U.G92*)+"<M+6895$JC9=V2
M2O4JAZI6DUWC(M>]B)A*"RA3J4"U/-:RQ +T:!2]XYO.4P=#5KR:!"1458->
MI.&UW\,L7Y)EH[<JQQB,IS2L=28I BAU!*@GWB=J'B_(>5EY719'I\FX'OR>
M@TTZD6.'U3,4<XZBNW ^SE7^T?+IRS]41E"QBAJO[]CFZJ7N4UGQO!H>4JY4
M!<YL2_*4L@KKR-Y&PTH<;2YOV?<T:G=!:I9K>3<Y+_.OOE9)FO:R_<:SZB^B
MKC+'L5ST5&UQ"\W"+(MR%9>1N8FJ&'[[!RJJJ)JI(LA20_MJLOG?5-99W1(O
MY7MVB'S/DJ)"N;:PL4I+J[]],I<78=(SK@IH@!2RAG@RG_1U(4U[O7DM^:C6
MGZ8^QUL>@>P@$)4))2VR_D2A:=QM:Z54<C*<V9<PS:>JL\#//[N#]<OW+^.P
M5(NVS#A>O8$?ELIJ!5:SQ2?"Y2?D'TJYMK@%W'Q+O3!G%JUM%NU@*OV_MBXY
MH3R*BM2IGF[_>\GP*'M'R3*]I<E>WIA&NR[S5\-DRD]]",=WU5.7!R%)HPQJ
M^44K'='2:%+VZJBN:/;>94L#F@6']G)1KL(*JHM"&4Y1$9B%A5; ]2Y\3-+%
ML/M$-A68K^BSE2A-U4*A"B>$0/]L#[6W9HPN=5*S=8=:Y<IC5FW*E]![Z11L
M%4#-2IL-%30K13:+/W^^D\0 B[.HZ2NJ#5QY;:_FRJE0V9<R5?V08IR &8P+
MWS \ UF.YWFF[17%. 'W P.]V6*<KS)&?5V$&.ND[<;PO>"RG!-7(WZ>E;6[
MR3+5\.OB0L$M+A348?4@^NLE_74Q7B0D9.452O(8%YE9]E=WJ0),F9Q46"NE
M15>\?Q*%$K"+U'4I:>ZG<27^AC5>4_74TZ*?FC+X5/CUNKB'7Z2_/X7I2#:"
M&:E[S47/-?!FD^EU]2OXL?!%>9*N6+>+OQ8W,L6]"J@L1<_VI:PD :ATX,(7
MOPOC=/ 8CN>@X&6GN,I+DH64Z4@YO0N%5B.9O%9<HUIQ<ZV(\C^%Z1(NOWYQ
M(:=HFL5Y5)6DEZDC;[84\SR6'B3I*K.LIGA6=1AE@6P\JAQ5R<%5[P X.^FU
M%35&=29=<U073)"UL^(&[BK1-JF\:N"OP;=D%@\'H,NNF7$S^+4.C&2V[+%9
M;*/81=DNH$S+>U1),F 1C.(BQ5*9:@7_%TVGY$(VL^MCV:6M9-*!W4RR6=8X
M@]$BPT^+MR_S\<O'%'0JT+;(ZVD[D*(B,1P/YT7YX3RK6L4Y8'C^?OUU"%95
M5-VH7LM(JWS#)!E%XZL"B->EP*I_N ;V+<[Q:N5'Z2W(\U8^VLJ1UO ^*F+^
MY:60W#TL(QS]UUSUT"@.'-XP?@8Q%4_+:U^UH+*L8;&NK1R:)ZNLIWJZUK(U
M%J&;PO:7AF,9AEP)DQ9_:>=/=?%5E3G62+:D:<&C\T5@8 NR5+.XN2QD+[J)
M:#G7Z]*EME^F'>9%>[SY!%A,R:/"<9F #*BDC#JZ4C5ODE9; L.UM@:E$;#6
M@ZMJH*6RJ8K<HF6"9.%9=6\ G:JECMI/T3$3S*293*!ZE$+V!T6T9 X?'V4_
M?KP ONDSF7"HRG'V\:)6YGS(L8QU LC?ZU\SE3V/QRN3*9!\S^+!!?</H_&X
M?,^?/Q@?U._9+!Q6OQ_N_P&8[N-IL<APGB?5"\7X%O7*4SS*'^#=0(ARMH,J
MKY]ET<?JAT9X;KGN^A2:Y;P'WCI':/]!-L6:*/KC[HD2K4,ORCV]\./X=;]>
M;UYO_NUO_D)FR*T/Y#U4N_4WR=C<-:EQ9=1/<V9/SV/B&AI5=& ,B*4-*4VU
M7PH3S5<F6G4E=0 M-:]I7MO-:U_!&7@1IVE1U_?0]A[8KTG+_2>@O2:WMGJ1
MKRH".YL<IQGTC3!H,T58ZVC-@UI(:B&I&?1P(:F'0^\90/XMRJ(P'1;]S4?1
M8S1.9O)>X#4EP?G/VWV%$=#O:\(S,D3OE#L;;NIS>O,%R;RST]):L&G!UC7=
MK&;YGY9K6JYIN:;EVD7+-4PZ"V"=/S=IP:8%VYFPHA9L?7NB9K.7HA9L1PBV
M"[GQ/1D@_Z/L'*N*[%<F+A\32,;GG8W0,T@9HIV!= >AW@H<SP]Y9V=.:' 5
MIKW5V;V@!I<&EP;7BGEY9;1T!-/PTO#2\.K",+2Z\][>";ATZL2^-9MJWM+&
M0DS5L:?L-B.+.I-969R>]<.1!#BR[#O]$NR>?Y#B%4)>NPC]SF)B'#='WIZ<
MM&?#C_HVX#Q-("T[M>P\/]E)A/7ZI#T;?M2R4\M.+3NU[-PW6(;-[O*"M?34
MTE-+3RT]WXOT-'E/L5 M.S>'4/^DNEFUO?]D"]O6[JLW9NM\I:\SU72>E=WW
M=O>O7+2<K(T/+B<97E>3#,,LFT^6'89'41ZE$]AI2Y=+V7]7SFE8[=%8MI,\
MOC7=<L-6!T2S#E23Q[#BQ?69ZZ.)'#Z/)G+DHIMYZ=6_E]5?2*[IV3DNB^6R
M\\X:T(W4-*^]#5[3C=1>F_U>(T'J@ENPG%F/(,V#W?'@.;&9;H?V9ME,B[J^
MZ:89]'TP:$_MT&#CYW2]=[I>:''V^^!.^GZ+Z<-R^G)74J!3DE[@_1.ZH>AD
MM%RRVBL1LU]6;0Z>/0>F?&-VDT;S5C3S[A(9-9K/D"DUFH\DW+D"]ES5K\:D
MQN1[Q23KO[O0.\3DX?[N&W9K_YZ,PSP>Q_GS:\:SSA. )K\AG2'P'0)-1]\U
MDDHDD1O2656P1I)&TOM%$KOAG;4$TDC22'J_2*(W^/]G[UN;V\:1M3_O^16H
MU$X=YY2LT?V2[&Z5K_MF*S/))MF=.N<;1$(6-A2I(4@[GE__=@/@31=;MDF9
MDOK#3"R)%Z#13]_0Z";K;I=N5(V"'3LCY]6/A7 BX3)/W@K%3NX%#]5;BH)L
M7TZFV:F^>/RAG"VC<".%&Y\+M'YS6%XI5P(: >WU"5=/H)%&(Z 1T'8"M%;U
M62B' C3:%5OGM<'+)6#99?=2>"X%4=;+I5&GW2D]PG1$H10*2A*>"$^$)\(3
MX8GP1'@B/!TVGO:G!%RAL%I_46%AM3T>.M:$6ZGF5BS8ME2BC;EQ"!RM*[M%
MNJ ,UH=3\@>;![K<A]#E/E;F_N*A8@&13+YU6PVV]BCSB]\#] A%!>/_<[O9
MK6*X"Q$R->.A68@*QMUJCBH==X.%0F'00MX*[[ZY.H7ZP6;/$6^K0*8:<?@>
M8)O$C9Q@#DAFICXC5H(4[#;-M,Y5>F12,=,>*%[ IRA[[G\K%MS![_.%)^'G
MW-W2Q\=/I&]:"=W):*9O7',IEHK$YW\7$?Z-+8AX:"H;ZK=(H9H,)R.R-(5I
ML1+E- B9@"<']R"EM/A2!MQ+PU;Z]5,<P%Q$L\"%:0<8/'/U(V)8EI"=?;W(
MI,^P/3IM@P2ZFTEGQJS<- 4UL3-2R)THYA[#*I@X^&@#S1/1"I>4#[!(^$RG
M;%0A(I.%2U3&K5"1U@IVQN6_<QK$867SP67F?CJ;2B: *K*B\6\#!!!2IPD8
MUL-@$^<:+C7O* :5EZ3!'R(,&FPB'!XKD6=Z-N.*^0*HRQ9<@HCA:I8^2FF]
MM0 = ,+/L]<&NE2!KY^,!64#I@(S@E"J[Z>KQ0RPHJV!J^  28UV=@>/XIX*
M\C.%%]UR$#' K&H6A-&IGFKA65:PY >/[#WG2%QD$]\'&L$2Z!=.A8QBH*8>
M126<T^ZOFN?E\/RR;0>DQMJ\*9\T*IC-:(>3 9:2\,N<^P#K.?"3YC7DTQ5,
M #^& )\@7%K].^EY8* X08CMS%V)[P" (-A\X')I,&)AD[$#,![P!+CYP//1
M#)@FST%N\:GZ#P"'5GJ@<9&)'WF\X5/]CAE8$2LO:>Z!);+'1M1913I[5SY.
M [D*> <%9 4>0[<Q[/<;K=9JCO++D0YTCWT$S(VO)7"A-Z43H @7'K?X#^)(
M18 WJ?M4VOKD,QZAMDK5)5PW$2SW2-0:^KG DG[TL &G>U_"TRU@X2O4<GS5
MJ88K)5B6E;!-ISE<S19X.:FUM4*2A"3)@Y($#:*;FU#<5&;_= :-?JM5D3S1
M(0AE7<S,\=4&,MJDX:VU*R78NMP';]CX@YM$0J?5&K(//M9(D[>"??:XWP#S
MTO%B+84JL Y;C6YK7"UU5#SY#PC+99%:H-BR^961:0$T:+)//OM'#/9]NV=X
ML6%\;WS!+/#@6I"Z"W2\A6DW@=<L$1+-], ZW<;[!$M>QP3L.*5O;UU9 [.@
MX-_X:BK"$"PDM/(P:%9)L \69=SI5KLHV>R1/:>QM@MMF,,X/+ VW/U/K"(T
M?7/462&L,7FY.Y>^5$"D",WI:;IX64,/$^/ #^!#S@3Z0G;AP<B^1]\OF*,G
M*D)'*AQ;D_W;A@:, E3K0LKHX:'TF(&R!*,\@@<X0E031JXRCF#(F,Q.V_A@
M%T@,<<:^)Y32WJ<,8@4XL$02;@/=7319K!&_7Z$@W0X<F<*XW+B.%,*M/H2;
M->,Q[5Y4/)_S$*Y+HHKH,\I;&TG-*:OGM]C9X[79])+</86-[J/JP=,NI0=/
M?[!7G51J=GMGKT>_5Y.GQA('4<RZ-O6JOP41][;53#L;U:_Q?"+0B*_=R+X:
M[Z5VXSKYX(/Y#K8Y.+?E'7,GP9$-MTN"(_^,WVR(N'9(.#,AZ]J-Z\IZS+4;
MV&?,DB&)01*C:F F<?;:(>"#'X725]*IW<C^C7FLM1O5\XP-JENT3?3H4VZ'
M@D?L']R/>7B?":+VAKVP.IQ&W\>&"=U&9U!:A<R-U*Q-]P,J&5%/HZ%THZK^
MK+A]1L[.&/"P9%NGV1^19"/)5A-WZ-'(Z^N8(J\*T5=CS*. [4M+ZXP.RK/X
MN\E7>4VCI)YZLCTHS9TZ%.10F*\\O?9BH+PN.)J=(:&#T$'H> U..A3$5!;[
M/2P3+=DC+,U(.X)BHR?M06D*Z@BZ]=6S!<*Q:K_J\/G*1F._>DP>BFXDH.W#
MMDDMA7DM=D;J:1;TJ:<&A4F?PS@7>$S6*]$$KR#+JYZ0.^DTQOWR<BFVI!N9
MY!1W.KJX4[?9HJ@LH>/5S>5:RM/2K.*]U<055(L^%"E!6<C/R4+>KAY/*99>
M%RP]-XCQ!'IBZAU!%-O4P7E]BAX*S"FH5B,KH1;<1D&U,C**>ST*JY$((A%$
M(NAP7)M:\$:]?)Y#=FUL@;M<F;\:N#B'X\GT&^/A:MW(JNAV*!"EX"4%+REX
M:9V,,>UMD'@@\4#B@?8VGFOG4WO+_1^ZKFJ>-B>029$BT]S2E"+/;]/X;L&G
M20IY@V^S,M<7#VVW[2P!L$YLVJ*DI>%USR\O4#AUT^?O@4XGA5+_7+%0+((P
M,@]"*O]Z]O7R[)_L@B]DQ#WV"P]UX[XJJIGOC'*5-+/X<ZO96S7.7C[8M)VF
MK>6_B>N9^#WFGJGCOX#%UST 7#F= IM@=XN)B.Z$*'*';@@[-TN:]H7=CE-\
MT\PA*79?9#3=(L*[EUEWGH>[S21__^7G6)W><+YX=RD5#C(.Q:?I1:X3T!?3
M ^@B4)'2!4?/D>L_\WO=">$;"*!S#\;WM__ZTU_RCX+W2C\6[B?3UP<&]#GP
MI'.?WJ";Y,&'+V+ZUS?7E\AX_^S\[[?+-TRZ\ 5WHM/>>'!]?MF[N+IH79V-
MKJ['O>OS\\OV1:MU=MX9]?IO_K8D'_/K_4CY[W7J=+UXS>G7G8A;\Q'O?8<"
M0#KFL7FBLHRJ%>#J(:.F@HE5,(,SQ5RAG%!.@%;29[\&@-YVNY'ON S8#;%1
MA&FR_%4L(J'K_%HIV"]T79P#7/%S*#QQB\T9X-EPL^2Z88B1X,F#$;4(49#=
M0;9,(.AGV.<1KU?<,RV&86AN?EFSZQML$8?8)4=WBKD^^WK.O@4+D#R=5O^T
M T/\;+H\FF9=( 2NI<]]_=*O\*4P;4I.V0:N:>C7YQ[;'>AGX@"B^X;N9!*9
MBZY^C^4"']=DEYNH=RD<2SQ3$:[?*% /&X!Y(K+=:/3LK=C*T6H1!F[L1"H5
M=$GS,:Z4B-0CG3#6R[-'A="2U (ISKV_AT&\4!^2/D/KGY-)RZ<(M$YO.&Q=
M7[5;E^>C[G7OHGL^[!N!=GG=[5U?5"[0JI!7=INBU>J-A_9'T[(-/!K/?5!X
M-=B97ESV_Q)H? 7FV -KN!I#?I.F&50YE1RHL:%/-$NQ#1@U6,XW\52PIKJS
MJ?:L5=+G=!V0SR;8 &FUH'LIU%?QXH$MHP<8?Q'EPSK#GEDF>-S:]7NY-7DR
M13'MWWMOV==X@MURL?_H-W2+K+#[OQBDH__'L=,I\%VX1$1AX+]EGT+49(&G
M]U>NI3=_:2>D5\'6 8F)O S0]7RU907HUTT+0V%Z NMNYAR$B0Q=M@ Q<L^F
M,IRCE  U+E64:/V%:0AL>Y_#E+&UF6Z[!E)G2:#DK*BL^Q\VO([D5'L\BT W
MN(9+N0/62BBP\_#GG/V4=5JS=D<ZXJ*AHEMJ<Z9BQ\$68U,ATKN79R1UPS8^
M#V+3U[0"]W9<6:=&E#J:!+IAW(+?5S#\2CIM Z%#P6W#<-.F+Q2W LP*T_K<
M>*7P#KAJ_IC-6$^@51LC?!T9D786#L)[QL.0^S?60\EU&%XC"+#!8$X03&*%
MC1.5$1P.J#,.,)QKUR/M.VJOS1J5-]F_TOZ9>2&@1&$H:R5!*+1D 1>K( L
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M/&$^XKWO9 0FE6,>FQ!7"XN,O,S0=V5Q7\R5+)?8S@HO1P),)<@+<>K)6RV
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MN%U$$7([M=9L5(G=".SG Y1 U<E(VZ'& /X]EMJ -_(D2=8"DRL2-U9JX/=
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MVP;?^(^G[PE<MZ_:X^[EN',Q[ ^N.M=G5\.6V1,8CUK#ZU;E>P*ON0%@Z,:
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MLVC#1E;ZFY<!2?*Q#IBNO=:F(V1&YKKWZ1=I\F+V4PJ#?*[4?V+W!A_=0(:
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MZ"O-1@;20._@A>(&=Y "<&[@C;YSWUA6X,LO-#+LN]A$!#,"%.1X*AX>BJ-
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M]=N3"@XV?=W,.(MHQ MCTQ=)8PJX^_K "095L6N1*>"YKOR+R: SMHJ;FLK
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MUA0BJ0C-60P-%O'P1NC-0T 5UXI[5?4W&?NT1BVCJ,_N7]%O14T&1H61U7I
M\TG@W,,=<\G9R=6WMPCT4+BQ(U;5(M-^W?8['P\QRZIB>+D7CJ398(2@*,O4
M9XY6=P'[+NX-S=^!M /;PN4AW@F+XVNS#6._OMW#59F;"\]QA1-J\P-)CG$E
MI+8KE?X.O'[]0D=7LY_@A;#,-_#_4#HFDI.H7ZMNW^LO%Z&</S "1S\<Q*\K
M/ Y#B)U(*VRP-'V0<?@N):.8G5Q>?/CZEDUAB=D$IC7'Z4K_%OQ*L%W,<.R+
M'XDX;)&&0D*;A/8^">VK'PN-OS@LN&VI^S2Y!W-XEC/0,S\);KL1*%46,^D
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M_!LF#0(G%UG5*8:^,A+7;)2*U5@->%%3T"^!V57-/SSD*-)S49"$D> WHXC
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MM2P!!O4X0,!--]>M8,8L78,-/=_<"<HL*0F_G(/JF,=S0R4GN 5UC7<KT-;
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MN5,(CIU/95F#T@>6#M/MY\"])ODP[4%S'87HF:R,_H;W]P8;/J"]X?V=8R/
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M]?_;I737(HUW!R=7&QQ,U?/LB5*\J:3"-O=10B)"HN6D,<N+-:H#2]0N]>B
MU:2;T+>^G]YQJ0YVINB,W[F&5$M"E08_>XLR%>@[AX(J]0.0P]=>""5JB1(=
MH[3FUX>"#N2S69-WOD:!->%QR,LLP*.Z\$DY;S"VY;7M1LE>(GN)/#?DN3E
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MB?]&S@-W02%_7I$O,0%IXTRMNA"PHMB8U13;NP@8<] P>L:VR'0HH2[D.2(
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MP@,F7-C$B7AXRO'\>*9:=]^]>W>LWD9-N6MJ*-%VC_]]/1PKT1_]_H-E*57
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M&I8$2Z>59MDJ:M2V1,4__:6'R%]I@Y!]V+YM2$CAG:I/8R0^\^K[L?#;,7#
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MET#0'U@@!N/5O2#\_.J)>1;79%MEAP]M/^YR63+NV)UC87'16GU/<2P<UE]
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M8DFX9J8P%_^AF>M$2'O0=V*"MC_B7'VQL,7J\_)Z-=OB%3/5YT&YWQU8>]H
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M?9"[RJ;X<1QT\L6T."+&=[;/<-@&1&NAO8%:(&(,P/6R0%HJ^8YS$K0LQ]O
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M6L^KJ#Y=;+X<K]3[9,W>#AGCSFE'2$P9[0&&L*X4X91E(JV01NM1K)U(D+9
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M0)$U4NC*^4)A8(_ER^A(,#W4EFMEN<WCE5O\7@:-9AP:KC"7PCN-@:Z\+*7
M?;GV'8Q=OA@W[0UDOAP!AAK4_'$9CKSXH:LO>93.\QLU7DZ_KNM)?MQ,X4A8
M4<,1,H,<"G<J  DVD$H;I$#U0"&=X#U%FB4&'5V$<9ZS<2= ]W$3V$QNQ[2/
M1J\>ZYII##VT6BL $<-,>:I=#28P>TJT#R"0J75J/N>6;I![Y>PRM"BIP7/)
MI;@C^AQ.YZNU0W"^N5:6QTMT'.N;"0B5-#A: :4&Q(85UBJ& J"GNI!-;WFM
M$6\W5[2&4W]L8:?E>#/K?'(Z8QSJG2%J =800XN\P$X")ZO@* 7TP!)0=\T:
M+2+5 W-L2DO79ZD>S4;SJ,3E^5+-)P]YQ^*J@FZ^6N2EO@__\:4H1[._+XK5
MES(,,5O%^(/=*S^B(_<S@0P*!B4BX?\8<QY!#6Q%5!4HG>0<VEM<_Q!4[$'2
MJ8<-<M(28D+GHYI8XH@959Y)# S$#G$K,72@AH9!,%Q]?FBL4UR2'G^R[".(
MAG:G^$$YM87GI'7.\O%T--.K<CK/R^H*=B2!_^%N&4/22X<HY]%5S&C/):HF
MCK0=UIVC<^H4G2'7OZ+Y=JNKG*8=/NZ502:]YP81S#3!2COC3;5$YT222M=Q
M,;E!JW1G@'LY_CDJN@[VRW1<DH"6D7 .Z[!=$(/5,L-%7K\4G2J-=LWXX2RH
M7BUG#%QU&0!#],X('_(R#Y^Y#:J:S;_FL^)+G/4VV.QXQK#CO3,!F?;84^RY
M-L!J@F05?*%B/.2@])&6J/<\M5CK,/5B IV%,6_^GL^#_C5;J_)W@1+ENJS
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M_&T>,/XC,NPV!^$J<&I\#IF6T5>N',TG5]?7>5Q1E89EKP&ZH^]ED!E)N(8
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M(5+N46!&2XW:_(K&'H#,0NJ!%*8N)J[?ZQ^*,='6(T$[TRF2TOQ+BU(-5;+
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M"ISA,9B+VIEVZP?IL\*;J [^DG\[N0VB*K?LRU5^<NS]+0R88"_-?'X]1 1
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MBVS6L$L#NVH,\:72FF##PA;_ CWP&)9W?1'*^VR_7=<?\U5>?,W7"Y_9CP'
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M(,$VJ=/57V$*Y<3WC<O7E%>5H1G)KK(+YS17CP_ER7E[<\#R(0<+G*8I,TL
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MR'.J&SVNL' I2I@B;P;1P)@KI86'2Z'F\$NY+9^;*+)]>&W4<Q./)FY B9^
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MJR-4/7R!CS.?0!"H\83+<MCN[HA3'S*H3$KBZ51236:ZK/[U _"5*5F9 D"
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M(Q(2PPFMQ:3&><>G.U>\T].7XK&J]^ C;]ZDH:.]G(_$A'$N]\@)XLL&6V#
M94,'^5..+@BA#F;M$$ MEESN"36!G8F"-RR&^<^/W2P,"/52#T9>Z YCLO12
MJO?YM)$,BYY^H7NF<DI[<Q-=,TGI#'A%F]8MLC5WD2=YO9/DUVK%D[5%3/.4
M&!)5O2]%4["_>X]VFZSX7FRKMHHNZ1Z%CLOG,*4^A3Z-4NQD:> E\3"R'\52
M#ZITC&=8 0>([:WR$Y"*JU@M#(M)V-SDR@G965Y[@ LM9P5(NZ!J.BFW0]NT
M6E29FZ"RFW5;]J=WOQ4[MGK>MFU%'\I=V>SY6OI[T4,8EM0D<+V(.CA#,<T<
M%&(G#(\;AJ'D&:K.D4TO>3NP5Z"'V[<J/@6LO)FGU0&BVWI+<2\GC2*T#V 7
MV_63H/+B_I\)E]@AG89L^VE/T!R#HG*JYV[@Q[$M,Z2$4HRHEP4.]#*<Q.EX
M0N,[F52*.3>V=[8@%VL6;X?7Q53>9H=+QH$SK@6(/_VZZ];_-T_/IL#G_*G]
M;?1G7F^NGO]GW# Q?QN)&9H=<R&J+#4%[(@[BUE?V?$A2I;<[0 4F]?Q]?%S
ME?EN3!-,L!]@)\IBZ&?CL1K.Y'9\-0UI.-*,*$'#88).7]:G@M)7"Y,LIZN)
M<+%HL #7<B)_I/FLW),W:#93)E>(N LBK)EY.[15MU$OZ]^:X$SAU6A>[W@S
M1B;# Y!RS7=IRNV!=SW@CWB.;UAC&*2.FV51YE$'1KZ+/=BA21PW@H[BNU"M
M&.:\&] #YVEV]TU?M75LUMU.9P=?^1FG7L\([IM8X!3)S%G6'_W[2K#88WY%
MCB]MK1CVFAV";-S*\P\B#;+ZEF3?Y=OB9R@#DF\5"QH/U:[]E_MJRUS0O("3
M$@H=WW51BGR,PC#AN^D]')QA7T2SC8,P?MF>X^LDH6%)%B]0QY2@;<?SJ> G
MZXU@=17S[K@LU%9Y0E&IKT>E/@HU^%:!4R_UX$&GU4*55V;VTZ9:'QZ&<DOO
MPU_/(%OCMQ=!EC/6ADXG])TV<$[E\)7(.9M;E@V=\YE9S3S=Y=8[G]G,*NJ:
M+;;V;)#/>7U=M[=M-G_/MX=B@+?*4NSY#DPS-C9E41P2%W6USCR2H$SJT8:F
M(0T'QA$E:#C,*_"8U^ [1PA^.30;\,B^\W9/Z"]RRQA=A(NM6A;@6B[T'6G^
MVM',,+*OOKO;MP$MS*.FSKL<$2/OPNI#,_MV+#9T&U49G;%3U+!+BM%A?U_5
M?$-^A7W?=YP@<$B:Q&%*,/*#85#D0:DN<Q.'FEO]FFZ!D(\(IZB>/+$J:F>4
MTXDJUZ^WT-MTSJ!L+XD25C1EAFU4,G5C+BK81(ZF*%=;>7&S"M, IB%*H.>2
M)/-2AU)O'#!#X535$AQF(<4J6W33U4J43'6E,L"C'I7Z<)G"V12JPR&I3I*L
MVJM,LH8(J)(2-U,4Z?JP;_;YCK? 6$'JA"E*(Q^'(4+(=6.7#J/&28RFRI+,
M6 MI4W6$.%V@I+A55RE3M.J1JFL!1F?3JQ,PDJ*E0K*]RJ5DC8!\J;,DJF']
MIMS%E2A;A(:I [,T\#//3SWDN7@8V4>!5&TF'>/-<V"D=U-,"\]BFC8WQ7*Z
M-AP86+<7)D#;!8W32;H=.J?5HLK<%%76NY_6K=2A6>B&:>;%81*@+/&"<!S1
M<:4VOZ:,,ZN^3=SVFL2GM)X9I7**CBV\VW6!(C'-4B;6.JU2M^2\1DUD1UF;
M^M5KXD9QF,4Q#1W'B>,@08$_9GX9E;IYJ3K&$IJDLK&ES*&B%AF@;[H.72VR
MH76&&QD!DF334O&1M>(MX5%B15ET3M><Q'7=C-(0IC1T7>3[\+AOYH4.6GTO
MZIM*67MDAI+Y@DY139,@Y?VK:;0JBI$I/G4HTF+[5I=8DM$F%7(M%2@E4]Y2
M*75^1*7J6UWDS:%^.AETE89A H,0NY0-X=,DB;)H&(E&GM2#/96?;S@O&B ]
MER4Y*5*B34R!3#,F)SPC6<^D9UZU>861"R(SA3\[M&62!96^V22?])3[MB\N
MVFVZ(N)WQ8YWOSWIDWO#JVNL]ZLTY=OM(29^B+,HC:A+NYUWG_AI$+]U;=_,
MH&;C=X^S?3OU#.EI ^X_!K S/Z*2(O*-$*_?(79\EX9L>R4),,6@UF_Y>,D\
M]$B:)8&;0NID849@Y'D#"!@1J81!\]"&<XF/Q5V^!9_K:ET4/$MKVKHAYS]U
M^06/3C=HU%0S'C EJHN]397C<JJNRCOE'0FK@G$JRJK*H6)U[#1G4YI7>"F*
M?5N!;%/RQV3Y]HBH29_8OSQ63;[]K:X.CPW[$=L#5YO7NQETC4+CV$OC.&(X
MH4L"!MM%?6WO$ =>ZLIM,]F"VOB.U8 9=*"OP @;G&T>LD1_X9D<<D&1;)L2
M=DB9=:Q<+HV]/#XI\90"\BE_*/J2WS"-7!>ZT/-#2D*?HCBE YHD(I)B: K%
MS.(&.+2%:M\K4GA!CDP[Q0YY,6YE->]4EZC9T2UYMWTUUBB*,'2"Q/7]&"49
M#'PO'0:  1*Z5Z3P8PTO)WLPDI6A5>BYO!0TS(S<,F\^4B1*4)@C1ZVHA#!)
M8M4AGIGWBNI.X,"""@Z*P*O)_I>0N_\^/&Z+W;_[ 7!,29Q@Y'G\;A2"3A+#
M,9VB*!*6.[D?:UCN>C J7[8D/0)R9XX9.;F;CQ0)N3-'CIK<"9,D)G?/S#LG
M=VH<6"!WBL"KR?Z?L+B[G&IBEFV6F_Y?5@2R[#+SLX@F$$,8^GBH<1-BGX12
M;P*-@3!]J:':L^B_/H4D=]9@CGVQ4P<KB)=3ZN?+Z;>W"OG9D(A_S*^X)?@5
M77*;<)F%:VXC9EY:=)OC52@-E<#RK<YW3;[N8#7[9@53%'I)[$01Q9[GNP'-
MQDV */73U:ZXXV^4O@GFKB:Q"*E$TJG$3[ ECHN;!C1=VQDFU@R81'9GU!4"
M"?+B],\DTB?@NT8OMOA((E^WQ5=JV;U)GXDM"";P=V[Y,(=++%ALS&)F-?-4
M-Q,PGP7O3\5^E;K$=Z 'W2 .?9>@&(_;2)D/,RB\RV,2A.&%3'^7JNF*23,;
MBBNP*_:\'/T,@5/>)7H#IU%OS+JZN>*%P&UQDIG(:=19<T5.":=I#YTO"=00
M.I5]\KY"I[J9BJ%S(J_RC71X"X%G5_32I^._/IUTAW"R)(BHDV2>2[ 7P8CT
M%TV(ZU$DM?FG?W3#P?*T6<O'<E_>=5VOOA;[_;:]WR-YX=@ _6*[?\LR+Q<8
MGY'.T+ZX=WSS=/(;3Q9UQQ%D]L*&GSDOV;'39]"^L[UPS# IM%0Y>6Z*ZH*W
ME*^_%QM:U?2P/]0%?R+/+P>^;,>388)"F*8N3G"<!!Z"O?!G'D10J*B_P>$-
M*^[I0VS ^W4,N,%M58,..1B@2Z2_AGPAL#I9W@UR\OO, ^C4 _1G#TSK=V/(
M*1*KD>6=H[8..2W\T'XF]>EG<MLYJ>S1_W7BBD.)I'-K#;.,6[#*,&Q@-=OL
M-7:[X$OQO6"_L?(((ED8!$F J8,=1..H[YH<>L@)I=K7&!C><*3C?=SJ#HJQ
MFP3"3&N_0V""9-/[:U_>\,;2]P9Z?'IN#,@ZR(X5A$D#U6\)J'&I^[CC^+@(
MW^>[7;&]OMGV.Q;-RD-AXD4I#C".($Q]BFG60_/#.,0&[PI,PC7/O8$C1+#N
M,(+J"-+,+OLT=^D]%C'OHIDD_,21O27@VFY'FCDZF<VA<QVC*#I6^Y'*)6(U
M'*]H\9L%BZ#9358\=M'(MY%KV,V^N;[]K:HVS==JNUEYD>O1B"W2D!<CQXNC
M" X)AN_[(9*(XG/ F2=X<UC\K,#T8DK>&]I7568\,-OU!0:>.ZJ%#SA^:Y=:
M+XG6=4M;T7WO;O&E;NF4N]J3V#6@WUGQ6!?KLHLTNPUZJ.I]^>\NTTM@ZCEA
M#%WHT( 0%_HH&,"E?NJ:E?(IR&9:DIU XJ*Q+NI]7NY OO[7H>0MIDJ6=.[N
M2G[\D#=-(7L4/Y<;M<< XZZ;*1R<VM&6%SNUQ-K <(%]/3%"AWO?7;C08K1Z
MY-#'N>X]/7ZFPWXF6YML,I;>;JM'OMA>!5X$8\>/TA0&$:&.GP3Q ,J-HL#@
M;IXBHGF"Q@"NU9/-$9Z9C1]5Y^C=NS/ID-D.7D[<EMGJ-C,[=3.X;ZX].FDW
M:M^=>YU,#?MR$[WTOG;DIAJKN!>GA6,#J[C?BAW[U;8MW_=0[DI>F&9??B_(
MC\=BUQ2K $<T20GQ8R>)_# -78(&@#&B,D=K"Z";)S!_[9X678&[#NY5JQ'Y
M,\3&UF^3':A]#3>+TV8*WKTMW1+NF36@-\?:Q=P;;M"SH-/EZW>WJ--FN/K"
M3B_W!F)+_XO=75<WEE]67Z4IYI=($(S\)(0AQ6%X7''2D!JZ%J<"Q?05N6KW
M:S7  F6+"_Q2=,Z3;&9MVBG:8X1I?YB."R-^\*%W'#?AO->6#@:O\*TG $QQ
MY+L3_4G&J@O]=([E^@OP 2CCZ54PS:=B?WW[+?^QBB,:I2C*,AR' 4[3 -)Q
M[8+2+)&1<JT#&Q;N]ME>6V!@<ZH.U0ATB6+^8M1=^.:->,".+]R,::_6QC?"
MG^C7>[V_+^H.!TL*VW_K<\&L_+E#B4>A$X41]1(_2"(4Q!3U&)+(\1*ISU?O
MR(:_WQ;>&+>)4L*EF6JQ_&HYEN72J6<$\Y5S]QL]5CMZ*TEQ>4$VS?C$#MTT
M9%LUQZQ6K1S1=KE,\Z;8X.J!H^C.3>N:3?"N*$+Z=/P[G_,G_GOHS[S>=*U+
M2!)#/XV#%,* 7ZXD*.P7W<B+ B=4JRAA&I5AQ3TM>M#"_/6&XP2GQH!3:W@=
MA-._V%L$6I/>[)FTM(O%U-Q.[\HI_<R.-5SC8J(?+D2)^7UM1P19P.ZSM3+F
M95ZXA7JYY^ ^[#;E]W)SR+?H1]FL? )12*,D#C')$&+K^2 8QB(Q=J6:J"N-
M8#@BM*"X:AQA@3\X,$E55Z1/3*'-,R>GM@JDF6FI_AHO%]1O&H]V*-E$&UXV
M5M? B++"_*/<WW\IMMV6Q'WY^*TBNWVY?^J[;V60N!["D9]F0>)3+TK=$86+
M'*G"!;K'7D"5_F2(P2EDL*] !_KM]G?S.$11S6;TA9S.J;(]C]A=IDU&!C4Y
MP%*!U&7=6]*IE46A*\[?_JS^NZC;__O*G^5]8 3M^,G[9S:-AZ9>(?0#!_E.
MFD2^%U 24S@,B](4"Q<ZTS&88=ED_W$$1ER  U-I0*6%ULM:N BCDDG>GQ7@
MT+I_M !MX5;BCO#<'*O= M;!M=@U7P$^SEWDU4FE!5=UM9I3&9IRDKO';^TL
MG-M8^%CNB@_[XJ%9491F+@.6Q B[.(3$0>/F0N*[OM2VL7DXIO>+!;82W]A)
MY+: UAC9?>(9G"FX06R7'R5WAN=QH9D=X<G$7]H*GL^K=BP,YC3XY>;OW%P;
MCQC7C^TRYS?V%_?-A]WGHBZKS3^*\NY^7VS0]Z+.[XKV#[-\7]"\K/^>;P_%
M*H(T<#(_"?DSSXP0GR398(7GX6R6\&((N^%8-  $>8<0%#^*>ETV!7BLRW5Q
M!>XXY.)\M8_W,0$,AR0+?#]S_.)WA%N;KT!G-2AWH+/["HR3JC>]^RN &P^X
M]: U_YU$/37?F@B1AF?9.X^GIMG1%7QG\:)4I+YY:47[NPTZ[.^KNOQWL?G;
MCCF]+57=@>=+SH;T@>(SCQ-?N-77AWVSSW?\HG=OY NSOA1\SY+],>_B4.?K
M_2'??BOJ!V^%0X>X)$Z<. K#Q"'8=9S!.B=(8ND(_@YL,AS9>WP-;WP]  /L
MYSPHA/)WP*9,B'\'YLP?^J^Z8-^ (PW@P'GHVTET%K;;ABSH#V2 E@W0TL%R
M@B,AQ_S@IVQ@9 6<T *^79J:YE*"Y>?"6ZG"\@B%9ZM%*<1[8NVUU.(]X=>0
M<OR<.-V<29S^7C0<_&[#KU&O>4F#BO]6;SF_RR9HH+L*?(JRE, T"(A#8Q>F
MQ]T/#P5R_?'>CUGS)![@.X//15Y7SF$EEY/2#BLM>A^;#ATA[?.;@1)^EX;_
M]IB<<%K>7?JQQ)R0SD"LGK@V)R%V$R>4A]AM@O@U)\*BTT/> MRQ<7A*1:OZ
MMBAY^ZTO?.^EJD_W:CA\\O"XK9Z*HEDE4>*'- E<# GV$(Q3ZH^76;-8*'68
M 8;A4#^"9T(\H.==['KXH.8[OKRK7=59,)PF<*DN!B,D[OD8]IG [2I[W"47
M>X^>.@('1^3@2[LWSSS5@P<]>O"M L0^3TG<U;+'8VJWN+1\8U/;2$XB\=S5
MKWD\8\&EL)D,K6:?]8;#[==B5U;U[_DN[_*-588<'_M1G&1>&$1QF*%TO.V,
M7 J-1EUI-!8'WZ:U!3R,QAB6=GE/&HK%1ITX7TCNS "_V^L_PQ':J!_G#]0_
M?8]+!.R7G.J,V\K^>J?A6]W>J5%\(M-BP;S/%+X6]?=R7;Q^%^)ON[I85W<[
MCOKT]]M>/ZL@R2"D"0ZC,/82$B'DCZ@H=B46T.:Q& [DI^# ^G1C=,W@R2C[
M#&X1B<MV>40R*O?@08^^VXT&Z<^[UL_<]NQ/6ALL\YM,/+;+?XK1V+@?!0/Q
M9#+/AN'YW&1#$)[1VFJ9CV'6 /QBZ[V[AGA]^Z7[+UJ1B&GDIRD*G"1S(,6A
M1[.^&!GR(25"Q:SM06LXB!]+)O<UKAOPY\N[]8\M[%D#@PXWSQ+R9_;P0DG!
MSZ?1G:'@^A:<F/KNILBLV<7,4V7A_&/JE)DK37G;*^82&8TSXC\BU=')A]YD
M2+NGC+])_'3@;^O[ GLG]R]7OI=Y),B\+" ^(A#"#"8#S@@%4E7LYD<WQQOW
MMF/XNGIX8%K6M)?(V>^QJ=/MBX*R:0XY^QQF>ENH[DB).W[6^G#VJWJ=56/I
MU--W!>_DY=\YOYAXVS=Y#EATZVT9^W6]S]/DB67>RO]6\^XIL8O<-$B(%V(W
M(BE,O"@<D+I^(%2=:TE\\\2FYG#S/\5ZSX_?JI-W2\_BU8NCNB5?P0NZUG"L
MFLFKRUTL__DU>VO=.PE9Y]TSVX-TN<GPSL.6#@:,/BQ7\<;<2ZKO>;GEM\%I
M5;?@5Y$;$.B&&4$HRM*8_3H;WKK[./#D7X,O 7*>()8/N-H5U>VAO6G21BO!
M \C%>9IY=674CQ8LLI[-A];"=Q*ZWO#3#(LNY:GQSH.8-AH,+<$F^L5X.&O_
M\??NM6L7==U5ZL( DS#"E! WB!V&DHX0D3-/Q4L58(;#5H^F/PIM-PB766,I
M.<UPJ#+MK]G#4U?J<O#YY\O'WW:%HU=\82($37'Y.P\[DTS7%6JF\V^\[@7Y
M\5AV'58[@*N !B0,8XJB@,9Q2(F'R8 OP0&9I6R%-"KC]V^Z*%)P7$7?P)C?
MN&<1YNYB&KRTMR2"BG6.FCVB'*U9+ISH\,);L6163UL42.:U6U?!@XG,"UWY
MQ-NJX4&*5W:ZOL7M*45;_FD5)9"&*<J<!)/8SV+L.$/9?]\/0O%F+.I#&!;W
M'EA7DY@K^OZ^:!4DWSW]K^;9D8W$U;D)C I<B9R'3#D!'GCLBO9=WX(.5E?A
M;Q[F)&X*SL.@VO6^GV;DZ1R<^GCOK.'G;M!-9\J":V\:C*BTSAZY_/Y3SO?>
MKV_[[MYMRT,'N7$:4K:&P"AVG<R/B->-%#E)E"8RF;K*SS<LRQTD/OM[4$I-
M3I6($TN:37,FI[[2=!E)85_AY$(R.H5!.]+*2194^N:3G)I\V+'OL7SHTLGV
MYNRG:H^VG,R;;=$W_W/]E#B>S_\_&SX(4#34!(]<#V>!C+QH&="PWO08QYL9
MW?UXAA.,0!6;ENJA6TR49F=:3J6TD&Q$N42(NR!E6GFW0]OTFE09G*<2"]V/
M!?N?7F&;OK,=#4./Y<@ATU?D$ 0=FM!AF"A!XDM<E1]N6-5:2$-*T*BTOU1B
M3& ):YHL.6%:B">)!:MIOM26JK*\B:U17['UW.IT"BT6K$LGP:\T30\)_40W
MS;[.V138_/?A<5OL_CT,E28)3U5C%-#(3=,DC,>AO"06?\ZM.H!A'>UAM36A
M>V J(J%,GX"@SL&<G*@N39J$NLY!GIK"*I$H)K-GC#XGM5,YLD!N)YM0:9PS
M<HOVK&P>JR;?_E97A\</N_7VP%^4L-_E+9C*W:'8]%4BJMUOQ8[]:HMV&[1Y
M*'<EA\F[.??A816X2192Z@>1%T6)ER4>]@> ?NQ+/>&9$99AB1\L :TI5V T
M!IQ: T9SKD!O4/MI/C=IR(CF7</J\\6%E>X"#K=C/;R$X=7B'YM$;L@6\[QM
M?'Y75+>8O[VN/[,AV>\TZ/:VK=%_\_1AEV^*?QWR?;%]:@OQ5]MML4GK(O_G
M_IY9=7<__)?E+OVV_KP*HRQ(711$492B,,$9'?H$,3&E82J<6"Z"SK!D'6UJ
M3PE;;."Q-PODO5W\UDMY8EG7M*\U#=R<V';\ >4._,+M^POXA?WRL1OE+Q(I
MVS)302!)MGX6R&78SR= !PL,%@%T,@%.C0)'J\"I6<<?,$X ZWTND>-;[WNU
M!<)R<T!LE6&"]G-+E$5=;,'Z9EG[*UL^-HFD12*EPNWOW#$;/I;Y3;DM]T^4
MT9^5;3,Z?GB+[NJBJXM,$@H#Q'*JS&/0,AC2H9Y#Y#J$"%VC7A*?X<3EZV&]
M+IH&W!8%6(^PF2IM#@6OF;"_+^L-2T3J_9-$!%K*EP)YQSMPHUSF(;]:/MH%
M1L, MPR<F 9&V]Z!WR5RCW?@?[7L8[EY()9]F"'^7/ZQL)LMR$"69J"RYZ-;
M/ OI<[#J]DO1]W=H2SA\*;X7[$>NHLB-/"=+$*9QC)&+TVC<IR9.XBR<HTQ$
M;]UNL:3N78&> +ZJ&R@ '0>@)V'Q&#EUABV6.<TXN2S+J_ZWF%>+9V8SSB]+
M\[9)\VS)W.ZRZ^;-_#1-H__8O% 7/^:S1JV>G"&G?+9_5^V:<M/_W17Q0A(D
M&0VA1_T$)UY"QENY_']G2AO5 <ZWMW4%\@;DPP':<$QW"A;4Q;I@TV5S]=8^
M&/A%X1QNL3E@/+&;Q_U+Y&YCX!Q.=$ZM>P^^GRWYFF<.+)E?J<V%.;*GL]R;
M29"FN_K=YT :*-"7YNCRA[E,YDNQ9_]DOT5YT_&8)*[OID'HAQBG64!@,*)R
M$['7C'-A,9R?C&!XAM+\E':8CC"2?C&52)ASR8PYP]&5W K+/&<Z#3#GP04B
MOJ G#4;V9W1J#>)JCGJO\5K1VLFA>0K+,T7ALTG#EWX1O$HP@M@-0IC&+@P)
M2B*$QEO)*19_1F8#V&7C./@E;X1V'HSO)^B> [.D!/.Z?[&<X>("$PRVOK<9
M,FOJ,>],63PWF3ACYLI@WO2*N11'WX3XC\B!--*A-TG2[2?=651_-O1[N2V:
M?;4K/E<M^'S;'1T=?[\K%MJL,I(%042P2UP/AT'@^]YXB$29)2:R)^T@K;NW
MTUL(1E.8 @Y&#N?9XY\-)84-+<;U3PF]R=2BL\%T$O6?/1',Y$R+3HBY<B7-
M$T-[BB3K! VID3&_OZ^4R!P-BJF08;^(%K-XT:G]>4^FZ\/8,+4KL;'>KU(G
M<@*:!;$7D,#C+9JBON9Y3!#+S61*5F@?W'#*P@!R[U7U?\G5G=1/\N5DP0I^
MY9*  2KHL?[<\^X$[Q4+ -L#_]M_#-!G+E(IR^PK0F[<2784ZS!G7C739)<L
M$%[LF?!7#\5'WI*5),0GGHMPBG"4Q3$,_' 8(TXCNF)@;RKAXN!2/UOF8SV%
M(2Z'Q1Z4+1[PRY8A$MR_5F1*3/+,422G9YR;#STW',I? -KOZ_+FL&]+Z^XK
MEGW6Q=QM.Y^Q<T&3U%BT0W 4L;^L 3Z! =VY5YHWY7J4+10YR VHY[HA1H$'
M?3]Q!RPD"85N_9I%8'KCJ-A5#^7.8!XF2;C>9,P<UT8SLA:V]?G8,W(U)&5J
MSK)#* W;J)B>36'4B/"N6)(8A2[Q0Q@&H9,$7A:,&!")D5P.IW=LXSG>J )Y
MKP*[406&7DB=&%1'Z 9%^6UG&!!CK5XP+\(6*Z\NQ17VR#M46G';IBBL)(.3
ME+7?K/EY);[YGT.S;]LK#GH?L'PZSM(@#F/L>IBMT)-Q3>ZP_YN<W&K$8CC-
M)6UU+OZE;SAF7LNV*=:'NMR7HC>,9_/*!-%=R"%R,LR6@G7[>#3?@I\DN1?B
ME^O[;/!:[TBK4F-QUF4EVX _+19Q$]:*R+HQEL4[EXU?1-]TL85R^A%\JWYN
MQGYLLLMO1F>8 8B=.,H2S#)\DH[ ,L>'<GW-C,,Q+/=MTTI0=?W-9=N:F?>%
MF,);Y@9UD1\ZYHI)^Y"-OVQF?F+7W#W4IOKA@NS/Z&0[E'].@W_JSC8SUUKU
M'^?;[76G:&BW^4?.83%$+!01Y#FIXP0HR<(HHS3N$5&84:%R9W/@,*SX PX#
M8J]*O$:5GX'S&>6=6P-Z<]HN(V\Z;SE=?YWYJ8(^T9_O2,FG6JHBX5K8-;Q)
MLX)!YA/DD@"1Q,<>1E$ !S1)XKFK?<6,-+HY\R8&*<T>X4I<2>VEX7&\5OIL
M&WR6?9FW'6%T/T:K#_1LAP_7P7[>$P='W.]BVT7_=HNPN^R0:.-6ZME>D61U
MXLGD.3PKC+TH"7 <9Q$,(Q)E4> -*#S'HY,E><+8AJ6X_]8/?,5=[L ZWZX/
MVYP_+^LVS-EO%WF]8__>OK[N!%K+T:2Z-R8=3L[B"*/'D[T%%@CQ>3;ECR@G
M^\5BX=5AG=@QI286A9Y^?EW?%YO#MKB^_7IX>,CK)_:+\FY7WI9KEG:C];HZ
MM.]4/U?;<ET6S3>>I*\"/Z,A&]#%"8Y(ZB=AV"7C@9/&"1%Z^6!P>-/[TSUH
M<,V^[0YV^\LC<'!$#@;HX(\6O$R384/.N2R]EOA%3GW?NTLD'CHN[QJU)XR&
M7"3V,%&)M%?BWPP>L. QH6$#J]EFL]R*XRN;T>WV%/G7H=P_X>KAL=KQ@P/T
MHVQ6(241]"(8APA&&,>9 X-A3 \AH3)0>D8R?=NFQ02.H, ?'):@2FHB4VQY
M,!^/<N%(FD(CZ?Y%=BXD]WI8M2.5UV1+96+>R:G3BZ&RZB$O=VPLB)%+J1="
M A,O=6$6#6/Y:9;(J)+:"#.K$?BCPR4I1XKLB<F0>>*FR<_;G!G1GU=IN: [
MTVBT0V\FVE#IG%AR^M*?R/&[5[\7?"-BY8781RX,/,>+$B_.8D3\81P2!D+U
MJ=5_NF%=&<Z]V[MF?W28)#5%@3$Q/3%+EIR6R/%D1$=^HN."AJA39X=^3,!?
MZ9I$<KKQN:X>BWK_]'G+%VR[#=>L1YX;I4_?V ]J,R+DQR@(DXAF;H PI1@B
MW(^,<>9(92DZQC.L+0/$*]"";&_)C#"O (>IM*;20K68!,W-LIPH:2#8B%()
ML'9!NW1R;H>::;6H,C=#-2D>'[?/T5R7+?T"@EV,O"2+*(Y]=QC9BQRI&_TZ
MQK-!\906;EK(GJAYAG@VH'F+K/,$>%-1/076+5<]%8M$54^9+:%CXG$8>JAW
M71/)W8:6/_BOFCZ]Q"A-(N(Z!!.7(B^,43)L>^$$4J$'J]H&FV%7JH78?H8M
MSN:^O5\CMY341Z[ H>[<O,IO6G64CO  XN3V !=C5N)L=FZ&U4YBIS,M=N@J
MP,:Y(U:=1%IPH*K5G,K0A#-X:^ACN2L^[(N'9D73S'?3)&2).:34"9S =<;8
MA*AK[.:0. 1+;P]Q T!K@<G[*A*>$H@X=CA)+@[]Q_C'X)TB,WZ:]UZ1B+_,
M7"X:V=-UP4C>'1;$Q!F,G'+12)53B4VD=5%L&LI8^= TAYPQ=GU[?.Y&DM"C
M&$8)<6@6Q2BBX3!H!,-,<O]HRE#FMXY:=(#/#U#V^/B]^3^57@5/)59XKV@N
M3J6WB4[H_'!"YS+O="\3=7E?2 ?#UFP):3'FY]T@?1R)*E=6W.P_[)I]W09K
MFJ\+],#%<Q4B/_!HZI$LQ0B3"&*:#L-E* SEJD,J#R/S;2D5@N3(0#E"NP*W
M#!S(6W3S?ESG.+KP64VFU8X/:KH9E>;I)M-O[=E87PKVJW+-D][JEAYV&]X$
MKJPVJQ2%#H;$QS"&O#"AXQ(ZC S=3.@,2>=XAA.!$UP\7-UR9%?\O2+#!GXI
M=V"3/XD6UM=*L\!"=P&&Y=*"5K,^G&C6"[9IQW:'<P&.93I]S<^U8M,N+9P+
M=MX2(N7<@E,SI1:L+G5;5)F;@!*!HWLA6MU^9A.17S?/ROQNQ_*7S3_*_7U:
M%WFSQSP'K(>_@':[0[[=/J']_UO>W7\IFW]6MUG9L+]8?.$55.N"_>T5SA(O
M<XB7N(X3D1!YR!F>TV"'$J$^"DOB,QR8CB^Y'WO88#,8!OYDEH&;UC2P;FT[
M_JV\MP[D>W#/[ ,U,[ K8]N:R-N=]S9*2.Y2DT @#+X#_\N%S:/K!\1@M EP
MHT!G%>C,.OZMP3" ]H";!K[TKN^M U_>D^LEHO,[F )JT7S1J2"6!)CA_ES2
ML+"G+4@REF:@LN>[FR.)626^Y\5!G"609)GO9###R0 F<(AX+W%S$.Q*1:[&
M%&2.(/.V?TRF$%I=,W.68(=WYHCR6KVT4"!?*DIK#\3"SGC/L5;<2"WA5))3
MT4,7M-U6?_(!:55GU>%F?WO8]H?6#0O71?F]+8R!'"? 4>QB0HD+71S$$1H&
MIQ$4BI":AS0<$4>4X+:JP:;'"?(>J-S9L2Z6Q<Z0%R!8+JX]YW: .%RG:< 1
MY+S'7F+$73@$T\R\'4=BNHVJC,Y6B07#[_F/\N'P\'N^YRV?GKKMU6\5KG9-
MR3AEP/@*9OOTL?S7H=P\WYUM4(/SYA[M-OQ_^'79[^Q'\L/QA,EQ3$D:^VZ(
MHS1S8.:/.AUA\1IVR\ S+*L=Y%^W+6:P>7[BW8"'WMCV3$XB>UW(E0+K#ON]
M**?=O3U@,*@_9@+?*C#8!)A1H+,*=&:!%T=6+.=M +>I?1_0_N+$.OO]+K&B
ML=__:JN=)>>!V'K("//GUDK+NMF"==3"!%36?'*R37Z^LY]>U4^?BOTJBTD8
M^&P8@L,(TR2.H^%*4!;C6.IRKM0/-AST!RS2737EV!%;'1DC1BZ.CC"N  ,R
M=X^;(P475C-*3-FQ9E&#_E-;&67[I3__?U3U/S_LVGNW3;,*L.]"B.(0DH3Z
M7@;C8#@=R3S!)\\3AYA/$J[ GPS9K^7NU\<.FZ)&2%(HJ1;FV%/6#0Z)]V7H
M05V!W^KJ GMFI>09/R*BHD:H9?*B:,0YH9G"B;3DT)(7%R@VOU75IEFYB9_$
MF&(7^U'@P\0/O.%.?T;BS%>2'+DAYI2<VQX9N./0%!5'DD%)Q3%'GK+B#)!
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MPI;Q^5WQZ?!P4]37MUV3^>O#OMFSX-O7[%VO8.@B+_:]R(\(8@@01,.5M#1
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MY\/(=]T89C$9H$(?IE*5#!8!^$XCV4?5TJ;+S(+90YJ9"6!'6!/QO>VQ[:-
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M_7)S^77376O\L:A[--;+3;_969/Y(=]_KOZ/<L$2P",@0HD$A"&.!1']":&
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M^.KG[QCA?P0MQN#7'J5RSN?F^E<EYIYY0/TP/X\+8!W;5/B<JX8/Y9<Z'UH
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MJ5/7#9^L&2J'.F$.M>,''EY0#U/6YJ,?QA8\HR!V;.AK2*M8[5B"QH@F4B"
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M[><EQ=JC?BMWP'D:7I/;?VVX<TRRE;W$_<CWDQX$8(71B:=<.Z<XULRQO <
MYT40"9:$11;//RV\_3P!5S^U6\E:'6;WZ=?!C^K'Y*XAB47<0T 9H5P 07A0
M,T&Y.<9C30KOT"I?$XG;B>C)Y>CZ]I$7?#*!2^-%_M/^@)Y=HQ*I!,;"Y*6@
ML)8:0%'T"H88*1$KD-ZAO;T^*K<"I/O G[L@*\.9O,9_U4OCL5,D*'PY4C(
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MJ );+^:*T"B*6R%^-[+Z12[GU]E@.M^P]>DSO)JN^NA606G<Q DD!E,. ;;
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M@$[E:Q, .HC1!MC2"5ZOIO/E;-7[.%TL)FN_3SBCTO'W RT*CITJL9XAA3!
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M1=EYUOB>"4,15C;?F>3.6T**#N8J$"S2+W=\L/(9PN-T<K81595-LY?K+'I
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MVB\9_[=T&GZ:K%AQ/YZ.<S_?8OR]Z)!84U;#_I<DQ' OM7-8 ,DQTPRZPMR
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MBP&#GD).PK6O5&9(;&N:LT%9O3#8!;:3Z=X1M% 4M#:C$HB\,P!:HC#A@4G
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M.+F;?PQF>36&^76V"'0<#R:3QR_I8C%)\SO7U:JKU!;01<R26*HY=5@3"AP
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M+:!D'>@_>EKNP="%'2.20!WOH6%262N=M<C(\FMRGEQ.C^-36?OZ&E8+/=N
M2M$V^<LPJ**S<7;@S-GZ?(+#)T2T%MH;J 4BQH#R8':!&1=SI:GYT*F#FFV
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M+RE+Z13F9^W0-\J)'%[^.)U\O4MG@X=TN1@/Y[G+^U!QSCV#$@N@0T1[(P5
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MS,X.^5-V1,T?6-R'^3;2-NJ K,.&2S2>,Z]/U$LX\PT!,BFX9SZE9P.G8+2
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MX-I]/]^D=;U:WL^_S>\?9HN&,,^#SP?LJ&+1J!7,.*N49U% 5\MRPHR19#<
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M0H!JB1C;&^UD<3G'#U0\[X+ P^_1G4/UZK<J 91Q9+UQ1@L$>6HJM"<S9E$
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M\=BU"FHO&03<T"KZ@!K(,U,$)UC=JM/SY6)"#HZ,Y 1H/%N.#0E0,2<=E(#
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M,#$V,#8S,"YX;6Q02P$"% ,4    " !'APE)[<$DT^$9  #+&@$ $0
M        @ '-6@$ 9V%L92TR,#$V,#8S,"YX<V102P$"% ,4    " !'APE)
M&+1R<^(;  "4&0$ %0              @ '== $ 9V%L92TR,#$V,#8S,%]C
M86PN>&UL4$L! A0#%     @ 1X<)26/^GPA&9P  *@<% !4
M ( !\I ! &=A;&4M,C Q-C V,S!?9&5F+GAM;%!+ 0(4 Q0    ( $>'"4D<
M(]#[2.<  ,**#  5              "  6OX 0!G86QE+3(P,38P-C,P7VQA
M8BYX;6Q02P$"% ,4    " !'APE)3NH"SPN7  "CCP< %0
M@ 'FWP( 9V%L92TR,#$V,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$  "1W
$ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
